



(51) International Patent Classification:

C07K 16/08 (2006.01) *C07K 14/705* (2006.01)
A61K 39/395 (2006.01) *C07K 19/00* (2006.01)
A61K 47/68 (2017.01) *C12N 15/13* (2006.01)
A61K 51/10 (2006.01) *C12N 15/62* (2006.01)
A61P 35/00 (2006.01) *C12N 5/10* (2006.01)
C07K 14/07 (2006.01) *C12P 21/08* (2006.01)

(21) International Application Number:

PCT/CA2020/051230

(22) International Filing Date:

11 September 2020 (11.09.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/900,303 13 September 2019 (13.09.2019) US

(71) Applicants: CENTRE FOR DRUG RESEARCH AND DEVELOPMENT [CA/CA]; 2405 Wesbrook Mall, Fourth Floor, Vancouver, British Columbia V6T 1Z3 (CA).

PROVINCIAL HEALTH SERVICES AUTHORITY


[CA/CA]; 600 10th Avenue West, Vancouver, British Columbia V5Z 4E6 (CA). **UVIC INDUSTRY PARTNERSHIPS INC.** [CA/CA]; University of Victoria, Sedgewick A Wing, P.O. Box 1700 STN CSC, Victoria, British Columbia V8W 2Y2 (CA).

(72) Inventors: CUMMINS, Emma J.; 2495 5th Avenue West, Vancouver, British Columbia V6K 1S7 (CA).

BERGQVIST, Jan Peter; 315-2255 Cypress Street, Vancouver, British Columbia V6J 3M6 (CA). **NELSON, Brad**; 312-225 Menzies Street, Victoria, British Columbia V8V 2G6 (CA). **TWUMASI-BOATENG, Kwame**; 2475 Regatta Avenue, Nepean, Ontario K2J 5V6 (CA). **KWOK, Yin Yu Eunice**; 3019 29th Avenue West, Vancouver, British Columbia V6L 1Y5 (CA). **SMAZYNSKI, Julian**; 1615 Ryan St, Victoria, British Columbia V8R 2X4 (CA). **BENARD, Francois**; 3505 West 23rd Avenue, Vancouver, British Columbia V6S 1K4 (CA). **ROUSSEAU, Julie Marie**; 203-1533 East 8th Avenue, Vancouver, British Columbia V5N 0A4 (CA). **LIN, Kuo-shyan**; #510 - 7688

(54) Title: ANTI-ONCOLYTIC VIRUS ANTIGEN ANTIBODIES AND METHODS OF USING SAME

FIG. 13B



(57) **Abstract:** Provided are antibodies that specifically bind Vaccinia Virus (VV) A56 or B5 antigen. Also provided are fusion proteins and conjugates that comprise the antibodies. Pharmaceutical compositions and kits that comprise the antibodies, fusion proteins and conjugates are also provided. Aspects of the present disclosure further include methods of using the antibodies, fusion proteins and conjugates, e.g., for therapeutic purposes. In certain embodiments, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual having cancer, wherein the individual comprises cancer cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cancer cells by VV antigens expressed on the surface of the infected cancer cells. Aspects of the present disclosure further include methods of targeting an antibody, fusion protein, or conjugate that specifically binds an oncolytic virus (OV) antigen to cancer cells in an individual.



Alderbridge Way, Richmond, British Columbia V6X 0P7
(CA).

(74) **Agent: SMART & BIGGAR LLP**; 2300-1055 West Georgia Street, PO Box 11115, Vancouver, V6E 3P3 (CA).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

ANTI-ONCOLYTIC VIRUS ANTIGEN ANTIBODIES AND METHODS OF USING SAME

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application No. 62/900,303, filed September 13, 2019, which application is incorporated herein by reference
5 in its entirety.

INTRODUCTION

Immunotherapy has emerged as an effective therapeutic option against multiple malignancies. Oncolytic viruses (OVs), which can be engineered to replicate selectively in and lyse tumor tissues while sparing the normal non-neoplastic host cells and simultaneously
10 restoring antitumor immunity, constitute a next-generation immunotherapeutic approach for the treatment of tumors. The unique ability of OVs to target malignancies without dependence on specific antigen expression patterns makes them an attractive alternative to other immunotherapy approaches. In addition, OVs can promote the recruitment of tumor-infiltrating lymphocytes (TILs), reprogram the immunosuppressive tumor microenvironment
15 (TME), and boost systemic antitumor immunity.

Genetic engineering has enabled the design of live replicating viruses to not only be highly tumor selective through cell entry and transcription targeting but also armed with reporter genes for noninvasive monitoring of the pharmacokinetics of virotherapy, and for enhancing cytotoxic activity or immunogenic cell death, or immune modulators. Three OVs
20 are currently commercially available for the treatment of cancer. These include Rigvir, approved in Latvia, Georgia, and Armenia; Oncorine H101 approved in China; and talimogene laherparepvec (T-VEC) approved in the United States. Rigvir (Riga virus) is an unmodified Enteric Cytopathogenic Human Orphan type 7 (ECHO-7) picornavirus for which limited data has been published to describe its efficacy. Oncorine became the first approved
25 oncolytic virus for clinical use in China, and the world's first recombinant oncolytic virus to gain regulatory approval. It is an attenuated serotype 5 adenoviral vector deleted for viral E1B-55k and with four deletions in viral E3. Oncorine remains the only approved adenovirus for cancer therapy, and only when given in combination with chemotherapy. T-VEC (Imlygic™) was approved by the US Food and Drug Administration (FDA) in 2015 for the

treatment of non-resectable metastatic melanoma, and later in the EU for locally advanced or metastatic cutaneous melanoma, making it the most recent oncolytic virus to gain national regulatory approval and the first to gain approval in the United States. T-VEC is a recombinant human herpes simplex virus type 1 (HSV1) deleted for both copies of the HSV1 gamma34.5 and viral ICP47, which accelerates the expression of US11, and encodes 2 copies of human granulocyte-macrophage colony stimulating factor (GM-CSF) under cytomegalovirus (CMV) promoters. T-VEC is currently approved for intratumoral injection into cutaneous high-grade melanoma lesions and exhibits single-agent efficacy for this indication.

OVs in clinical development include measles virus, newcastle disease virus (NDV), rhabdoviruses, adenovirus, vaccinia virus (VV), herpes viruses, coxsackievirus, reovirus, and retrovirus.

Measles virus is a negative strand RNA paramyxovirus which is highly fusogenic and induces extensive cytopathic effects of syncytial formation. Intercellular fusion increases bystander killing of tumor cells and induces immunogenic danger signals which can elicit host mediated cellular antitumor activity. Recombinant Edmonston strain measles virus encoding the sodium iodide symporter (MV-NIS) or soluble carcinoembryonic antigen (MV-CEA) are in Phase I/II clinical testing in patients with relapsed or recurrent cancers including multiple myeloma, ovarian cancer, glioma, breast cancer and mesothelioma.

NDV is an avian paramyxovirus and has been tested as an oncolytic or oncolysate cancer vaccine. NDV strains MTH-68/H, HUU, and PV701 have been tested clinically. A recombinant NDV based on the mesogenic NDV-73T strain with compromised infection of avian cells but not mammalian cells and encoding GM-CSF (Medimmune, MEDI5395) is in preclinical testing.

Rhabdoviruses are negative sense RNA viruses with rapid, ~12-hour lytic replication cycles in permissive cells. The best studied oncolytic rhabdovirus Vesicular Stomatitis Virus (VSV) uses the low-density lipoprotein (LDL) receptor for cell entry, allowing VSV to infect nearly all cell types and cause lytic infection in a wide variety of permissive cells.

Adenoviruses are non-enveloped icosahedral double-stranded DNA viruses with long fiber knobs protruding from each capsid vertex. Clinical data has been published for telomelysin in solid tumors, CG0070 in bladder cancer, DNX-2401 in malignant brain tumors.

Vaccinia virus (VV) is a large, enveloped, double-stranded DNA virus with a linear genome approximately 190 kb in length. Attenuation or tumor-specific targeting of these viruses has been accomplished using a variety of deletions and insertional mutations, with

loss of thymidine kinase function being a common denominator among the clinical oncolytic vaccinia viruses. JX-594 is deleted for viral thymidine kinase, TG6002 is doubly deleted for thymidine kinase and viral ribonucleotide reductase, and GL-ONC1 has insertional mutations in its thymidine kinase (J2R), hemagglutinin HA (A56R), and *F14.5L* genes. The TK loss of function limits the virus' ability to replicate in non-dividing cells, and the deletion of viral ribonucleotide reductase further limits this ability. Two clinical vaccinia vectors designed to enhance oncolytic efficacy include transgenes designed to improve tumor cell killing: JX-594, like T-VEC, includes GM-CSF, and TG6002 incorporates a nucleoside analog converting enzyme FCU1, which converts 5-fluorocytosine (5-FC) to 5-FU in infected cells.

HSV1 is a large double stranded DNA virus approximately 152 kb in length. Clinically evaluated gamma34.5-deficient viruses include the now FDA-approved T-VEC, HSV1716 (Seprehvir), G207, and RP1. Attempts to boost the anticancer effects of HSV in metastatic diseases involve the inclusion of therapeutic transgenes used to simultaneously boost anti-cancer and antiviral immunity, with the goal of developing an adaptive anti-tumor response in treated patients.

Coxsackievirus is a single stranded positive RNA picornavirus of approximately 7.4 kb, enclosed in an icosahedral capsid. Oncolytic CVA21 (Viralytics, CAVATAK) is derived from the Kuykendall strain and uses ICAM-1 as the primary receptor for cell entry. Phase I testing of intratumoral CVA21 virus injection in combination with pembrolizumab or ipilimumab is ongoing to enhance the overall efficacy of these drugs.

Reovirus is a double stranded RNA virus, non-enveloped and has an icosahedral capsid composed of an outer and inner protein shell. Reovirus as a monotherapy was investigated in several Phase I trials (Oncolytics Biotech, Reolysin™) as an intratumoral or intravenous administration.

Retroviral replicating vector (Tocagen, Toca-511, vocimagene amiretrorepvec) encodes yeast cytosine deaminase (CD) that converts the prodrug 5-FC to the anticancer drug, 5-FU, thereby enhancing local concentration of 5-FU in the tumor and decreasing overall systemic toxicity of the drug. A phase 1 trial of Toca-511 in patients with recurrent high-grade glioma resulted in overall survival of 13.6 months and was statistically improved relative to an external control.

Despite the recent advances in OV-based therapies, there remains a need for new and improved OV-based methods for the treatment, alleviation, and/or prevention of cancer and for methods of improving survival in subjects with cancer.

SUMMARY

Provided are antibodies that specifically bind Vaccinia Virus (VV or VACV) A56 or B5 antigen. Also provided are fusion proteins and conjugates that comprise the antibodies. Pharmaceutical compositions and kits that comprise the antibodies, fusion proteins and
5 conjugates are also provided. Aspects of the present disclosure further include methods of using the antibodies, fusion proteins and conjugates, e.g., for therapeutic purposes. In certain embodiments, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual having cancer, wherein the individual comprises cancer cells infected with VV, and wherein the antibody, fusion protein or
10 conjugate is targeted to the infected cancer cells by VV antigens expressed on the surface of the infected cancer cells. Aspects of the present disclosure further include methods of targeting an antibody, fusion protein, or conjugate that specifically binds an oncolytic virus (OV) antigen to cancer cells in an individual.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows flow cytometry data for antibody binding to A549 and CaOV3 cells infected with VV Western Reserve VVdd(eGFP).

FIG. 2 shows flow cytometry data for antibody binding to A56 or B5 expressing HEK cells (Wyeth VV sequence).

FIG. 3 shows data for antibody binding to HEK-B5 cells. The highest concentration tested in a flow cytometry assay (top panel) or ELISA (bottom panel) for binding to HEK-B5 is plotted, 5 µg/ml for rabbit and murine isotype controls (Rb IgG Isotype and mIgG Isotype, respectively), and the anti-B5 Immunotech antibody, IT anti-B5 IgG, (identified as anti-B5 mIgG in FIG. 3), and 1:1000 for the rabbit polyclonal antibody (c-VV).

FIG. 4 shows binding of A048 antibody, the Immunotech anti-B5 antibody, IT anti-B5 IgG (identified as IT anti-B5 mIgG in FIG. 4), and a human isotype control to VV Western Reserve VVdd(eGFP)-infected A549 cells (top panel) and HT29 cells (bottom panel) measured by flow cytometry.

FIG. 5 shows antibody binding to VV-infected cells. Antibodies were tested for binding to VVdd(eGFP) infected A549 cells by flow cytometry. All formats have similar EC50s, and
30 no binding was observed to uninfected cells.

FIG. 6 shows binding of antibody A049 to virus-infected tumor tissue by immunofluorescence, in particular A049 anti-A56 hlgG1 binding to virus-infected colorectal tumor tissue. The top 2 panels are hematoxylin and eosin (H&E) stained. This is compared to a polyclonal anti-Vaccinia Virus antibody showing some non-specific staining to uninfected tissue.

FIG. 7 provides epitope binning data showing binding of biotinylated antibodies to VVdd(eGFP)-infected cells pre-incubated with non-biotinylated antibodies. Reduced biotinylated antibody binding indicates a similar or overlapping epitope to the test antibody. Antibodies A047 and A049 appear to bind different epitopes on A56. Antibodies A048 and A051 appear to bind different epitopes on B5.

FIG. 8 shows data for antibody binding to virus particles. Virus particles (VVdd(eGFP)) were coated on a plate and incubated with antibodies, or positive control NKp30. All antibodies bound the virus except antibody A054.

FIG. 9 provides data showing virus infection neutralization. Antibodies were added to A549 cells at the same time as VVdd(eGFP) infection. Similar levels of infection were observed to infection without antibody ('No Ab').

FIG. 10 shows antibody binding to murine cell lines infected with VVCopenhagen (YFP). Percent YFP expression in each infected cell line indicates the proportion of cells infected with VVcopenhagen (YFP). The anti-A56-PE and anti-B5-PE antibodies bind B16F10, CT26LacZ, and MC38 cells infected with VVcopenhagen (YFP).

FIG. 11 shows immunohistochemistry data for specific binding of antibodies to HEK cell surface expressed A56 or B5 antigen or VVCopenhagen virus-infected U2OS cells. Rabbit/murine chimeric (antibodies A059 and A058) and full rabbit IgG format (antibodies A056 and A073) antibodies specific for A56 or B5 were able to specifically detect target antigen on stably expressed HEK-A56 and HEK-B5 cells, respectively. Both anti-A56 and anti-B5 antibodies were able to detect protein expression on VVCopenhagen-infected U2OS cells.

FIG. 12 shows detection of A56 and B5 from VV-treated tumors by immunohistochemistry. The data shows detection of A56 and B5 proteins on the surface of vaccinia virus-treated tumors.

FIG. 13 Panel A: Representative schematic of an example design of an anti-VV chimeric antigen receptor (CAR) construct. Panel B: Schematic illustration of a therapeutic approach according to embodiments of the present disclosure. As shown, an OV infects a

cancer cell, followed by display of OV antigens on the surface of the cancer cell (in this example, A56 or B5 OV antigens, which in some embodiments may be the native A56 or B5 antigen of the OV). Treatment of the infected cancer cell with a CAR T cell comprising a CAR specific for a displayed OV antigen results in destruction of the infected cancer cell.

5 Neighboring cancer cells infected by OVs released by the destroyed cancer cell may in turn be destroyed by a CAR T cell comprising the CAR specific for the displayed OV antigen.

FIG. 14 provides flow cytometry data showing VV CAR detection following lentiviral transduction. The data depicts VV-CAR expression on transduced Jurkat cells. CAR downregulation, indicative of specific target binding, is evident across all VV-CAR constructs

10 tested.

FIG. 15 shows CAR and eGFP expression on activated A56-CAR-06 positive Jurkat cells. The data depicts co-expression of A56-CAR-06 and eGFP on transduced Jurkat cell line. Following culture with target HEK A56 line the activated CAR population (CD69 positive) can be identified within the scFv negative fraction by gating the eGFP positive population.

15 **FIG. 16** provides data showing specific activation of Jurkat cells expressing VV-CARs when co-cultured with target HEK cell lines. All VV-CARs tested show specific on target activation indicated by CD69 upregulation. Minimal cross reactivity/endogenous activation occurred when VV-CAR lines were co-cultured with negative/irrelevant target cell lines.

FIG. 17 shows transduction and enrichment for A56-CAR-06 expression of primary

20 healthy donor T cells. The data depicts stable expression of A56-CAR-06 on primary human T cells following a standard clinical manufacturing protocol. An enriched A56-CAR-06 population was established by cell sorting on CAR expression followed by repeated clinical expansion.

FIG. 18 shows specific activation of human T cells expressing A56-CAR-06 when co-

25 cultured with target expressing HEK-A56 lines. Primary human T cells expressing A56-CAR-06 showed significant upregulation of CD69 and CD137 following co-culture with target HEK-A56 line. Minimal cross-reactivity observed with negative/irrelevant target cell lines.

FIG. 19 provides data demonstrating that primary human T cells expressing A56-CAR-06 show morphological signs of direct tumor killing at 48 h following co-culture with target

30 HEK-A56 cells.

FIG. 20 provides data demonstrating that human T cells expressing B5-CAR-011 show high percent specific cytotoxicity. Primary human T cells expressing B5-CAR-011

exhibited specific cell lysis at 24h as determined by percent decrease of relative luminescence unit (RLU).

FIG. 21 shows representative maximum intensity projection positron emission tomography (PET) images of the ^{89}Zr -DFO-A049 (anti-A56 antibody, DFO: deferoxamine) at 1, 3 and 5 days post-injection for the same mouse. Tumor types: HEK-A56 (expressing A56, on the left shoulder) and the parental HEK (non expressing, on the right shoulder), in addition to the spleen and liver are indicated by arrows. Results are shown as percentage of the injected dose per gram of tissue (%ID/g). Clear preclinical A56-positive tumor PET imaging is shown with efficient and specific accumulation of the ^{89}Zr -DFO-A049 in the positive tumor, and expected radioimmunoconjugate pharmacokinetics.

DETAILED DESCRIPTION

Before the antibodies, compositions and methods of the present disclosure are described in greater detail, it is to be understood that the antibodies, compositions and methods are not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the antibodies, compositions and methods will be limited only by the appended claims.

Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the antibodies, compositions and methods. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the antibodies, compositions and methods.

Certain ranges are presented herein with numerical values being preceded by the term "about." The term "about" is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrecited number may be a number which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the antibodies, compositions and methods belong. Although any antibodies, compositions and methods similar or equivalent to those described herein can also be used in the practice or testing of the antibodies, compositions and methods, representative illustrative antibodies, compositions and methods are now described.

All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the materials and/or methods in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present antibodies, compositions and methods are not entitled to antedate such publication, as the date of publication provided may be different from the actual publication date which may need to be independently confirmed.

It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.

It is appreciated that certain features of the antibodies, compositions and methods, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the antibodies, compositions and methods, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments are specifically embraced by the present disclosure and are disclosed herein just as if each and every combination was individually and explicitly disclosed, to the extent that such combinations embrace operable processes and/or compositions. In addition, all sub-combinations listed in the embodiments describing such variables are also specifically embraced by the present antibodies, compositions and methods and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.

As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present methods.

5 Any recited method can be carried out in the order of events recited or in any other order that is logically possible.

ANTIBODIES

The present disclosure provides antibodies that specifically bind vaccinia virus (VV or VACV) antigens. Vaccinia viruses are members of the poxvirus family characterized by an
10 approximately 192kb double-stranded DNA genome that encodes numerous viral enzymes and factors that enable the virus to replicate independently from the host cell machinery. VV can stably accommodate up to 25 kb of cloned exogenous DNA. Structurally, it consists of a core region composed of viral DNA and various viral enzymes including RNA polymerase and polyA polymerase encased in a lipoprotein core membrane. The outer layer of the virus
15 consists of double lipid membrane envelope. VV has many inherent characteristics that make VV possess attributes suitable for use in oncolytic viral therapy such as natural tropism for tumors, strong lytic ability, short life cycle with rapid cell-to-cell spread, efficient gene expression and a large cloning capacity. VV has a short life cycle of about 8 hours that takes place in the cytoplasm eliminating the risk of genome integration. Replication typically starts
20 about 2 hours after infection, at which time host cell nucleic acid synthesis shuts down and cellular resources are directed toward viral replication. Cell lysis takes place between 12 and 48 hours releasing packaged viral particles. VV does not depend on host mechanisms for mRNA transcription making it less susceptible to biological changes of the host cell. Unlike other oncolytic viruses (OVs), VV does not require a specific surface receptor for cell entry,
25 allowing it to infect a wide range of cells.

The term "antibody" (also used interchangeably with "immunoglobulin") encompasses polyclonal (e.g., rabbit polyclonal) and monoclonal antibody preparations where the antibody may be an antibody or immunoglobulin of any isotype (e.g., IgG (e.g., IgG1, IgG2, IgG3, or IgG4), IgE, IgD, IgA, IgM, etc.), whole antibodies (e.g., antibodies composed of a tetramer
30 which in turn is composed of two dimers of a heavy and light chain polypeptide); single chain antibodies (e.g., scFv); fragments of antibodies (e.g., fragments of whole or single chain

antibodies) which retain specific binding to the compound, including, but not limited to single chain Fv (scFv), Fab, (Fab')₂, (scFv')₂, and diabodies; chimeric antibodies; monoclonal antibodies, humanized antibodies, human antibodies; and fusion proteins comprising an antigen-binding portion of an antibody and a non-antibody protein. In some embodiments, the antibody is selected from an IgG, Fv, single chain antibody, scFv, a Fab, a F(ab')₂, and a F(ab'). The antibodies may be further conjugated to other moieties, such as members of specific binding pairs, e.g., biotin (member of biotin-avidin specific binding pair), and the like.

Immunoglobulin polypeptides include the kappa and lambda light chains and the alpha, gamma (IgG₁, IgG₂, IgG₃, IgG₄), delta, epsilon and mu heavy chains or equivalents in other species. Full-length immunoglobulin "light chains" (usually of about 25 kDa or about 214 amino acids) comprise a variable region of about 110 amino acids at the NH₂-terminus and a kappa or lambda constant region at the COOH-terminus. Full-length immunoglobulin "heavy chains" (of about 150 kDa or about 446 amino acids), similarly comprise a variable region (of about 116 amino acids) and one of the aforementioned heavy chain constant regions, e.g., gamma (of about 330 amino acids).

An immunoglobulin light or heavy chain variable region (V_L and V_H, respectively) is composed of a "framework" region (FR) interrupted by three hypervariable regions, also called "complementarity determining regions" or "CDRs". The extent of the framework region and CDRs have been defined (see, E. Kabat et al., *Sequences of proteins of immunological interest*, 4th ed. U.S. Dept. Health and Human Services, Public Health Services, Bethesda, MD (1987); and Lefranc et al. IMGT, the international ImMunoGeneTics information system®. Nucl. Acids Res., 2005, 33, D593-D597)). The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs. The CDRs are primarily responsible for binding to an epitope of an antigen. All CDRs and framework provided by the present disclosure are defined according to Kabat, *supra*, unless otherwise indicated.

An "antibody" thus encompasses a protein having one or more polypeptides that can be genetically encodable, e.g., by immunoglobulin genes or fragments of immunoglobulin genes. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are

classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. In some embodiments, an antibody of the present disclosure is an IgG antibody, e.g., an IgG1 antibody, such as a human IgG1 antibody. In some embodiments, an antibody of the present disclosure comprises a human
5 Fc domain.

A typical immunoglobulin (antibody) structural unit is known to comprise a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for
10 antigen recognition. The terms variable light chain (V_L) and variable heavy chain (V_H) refer to these light and heavy chains respectively.

Antibodies encompass intact immunoglobulins as well as a number of well characterized fragments which may be genetically encoded or produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide
15 linkages in the hinge region to produce $F(ab')_2$, a dimer of Fab which itself is a light chain joined to $VH-CHI$ by a disulfide bond. The $F(ab')_2$ may be reduced under mild conditions to break the disulfide linkage in the hinge region thereby converting the $(Fab')_2$ dimer into an Fab' monomer. The Fab' monomer is essentially a Fab with part of the hinge region (see, *Fundamental Immunology*, W.E. Paul, ed., Raven Press, N.Y. (1993), for a more detailed
20 description of other antibody fragments). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such Fab' fragments may be synthesized *de novo* either chemically or by utilizing recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments
25 either produced by the modification of whole antibodies or synthesized *de novo* using recombinant DNA methodologies, including, but are not limited to, Fab'_2 , IgG, IgM, IgA, scFv, dAb, nanobodies, unibodies, and diabodies. In certain embodiments, an antibody of the present disclosure is selected from an IgG, Fv, single chain antibody, scFv, Fab, $F(ab')_2$, and Fab'.

According to some embodiments, an antibody of the present disclosure is a
30 monoclonal antibody. "Monoclonal antibody" refers to a composition comprising one or more antibodies obtained from a population of substantially homogeneous antibodies, i.e., a population the individual antibodies of which are identical except for any naturally occurring

mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site and generally to a single epitope on an antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and does not require that the antibody
5 be produced by any particular method or be the only antibody in the composition.

In certain embodiments, an antibody of the present disclosure is a humanized antibody. As used herein, a humanized antibody is a recombinant polypeptide that is derived from a non-human (e.g., rabbit, rodent, or the like) antibody and has been modified to contain at least a portion of the framework and/or constant regions of a human antibody. Humanized
10 antibodies also encompass chimeric antibodies and CDR-grafted antibodies in which various regions may be derived from different species. Chimeric antibodies may be antibodies that include a variable region from any source linked to a human constant region (e.g., a human Fc domain). Thus, in chimeric antibodies, the variable region can be non-human, and the constant region is human. CDR-grafted antibodies are antibodies that include the CDRs from
15 a non-human "donor" antibody linked to the framework region from a human "recipient" antibody. For example, an antibody of the present disclosure in a form of an scFV may be linked to a human constant region (e.g., Fc domain) to be made into a human immunoglobulin.

In general, humanized antibodies produce a reduced immune response in a human
20 host, as compared to a non-humanized version of the same antibody. Antibodies can be humanized using a variety of techniques including, for example, CDR-grafting, veneering or resurfacing, chain shuffling, and the like. In certain embodiments, framework substitutions are identified by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify
25 unusual framework residues at particular positions.

Accordingly, any of the antibodies described herein may be humanized using available methods. The substitution of rabbit or mouse CDRs into a human variable domain framework can result in retention of their correct spatial orientation where, e.g., the human variable domain framework adopts the same or similar conformation to the rabbit or mouse variable
30 framework from which the CDRs originated. This can be achieved by obtaining the human variable domains from human antibodies whose framework sequences exhibit a high degree of sequence identity with the rabbit or mouse variable framework domains from which the

CDRs were derived. The heavy and light chain variable framework regions can be derived from the same or different human antibody sequences. The human antibody sequences can be the sequences of naturally occurring human antibodies or can be consensus sequences of several human antibodies.

5 Having identified the complementarity determining regions of the rabbit or mouse donor immunoglobulin and appropriate human acceptor immunoglobulins, the next step is to determine which, if any, residues from these components should be substituted to optimize the properties of the resulting humanized antibody. In general, substitution of human amino acid residues with rabbit or mouse should be minimized, because introduction of rabbit or
10 mouse residues increases the risk of the antibody eliciting a human-anti-rabbit-antibody (HARA) or human-anti-mouse-antibody (HAMA) response in humans. Art-recognized methods of determining immune response can be performed to monitor a HARA or HAMA response in a particular patient or during clinical trials. Patients administered humanized antibodies can be given an immunogenicity assessment at the beginning and throughout the
15 administration of said therapy. The HARA or HAMA response is measured, for example, by detecting antibodies to the humanized therapeutic reagent, in serum samples from the patient using a method known to one in the art, including surface plasmon resonance technology (BIAcore) and/or solid-phase ELISA analysis. In many embodiments, a subject humanized antibody does not substantially elicit a HARA response in a human subject.

20 Certain amino acids from the human variable region framework residues are selected for substitution based on their possible influence on CDR conformation and/or binding to antigen. The unnatural juxtaposition of rabbit or murine CDR regions with human variable framework region can result in unnatural conformational restraints, which, unless corrected by substitution of certain amino acid residues, lead to loss of binding affinity. The selection of
25 amino acid residues for substitution can be determined, in part, by computer modeling. Computer hardware and software for producing three-dimensional images of immunoglobulin molecules are known in the art. In general, molecular models are produced starting from solved structures for immunoglobulin chains or domains thereof. The chains to be modeled are compared for amino acid sequence similarity with chains or domains of solved three-
30 dimensional structures, and the chains or domains showing the greatest sequence similarity is/are selected as starting points for construction of the molecular model. Chains or domains sharing at least 50% sequence identity are selected for modeling, and preferably those

sharing at least 60%, 70%, 80%, 90% sequence identity or more are selected for modeling. The solved starting structures are modified to allow for differences between the actual amino acids in the immunoglobulin chains or domains being modeled, and those in the starting structure. The modified structures are then assembled into a composite immunoglobulin.

5 Finally, the model is refined by energy minimization and by verifying that all atoms are within appropriate distances from one another and that bond lengths and angles are within chemically acceptable limits.

When framework residues, as defined by, e.g., Kabat, constitute structural loop residues as defined by, e.g., Chothia, the amino acids present in the rabbit or mouse antibody

10 may be selected for substitution into the humanized antibody. Residues which are “adjacent to a CDR region” include amino acid residues in positions immediately adjacent to one or more of the CDRs in the primary sequence of the humanized immunoglobulin chain, for example, in positions immediately adjacent to a CDR as defined by Kabat, or a CDR as defined by Chothia (See e.g., Chothia and Lesk JMB 196:901 (1987)). These amino acids

15 are particularly likely to interact with the amino acids in the CDRs and, if chosen from the acceptor, to distort the donor CDRs and reduce affinity. Moreover, the adjacent amino acids may interact directly with the antigen (Amit et al., Science, 233:747 (1986)) and selecting these amino acids from the donor may be desirable to keep all the antigen contacts that provide affinity in the original antibody. Approaches that may be employed to humanize any

20 of the antibodies described herein include, but are not limited to, those described in Williams, D., Matthews, D. & Jones, T. Humanising Antibodies by CDR Grafting. *Antibody Engineering* 319–339 (2010) doi:10.1007/978-3-642-01144-3_21; Kuramochi, T., Igawa, T., Tsunoda, H. & Hattori, K. Humanization and simultaneous optimization of monoclonal antibody. *Methods Mol. Biol.* **1060**, 123–37 (2014); Hwang, W. Y., Almagro, J. C., Buss, T.

25 N., Tan, P. & Foote, J. Use of human germline genes in a CDR homology-based approach to antibody humanization. *Methods* **36**, 35–42 (2005); Lo, B. K. Antibody humanization by CDR grafting. *Methods Mol. Biol.* **248**, 135–59 (2004); and Lefranc, M.-P. P., Ehrenmann, F., Ginestoux, C., Giudicelli, V. & Duroux, P. Use of IMGT(®) databases and tools for antibody engineering and humanization. *Methods Mol. Biol.* **907**, 3–37 (2012); the disclosures of which

30 are incorporated herein by reference in their entireties for all purposes.

An antibody of the present disclosure specifically binds to the VV A56 or VV B5 antigen. An antibody “specifically binds” or “preferentially binds” to a target if it binds with

greater affinity, avidity, more readily, and/or with greater duration than it binds to other substances, e.g., in a sample. In certain embodiments, an antibody “specifically binds” an antigen if it binds to or associates with the antigen with an affinity or K_a (that is, an association rate constant of a particular binding interaction with units of $1/M$) of, for example, greater than or equal to about $10^4 M^{-1}$. Alternatively, affinity may be defined as an equilibrium dissociation constant (K_D) of a particular binding interaction with units of M (e.g., $10^{-5} M$ to $10^{-13} M$, or less). In certain aspects, specific binding means the antibody binds to the antigen with a K_D of less than or equal to about $10^{-5} M$, less than or equal to about $10^{-6} M$, less than or equal to about $10^{-7} M$, less than or equal to about $10^{-8} M$, or less than or equal to about $10^{-9} M$, $10^{-10} M$, $10^{-11} M$, or $10^{-12} M$ or less. The binding affinity of the antibody for the antigen can be readily determined using conventional techniques, e.g., by competitive ELISA (enzyme-linked immunosorbent assay), equilibrium dialysis, by using surface plasmon resonance (SPR) technology (e.g., the BIAcore 2000 or BIAcore T200 instrument, using general procedures outlined by the manufacturer); by radioimmunoassay; or the like.

Whether an antibody of the present disclosure “competes with” a second antibody for binding to the antigen may be readily determined using competitive binding assays known in the art. Competing antibodies may be identified, for example, via an antibody competition assay. For example, a sample of a first antibody can be bound to a solid support. Then, a sample of a second antibody suspected of being able to compete with such first antibody is added. One of the two antibodies is labeled. If the labeled antibody and the unlabeled antibody bind to separate and discrete sites on the antigen, the labeled antibody will bind to the same level whether or not the suspected competing antibody is present. However, if the sites of interaction are identical or overlapping, the unlabeled antibody will compete, and the amount of labeled antibody bound to the antigen will be lowered. If the unlabeled antibody is present in excess, very little, if any, labeled antibody will bind.

For purposes of the present disclosure, competing antibodies are those that decrease the binding of an antibody to the antigen by about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, or about 99% or more. Details of procedures for carrying out such competition assays are known and can be found, for example, in Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1988, 567-569, 1988, ISBN 0-87969-314-2. Such assays can be made quantitative by using purified

antibodies. A standard curve may be established by titrating one antibody against itself, i.e., the same antibody is used for both the label and the competitor. The capacity of an unlabeled competing antibody to inhibit the binding of the labeled antibody to the plate may be titrated. The results may be plotted, and the concentrations necessary to achieve the desired degree of binding inhibition may be compared.

Anti-VV A56 Antibodies

According to some embodiments, provided are antibodies that specifically bind a VV A56 antigen (VV A56). While the vaccinia virus A56 protein was originally characterized as a haemagglutinin protein, A56 has other functions as well. The A56 protein is capable of binding two viral proteins, a serine protease inhibitor (K2) and the vaccinia virus complement control protein (VCP), and anchoring them to the surface of infected cells. While both proteins have biologically relevant functions at the cell surface, neither one can locate there on its own. The A56-K2 complex reduces the amount of virus superinfecting an infected cell and also prevents the formation of syncytia by infected cells. The A56-VCP complex can protect infected cells from complement attack. Deletion of the A56R gene results in varying effects on vaccinia virus virulence. Because the gene encoding the A56 protein is non-essential, it may be used as an insertion point for foreign genes and has been deleted in some viruses that are in clinical development as oncolytic agents.

In certain embodiments, an antibody of the present disclosure specifically binds VV A56 and competes for binding to VV A56 with an antibody having one, two, three, four, five, or all six complementarity determining regions (CDRs) of one or more of the anti-VV A56 antibodies designated herein as A047/A057, A049/A059/A056, A050, and A054. According to some embodiments, an antibody of the present disclosure specifically binds VV A56 and comprises one, two, three, four, five, or all six CDRs of the anti-VV A56 antibody designated herein as A047/A057, A049/A059/A056, A050, or A054. The amino acid sequences of the variable heavy chain (V_H) polypeptides, the variable light chain (V_L) polypeptides, and the CDRs of the A047/A057, A049/A059/A056, A050, and A054 antibodies are provided in Table 1 below. All CDRs and framework regions described throughout the present disclosure are defined according to Kabat unless otherwise indicated.

Table 1 – Amino Acid Sequences of Example Anti-VV A56 Antibodies

A047/A057 V _H (SEQ ID NO:1)	QEQLEESGGDLVKPEGSLTLTCTASGFSFSSSYWICWVRQAPG KGLEWIA <u>CIYAGSGGSTYYATWAKGRFTISKTSSTTVTLQMTSLT</u> AADTASYFCVRAYS <u>SDRSGGYSFNL</u> WGPGTLTVSS
A047/A057 V _L (SEQ ID NO:2)	QVLTQTASPVSAAVGGTVTINC <u>QASQSVDNNNYLA</u> WYQQKPGQ PPKQLIY <u>SASSLAS</u> GVPSRFKSGSGTQFTLTISDVQCDDAATYY <u>CLGSYDCSDADCYA</u> FGGGTEVVK
A047/A057 V _H CDR1 (SEQ ID NO:3)	SSYWIC
A047/A057 V _H CDR2 (SEQ ID NO:4)	CIYAGSGGSTYYATWAKG
A047/A057 V _H CDR3 (SEQ ID NO:5)	AYSDRSGGYSFNL
A047/A057 V _L CDR1 (SEQ ID NO:6)	QASQSVDNNNYLA
A047/A057 V _L CDR2 (SEQ ID NO:7)	SASSLAS
A047/A057 V _L CDR3 (SEQ ID NO:8)	LGSYDCSDADCYA
A049/A059/A056 V _H (SEQ ID NO:9)	QSLEESGGDLVKPGASLTTLTCTASGIDFS <u>DIYYIS</u> WVRQAPGKGL EWIA <u>CTYAGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAAD</u> TATYFCARDRYPGTSGRVYGMDLWGPGTLTVSS
A049/A059/A056 V _L (SEQ ID NO:10)	VVMTQTPSSVSEPVGTVTIKC <u>QASQSISDLLS</u> WYQQKPGQPPK LLIY <u>SASTLAS</u> GVSSRFKSGSGTEFTLTISDLECADAAATYYC <u>QC</u> <u>NYYSPTYGNG</u> FGGGTEVVK
A049/A059/A056 V _H CDR1 (SEQ ID NO:11)	DIYYIS
A049/A059/A056 V _H CDR2 (SEQ ID NO:12)	CTYAGSSGSTYYATWAKG
A049/A059/A056 V _H CDR3 (SEQ ID NO:13)	DRYPGTSGRVYGMDL

A049/A059/A056 V _L CDR1 (SEQ ID NO:14)	QASQSIDLLS
A049/A059/A056 V _L CDR2 (SEQ ID NO:15)	SASTLAS
A049/A059/A056 V _L CDR3 (SEQ ID NO:16)	QCNYYSPTYGNG
A050 V _H (SEQ ID NO:17)	QSLEESGGDLVKPGASLTLTCTASGFSFSSSYWLCWARQAPGK GPEWIACTYNGDGSTHYASWAKGRFTISKSSSTTVTLQMTSLTAA DTATYFCARDYTYNFYTYGFNLWGPGLTVTVSS
A050 V _L (SEQ ID NO:18)	FELTQTPSSVEAAVGGTVTINCQASQSVNIWASWYQQKPGQPP KLLIYKASTLASGVPSRFKSGSGTEFTLTISDLECADAATYYCQ GGYPSSSSSGWAFGGGTEVVK
A050 V _H CDR1 (SEQ ID NO:19)	SSYWLC
A050 V _H CDR2 (SEQ ID NO:20)	CIYNGDGSTHYASWAKG
A050 V _H CDR3 (SEQ ID NO:21)	DYTYNFYTYGFNL
A050 V _L CDR1 (SEQ ID NO:22)	QASQSVNIWAS
A050 V _L CDR2 (SEQ ID NO:23)	KASTLAS
A050 V _L CDR3 (SEQ ID NO:24)	QGGYPSSSSGWA
A054 V _H (SEQ ID NO:25)	QEQVVESGGGLVKPGASLTLTCTASGFTLSSSYWICWWRQAPG KGPEWIACTYNGDGSTHYASWAKGRFTISKSSSTTVTLQMTSLT AADTATYFCARDYTDAFYTYGFNLWGPGLTVTVSS
A054 V _L (SEQ ID NO:26)	DIVMTQTPASVSEPVGGTVTIKCQASQSTSSYLAWYQQKPGQPP KLLIYRASSLASGVPSRFKSGSATEFTLTISDLECADAATYYCQT GFYGGSSGHTFGGGTEVVK
A054 V _H CDR1	SSYWIC

(SEQ ID NO:27)	
A054 V _H CDR2 (SEQ ID NO:28)	CTYNGDGSTHYASWAKG
A054 V _H CDR3 (SEQ ID NO:29)	DYTDAFYTYGFNL
A054 V _L CDR1 (SEQ ID NO:30)	QASQSTSSYLA
A054 V _L CDR2 (SEQ ID NO:31)	RASSLAS
A054 V _L CDR3 (SEQ ID NO:32)	QTGFYGGSSGHT
V _L of A56-CAR-01, A56-CAR-02, A56-CAR-05, A56-CAR-06, A56-CAR-07, A56-CAR-08, A56-CAR-010, A56-CAR-020, A56-CAR-021 (SEQ ID NO:62)	DVVM TQTPSSVSEPVGGTVTIKC <u>QASQ</u> SISD <u>LLS</u> WYQQKPGQPP KLLIY <u>SASTLAS</u> GVSSRFKGS GSGTEFTLTISDLECADAATYYC <u>Q</u> <u>CNYYSPTYGNG</u> FGGGTEVVK
V _L of A56-CAR-029, A56-CAR-030 (SEQ ID NO:63)	DVVM TQTPSSVSEPVGGTVTIKC <u>QASQ</u> SISD <u>LLS</u> WYQQKPGQPP KLLIY <u>SASTLAS</u> GVSSRFKGS GSGTEFTLTISDLECADAATYYC <u>Q</u> <u>CNYYSPTYGNG</u> FGGGTEVVK

In certain embodiments, an antibody of the present disclosure specifically binds VV A56 and competes for binding to VV A56 with an antibody comprising:

a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence SSYWIC (SEQ ID NO:3),

a V_H CDR2 comprising the amino acid sequence CIYAGSGGSTYYATWAKG (SEQ ID NO:4), and

a V_H CDR3 comprising the amino acid sequence AYSDRSGGYSFNL (SEQ ID NO:5); and

a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSVDNNNYLA (SEQ ID NO:6),
a V_L CDR2 comprising the amino acid sequence SASSLAS (SEQ ID NO:7), and
a V_L CDR3 comprising the amino acid sequence LGSYDCSDADCYA (SEQ ID NO:8).

In certain embodiments, such an antibody comprises the six CDRs set forth in SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8. According to some embodiments, the antibody comprises: a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:1; a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:2; or both.

According to some embodiments, an antibody of the present disclosure specifically binds VV A56 and competes for binding to VV A56 with an antibody comprising:

a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence DIYYIS (SEQ ID NO:11),

a V_H CDR2 comprising the amino acid sequence CTYAGSSGSTYYATWAKG (SEQ ID NO:12), and

a V_H CDR3 comprising the amino acid sequence DRYPGTSGRVYGM DL (SEQ ID NO:13); and

a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSISD LLS (SEQ ID NO:14),

a V_L CDR2 comprising the amino acid sequence SASTLAS (SEQ ID NO:15), and

a V_L CDR3 comprising the amino acid sequence QCNYYSP TYGNG (SEQ ID NO:16).

In certain embodiments, such an antibody comprises the six CDRs set forth in SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16. According to some embodiments, the antibody comprises: a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater,

80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:9; a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:10; or both. In certain embodiments, the antibody comprises: a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:9; a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:62; or both. According to some embodiments, the antibody comprises: a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:9; a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:63; or both.

In certain embodiments, an antibody of the present disclosure specifically binds VV A56 and competes for binding to VV A56 with an antibody comprising:

- 20 a variable heavy chain (V_H) polypeptide comprising
 - a V_H CDR1 comprising the amino acid sequence SSYWLC (SEQ ID NO:19),
 - a V_H CDR2 comprising the amino acid sequence CIYNGDGSTHYASWAKG (SEQ ID NO:20), and
 - 25 a V_H CDR3 comprising the amino acid sequence DYTYNFYTYGFNL (SEQ ID NO:21); and
- a variable light chain (V_L) polypeptide comprising
 - a V_L CDR1 comprising the amino acid sequence QASQSVNIWAS (SEQ ID NO:22),
 - a V_L CDR2 comprising the amino acid sequence KASTLAS (SEQ ID NO:23), and
 - 30 a V_L CDR3 comprising the amino acid sequence QGGYPSSSSGWA (SEQ ID NO:24).

In certain embodiments, such an antibody comprises the six CDRs set forth in SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24. According to some embodiments, the antibody comprises: a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:17; a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:18; or both.

According to some embodiments, an antibody of the present disclosure specifically binds VV A56 and competes for binding to VV A56 with an antibody comprising:

a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence SSYWIC (SEQ ID NO:27),

a V_H CDR2 comprising the amino acid sequence CTYNGDGSTHYASWAKG (SEQ ID NO:28), and

a V_H CDR3 comprising the amino acid sequence DYTDAFYTYGFNL (SEQ ID NO:29); and

a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSTSSYLA (SEQ ID NO:30),

a V_L CDR2 comprising the amino acid sequence RASSLAS (SEQ ID NO:31), and

a V_L CDR3 comprising the amino acid sequence QTGFYGGSSGHT (SEQ ID NO:32).

In certain embodiments, such an antibody comprises the six CDRs set forth in SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32. According to some embodiments, the antibody comprises: a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:25; a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or

greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:26; or both.

Suitable VV A56 antigens for determining whether an anti-VV A56 antibody of the present disclosure “competes with” a second antibody for binding to the VV A56 antigen include the Wyeth, Western Reserve and Copenhagen A56 antigens having the amino acid sequences shown in Table 2 below.

Table 2 - A56 antigen sequences for Wyeth, Western Reserve and Copenhagen VV

Wyeth_VV-_A56 (SEQ ID NO:180)	MTRLPILLLLISLVYATPFPQTSKKIGDDATLSCNRNNTNDYVVM AWYKEPNSIILLAAKSDVLYFDNYTKDKISYDSPYDDLVTITIKSL TARDAGTYVCAFFMTSPTNDTDKVDYEEYSTELIVNTDSESTIDII LSGSTHSPETSSEKPDYIDNSNCSSVFEIATPEPITDNVEDHTDTV TYTSDSINTVSATSGESTTDETPEPITDKEDHTVTDVSYTTVSTS SGIVTTKSTTDDTYNDNDTVPPTTVGGSTTSISNYKTKDFVEIFGI TALIILSAVAIFCITYYICNKRSRKYKTENKV
Western_reserve_-_A56 (Q01218 Uniprot) (SEQ ID NO:182)	MTRLPILLLLISLVYATPFPQTSKKIGDDATLSCNRNNTNDYVVM AWYKEPNSIILLAAKSDVLYFDNYTKDKISYDSPYDDLVTITIKSL TARDAGTYVCAFFMTSTTNDTDKVDYEEYSTELIVNTDSESTIDIIL SGSTHSPETSSKKPDYIDNSNCSSVFEIATPEPITDNVEDHTDVT YTSDSINTVSASSGESTTDETPEPITDKEDHTVTDVSYTTVSTSS GIVTTKSTTDDADLYDTYNDNDTVPPTTVGGSTTSISNYKTKDFV EIFGITALIILSAVAIFCITYYIYNKRSRKYKTENKV
Copenhagen_-_A56 (P20978 Uniprot) (SEQ ID NO:184)	MTRLPILLLLISLVYATPFPQTSKKIGDDATLSCNRNNTNDYVVM AWYKEPNSIILLAAKSDVLYFDNYTKDKISYDSPYDDLVTITIKSL TARDAGTYVCAFFMTSPTNDTDKVDYEEYSTELIVNTDSESTIDII LSGSTHSPETSSEKPDYIDNSNCSSVFEIATPEPITDNVEDHTDTV TYTSDSINTVSATSGESTTDETPEPITDKEDHTVTDVSYTTVST SSGIVTTKSTTDDADLYDTYNDNDTVPSTTVGSSTTSISNYKTKD FVEIFGITALIILSAVAIFCITYYICNKRSRKYKTENKV

Anti-VV B5 Antibodies

According to some embodiments, provided are antibodies that specifically bind a VV B5 antigen (VV B5). VV B5 protein is a 42 kDa type I transmembrane glycoprotein with an extracellular domain composed of four short consensus repeats (SCRs) characteristic of complement control proteins. After the SCRs, B5 has a stalk region before the transmembrane domain and a short cytoplasmic tail (CT). Both the SCRs and CT are dispensable for targeting B5 to the extracellular enveloped virus (EEV) membrane, although the latter affects its transport to the cell surface and recycling via endosomes. B5 is needed for intracellular mature virus (IMV) wrapping to form intracellular enveloped virus (IEV).

In certain embodiments, an antibody of the present disclosure specifically binds VV B5 and competes for binding to VV B5 with an antibody having one, two, three, four, five, or all six complementarity determining regions (CDRs) of one or more of the anti-VV B5 antibodies designated herein as A048/A058/A073 and A051. According to some

5 embodiments, an antibody of the present disclosure specifically binds VV B5 and comprises one, two, three, four, five, or all six CDRs of the anti-VV B5 antibody designated herein as A048/A058/A073 or A051. The amino acid sequences of the variable heavy chain (V_H) polypeptides, the variable light chain (V_L) polypeptides, and the CDRs of the A048/A058/A073 and A051 antibodies are provided in Table 3 below.

10 Table 3 – Amino Acid Sequences of Example Anti-VV B5 Antibodies

A048/A058/A073 V _H (SEQ ID NO:33)	QEQLEESGGGLVKPEGSLTLTCTASGFSFSSSYMCWWRQAPG RGLewIACIYTSSGSAYYANWAKGRFTISRSTTVTLQMTRLTA ADTATYFCVRNAVGSYYLYLWGPGLTVSS
A048/A058/A073 V _L (SEQ ID NO:34)	QVLTQTPSPVSAAVGGTVTISCQASQSVAGNNYLSWYQQKPGQ PPNLLIYSVSTLASGVPSRFKSGSGTQFTLTISDLECDDAATYY CQGYNDGIWAFGGGTEVVK
A048/A058/A073 V _H CDR1 (SEQ ID NO:35)	SSYYMC
A048/A058/A073 V _H CDR2 (SEQ ID NO:36)	CIYTSSGSAYYANWAKG
A048/A058/A073 V _H CDR3 (SEQ ID NO:37)	NAVGSYYLYL
A048/A058/A073 V _L CDR1 (SEQ ID NO:38)	QASQSVAGNNYLS
A048/A058/A073 V _L CDR2 (SEQ ID NO:39)	SVSTLAS
A048/A058/A073 V _L CDR3 (SEQ ID NO:40)	QGYNDGIWA

A051 V _H (SEQ ID NO:41)	QEQVEESGGGLAKPGASLTLTCEASGFTLSS <u>SYWMC</u> WVRQAPG KGLEWIA <u>CIYGGSSGSTYYSNWAKGRFTISKTSSTTVTLQMTSLT</u> AADTATYFCARD <u>DGSTWDYFRL</u> WGPGLTVTVSS
A051 V _L (SEQ ID NO:42)	YDMTQTPSSVEAAVGGTVTIKC <u>QASQSINTNYLS</u> WYQQKPGQP PKLLIY <u>QASTLES</u> GVPSRFKSGSGSGTEYTLTISDLECAATAATYYC <u>QGYTVENIGNP</u> FGGGTEVVK
A051 V _H CDR1 (SEQ ID NO:43)	SYWMC
A051 V _H CDR2 (SEQ ID NO:44)	CIYGGSSGSTYYSNWAKG
A051 V _H CDR3 (SEQ ID NO:45)	DGSTWDYFRL
A051 V _L CDR1 (SEQ ID NO:46)	QASQSINTNYLS
A051 V _L CDR2 (SEQ ID NO:47)	QASTLES
A051 V _L CDR3 (SEQ ID NO:48)	QGYTVENIGNP

In certain embodiments, an antibody of the present disclosure specifically binds VV B5 and competes for binding to VV B5 with an antibody comprising:

- 5 a variable heavy chain (V_H) polypeptide comprising
 - a V_H CDR1 comprising the amino acid sequence SSYYMC (SEQ ID NO:35),
 - a V_H CDR2 comprising the amino acid sequence CIYTSSGSAYYANWAKG (SEQ ID NO:36), and
 - a V_H CDR3 comprising the amino acid sequence NAVGSSYYLYL (SEQ ID NO:37); and
- 10 a variable light chain (V_L) polypeptide comprising
 - a V_L CDR1 comprising the amino acid sequence QASQSVAGNNYLS (SEQ ID NO:38),

a V_L CDR2 comprising the amino acid sequence SVSTLAS (SEQ ID NO:39), and
a V_L CDR3 comprising the amino acid sequence QGYNDGIWA (SEQ ID NO:40).

In certain embodiments, such an antibody comprises the six CDRs set forth in SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, and SEQ ID NO:40. According to some embodiments, the antibody comprises: a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:33; a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:34; or both.

According to some embodiments, an antibody of the present disclosure specifically binds VV B5 and competes for binding to VV B5 with an antibody comprising:

a variable heavy chain (V_H) polypeptide comprising
a V_H CDR1 comprising the amino acid sequence SYWMC (SEQ ID NO:43),
a V_H CDR2 comprising the amino acid sequence CIYGGSSGSTYYSNWAKG (SEQ ID NO:44), and
a V_H CDR3 comprising the amino acid sequence DGSTWDYFRL (SEQ ID NO:45);
and
a variable light chain (V_L) polypeptide comprising
a V_L CDR1 comprising the amino acid sequence QASQSINTNYLS (SEQ ID NO:46),
a V_L CDR2 comprising the amino acid sequence QASTLES (SEQ ID NO:47), and
a V_L CDR3 comprising the amino acid sequence QGYTVENIGNP (SEQ ID NO:48).

In certain embodiments, such an antibody comprises the six CDRs set forth in SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, and SEQ ID NO:48. According to some embodiments, the antibody comprises: a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino

acid sequence set forth in SEQ ID NO:41; a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence set forth in SEQ ID NO:42; or both.

- 5 Suitable VV B5 antigens for determining whether an anti-VV B5 antibody of the present disclosure “competes with” a second antibody for binding to the VV B5 antigen include the Wyeth, Western Reserve and Copenhagen B5 antigens having the amino acid sequences shown in Table 4 below.

Table 4 – B5 antigen sequences for Wyeth, Western Reserve and Copenhagen VV

Wyeth_VV-_B5 (SEQ ID NO:181)	MKTISVVTLLCVLPVAVYSTCTVPTMNNAKLTSTETSFNNNQKVT FTCDQGYHSSDPNAVCEIDKWKYENPCKKMCTVSDYVSELYDK PLYEVNSTMTLSCNGETKYFRCEEKNGNTSWNDTVTCPNAECQ PLQLEHGSCQPVKEKYSFGEYITINCDVGVEVIGASYISCTANSW NVIPSCQQKCDIPSLSNGLISGSTFSIGGVIHLSCKSGFILTGPSS TCIDGKWNPIPTCVRSNEKFDPVDDGPDDDETDLKSLSKDVVQY EQEIESLEATYHIIIVALTIMGVIFLISVIVLVCSCDKNNDQYKFHKL P
Western_reserve_-_B5 (Q01227 Uniprot) (SEQ ID NO:183)	MKTISVVTLLCVLPVAVYSTCTVPTMNNAKLTSTETSFNDKQKVT FTCDQGYHSSDPNAVCEIDKWKYENPCKKMCTVSDYISELYNK PLYEVNSTMTLSCNGETKYFRCEEKNGNTSWNDTVTCPNAECQ PLQLEHGSCQPVKEKYSFGEYMTINCDVGVEVIGASYISCTANS WNVIPSCQQKCDMPSLSNGLISGSTFSIGGVIHLSCKSGFTLTGS PSSTCIDGKWNPVLPICVRTNEEFDPVDDGPDDDETDLKSLSKDV VQYEQEIESLEATYHIIIVALTIMGVIFLISVIVLVCSCDKNNDQYKF HKLLP
Copenhagen_-_B5 (P21115 Uniprot) (SEQ ID NO:185)	MKTISVVTLLCVLPVAVYSTCTVPTMNNAKLTSTETSFNNNQKVT FTCDQGYHSSDPNAVCEIDKWKYENPCKKMCTVSDYISELYNK PLYEVNSTMTLSCNGETKYFRCEEKNGNTSWNDTVTCPNAECQ PLQLEHGSCQPVKEKYSFGEYMTINCDVGVEVIGASYISCTANS WNVIPSCQQKCDIPSLSNGLISGSTFSIGGVIHLSCKSGFILTGP SSTCIDGKWNPVLPICVRTNEEFDPVDDGPDDDETDLKSLSKDV VQYEQEIESLEATYHIIIVALTIMGVIFLISVIVLVCSCDKNNDQYKF HKL

10 Bispecific Antibodies

- Also provided are bispecific antibodies. In certain embodiments, a bispecific antibody of the present disclosure comprises a first antigen-binding domain comprising a V_H polypeptide-V_L polypeptide pair of any of the anti-VV A56 and anti-VV B5 antibodies of the present disclosure, including any of such antibodies described hereinabove. The bispecific
- 15 antibody may include a second antigen-binding domain that specifically binds the VV antigen bound by the first antigen-binding domain. In certain embodiments, the bispecific antibody

includes a second antigen-binding domain that specifically binds a VV antigen other than the VV antigen bound by the first antigen-binding domain.

According to some embodiments, a bispecific antibody of the present disclosure includes a second antigen-binding domain that specifically binds an antigen other than a VV antigen. In certain embodiments, the antigen other than a VV antigen is an immune cell surface antigen. Non-limiting examples of immune cell surface antigens are immune effector cell surface antigens, e.g., a T cell surface antigen, a natural killer (NK) cell surface antigen, a macrophage cell surface antigen, and the like. Examples of T cell surface antigens that may be bound by the second antigen-binding domain include, but are not limited to, a T cell stimulatory molecule, e.g., CD3, CD28, etc.

Bispecific antibodies of the present disclosure include antibodies having a full-length antibody structure, and bispecific antibody fragments. "Full-length" as used herein refers to an antibody having two full-length antibody heavy chains and two full length antibody light chains. A full-length antibody heavy chain (HC) consists of well-known heavy chain variable and constant domains VH, CH1, CH2, and CH3. A full-length antibody light chain (LC) consists of well-known light chain variable and constant domains VL and CL. The full-length antibody may be lacking the C-terminal lysine in either one or both heavy chains. The term "Fab arm" refers to one heavy chain:light chain pair that specifically binds an antigen.

Full-length bispecific antibodies may be generated for example using Fab arm exchange (or half molecule exchange) between two monospecific bivalent antibodies by introducing substitutions at the heavy chain CH3 interface in each half molecule to favor heterodimer formation of two antibody half molecules having distinct specificity either *in vitro* in a cell-free environment or using co-expression. The Fab arm exchange reaction is the result of a disulfide-bond isomerization reaction and dissociation-association of CH3 domains. The heavy chain disulfide bonds in the hinge regions of the parent monospecific antibodies are reduced. The resulting free cysteines of one of the parent monospecific antibodies form an inter heavy-chain disulfide bond with cysteine residues of a second parent monospecific antibody molecule and simultaneously CH3 domains of the parent antibodies release and reform by dissociation-association. The CH3 domains of the Fab arms may be engineered to favor heterodimerization over homodimerization. The resulting product is a bispecific antibody having two Fab arms or half molecules which each bind a distinct epitope.

The “knob-in-hole” strategy (see, e.g., WO 2006/028936) may be used to generate full length bispecific antibodies. Briefly, selected amino acids forming the interface of the CH3 domains in human IgG can be mutated at positions affecting CH3 domain interactions to promote heterodimer formation. An amino acid with a small side chain (hole) is introduced into a heavy chain of an antibody specifically binding a first antigen and an amino acid with a large side chain (knob) is introduced into a heavy chain of an antibody specifically binding a second antigen. After co-expression of the two antibodies, a heterodimer is formed as a result of the preferential interaction of the heavy chain with a “hole” with the heavy chain with a “knob”. Exemplary CH3 substitution pairs forming a knob and a hole are (expressed as modified position in the first CH3 domain of the first heavy chain/modified position in the second CH3 domain of the second heavy chain): T366Y7F405A, T366W/F405W, F405W/Y407A, T394W/Y407T, T394S/Y407A, T366W/T394S, F405W/T394S and T366W/T366S_L368A_Y407V.

Other strategies such as promoting heavy chain heterodimerization using electrostatic interactions by substituting positively charged residues at one CH3 surface and negatively charged residues at a second CH3 surface may be used, as described in US2010/0015133; US2009/0182127; US2010/028637 or US2011/0123532. In other strategies, heterodimerization may be promoted by the following substitutions (expressed as modified position in the first CH3 domain of the first heavy chain/modified position in the second CH3 domain of the second heavy chain): L351 Y_F405A_Y407V T394W, T366I_K392M_T394W/F405A_Y407V, T366L_K392M_T394W/F405A_Y407V, L351 Y_Y407A/T366A_K409F, L351Y_Y407A/T366V_K409F, Y407A/T366A_K409F, or T350V_L351Y_F405A_Y407V/T350V_T366L_K392L_T394W as described in US2012/0149876 or US2013/0195849.

Also provided are single chain bispecific antibodies. In some embodiments, a single chain bispecific antibody of the present disclosure is a bispecific scFv. Details regarding bispecific scFvs may be found, e.g., in Zhou et al. (2017) *J Cancer* 8(18):3689-3696.

Approaches that may be employed to produce multispecific (e.g., bispecific) antibodies from the antibodies described herein include, but are not limited to, Ellerman, D. (2019). "Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety." *Methods* 154: 102-117; Brinkmann, U. and R. E. Kontermann (2017). "The making of

bispecific antibodies." mAbs 9(2): 182-212; and Suurs, F. V., et al. (2019). "A review of bispecific antibodies and antibody constructs in oncology and clinical challenges." Pharmacol Ther 201: 103-119; the disclosures of which are incorporated herein by reference in their entireties for all purposes.

5 Fusion Proteins

Also provided are fusion proteins. In certain embodiments, a fusion protein of the present disclosure comprises a chain of any of the anti-VV A56 or anti-VV B5 antibodies of the present disclosure, fused to a heterologous sequence of amino acids. The heterologous sequence of amino acids may be fused to the C-terminus of the chain of the antibody or the N-terminus of the chain of the antibody. In certain embodiments, a fusion protein of the present disclosure includes a heterologous sequence at the C-terminus of the chain of the antibody and a heterologous sequence at the N-terminus of the chain of the antibody, wherein the heterologous sequences may be the same sequence or different sequences. "Heterologous" as used in the context of a nucleic acid or polypeptide generally means that the nucleic acid or polypeptide is from a different origin (e.g., molecule of different sequence, different species origin, and the like) than that with which the nucleic acid or polypeptide is associated or joined, such that the nucleic acid or polypeptide is one that is not found in nature. For example, in a fusion protein, a light chain polypeptide and a reporter polypeptide (e.g., GFP, red fluorescent protein (e.g., mCherry), luciferase, etc.) are said to be "heterologous" to one another. Similarly, a CDR from a mouse antibody and a constant region from a human antibody are "heterologous" to one another.

The chain of the anti-VV A56 or anti-VV B5 antibody may be fused to any heterologous sequence of interest. Heterologous sequences of interest include, but are not limited to, an albumin, a transferrin, XTEN, a homo-amino acid polymer, a proline-alanine-serine polymer, an elastin-like peptide, or any combination thereof. In certain aspects, the heterologous polypeptide increases the stability and/or serum half-life of the antibody upon its administration to an individual in need thereof, as compared to the same antibody which is not fused to the heterologous sequence.

In certain embodiments, a fusion protein of the present disclosure comprises a single chain antibody, e.g., a single chain antibody (e.g., scFv) comprising a V_H polypeptide-V_L polypeptide pair of any of the anti-VV A56 and anti-VV B5 antibodies of the present

disclosure, including any of such antibodies described hereinabove. scFvs of the present disclosure include, but are not limited to, scFvs comprising the six CDRs of an scFv set forth in Table 5 below, which scFv in some embodiments comprises a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence of the V_H of the scFv set forth in Table 5; and a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, or 100% identity to the amino acid sequence of the V_L of the scFv set forth in Table 5. In Table 5, segments/domains of the polypeptides are indicated by alternating underlining, and the identities of the segments/domains are provided in the left column.

Table 5 – Example scFv Amino Acid Sequences

scFv of A56-CAR-01, A56-CAR-05, A56-CAR-06, A56-CAR-07, A56-CAR-020, A56-CAR-021 • V_H • <u>Linker</u> • V_L (SEQ ID NO:64)	QSLEESGGDLVKPGASLTLTCTASGIDFSDIYYISWVRQAPGKGLE WIACTYAGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADTA TYFCARDRYPGTSGRVYGM DLWGPGLTVTVSS <u>SGSTSGSGKPGSG</u> <u>EGSTKG</u> DVVM TQTPSSVSEPVGGTVTIKCQASQSISDLLSWYQQK PGQPPKLLIYSASTLASGVSSRFKSGSGSGTEFTLTISDLECADAATY YCQCNYYSPTYGNGFGGGTEVWKK
scFv of A56-CAR-02, A56-CAR-08, A56-CAR-010 • V_L • <u>Linker</u> • V_H (SEQ ID NO:65)	DVVM TQTPSSVSEPVGGTVTIKCQASQSISDLLSWYQQKPGQPPK LLIYSASTLASGVSSRFKSGSGSGTEFTLTISDLECADAATY YCQCNY YSPTYGNGFGGGTEVWKK <u>GSTSGSGKPGSGEGSTKG</u> QSLEESG GDLVKPGASLTLTCTASGIDFSDIYYISWVRQAPGKGLEWIACTYAG SSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADTATYFCARDR YPGTSGRVYGM DLWGPGLTVTVSS
scFv of A56-CAR-27 • V_H • <u>Linker</u> • V_L	QSLEESGGDLVKPGASLTLTCTASGIDFSDIYYISWVRQAPGKGLE WIACTYAGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADTA TYFCARDRYPGTSGRVYGM DLWGPGLTVTVSS <u>SGSTSGSGKPGSG</u> <u>EGSTKG</u> VVM TQTPSSVSEPVGGTVTIKCQASQSISDLLSWYQQK

(SEQ ID NO:66)	GQPPKLLIYSASTLASGVSSRFKSGSGTEFTLTISDLECADAATYY CQCNYYSPTYGNGFGGGTEVVVK
scFv of A56-CAR-28 • V_L • <u>Linker</u> • V_H	VVMTQTPSSVSEPVGTVTIKCQASQSISDLLSWYQQKPGQPPKL LIYSASTLASGVSSRFKSGSGTEFTLTISDLECADAATYYCQCNY SPTYGNGFGGGTEVVVK <u>GSTSGSGKPGSGEGSTKG</u> QSLEESGG LVKPGASLTLTCTASGIDFSDIYYISWVRQAPGKGLEWIACTYAGSS GSTYYATWAKGRFTISKASSTTVTLQMTSLTAADTATYFCARDRYP GTSGRVYGM DLWGPGLTVTVSS
(SEQ ID NO:67)	
scFv of A56-CAR-029 • V_H • <u>Linker</u> • V_L	QSLEESGGDLVKPGASLTLTCTASGIDFSDIYYISWVRQAPGKGLE WIACTYAGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADTA TYFCARDRYPGTSGRVYGM DLWGPGLTVTVSS <u>GSTSGSGKPGSG</u> <u>EGSTKG</u> DVMTQTPSSVSEPVGTVTIKCQASQSISDLLSWYQQK PGQPPKLLIYSASTLASGVSSRFKSGSGTEFTLTISDLECADAATY YCQCNYYSPTYGNGFGGGTEVVVK
(SEQ ID NO:68)	
scFv of A56-CAR-030 • V_L • <u>Linker</u> • V_H	DVMTQTPSSVSEPVGTVTIKCQASQSISDLLSWYQQKPGQPPK LLIYSASTLASGVSSRFKSGSGTEFTLTISDLECADAATYYCQCNY YSPTYGNGFGGGTEVVVK <u>GSTSGSGKPGSGEGSTKG</u> QSLEESGG DLVKPGASLTLTCTASGIDFSDIYYISWVRQAPGKGLEWIACTYAGS SGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADTATYFCARDRY PGTSGRVYGM DLWGPGLTVTVSS
(SEQ ID NO:69)	
scFv of B5-CAR-03, B5- CAR-011, B5-CAR-013, B5- CAR-019, B5-CAR-022 • V_H • <u>Linker</u> • V_L	QEQLLEESGGGLVKPEGSLLTCTASGFSFSSSYMCWVRQAPGR GLEWIACTYSSGSAYYANWAKGRFTISRTSSTTVTLQMTRLTAAD TATYFCVRNAVGSYYLYLWGPGLTVTVSS <u>GSTSGSGKPGSGEG</u> <u>STKGQVLTQTPSPVSAAVGGTVTISCQASQSVAGNNYLSWYQQKP</u> GQPPNLLIYSVSTLASGVPSRFKSGSGTQFTLTISDLECDDAATYY CQGYNDGIWAFGGGTEVVVK
(SEQ ID NO:70)	
scFv of B5-CAR-04, B5- CAR-014, B5-CAR-016 • V_L • <u>Linker</u> • V_H	QVLTQTPSPVSAAVGGTVTISCQASQSVAGNNYLSWYQQKPGQP PNLLIYSVSTLASGVPSRFKSGSGTQFTLTISDLECDDAATYYCQ GYNDGIWAFGGGTEVVVK <u>GSTSGSGKPGSGEGSTKG</u> QEQLLEES GGGLVKPEGSLLTCTASGFSFSSSYMCWVRQAPGRGLEWIACTY

(SEQ ID NO:71)	YTSSGSAYYANWAKGRFTISRTSSTTVTLQMTRLTAADTATYFCVR NAVGSYYLYLWGPGLTVTVSS

According to some embodiments, when the fusion protein comprises a single chain antibody (e.g., any of the single chain antibodies of the present disclosure, including any of the scFvs described herein), the fusion protein is a chimeric antigen receptor (CAR) comprising the single chain antibody, a transmembrane domain, and an intracellular signaling domain.

A CAR of the present disclosure may include one or more linker sequences between the various domains. A “variable region linking sequence” is an amino acid sequence that connects a heavy chain variable region to a light chain variable region and provides a spacer function compatible with interaction of the two sub-binding domains so that the resulting polypeptide retains a specific binding affinity to the same target molecule as an antibody that includes the same light and heavy chain variable regions. A non-limiting example of a variable region linking sequence is a serine-glycine linker, such as a serine-glycine linker that includes the amino acid sequence GGGGSGGGGSGGGGS (G₄S)₃ (SEQ ID NO:49). In certain aspects, a linker separates one or more heavy or light chain variable domains, hinge domains, transmembrane domains, co-stimulatory domains, and/or primary signaling domains. In particular embodiments, the CAR includes one, two, three, four, or five or more linkers. In particular embodiments, the length of a linker is about 1 to about 25 amino acids, about 5 to about 20 amino acids, or about 10 to about 20 amino acids, or any intervening length of amino acids. In some embodiments, the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more amino acids in length.

In some embodiments, the antigen binding domain of the CAR is followed by one or more spacer domains that moves the antigen binding domain away from the effector cell surface (e.g., the surface of a T cell expressing the CAR) to enable proper cell/cell contact, antigen binding and/or activation. The spacer domain (and any other spacer domains, linkers, and/or the like described herein) may be derived either from a natural, synthetic, semi-synthetic, or recombinant source. In certain embodiments, a spacer domain is a portion of an immunoglobulin, including, but not limited to, one or more heavy chain constant regions, e.g., CH2 and CH3. The spacer domain may include the amino acid sequence of a naturally

occurring immunoglobulin hinge region or an altered immunoglobulin hinge region. In one embodiment, the spacer domain includes the CH2 and/or CH3 of IgG1, IgG4, or IgD. Illustrative spacer domains suitable for use in the CARs described herein include the hinge region derived from the extracellular regions of type 1 membrane proteins such as CD8 α and CD4, which may be wild-type hinge regions from these molecules or variants thereof. In certain aspects, the hinge domain includes a CD8 α hinge region. In some embodiments, the hinge is a PD-1 hinge or CD152 hinge.

The "transmembrane domain" (Tm domain) is the portion of the CAR that fuses the extracellular binding portion and intracellular signaling domain and anchors the CAR to the plasma membrane of the cell (e.g., immune effector cell). The Tm domain may be derived either from a natural, synthetic, semi-synthetic, or recombinant source. In some embodiments, the Tm domain is derived from (e.g., includes at least the transmembrane region(s) or a functional portion thereof) of the alpha or beta chain of the T-cell receptor, CD35, CD3 ζ , CD3 γ , CD3 δ , CD4, CD5, CD8 α , CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD152, CD154, or PD-1.

In one embodiment, a CAR includes a Tm domain derived from CD8 α . In certain aspects, a CAR includes a Tm domain derived from CD8 α and a short oligo- or polypeptide linker, e.g., between 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids in length, that links the Tm domain and the intracellular signaling domain of the CAR. A glycine-serine linker may be employed as such a linker, for example.

The "intracellular signaling" domain of a CAR refers to the part of a CAR that participates in transducing the signal from CAR binding to a target molecule/antigen into the interior of the immune effector cell to elicit effector cell function, e.g., activation, cytokine production, proliferation and/or cytotoxic activity, including the release of cytotoxic factors to the CAR-bound target cell, or other cellular responses elicited with target molecule/antigen binding to the extracellular CAR domain. Accordingly, the term "intracellular signaling domain" refers to the portion of a protein which transduces the effector function signal and that directs the cell to perform a specialized function. To the extent that a truncated portion of an intracellular signaling domain is used, such truncated portion may be used in place of a full-length intracellular signaling domain as long as it transduces the effector function signal. The term intracellular signaling domain is meant to include any truncated portion of an intracellular signaling domain sufficient for transducing effector function signal.

Signals generated through the T cell receptor (TCR) alone are insufficient for full activation of the T cell, and a secondary or costimulatory signal is also required. Thus, T cell activation is mediated by two distinct classes of intracellular signaling domains: primary signaling domains that initiate antigen-dependent primary activation through the TCR (e.g., a TCR/CD3 complex) and costimulatory signaling domains that act in an antigen-independent manner to provide a secondary or costimulatory signal. As such, a CAR of the present disclosure may include an intracellular signaling domain that includes one or more “costimulatory signaling domains” and a “primary signaling domain.”

Primary signaling domains regulate primary activation of the TCR complex either in a stimulatory manner, or in an inhibitory manner. Primary signaling domains that act in a stimulatory manner may contain signaling motifs which are known as immunoreceptor tyrosine-based activation motifs (or “ITAMs”). Non-limiting examples of ITAM-containing primary signaling domains suitable for use in a CAR of the present disclosure include those derived from FcR γ , FcR β , CD3 γ , CD3 δ , CD3 ϵ , CD3 ζ , CD22, CD79 α , CD79 β , and CD66 δ . In certain embodiments, a CAR includes a CD3 ζ primary signaling domain and one or more costimulatory signaling domains. The intracellular primary signaling and costimulatory signaling domains are operably linked to the carboxyl terminus of the transmembrane domain.

In some embodiments, the CAR includes one or more costimulatory signaling domains to enhance the efficacy and expansion of immune effector cells (e.g., T cells) expressing the CAR. As used herein, the term “costimulatory signaling domain” or “costimulatory domain” refers to an intracellular signaling domain of a costimulatory molecule or an active fragment thereof. Example costimulatory molecules suitable for use in CARs contemplated in particular embodiments include TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DAP10, LAT, KD2C, SLP76, TRIM, and ZAP70. In some embodiments, the CAR includes one or more costimulatory signaling domains selected from the group consisting of 4-1BB (CD137), CD28, and CD134, and a CD3 ζ primary signaling domain.

A CAR of the present disclosure may include any variety of suitable domains including but not limited to a leader sequence; hinge, spacer and/or linker domain(s); transmembrane domain(s); costimulatory domain(s); signaling domain(s) (e.g., CD3 ζ domain(s)); ribosomal skip element(s); restriction enzyme sequence(s); reporter protein domains; and/or the like.

Non-limiting examples of such domains that may be included in a CAR of the present disclosure include those provided in Table 6 below. As will be appreciated by one of ordinary skill in the art, the amino acid sequence of one or more of the domains indicated in Table 6 (e.g., linker, hinge, transmembrane, co-stimulatory, signaling, ribosomal skip element; 5 restriction enzyme sequence; reporter protein etc.) may be modified as desired, e.g., for improved functionality, etc. of the CAR.

Table 6 – Example CAR Domain Amino Acid Sequences

Leader Signal Peptide(s)	
GM-CSFR alpha (P15509) (SEQ ID NO:113)	MLLLVTSLLLCELPHPAFLIP
Hinge/Spacer/Linker domain(s)	
(SEQ ID NO:114)	GSTSGSGKPGSGEGSTKG
(SEQ ID NO: 49)	GGGGSGGGGSGGGGS
CD8a hinge (SEQ ID NO:115)	TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD
CD8a hinge 2 (SEQ ID NO:116)	AKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDF ACD
extended CD8 hinge (SEQ ID NO:117)	GGGGSGGGGSGGGGSGGTTTPAPRPPTPAPTIASQPLSLRPEA CRPAAGGAVHTRGLDFACD
CD28 hinge (SEQ ID NO:118)	IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFPGPSKP
GSG linker (SEQ ID NO:119)	GGGSSGGGSG
IgG4 hinge (SEQ ID NO:120)	ESKYGPPCPSCP
IgG4(CH3) (SEQ ID NO:121)	GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCVM HEALHNHYTQKSLSLGLK
IgG4 (P01861) (SEQ ID NO:122)	ESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCV VDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTL PSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPP VLDSDGSFFLYSRLTVDKSRWQEGNVFSCVMHEALHNHYTQKS LSLSLGLK

Transmembrane domain(s)	
CD8tm (NM_001768) (SEQ ID NO:123)	IYIWAPLAGTCGVLLLSLVITLYC
CD8tm2 (NM_001768) (SEQ ID NO:124)	IYIWAPLAGTCGVLLLSLVITLY
CD8tm3 (NM_001768) (SEQ ID NO:125)	IYIWAPLAGTCGVLLLSLVITL
CD28tm (NM_006139) (SEQ ID NO:126)	FWWLVVVGVLACYSLLVTVAFIIFWW
CD28tm2 (NM_006139) (SEQ ID NO:127)	MFWWLVVVGVLACYSLLVTVAFIIFWW
CD3z (J04132.1) (SEQ ID NO:128)	LCYLLDGILFIYGVILTALFL
CD4tm (M35160) (SEQ ID NO:129)	MALIVLGGVAGLLLFIGLGIFF
4-1BB (NM_001561) (SEQ ID NO:130)	IISFFLALTSTALLFLLFFLTRFSVV
Costimulatory domain(s)	
4-1BB (NM_001561) (SEQ ID NO:131)	KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
CD28 (NM_006139) (SEQ ID NO:132)	RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS
CD28gg (NM_006139) (SEQ ID NO:133)	RSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS
OX40 (P43489) (SEQ ID NO:134)	ALYLLRRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI
CD3 ζ domain(s)	
CD3 ζ (SEQ ID NO:135)	RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDP EMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH DGLYQGLSTATKDTYDALHMQALPPR
Ribosomal Skip Element(s)	

E2A (SEQ ID NO:136)	GSGQCTNYALLKLAGDVESNPGP
T2A (SEQ ID NO:137)	GSGEGRGSLTTCGDVEENPGP
Restriction Enzyme Sequence(s)	
PacI	LIN
Reporter Protein(s)	
eGFP (SEQ ID NO:138)	MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLT KFICTTGKLPVPWPTLVTTLTLYGVQCFSRYPDHMKQHDFFKSAMP EGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGN ILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADH YQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMLLEFVTA AGITLGMDELYK
mCherry (SEQ ID NO:139)	MVSKGEEDNMAIIEKFMRFKVHMEGSVNGHEFEIEGEGEGRPYE GTQTAKLKVTGKGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLK LSFPEGFKWERVMNFEDGGWVTVTQDSSLQDGEFIYKVKLRGTN FPSDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRLKLDGG HYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERA EGRHSTGGMDELYK

In certain aspects, a CAR of the present disclosure includes a single chain antibody (e.g., any of the scFvs of the present disclosure) that binds to the antigen of interest (e.g., VV A56 antigen or VV B5 antigen); a transmembrane domain from a polypeptide selected from the group consisting of: CD4, CD8 α , CD154, and PD-1; one or more intracellular costimulatory signaling domains from a polypeptide selected from the group consisting of: 4-1BB (CD137), CD28, and CD134; and an intracellular signaling domain from a polypeptide selected from the group consisting of: FcR γ , FcR β , CD3 γ , CD3 δ , CD3 ϵ , CD3 ζ , CD22, CD79 α , CD79 β , and CD66 δ . Such a CAR may further include a spacer domain between the antigen-binding portion and the transmembrane domain, e.g., a CD8 alpha hinge.

According to some embodiments, provided are CARs that comprise – from N-terminus to C-terminus – a variable heavy chain (V_H) polypeptide of an antibody described herein, a

linker, the variable light chain (V_L) of the antibody, a CD8 hinge region (which in some embodiments is an extended CD8 hinge region), a CD8 transmembrane domain, a 4-1BB costimulatory domain, and a CD3 ζ signaling domain. According to certain embodiments, provided are CARs that comprise – from N-terminus to C-terminus – a variable light chain (V_L) polypeptide of an antibody described herein, a linker, the variable heavy chain (V_H) of the antibody, a CD8 hinge region (which in some embodiments is an extended CD8 hinge region), a CD8 transmembrane domain, a 4-1BB costimulatory domain, and a CD3 ζ signaling domain. In certain embodiments, provided are CARs that comprise – from N-terminus to C-terminus – a variable heavy chain (V_H) polypeptide of an antibody described herein, a linker, the variable light chain (V_L) of the antibody, a CD28 hinge region, a CD28 transmembrane domain, a 4-1BB costimulatory domain, and a CD3 ζ signaling domain. According to some embodiments, provided are CARs that comprise – from N-terminus to C-terminus – a variable light chain (V_L) polypeptide of an antibody described herein, a linker, the variable heavy chain (V_H) of the antibody, a CD28 hinge region, a CD28 transmembrane domain, a 4-1BB costimulatory domain, and a CD3 ζ signaling domain. Any of the CARs of the present disclosure may include a domain N-terminal to the V_H polypeptide. For example, a leader sequence (e.g., a GM-CSFR leader sequence) may be present at the N-terminus of a CAR of the present disclosure.

The amino acid sequences of example anti-A56 CARs of the present disclosure are provided in Tables 7 and 8 below, where the amino acid sequences of the CARs in Table 7 include an amino acid sequence of an N-terminal leader sequence (here, an N-terminal GM-CSFR leader sequence), and the amino acid sequences of the CARs in Table 8 do not include the amino acid sequence of the leader sequence. Any desired leader sequence (e.g., a GM-CSFR leader sequence) may be present at the N-terminus of such CARs. As will be appreciated by one of ordinary skill in the art, the amino acid sequence of one or more of the domains indicated in Tables 7 and 8 (e.g., linker, hinge, transmembrane, co-stimulatory, signaling, etc.) may be modified as desired, e.g., to improve the functionality, etc. of the CAR. In Tables 7 and 8, segments/domains of the polypeptides are indicated by alternating underlining, and the identities of the segments/domains are provided in the left column.

Table 7 – CAR Sequences (including leader)

A56-CAR-01, A56-CAR-05, A56-CAR-06, A56-CAR-020 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:72)	<u>MLLLVTSLLLCELPHPAFLIPQSLEESGGDLVKPGASLTLTCTASG</u> IDFSDIYYISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKGRFTI SKASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM DLWG PGTLVTVSSGSTSGSGKPGSGEGSTKGDVVM TQTPSSVSEPVG GTVTIKCQASQSIDLLSWYQQKPGQPPKLLIYSASTLASGVSSRF KSGSGTEFTLTISDLECADAAATYYCQCNYYSPTYGNGFGGGTE VVVKKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGL <u>DFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRP</u> <u>VQTTQEEDGCSCRFPEEEEEGGCEL</u>RVKFSRSADAPAYQQGQNNQ LYNELNLGRREEYDVLDRRRGRDPEMGGKPRRKNPQEGLYNEL QKDKMAEAYSEIGMKGERRRRGKGGHDGLYQGLSTATKDTYDALH MQALPPR
A56-CAR-07 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>Extended CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:73)	<u>MLLLVTSLLLCELPHPAFLIPQSLEESGGDLVKPGASLTLTCTASG</u> IDFSDIYYISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKGRFTI SKASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM DLWG PGTLVTVSSGSTSGSGKPGSGEGSTKGDVVM TQTPSSVSEPVG GTVTIKCQASQSIDLLSWYQQKPGQPPKLLIYSASTLASGVSSRF KSGSGTEFTLTISDLECADAAATYYCQCNYYSPTYGNGFGGGTE VVVKKGGGGSGGGSGGGSGGGTTPAPRPPTPAPTIASQPLSL <u>RPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLY</u> <u>CKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGCEL</u>R VKFSRSADAPAYQQGQNNQLYNELNLGRREEYDVLDRRRGRDPE MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRRGKGGHD GLYQGLSTATKDTYDALHMQALPPR
A56-CAR-021 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>CD28 hinge</u> • CD28 transmembrane • <u>4-1BB</u> • CD3ζ	<u>MLLLVTSLLLCELPHPAFLIPQSLEESGGDLVKPGASLTLTCTASG</u> IDFSDIYYISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKGRFTI SKASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM DLWG PGTLVTVSSGSTSGSGKPGSGEGSTKGDVVM TQTPSSVSEPVG GTVTIKCQASQSIDLLSWYQQKPGQPPKLLIYSASTLASGVSSRF KSGSGTEFTLTISDLECADAAATYYCQCNYYSPTYGNGFGGGTE VVVKKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSP LFPGPSKPFW VLVVGGVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQT <u>TQEEDGCSCRFPEEEEEGGCEL</u>RVKFSRSADAPAYQQGQNNQLYN

(SEQ ID NO:74)	ELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKDTYDALHMQAL PPR
A56-CAR-02, A56-CAR-08 • <u>GM-CSFR Leader</u> • VL • <u>linker</u> • VH • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ	<u>MLLLVTSLLLCELPHPAFLIPDVVMTQTPSSVSEPVGTVTIKCQ</u> ASQSIDLLSWYQQKPGQPPKLLIYSASTLASGVSSRFKSGSGT EFTLTISDLECADAAATYYCQCNYYSPTYGNGFGGGTEVVKK <u>GST</u> <u>SGSGKPGSGEGSTKG</u> QSLEESGGDLVKPGASLTLTCTASGIDFS DIYYISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKGRFTISKA SSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM DLWGPGT LVTVSS <u>TTTPAPRPPTPAPT</u> IASQPLSLRPEACRPAAGGAVHTRG <u>LD</u> FACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMR <u>PVQTTQEEDGC</u> SCRFPEEEEEGGCELRVKFSRSADAPAYQQGQN QLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE LQKDKMAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKDTYDALH MQALPPR
A56-CAR-010 • <u>GM-CSFR Leader</u> • VL • <u>linker</u> • VH • <u>Extended CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ	<u>MLLLVTSLLLCELPHPAFLIPDVVMTQTPSSVSEPVGTVTIKCQ</u> ASQSIDLLSWYQQKPGQPPKLLIYSASTLASGVSSRFKSGSGT EFTLTISDLECADAAATYYCQCNYYSPTYGNGFGGGTEVVKK <u>GST</u> <u>SGSGKPGSGEGSTKG</u> QSLEESGGDLVKPGASLTLTCTASGIDFS DIYYISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKGRFTISKA SSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM DLWGPGT LVTVSSGGGGSGGGSGGGSGGGGSGGTTTPAPRPPTPAPT <u>IASQPLS</u> <u>LRPEACRPAAGGAVHTRGLD</u> FACDIYIWAPLAGTCGVLLLSLVITL YCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDP EMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGGH DGLYQGLSTATKDTYDALHMQALPPR
A56-CAR-027 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u>	<u>MLLLVTSLLLCELPHPAFLIP</u> QSLEESGGDLVKPGASLTLTCTASG IDFSDIYYISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKGRFTI SKASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM DLWG PGTLVTVSS <u>GSTSGSGKPGSGEGSTKG</u> VVMTQTPSSVSEPVG TVTIKCQASQSIDLLSWYQQKPGQPPKLLIYSASTLASGVSSRFK GSGSGTEFTLTISDLECADAAATYYCQCNYYSPTYGNGFGGGTEV VVKTTTPAPRPPTPAPT <u>IASQPLSLRPEACRPAAGGAVHTRGLD</u> <u>ACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQ</u>

CD3ζ (SEQ ID NO:77)	<u>TTQEEDGCSCRFPEEEEEGGCELRVKFSRSADAPAYQQGQNQLY</u> NELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKDTYDALHMQ ALPPR
A56-CAR-028 <u>GM-CSFR Leader</u> - VL <u>linker</u> - VH <u>CD8 hinge</u> - CD8 transmembrane <u>4-1BB</u> - CD3ζ (SEQ ID NO:78)	<u>MLLLVTSLLLCELPHPAFLIPVVMQTTPSSVSEPVG GTVTIKCQAS</u> QSISDLLSWYQQKPGQPPKLLIYSASTLASGVSSRFKSGSGSTEF TLTISDLECADAAATYYCQCNYYSPTYGNGFGGGTEVWVK <u>GSTSG</u> <u>SGKPGSGEGSTKG</u> QSLEESGGDLVKPGASLTLTCTASGIDFSDIY YISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKGRFTISKASST TVTLQMTSLTAADTATYFCARDRYPGTSGRVYGMDLWGPGLT VSSTTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDF <u>ACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQ</u> <u>TTQEEDGCSCRFPEEEEEGGCELRVKFSRSADAPAYQQGQNQLY</u> NELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKDTYDALHMQ ALPPR
A56-CAR-029 <u>GM-CSFR Leader</u> - VH <u>Linker</u> - VL <u>CD8 hinge</u> - CD8 transmembrane <u>4-1BB</u> - CD3ζ (SEQ ID NO:79)	<u>MLLLVTSLLLCELPHPAFLIP</u> QSLEESGGDLVKPGASLTLTCTASG IDFSDIYYISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKGRFTI SKASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGMDLWG PGLTTLTVSSGSGSGKPGSGEGSTKGDVVMQTTPSSVSEPVG GTVTIKCQASQSISDLLSWYQQKPGQPPKLLIYSASTLASGVSSRF KGSGSGSTEFTLTISDLECADAAATYYCQCNYYSPTYGNGFGGGTE VVVKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLD <u>FACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPV</u> <u>QTTQEEDGCSCRFPEEEEEGGCELRVKFSRSADAPAYQQGQNQL</u> YNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQ KDKMAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKDTYDALHM QALPPR
A56-CAR-030 <u>GM-CSFR Leader</u> - VL <u>Linker</u> - VH <u>CD8 hinge</u> - CD8 transmembrane	<u>MLLLVTSLLLCELPHPAFLIPDVVMQTTPSSVSEPVG GTVTIKCQ</u> ASQSISDLLSWYQQKPGQPPKLLIYSASTLASGVSSRFKSGSGST EFTLTISDLECADAAATYYCQCNYYSPTYGNGFGGGTEVWVK <u>GSTS</u> <u>GSGKPGSGEGSTKG</u> QSLEESGGDLVKPGASLTLTCTASGIDFSDI YYISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKGRFTISKASS TTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGMDLWGPGLTV TVSSTTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLD

• <u>4-1BB</u> • CD3ζ (SEQ ID NO:80)	<u>FACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPV</u> <u>QTTQEEDGCSCRFPEEEEEGGCELRVKFSRSADAPAYQQGQNQL</u> YNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQ KDKMAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKDTYDALHM QALPPR
B5-CAR-03, B5-CAR-011, B5-CAR-019 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:81)	<u>MLLLVTSLLLCELPHPAFLIPQEQLLEESGGGLVKPEGS�LTCTA</u> SGFSFSSSYMCWWRQAPGRGLEWACIYTSSGSAYYANWAKG RFTISRTSSTTVTLQMTRLTAADTATYFCVRNAVGSYLYLWGP GTLVTVSSGSTSGSGKPGSGEGSTKGQVLTQTPSPVSAAVGGTV TISCQASQSVAGNNYLSWYQQKPGQPPNLLIYSVSTLASGVPSRF KGSGSGTQFTLTISDLECDAAATYYCQGYNDGIWAFGGGTEVV VKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFA <u>CDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQT</u> <u>TQEEDGCSCRFPEEEEEGGCELRVKFSRSADAPAYQQGQNQLYN</u> ELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKD KMAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKDTYDALHMQAL PPR
B5-CAR-013 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>Extended CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:82)	<u>MLLLVTSLLLCELPHPAFLIPQEQLLEESGGGLVKPEGS�LTCTA</u> SGFSFSSSYMCWWRQAPGRGLEWACIYTSSGSAYYANWAKG RFTISRTSSTTVTLQMTRLTAADTATYFCVRNAVGSYLYLWGP GTLVTVSSGSTSGSGKPGSGEGSTKGQVLTQTPSPVSAAVGGTV TISCQASQSVAGNNYLSWYQQKPGQPPNLLIYSVSTLASGVPSRF KGSGSGTQFTLTISDLECDAAATYYCQGYNDGIWAFGGGTEVV VKGGGGSGGGSGGGSGGGGSGGTTTPAPRPPTPAPTIASQPLSLRP <u>EACRPAAGGAVHTRGLDFA</u><u>CDIYIWAPLAGTCGVLLLSLVITLYCK</u> <u>RGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGCELRVK</u> FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMG GKPRRKNPQEGLYNELQDKMAEAYSEIGMKGERRRGKGGHDGL YQGLSTATKDTYDALHMQALPPR
B5-CAR-022 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL	<u>MLLLVTSLLLCELPHPAFLIPQEQLLEESGGGLVKPEGS�LTCTA</u> SGFSFSSSYMCWWRQAPGRGLEWACIYTSSGSAYYANWAKG RFTISRTSSTTVTLQMTRLTAADTATYFCVRNAVGSYLYLWGP GTLVTVSSGSTSGSGKPGSGEGSTKGQVLTQTPSPVSAAVGGTV TISCQASQSVAGNNYLSWYQQKPGQPPNLLIYSVSTLASGVPSRF

• <u>CD28 hinge</u> • CD28 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:83)	KGSGSGTQFTLTISDLECDAAATYYCQGYNDGIWAFGGGTEVV VKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFLPGPSKPFWWLV VVGGLVACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQE EDGCSCRFPEEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELN LGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMA EAYSEIGMKGERRRGKGGHDGLYQGLSTATKDTYDALHMQALPPR
B5-CAR-04, B5-CAR-014 • <u>GM-CSFR Leader</u> • VL • <u>Linker</u> • VH • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:84)	MLLLVTSLLLCELPHPAFLIPQVLTQTPSPVSAAVGGT VTISCQAS QSVAGNNYLSWYQQKPGQPPNLLIYSVSTLASGVPSRFKSGSG TQFTLTISDLECDAAATYYCQGYNDGIWAFGGGTEVVVK<u>KGSTS</u> <u>GSGKPGSGEGSTKGQE</u>QLEESGGGLVKPEGSLLTCTASGFSFS SSYYMCWVRQAPGRGLEWIACIYTSSGSAYYANWAKGRFTISRT SSTTVTLQMTRLTAADTATYFCVRNAVGSYYLYLWGPGLTVTS STTPAPRPPTPAPTASQPLSLRPEACRPAAGGAVHTRGLDFAC DIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTT QEEDGCSCRFPEEEEEGGCELRVKFSRSADAPAYQQGQNQLYNE LNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK MAEAYSEIGMKGERRRGKGGHDGLYQGLSTATKDTYDALHMQALP PR
B5-CAR-016 • <u>GM-CSFR Leader</u> • VL • <u>Linker</u> • VH • <u>Extended CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:85)	MLLLVTSLLLCELPHPAFLIPQVLTQTPSPVSAAVGGT VTISCQAS QSVAGNNYLSWYQQKPGQPPNLLIYSVSTLASGVPSRFKSGSG TQFTLTISDLECDAAATYYCQGYNDGIWAFGGGTEVVVK<u>KGSTS</u> <u>GSGKPGSGEGSTKGQE</u>QLEESGGGLVKPEGSLLTCTASGFSFS SSYYMCWVRQAPGRGLEWIACIYTSSGSAYYANWAKGRFTISRT SSTTVTLQMTRLTAADTATYFCVRNAVGSYYLYLWGPGLTVTS SGGGGSGGGGSGGGGSGGTTTPAPRPPTPAPTASQPLSLRPE ACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKR GRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGCELRVKF SRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGG KPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGGHDGLY QGLSTATKDTYDALHMQALPPR

Table 8 – CAR Sequences (amino acid sequence of leader not included)

A56-CAR-01, A56-CAR-05, A56-CAR-06, A56-CAR-020 • VH • <u>Linker</u> • VL • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:86)	QSLEESGGDLVKPGASLTLTCTASGIDFSDIYYISWVRQAPGKGLE WIACTYAGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADT ATYFCARDRYPGTSGRVYGM DLWGPGLTVTVSSGSTSGSGKPG <u>SGEGSTKGDVVM</u>TQTPSSVSEPVG GTVTIKCQASQSISDLLSWY QQKPGQPPKLLIYSASTLASGVSSRFKSGSGSGTEFTLTISDLECAD AATYYCQCNYYSPTYGNGFGGGTEVVVKTTTTAPRPPTPAPTIA <u>SQPLSLRPEACRPAAGGAVHTRGLDFACDIYI</u>WAPLAGTCGVLLL SLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEE <u>GGCEL</u>RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKR RGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR RGKGHDGLYQGLSTATKDTYDALHMQALPPR
A56-CAR-07 • VH • <u>Linker</u> • VL • <u>Extended CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:87)	QSLEESGGDLVKPGASLTLTCTASGIDFSDIYYISWVRQAPGKGLE WIACTYAGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADT ATYFCARDRYPGTSGRVYGM DLWGPGLTVTVSSGSTSGSGKPG <u>SGEGSTKGDVVM</u>TQTPSSVSEPVG GTVTIKCQASQSISDLLSWY QQKPGQPPKLLIYSASTLASGVSSRFKSGSGSGTEFTLTISDLECAD AATYYCQCNYYSPTYGNGFGGGTEVVVKGGGGSGGGSGGG <u>GSGGTTTTAPRPPTPAPTIA</u>SQPLSLRPEACRPAAGGAVHTRGLD <u>FACDIYI</u>WAPLAGTCGVLLL SLVITLYCKRGRKKLLYIFKQPFMRPV <u>QTTQEEDGCSCRFPEEEEEGGCEL</u>RVKFSRSADAPAYQQGQNQL YNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQ KDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPR
A56-CAR-021 • VH • <u>Linker</u> • VL • <u>CD28 hinge</u> • CD28 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:88)	QSLEESGGDLVKPGASLTLTCTASGIDFSDIYYISWVRQAPGKGLE WIACTYAGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADT ATYFCARDRYPGTSGRVYGM DLWGPGLTVTVSSGSTSGSGKPG <u>SGEGSTKGDVVM</u>TQTPSSVSEPVG GTVTIKCQASQSISDLLSWY QQKPGQPPKLLIYSASTLASGVSSRFKSGSGSGTEFTLTISDLECAD AATYYCQCNYYSPTYGNGFGGGTEVVVKIEVMYPPPYLDNEKS <u>NGTIIHVKGKHLCPSP</u>LPFGPSKPFWWLVVVGVLACYSLLVTVAF IIFWWKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGC <u>EL</u>RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGR

	DPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGK GHDGLYQGLSTATKDTYDALHMQALPPR
A56-CAR-02, A56-CAR-08 - VL <u>linker</u> - VH <u>CD8 hinge</u> - CD8 transmembrane <u>4-1BB</u> - CD3ζ (SEQ ID NO:89)	DVVMTQTPSSVSEPVGTVTIKCQASQSISDLLSWYQQKPGQPP KLLIYSASTLASGVSSRFKSGSGTEFTLTISDLECADAATYYCQC NYYSPITYGNGFGGGTEVVKK <u>GSTSGSGKPGSGEGSTKG</u> QSLE ESGGDLVKPGASLTCTASGIDFSDIYYISWVRQAPGKGLEWIA TYAGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADTATYF CARDRYPGTSGRVYGM DLWGPGLTVTVSS <u>TTTPAPRPPTPAPT</u> <u>ASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLL</u> LSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEE <u>GGCEL</u> RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKR RGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR RGKGHDGLYQGLSTATKDTYDALHMQALPPR
A56-CAR-010 - VL <u>linker</u> - VH <u>Extended CD8 hinge</u> - CD8 transmembrane <u>4-1BB</u> - CD3ζ (SEQ ID NO:90)	DVVMTQTPSSVSEPVGTVTIKCQASQSISDLLSWYQQKPGQPP KLLIYSASTLASGVSSRFKSGSGTEFTLTISDLECADAATYYCQC NYYSPITYGNGFGGGTEVVKK <u>GSTSGSGKPGSGEGSTKG</u> QSLE ESGGDLVKPGASLTCTASGIDFSDIYYISWVRQAPGKGLEWIA TYAGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADTATYF CARDRYPGTSGRVYGM DLWGPGLTVTVSS <u>GGGGSGGGSGGG</u> <u>GSGGTTTPAPRPPTPAPT</u> IASQPLSLRPEACRPAAGGAVHTRGLD <u>FACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPV</u> <u>QTTQEEDGCSCRFPEEEEEGGCEL</u> RVKFSRSADAPAYQQGQNQL YNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQ KDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM QALPPR
A56-CAR-027 - VH <u>Linker</u> - VL <u>CD8 hinge</u> - CD8 transmembrane <u>4-1BB</u> - CD3ζ	QSLEESGGDLVKPGASLTCTASGIDFSDIYYISWVRQAPGKGLE WIACTYAGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADT ATYFCARDRYPGTSGRVYGM DLWGPGLTVTVSS <u>GSTSGSGKPG</u> <u>SGEGSTKG</u> VVMTQTPSSVSEPVGTVTIKCQASQSISDLLSWYQ QKPGQPPKLLIYSASTLASGVSSRFKSGSGTEFTLTISDLECADA ATYYCQCNYYSPTYGNGFGGGTEVVK <u>TTTPAPRPPTPAPT</u> IASQ <u>PLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLV</u> ITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGC <u>EL</u> RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGR

(SEQ ID NO:91)	DPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGK GHDGLYQGLSTATKDTYDALHMQALPPR
A56-CAR-028 - VL <u>linker</u> - VH <u>CD8 hinge</u> - CD8 transmembrane <u>4-1BB</u> - CD3ζ	VVMQTTPSSVSEPVGGTVTIKCQASQSISDLLSWYQQKPGQPPK LLIYSASTLASGVSSRFKSGSGTEFTLTISDLECADAAATYYCQCN YYSPYTYGNGFGGGTEVWVK <u>SGTSGSGKPGSGEGSTKGQSLEES</u> GGDLVKPGASLTLTCTASGIDFSDIYYISWRQAPGKGLEWIACTY AGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADTATYFCA RDRYPGTSGRVYGM DLWGPGLTVTVSSTTTTPAPRPPTPAPTIA <u>QPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLS</u> LVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEG <u>GCEL</u> RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRR GRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRR GKGHDGLYQGLSTATKDTYDALHMQALPPR
(SEQ ID NO:92)	
A56-CAR-029 - VH <u>Linker</u> - VL <u>CD8 hinge</u> - CD8 transmembrane <u>4-1BB</u> - CD3ζ	QSLEESGGDLVKPGASLTLTCTASGIDFSDIYYISWRQAPGKGLE WIACTYAGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADT ATYFCARDRYPGTSGRVYGM DLWGPGLTVTVSSGSTSGSGKPG <u>SGEGSTKG</u> DVVMQTTPSSVSEPVGGTVTIKCQASQSISDLLSWY QQKPGQPPKLLIYSASTLASGVSSRFKSGSGTEFTLTISDLECAD AATYYCQCNYYSPYTYGNGFGGGTEVWVKTTTPAPRPPTPAPTIA <u>QPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLS</u> LVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEG <u>GCEL</u> RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRR GRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRR GKGHDGLYQGLSTATKDTYDALHMQALPPR
(SEQ ID NO:93)	
A56-CAR-030 - VL <u>Linker</u> - VH <u>CD8 hinge</u> - CD8 transmembrane <u>4-1BB</u> - CD3ζ	DVVMQTTPSSVSEPVGGTVTIKCQASQSISDLLSWYQQKPGQPP KLLIYSASTLASGVSSRFKSGSGTEFTLTISDLECADAAATYYCQC NYYSPYTYGNGFGGGTEVWVK <u>SGTSGSGKPGSGEGSTKGQSLEE</u> SGGDLVKPGASLTLTCTASGIDFSDIYYISWRQAPGKGLEWIACT YAGSSGSTYYATWAKGRFTISKASSTTVTLQMTSLTAADTATYFC ARDRYPGTSGRVYGM DLWGPGLTVTVSSTTTTPAPRPPTPAPTIA <u>SQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLL</u> SLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEE <u>GGCEL</u> RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKR RGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERR RGKGHDGLYQGLSTATKDTYDALHMQALPPR
(SEQ ID NO:94)	

B5-CAR-03, B5-CAR-011, B5-CAR-019 • VH • <u>Linker</u> • VL • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:95)	QEQLEESGGGLVKPEGSLLTCTASGFSFSSSYMCWWRQAPG RGGLEWIACIYTSSGSAYYANWAKGRFTISRTSSTTVTLQMTRLTAA DTATYFCVRNAVGSYYLYLWGPGLTVTVSSGSGSGKPGSGE <u>GSTKGQVLTQTPSPVSAVGGTVTISCQASQSVAGNNYLSWYQQ</u> KPGQPPNLLIYVSTLASGVPSRFKSGSGTGFTLTISDLECDAA TYYCQGYNDGIWAFGGGTEVWVKTTTPAPRPPTPAPTASQPLS <u>LRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITL</u> YCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDP EMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH DGLYQGLSTATKDTYDALHMQALPPR
B5-CAR-013 • VH • <u>Linker</u> • VL • <u>Extended CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:96)	QEQLEESGGGLVKPEGSLLTCTASGFSFSSSYMCWWRQAPG RGGLEWIACIYTSSGSAYYANWAKGRFTISRTSSTTVTLQMTRLTAA DTATYFCVRNAVGSYYLYLWGPGLTVTVSSGSGSGKPGSGE <u>GSTKGQVLTQTPSPVSAVGGTVTISCQASQSVAGNNYLSWYQQ</u> KPGQPPNLLIYVSTLASGVPSRFKSGSGTGFTLTISDLECDAA TYYCQGYNDGIWAFGGGTEVWVKGGGGSGGGGSGGGGSGGT <u>TTPAPRPPTPAPTASQPLSLRPEACRPAAGGAVHTRGLDFACDIY</u> IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQE <u>EDGCSCRFPEEEEEGGCEL</u>RVKFSRSADAPAYQQGQNQLYNELN LGRREEYDVLDKRRGRDP EMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH DGLYQGLSTATKDTYDALHMQALPPR
B5-CAR-022 • VH • <u>Linker</u> • VL • <u>CD28 hinge</u> • CD28 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:97)	QEQLEESGGGLVKPEGSLLTCTASGFSFSSSYMCWWRQAPG RGGLEWIACIYTSSGSAYYANWAKGRFTISRTSSTTVTLQMTRLTAA DTATYFCVRNAVGSYYLYLWGPGLTVTVSSGSGSGKPGSGE <u>GSTKGQVLTQTPSPVSAVGGTVTISCQASQSVAGNNYLSWYQQ</u> KPGQPPNLLIYVSTLASGVPSRFKSGSGTGFTLTISDLECDAA TYYCQGYNDGIWAFGGGTEVWVKIEVMYPPPYLDNEKSNGTIIH <u>VKGKHLCPSPFLPGPSKPFWWLVVGGVLACYSLLVTVAFIIFWWK</u> <u>RGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGCEL</u>RVK FSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDP EMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH DGLYQGLSTATKDTYDALHMQALPPR

B5-CAR-04, B5-CAR-014 • VL • <u>Linker</u> • VH • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:98)	QVLTQTPSPVSAAVGGTVTISCQASQSVAGNNYLSWYQQKPGQP PNLLIYSVSTLASGVPSRFKSGSGGTQFTLTISDLECDAAATYYCQ GYNDGIWAFGGGTEVWVK<u>GSTSGSGKPGSGEGSTKGQEQLEE</u> SGGGLVKPEGSLTLTCTASGFSFSSSYMCWVRQAPGRGLEWIA CIYTSSGSAYYANWAKGRFTISRTSSTTVTLQMTRLTAADTATYFC VRNAVGSYYLYLWGPGLTVTVSS<u>TTTPAPRPPTPAPTIASQPLS</u> <u>LRPEACRPAAGGAVHTRGLDFACDIYWAPLAGTCGVLLLSLVITL</u> <u>YCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGCEL</u> RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDP EMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGH DGLYQGLSTATKDTYDALHMQALPPR
B5-CAR-016 • VL • <u>Linker</u> • VH • <u>Extended CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ (SEQ ID NO:99)	QVLTQTPSPVSAAVGGTVTISCQASQSVAGNNYLSWYQQKPGQP PNLLIYSVSTLASGVPSRFKSGSGGTQFTLTISDLECDAAATYYCQ GYNDGIWAFGGGTEVWVK<u>GSTSGSGKPGSGEGSTKGQEQLEE</u> SGGGLVKPEGSLTLTCTASGFSFSSSYMCWVRQAPGRGLEWIA CIYTSSGSAYYANWAKGRFTISRTSSTTVTLQMTRLTAADTATYFC VRNAVGSYYLYLWGPGLTVTVSS<u>GGGGSGGGGSGGGGSGGT</u> <u>TTAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIY</u> <u>IWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQE</u> <u>EDGCSCRFPEEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELN</u> LGRREEYDVLDKRRGRDP<u>EMGGKPRRKNPQEGLYNELQKDKMA</u> EAYSEIGMKGERRRGKGH<u>DGLYQGLSTATKDTYDALHMQALPPR</u>

A CAR of the present disclosure may include one or more additional domains as desired. Non-limiting examples of such additional domains include a ribosomal skip element, an enzymatic domain (e.g., a domain having nuclease activity, e.g., restriction endonuclease activity), a domain that enables detection of the CAR (e.g., a reporter protein domain (e.g., a fluorescent protein (e.g., eGFP, mCherry, or the like), a luminescent protein, and/or the like)), etc. For example, in certain embodiments, provided are CARs that comprise a ribosomal skip element, a restriction enzyme domain, and/or a reporter protein domain. The amino acid sequences of example anti-A56 CARs of the present disclosure having one or more of these features are provided in Table 9 below. As will be appreciated by one of ordinary skill in the art, the amino acid sequence of one or more of the domains indicated in Table 9 (e.g., linker, hinge, transmembrane, co-stimulatory, signaling, restriction enzyme, reporter protein, etc.)

may be modified as desired, e.g., to improve functionality, detection, etc. of the CAR. In Table 9, the CAR portion is shown in bold, and segments/domains of the polypeptides are indicated by alternating underlining. Identities of the segments/domains are provided in the left column.

Table 9 – CAR Sequences (leader and ribosomal skip element, restriction enzyme and/or

5 reporter protein included)

A56-CAR-05 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ • <u>T2A</u> • mCherry (SEQ ID NO:100)	<u>MLLLVTSLLLCELPHPAFLLIPQSLEESGGDLVKPGASLTLTCTA</u> SGIDFSDIYYISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKG RFTISKASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM DLWGPGTLVTVSS<u>SGSTSGSGKPGSGEGSTKGDV</u>VMTQTPSSVS EPVGGTVTIKCQASQSISDLLSWYQQKPGQPPKLLIYSASTLASG VSSRFKSGSGSGTEFTLTISDLECADAATYYCQCNYYSPTYGNGF GGGTEVVVKKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA <u>VHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRK</u>KLLYIF <u>KQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL</u>RVKFSRSADAPA YQQGQNQLYNELNLGRREEYDVLDKRRGRDPGEMGGKPRRKNP QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT KDTYDALHMQALPPRGSGEGRGSLLTCGDVEENPGPMVSKGEE DNMAIIEFMRFKVHMEGVSNGHEFEIEGEGEGRPYEGTQTAKLK VTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFK WERVMNFEDGGVTVTQDSSLQDGEFIYKVKLRGTNFPDGPV MQKKTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVK TTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTG GMDELYK
A56-CAR-06 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ • <u>PacI</u>	<u>MLLLVTSLLLCELPHPAFLLIPQSLEESGGDLVKPGASLTLTCTA</u> SGIDFSDIYYISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKG RFTISKASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM DLWGPGTLVTVSS<u>SGSTSGSGKPGSGEGSTKGDV</u>VMTQTPSSVS EPVGGTVTIKCQASQSISDLLSWYQQKPGQPPKLLIYSASTLASG VSSRFKSGSGSGTEFTLTISDLECADAATYYCQCNYYSPTYGNGF GGGTEVVVKKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGA <u>VHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRK</u>KLLYIF <u>KQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL</u>RVKFSRSADAPA YQQGQNQLYNELNLGRREEYDVLDKRRGRDPGEMGGKPRRKNP QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT

• E2A • <u>eGFP</u> (SEQ ID NO:101)	<u>KD</u><u>TYDALHMQALPPRL</u><u>INGSGQCTNYALLKLAGDVESNPGPMVS</u> <u>KGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLT</u><u>TKFI</u> <u>CTTGKLPVPWPTLVTTLT</u><u>YGVQCFSRYPDHMKQHDFFKSAMPEG</u> <u>YVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNIL</u> <u>GHKLEYNYN</u><u>SHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHY</u> <u>QQNTPIGDGPVLLPDNHYLSTQSALS</u><u>KDPNEKRDHMLLEFVTAA</u> <u>GITLGMDELYK</u>
A56-CAR-020 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ • <u>T2A</u> • eGFP (SEQ ID NO:102)	<u>MLLLVTSLLLCELPHPAFL</u><u>LIPQSLEESGGDLVKPGASLT</u><u>LTCTA</u> <u>SGIDFSDIYYISWRQAPGKGLEW</u><u>IACTYAGSSGSTYYATWAKG</u> <u>RFTISKASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM</u> <u>DLWGPGTLVTVSS</u><u>GSTSGSGKPGSGEGSTKGDVVM</u><u>TQTPSSVS</u> <u>EPVGGT</u><u>VTIKCQASQSISDLLSWYQQKPGQPPKLLIYSASTLASG</u> <u>VSSRFKSGSGSTEFTLTISDLECADAATYYCQC</u><u>NYYSP</u><u>TYGNGF</u> <u>GGGTEVVVKTTTT</u><u>PAPRPPTPAPT</u><u>IASQPLSLRPEACRPAAGGA</u> <u>VHTRGLDFACDIYI</u><u>WAPLAGTCGVLLLSL</u><u>VITLYCKRGRK</u><u>KLLYIF</u> <u>KQPFMRPVQTTQEEDGC</u><u>SCRFPEEEEGGCEL</u><u>RVKFSRSADAPA</u> <u>YQQGQNQLYNELNLGRREEYDVLDKRRGRDP</u><u>EMGGKPRRKNP</u> <u>QEGLYNELQKDKMAEAYSEIGMKGERRRGK</u><u>GHDGLYQGLSTAT</u> <u>KD</u><u>TYDALHMQALPPR</u><u>GS</u><u>GEGRGSLLTCGDVEENPGPMVSKGEE</u> <u>LFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLT</u><u>TKFI</u><u>CTTGK</u> <u>LPVPWPTLVTTLT</u><u>YGVQCFSRYPDHMKQHDFFKSAMPEGYVQER</u> <u>TIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEY</u> <u>NYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPI</u> <u>GDGPVLLPDNHYLSTQSALS</u><u>KDPNEKRDHMLLEFVTAA</u><u>GITLGM</u> <u>DELYK</u>
A56-CAR-07 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>Extended CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ • <u>T2A</u>	<u>MLLLVTSLLLCELPHPAFL</u><u>LIPQSLEESGGDLVKPGASLT</u><u>LTCTA</u> <u>SGIDFSDIYYISWRQAPGKGLEW</u><u>IACTYAGSSGSTYYATWAKG</u> <u>RFTISKASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM</u> <u>DLWGPGTLVTVSS</u><u>GSTSGSGKPGSGEGSTKGDVVM</u><u>TQTPSSVS</u> <u>EPVGGT</u><u>VTIKCQASQSISDLLSWYQQKPGQPPKLLIYSASTLASG</u> <u>VSSRFKSGSGSTEFTLTISDLECADAATYYCQC</u><u>NYYSP</u><u>TYGNGF</u> <u>GGGTEVVVK</u><u>GGGGSGGGGSGGGSGGTTTPAPRPPTPAPTIA</u> <u>SQPLSLRPEACRPAAGGAVHTRGLDFACDIYI</u><u>WAPLAGTCGVLL</u> <u>LSLVITLYCKRGRK</u><u>KLLYIFKQPFMRPVQTTQEEDGC</u><u>SCRFPEEE</u> <u>EGGCEL</u><u>RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK</u>

• mCherry (SEQ ID NO:103)	RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGE RRRGKGGHDGLYQGLSTATKDTYDALHMQALPPRGSGEGRGSLL TCGDVEENPGPMVSKGEEDNMAIIEFMRFKVHMEGSVNGHEFE IEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYV KHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGE FIYKVKLRGTNFPDGPVMQKKTMGWEASSERMYPEDGALKGEI KQRLKLDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNE DYTIVEQYERAEGRHSTGGMDELYK
A56-CAR-021 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>CD28 hinge</u> • CD28 transmembrane • <u>4-1BB</u> • CD3ζ • <u>T2A</u> • mCherry (SEQ ID NO:104)	<u>MLLLVTSLLLCELPHPAFLIP</u>QSLEESGGDLVKPGASLTLTCTA SGIDFSDIYYISWRQAPGKGLEWIACTYAGSSGSTYYATWAKG RFTISKASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM DLWGPGLTVTVSSGSTSGSGKPGSGEGSTKGDVVMVTQTPSSVS EPVGGTVTIKCQASQSISDLLSWYQQKPGQPPKLLIYSASTLASG VSSRFKGS GSGTEFTLTISDLECADAAATYYCQCNYYSPTYGNGF GGGTEVVVKKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFLPG PSKPFVWL VVVGVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQP FMRPVQTTQEEDGCSCRFPEEEEEGGCEL RVKFSRSADAPAYQQ GQNQLYNELNLGRREEYDVLDRRRGRDPEMGGKPRRKNPQEG LYNELQKDKMAEAYSEIGMKGERRRRGKGGHDGLYQGLSTATKDT YDALHMQALPPRGSGEGRGSLLTCGDVEENPGPMVSKGEEDN MAIIEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVT KGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWE RVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPDGPVMQK KTMGWEASSERMYPEDGALKGEIKQRLKLDGGHYDAEVKTTYK AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMD ELYK
A56-CAR-08 • <u>GM-CSFR Leader</u> • VL • <u>linker</u> • VH • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ	<u>MLLLVTSLLLCELPHPAFLIP</u>DVVMVTQTPSSVSEPVGTVTIKCQ ASQSISDLLSWYQQKPGQPPKLLIYSASTLASGVSSRFKGS GSG TEFTLTISDLECADAAATYYCQCNYYSPTYGNGFGGGTEVVVKK <u>STSGSGKPGSGEGSTKG</u>QSLEESGGDLVKPGASLTLTCTASGID FSDIYYISWRQAPGKGLEWIACTYAGSSGSTYYATWAKGRFTIS KASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM DLWG PGTLTVTVSS <u>TTTPAPRPPTPAPT</u>IASQPLSLRPEACRPAAGGAVH <u>TRGLDFACDIYI</u>WAPLAGTCGVLLL SLVITLYCKRGRKKLLYIFKQ PFMRPVQTTQEEDGCSCRFPEEEEEGGCEL RVKFSRSADAPAYQ

• <u>T2A</u> • mCherry (SEQ ID NO:105)	QGGNQQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQE GLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD TYDALHMQALPPRGSGEGRGSLTTCGDVEENPGPMVSKGEEDN MAIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVT KGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWE RVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPDGPVMQK KTMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYK AKKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMD ELYK
A56-CAR-010 • <u>GM-CSFR Leader</u> • VL • <u>linker</u> • VH • <u>Extended CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ • <u>T2A</u> • mCherry (SEQ ID NO:106)	<u>MLLLVTSLLLCELPHPAFLIPDVVMTQTPSSVSEPVGGTVTIKQ</u> ASQSISDLLSWYQQKPGQPPKLLIYSASTLASGVSSRFKGS GSG TEFTLTISDLECAATAATYQCQNYSPYTYGNGFGGGTEVVVK<u>G</u> <u>STSGSGKPGSGEGSTKG</u>QSLEESGGDLVKPGASLTCTCTASGID FSDIYYISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKGRFTIS KASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM DLWG PGTLVTVSSGGGGSGGGGSGGGGSGGTTTTAPRPPTPAPT<u>IAS</u> <u>QPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLL</u> SLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEE <u>GGCEL</u>RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKR RGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGER RRGKGHDGLYQGLSTATKDTYDALHMQALPPRGSGEGRGSLT CGDVEENPGPMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEI EGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYV KHPADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGE FIYKVKLRGTNFPDGPVMQKKTMGWEASSERMYPEDGALKGEI KQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNE DYTIVEQYERAEGRHSTGGMD ELYK
B5-CAR-011 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u>	<u>MLLLVTSLLLCELPHPAFLIPQE</u>QLEESGGGLVKPEGSLTLTCT ASGFSFSSSYMCWVRQAPGRGLEWIACIYTSSGSAYYANWAK GRFTISRTSSTTVTLQMTRLTAADTATYFCVRNAVGS SYLYLW GPGTLVTVSSGSTSGSGKPGSGEGSTKGQVLTQTPSPVSAAVG GTVTISCQASQSVAGNNYLSWYQQKPGQPPNLLIYSVSTLASGV PSRFKGS GSGTQFTLTISDLECDAAATYQCQGYNDGIWAFGGG TEVVVKTTTTAPRPPTPAPT<u>IASQPLSLRPEACRPAAGGAVHTR</u> <u>GLDFACDIYIWAPLAGTCGVLLL</u>SLVITLYCKRGRKKLLYIFKQPF

• CD3ζ • T2A • mCherry (SEQ ID NO:107)	<u>MRPVQTTQEEDGCSCRFPEEEEEGGCEL</u>RVKFSRSADAPAYQQG QNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGL YNELQKDKMAEAYSEIGMKGERRRRGKGHGDLGYQGLSTATKDTY DALHMQALPPRGSGEGRGSLTTCGDVEENPGPMVSKGEEDNM AIIKEFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTK GGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWER VMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKK TMGWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKA KKPVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDE LYK
B5-CAR-019 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ • T2A • eGFP (SEQ ID NO:108)	<u>MLLLVTSLLLCELPHPAFLIP</u>QEQL EESGGGLVKPEGSLTLTCT ASGFSFSSSYMCWVRQAPGRGLEWIACIYTSSGSAYYANWAK GRFTISRTSSTTVTLQMTRLTAADTATYFCVRNAVGSYYLYLW GPGTLVTVSSGSTSGSGKPGSGEGSTKGQVLTQTPSPVSAAVG GTVTISCQASQSVAGNNYLSWYQQKPGQPPNLLIYSVSTLASGV PSRFKSGSGTQFTLTISDLECDAAATYYCQGYNDGIWAFGGG TEVVVKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTR GLDFACDIYIWAFLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPF <u>MRPVQTTQEEDGCSCRFPEEEEEGGCEL</u>RVKFSRSADAPAYQQG QNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGL YNELQKDKMAEAYSEIGMKGERRRRGKGHGDLGYQGLSTATKDTY DALHMQALPPRGSGEGRGSLTTCGDVEENPGPMVSKGEELFTG VVPILVELDGDVNGHKFSVSGEGEGDATYGKLTCLKFICTTGKLPVP WPTLVTTLTLYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFF KDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYN SHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDG PVLLPDNHYLSTQSALSKDPNEKRDHMLLEFVTAAGITLGMDEL YK
B5-CAR-013 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>Extended CD8 hinge</u> • CD8 transmembrane	<u>MLLLVTSLLLCELPHPAFLIP</u>QEQL EESGGGLVKPEGSLTLTCT ASGFSFSSSYMCWVRQAPGRGLEWIACIYTSSGSAYYANWAK GRFTISRTSSTTVTLQMTRLTAADTATYFCVRNAVGSYYLYLW GPGTLVTVSSGSTSGSGKPGSGEGSTKGQVLTQTPSPVSAAVG GTVTISCQASQSVAGNNYLSWYQQKPGQPPNLLIYSVSTLASGV PSRFKSGSGTQFTLTISDLECDAAATYYCQGYNDGIWAFGGG TEVVVKGGGGSGGGSGGGGGSGGTTTPAPRPPTPAPTIASQPL

• <u>4-1BB</u> • CD3ζ • <u>T2A</u> • mCherry (SEQ ID NO:109)	<u>SLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVI</u> <u>TLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGC</u> <u>ELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGR</u> <u>DPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRG</u> <u>KGHDGLYQGLSTATKDTYDALHMQALPPRGSGEGRGSLTTCGD</u> <u>VEENPGPMVSKGEEDNMAIIEKFMRFKVHMEGSVNGHEFEIEGE</u> GEGRPYEGTQTAKLKVTKGGLPFAWDILSPQFMYGSKAYVKHP ADIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK VKLRGTNFPDGPVMQKKTMGWEASSERMYPEDGALKGEIKQR LKLKDGGHYDAEVKTTYKAKKPVLPGAYNVNIKLDITSHNEDYTI VEQYERAEGRHSTGGMDELYK
B5-CAR-022 • <u>GM-CSFR Leader</u> • VH • <u>Linker</u> • VL • <u>CD28 hinge</u> • CD28 transmembrane • <u>4-1BB</u> • CD3ζ • <u>T2A</u> • mCherry (SEQ ID NO:110)	<u>MLLLVTSLLLCELPHPAFLIPQEQLLEESGGGLVKPEGSLTLTCT</u> ASGFSFSSSYMCWVRQAPGRGLEWIACIYTSSGSAYYANWAK GRFTISRTSSTTVTLQMTRLTAADTATYFCVRNAVGSYYLYLW GPGTLVTVSS<u>SGTSGSGKPGSGEGSTKGQVLTQTPSPVSAAVG</u> GTVTISCQASQSVAGNNYLSWYQQKPGQPPNLLIYVSTLASGV PSRFKSGSGTQFTLTISDLECDAAATYYCQGYNDGIWAFGGG TEVVVKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPFPGPSKP FWVLVVVGVLACYSLLVTVAFIIFWVKRGRKKLLYIFKQPFMRP <u>VQTTQEEDGCSCRFPEEEEEGGCEL</u>RVKFSRSADAPAYQQGQN QLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYN ELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDA <u>LHMQALPPRGSGEGRGSLTTCGD</u>VEENPGPMVSKGEEDNMAIIEK EFMRFKVHMEGSVNGHEFEIEGEGEGRPYEGTQTAKLKVTKGGLP LFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVMN FEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPDGPVMQKKTMG WEASSERMYPEDGALKGEIKRLKLKDGGHYDAEVKTTYKAKKP VQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELYK
B5-CAR-014 • <u>GM-CSFR Leader</u> • VL • <u>Linker</u> • VH • <u>CD8 hinge</u> • CD8 transmembrane	<u>MLLLVTSLLLCELPHPAFLIPQVLTQTPSPVSAAVGGTVTISCQA</u> SQSVAGNNYLSWYQQKPGQPPNLLIYVSTLASGVPSRFKSGS SGTQFTLTISDLECDAAATYYCQGYNDGIWAFGGGTEVVVKGS <u>TSGSGKPGSGEGSTKGQEQLLEESGGGLVKPEGSLTLTCT</u>ASGF SFSSSYMCWVRQAPGRGLEWIACIYTSSGSAYYANWAKGRFTI SRTSSTTVTLQMTRLTAADTATYFCVRNAVGSYYLYLWGPGLT VTVSS<u>TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRG</u>

• <u>4-1BB</u> • CD3ζ • <u>T2A</u> • mCherry (SEQ ID NO:111)	<u>LD</u><u>FACDIYWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFM</u> <u>RPVQTTQEEDGCSCRFPEEEEEGGCEL</u><u>RVKFSRSADAPAYQQGQ</u> NQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYD <u>ALHMQALPPRGSGEGRGSLLTCGDVEENPGPMVSKGEEDNMAI</u> KEFMRFKVHMEGSGVNGHEFEIEGEGEGRPEYEGTQTAKLKVTGG PLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPEGFKWERVM NFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPDGPVMQKKT GWEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKK PVQLPGAYNVNIKLDITSHNEDYTIVEQYERAEGRHSTGGMDELY K
B5-CAR-016 • <u>GM-CSFR Leader</u> • VL • <u>Linker</u> • VH • <u>Extended CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ • <u>T2A</u> • mCherry (SEQ ID NO:112)	<u>MLLLVTSLLLCELPHPAFLLIPQVLTQTPSPVSAAVGGT</u><u>VTISCQA</u> SQSVAGNNYLSWYQQKPGQPPNLLIYSVSTLASGVPSRFKGS SGTQFTLTISDLECDAAATYYCQGYNDGIWAFGGGTEVVVK<u>GS</u> <u>TSGSGKPGSGEGSTKGQEQL</u><u>EESGGGLVKPEGSLT</u><u>LTCTASGF</u> SFSSSYMCWVRQAPGRGLEWACIYTSSGSAYYANWAKGRFTI SRTSSTTVTLQMTRLTAADTATYFCVRNAVGSYYLYLWGP<u>GTL</u> VTVSSGGGGSGGGGSGGGGSGGTTTPAPRPPTPAPT<u>IASQPLS</u> <u>LRPEACRPAAGGAVHTRGLDFACDIYWAPLAGTCGVLLLSLVIT</u> <u>LYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEEGGCE</u> <u>L</u><u>RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRD</u> PEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGK GHDGLYQGLSTATKDTYDALHMQALPPRGSGEGRGSLLTCGDV <u>EENPGPMVSKGEEDNMAI</u>KEFMRFKVHMEGSGVNGHEFEIEGEG EGRPEYEGTQTAKLKVTGGPLPFAWDILSPQFMYGSKAYVKHPA DIPDYLKLSFPEGFKWERVMNFEDGGVVTVTQDSSLQDGEFIYK VKLRGTNFPDGPVMQKKTMGWEASSERMYPEDGALKGEIKQRL KLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNEDYTIV EQYERAEGRHSTGGMDELYK

In certain embodiments, provided are CARs comprising one or more murine CAR domains. Non-limiting examples of murine CAR domains that may be included in a CAR of the present disclosure include one or more of the murine CAR domains provided in Table 10 below. As will be appreciated by one of ordinary skill in the art, the amino acid sequence of one or more of the domains indicated in Table 10 (e.g., leader sequence, linker, hinge,

transmembrane, co-stimulatory, signaling, ribosomal skip element; restriction enzyme sequence; reporter protein; etc.) may be modified as desired.

Table 10 – Murine CAR Domain Amino Acid Sequences

Leader Signal Peptide(s)	
CD8 alpha (P01731) (SEQ ID NO:144)	MASPLTRFLSLNLLLLGESIILGSGEA
GM-CSFR alpha (Q00941) (SEQ ID NO:145)	MTSSHAMNITPLAQLALLFSTLLPGTQA
Hinge/Spacer/Linker domain(s)	
(SEQ ID NO:114)	GSTSGSGKPGSGEGSTKG
CD8 alpha Hinge (P01731) (SEQ ID NO:146)	TTKPVLRTSPVHPTGTSQPQRPEDCRPRGSVKGTGLDFACDIY
CD28 Hinge (P31041) (SEQ ID NO:147)	FCKIEFMYPYPYLDNERSNGTIIHIKEKHLCHTQSSPKL
Transmembrane domain(s)	
CD8 alpha TM (P01731) (SEQ ID NO:148)	IWAPLAGICVALLLSLIITL
CD8 alpha TM + 4aa (P01731) (SEQ ID NO:149)	IWAPLAGICVALLLSLIITLICYH
CD28 TM (P31041) (SEQ ID NO:150)	FWALVWVAGVLFYGLLVTVALCVIWT
Costimulatory domain(s)	
41BB (P20334) (SEQ ID NO:151)	KWIRKKFPHIFKQPFKKTGAAQEEDACSCRCPQEEEGGGGGYEL
CD28 (P31041) (SEQ ID NO:152)	NSRRNRLLQSDYMNMTPRRPGLTRKPYQPYAPARDFAAAYRP
CD3 ζ domain(s)	
CD3z (P24161) (SEQ ID NO:153)	RAKFSSRSAETAANLQDPNQLYNELNLGRREEYDVLEKKRARDPEM GGKQQRRRNPPQEGVYNALQKDKMAEAYSEIGTKGERRRGKMGHD GLYQGLSTATKDTYDALHMQTLAPR
Ribosomal Skip Element(s)	

T2A (SEQ ID NO:137)	GSGEGRGSLLTCGDVEENPGP
Reporter Protein(s)	
Thy1.1 (SEQ ID NO:154)	MNPAISVALLLSVLQVSRGQKVTSLTACLVNQNLRLDCRHENNTKD NSIQHEFSLTREKRKHVLSGTLGIPEHTYRSRVTLNQPYIKVLTLA NFTTKDEGDYFCELRVSGANPMSSNKSISVYRDKLVKCGGISLLVQ NTSWMLLLLLLSLSLLQALDFISL

According to some embodiments, provided are murine CARs comprising one or more murine CAR domains (e.g., one or more of any of the domains set forth in Table 10 above). Non-limiting examples of murine CARs of the present disclosure include those provided in Table 11 below. As will be appreciated by one of ordinary skill in the art, the amino acid sequence of one or more of the domains indicated in Table 11 (e.g., leader sequence, V_H, linker, V_L, hinge, transmembrane, co-stimulatory, signaling, ribosomal skip element, etc.) may be modified as desired. In Table 11, the CAR portion is shown in bold. Segments/domains of the polypeptides are indicated by alternating underlining, and the identities of the segments/domains are provided in the left column.

Table 11 – Murine CAR Amino Acid Sequences

B5-CAR-031	<u>MASPLTRFLSLNLLLLGESIILGSGEAQEQLEESGGGLVKPEGSL</u>
• <u>CD8 Leader</u>	<u>TLTCTASGFSFSSSYMCWVRQAPGRGLEWIACIYTSSGSAYYA</u>
• <u>VH</u>	<u>NWAKGRFTISRTSSTTVTLQMTRLTAADTATYFCVRNAVSSYY</u>
• <u>Linker</u>	<u>LYLWGPGLTVTVSSGSTSGSGKPGSGEGSTKGQVLTQTPSPVS</u>
• <u>VL</u>	<u>AAVGGTVTISCQASQSVAGNNYLSWYQQKPGQPPNLLIYSVSTL</u>
• <u>CD8 hinge</u>	<u>ASGVPSRFKSGSGGTQFTLTISDLECDDAATYYCQGYNDGIWA</u>
• <u>CD8 transmembrane</u>	<u>FGGGTEVVVKTKPVL RTPSPVHPTGTSQPQRPEDCRPRGSVK</u>
• <u>4-1BB</u>	<u>GTGLDFACDIYWAPLAGICVALLLSLIITLCYHKWIRKKFPHIFKQ</u>
• <u>CD3ζ</u>	<u>PFKKTTGAAQEEDACSCRCPQEEEGGGGGYELRAKFSSAETA</u>
• <u>T2A</u>	<u>ANLQDPNQLYNELNLGRREEYDVLEKKRARDPEMGGKQRRR</u>
• <u>Thy1.1</u>	<u>NPQEGVYNALQKDKMAEAYSEIGTKGERRRGKGHDGLYQGLST</u>
(SEQ ID NO:140)	<u>ATKDTYDALHMQTLAPRGSGEGRGSLLTCGDVEENPGPMNPAI</u> <u>SVALLSVLQVSRGQKVTSLTACLVNQNLRLDCRHENNTKD NSIQ</u> <u>HEFSLTREKRKHVLSGTLGIPEHTYRSRVTLNQPYIKVLTLANFT</u>

	TKDEGDYFCELRVSGANPMSSNKSISVYRDKLVKCGGISLLVQNT SWMLLLLLLSLSLLQALDFISL
B5-CAR-032 • <u>CD8 Leader</u> • VL • <u>Linker</u> • VH • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ • <u>T2A</u> • Thy1.1 (SEQ ID NO:141)	<u>MASPLTRFLSLNLLLLGESIILGSGEAQVLTQTPSPVSAAVGGTV</u> TISCQASQSVAGNNYLSWYQQKPGQPPNLLIYSVSTLASGVPSR FKSGSGGTQFTLTISDLECDAAATYYCQGYNDGIWAFGGGTEV VVKGSTSGSGKPGSGEGSTKGQEQLEESGGGLVKPEGSLLTLC TASGFSFSSSYMCWVRQAPGRGLEWIACIYTSSGSAYYANWA KGRFTISRTSSTTVTLQMTRLTAADTATYFCVRNAVGSYYLYL WPGTLVTVSSTTKPVL RTPSPVHPTGTSQPQRPEDCRPRGSV <u>KGTGLDFACDIYWAPLAGICVALLLSLIITLICYPHWIRKKFPHIFK</u> <u>QPFKKTGAAQEEDACSCRCPQEEEGGGGGYELRAKFSRSAET</u> AANLQDPNQLYNELNLGRREEYDVLEKKRARDPEMGGKQRR RNPQEGVYNALQKDKMAEAYSEIGTKGERRRGKGHDGLYQGL <u>STATKDTYDALHMQTLAPRGSGEGRGSLTTCGDVEENPGPMNP</u> AISVALLSVLQVSRGQKVTSLTACLVNQNLRLDCRHENNTKDNSI QHEFSLTREKRKHVLSGTLGIPEHTYRSRVTLNQPYIKVLTANF TTKDEGDYFCELRVSGANPMSSNKSISVYRDKLVKCGGISLLVQN TSWMLLLLLLSLSLLQALDFISL
A56-CAR-033 • <u>CD8 Leader</u> • VH • <u>Linker</u> • VL • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ • <u>T2A</u> • Thy1.1 (SEQ ID NO:142)	<u>MASPLTRFLSLNLLLLGESIILGSGEAQSL</u> EESSGGDLVKPGASLT LTCTASGIDFSDIYISWVRQAPGKGLEWIACTYAGSSGSTYYAT WAKGRFTISKASSTTVTLQMTSLTAADTATYFCARDRYPGTSGR VYGMDLWPGTLVTVSSGSTSGSGKPGSGEGSTKGVVMTQTP SSVSEPVGGTVTIKCQASQSIDLLSWYQQKPGQPPKLLIYSAST LASGVSSRFKSGSGGTEFTLTISDLECDAAATYYCQCNYYSPTY GNGFGGGTEVVVKTKPVL RTPSPVHPTGTSQPQRPEDCRPRG <u>SVKGTGLDFACDIYWAPLAGICVALLLSLIITLICYPHWIRKKFPHI</u> <u>FKQPFKKTGAAQEEDACSCRCPQEEEGGGGGYELRAKFSRS</u> AETAANLQDPNQLYNELNLGRREEYDVLEKKRARDPEMGGKQ QRRRNPNQEGVYNALQKDKMAEAYSEIGTKGERRRGKGHDGLY <u>QGLSTATKDTYDALHMQTLAPRGSGEGRGSLTTCGDVEENPGP</u> MNPAISVALLSVLQVSRGQKVTSLTACLVNQNLRLDCRHENNTK DNSIQHEFSLTREKRKHVLSGTLGIPEHTYRSRVTLNQPYIKVLT

	ANFTTKDEGDYFCELRVSGANPMSSNKSISVYRDKLVKCGGISLL VQNTSWMLLLLLLSLLQALDFISL
A56-CAR-034 • <u>CD8 Leader</u> • VL • <u>Linker</u> • VH • <u>CD8 hinge</u> • CD8 transmembrane • <u>4-1BB</u> • CD3ζ • <u>T2A</u> • Thy1.1 (SEQ ID NO:143)	<u>MASPLTRFLSLNLLLLGESIILGSGEAVVMTQTPSSVSEPVGTV</u> TIKCQASQSISDLLSWYQQKPGQPPKLLIYSASTLASGVSSRFKG SGSGTEFTLTISDLECADATYYCQCNYYSPTYGNGFGGGTEVV VKGSTSGSGKPGSGEGSTKGQSLEESGGDLVKPGASLTLTCTA SGIDFSDIYYISWVRQAPGKGLEWIACTYAGSSGSTYYATWAKG RFTISKASSTTVTLQMTSLTAADTATYFCARDRYPGTSGRVYGM DLWGPGLTVTVSSSTTKPVL RTPSPVHPTGTSQPQRPEDCRPRG <u>SVKGTGLDFACDIYIWAPLAGICVALLLSLIITLICYHKWIRKKFPHI</u> <u>FKQPFKKTGAAQEEDACSCRCPQEEEGGGGYELRAKFSRS</u> AETAANLQDPNQLYNELNLGRREEYDVLEKKRARDPEMGGKQ QRRRNPPQEGVYNALQKDKMAEAYSEIGTKGERRRGKGHDGLY QGLSTATKDTYDALHMQTLAPRGSGEGRGSLTTCGDVEENPGP MNPASVALLSVLQVSRGQKVTSLTACLNVNQLRLDCRHENNTK DNSIQHEFSLTREKRKHVLSGTLGIPEHTYRSRVTLNQPYIKVLT ANFTTKDEGDYFCELRVSGANPMSSNKSISVYRDKLVKCGGISLL VQNTSWMLLLLLLSLLQALDFISL

According to some embodiments, a CAR of the present disclosure is provided by a single polypeptide. In certain embodiments, a CAR of the present disclosure is provided by two or more polypeptides. When the CAR is provided by two or more polypeptides, the CAR may be provided in any useful multi-polypeptide format, including universal CAR formats such as biotin-binding immune receptor (BBIR) format (see, e.g., Urbanska K, Powell DJ. Development of a novel universal immune receptor for antigen targeting to infinity and beyond. *Oncoimmunology*. 2012;1(5):777-779. doi:10.4161/onci.19730, and Urbanska K, Lanitis E, Poussin M, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T cell antigen receptor. 2013;72(7):1844-1852. doi:10.1158/0008-5472.CAN-11-3890.A); a switchable CAR format with peptide NeoEpitope (PNE) (see, e.g., Kim et al. (2015) *J Am Chem Soc*. 2015;137(8):2832-2835; Ma et al. (2016) *Proc Natl Acad Sci* 113(4):E450-8; Rodgers et al. (2016) *Proc Natl Acad Sci*. 113(4):E459-E468; Viaud et al. (2018) *Proc Natl Acad Sci* 115(46):E10898-E10906); a SUPRA CAR format with leucine zippers (see, e.g., Cho et al. (2108) *Cell* 173(6):1426-1438.e11); a CAR-T Adapter Molecule

(CAM)-based format with FITC-folic acid (see, e.g., Lee et al. (2019) Cancer Res. 79(2):387-396; and Lu et al. (2019) Front Oncol. 9:151); anti-FITC-folic acid adaptor format (see, e.g., Chu et al. (2018) Biosci Trends. 12(3):298-308); anti-FITC antibody adaptor CAR format (see, e.g., Tamada et al. (2012) Clin Cancer Res. 18(23):6436-6445); Fc-targeting (e.g., anti-CD16) CAR + anti-tumor antibody format (see, e.g., Kudo et al. (2014) Cancer Res. 74(1):93-103); and the like.

Conjugates

The present disclosure also provides conjugates. According to some embodiments, a conjugate of the present disclosure comprises any of the antibodies or fusion proteins of the present disclosure, and an agent conjugated to the antibody or fusion protein. The term “conjugated” generally refers to a chemical linkage, either covalent or non-covalent, usually covalent, that proximally associates one molecule of interest with a second molecule of interest. In certain embodiments, the agent conjugated to the antibody or fusion protein is selected from a chemotherapeutic agent, a toxin, a radiation-sensitizing agent, a radioactive isotope (e.g., a therapeutic radioactive isotope), a detectable label, and a half-life extending moiety.

According to some embodiments, the agent is a therapeutic agent, e.g., a chemotherapeutic agent. Therapeutic agents of interest include agents capable of affecting the function of a cell/tissue to which the conjugate binds via specific binding of the antibody portion of the conjugate to the antigen. When the function of the cell/tissue is pathological, an agent that reduces the function of the cell/tissue may be employed. In certain aspects, a conjugate of the present disclosure includes an agent that reduces the function of a target cell/tissue by inhibiting cell proliferation and/or killing the cell/tissue. Such agents may vary and include cytostatic agents and cytotoxic agents, e.g., an agent capable of killing a target cell tissue with or without being internalized into a target cell.

In certain embodiments, the therapeutic agent is a cytotoxic agent selected from an enediyne, a lexitropsin, a duocarmycin, a taxane, a puromycin, a dolastatin, a maytansinoid, and a vinca alkaloid. In some embodiments, the cytotoxic agent is paclitaxel, docetaxel, CC-1065, CPT-11 (SN-38), topotecan, doxorubicin, morpholino-doxorubicin, rhizoxin, cyanomorpholino-doxorubicin, dolastatin-10, echinomycin, combretastatin, calicheamicin, maytansine, maytansine DM1, maytansine DM4, DM-1, an auristatin or other dolastatin

derivatives, such as auristatin E or auristatin F, AEB (AEB-071), AEVB (5-benzoylvaleric acid-AE ester), AEFP (antibody-endostatin fusion protein), MMAE (monomethylauristatin E), MMAF (monomethylauristatin F), pyrrolobenzodiazepines (PBDs), eleutherobin, netropsin, or any combination thereof.

5 According to some embodiments, the agent is a toxin, such as a protein toxin selected from hemiasterlin and hemiasterlin analogs such as HTI-286 (e.g., see USPN 7,579,323; WO 2004/026293; and USPN 8,129,407, the full disclosures of which are incorporated herein by reference), abrin, brucine, cicutoxin, diphtheria toxin, batrachotoxin, botulism toxin, shiga toxin, endotoxin, *Pseudomonas* exotoxin, *Pseudomonas* endotoxin, tetanus toxin, pertussis toxin, anthrax toxin, cholera toxin, falcarinol, fumonisin B1, fumonisin B2, aflatoxin, maurotoxin, agitoxin, charybdotoxin, margatoxin, slyotoxin, scyllatoxin, heparin, calciseptine, taicatoxin, calciclutidine, geldanamycin, gelonin, lotaustralin, ocratoxin A, patulin, ricin, strychnine, trichothecene, zearalenone, and tetradoxin. Enzymatically active toxins and fragments thereof which may be employed include diphtheria A chain, non-binding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, *Phytolacca americana* proteins (PAPI, PAPII, and PAP-S), *Momordica charantia* inhibitor, curcin, crotin, *Saponaire officinalis* inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the tricothecenes.

20 In certain embodiments, the agent is a radiation-sensitizing agent. As used herein, a "radiation-sensitizing agent" is an agent that enhances the ability of radiation to kill tumor cells. Non-limiting examples of radiation-sensitizing agents that may be conjugated to the antibody or fusion protein include cisplatin, 5-fluorouracil (5-FU), AZD7762, selumetinib, and the like.

25 In certain embodiments, the agent is a radioisotope, e.g., useful for therapy and/or detection (e.g., imaging). Non-limiting examples of radioisotopes that may be conjugated to the antibody or fusion protein include but are not limited to ^{225}Ac , ^{111}Ag , ^{114}Ag , ^{71}As , ^{72}As , ^{77}As , ^{211}At , ^{198}Au , ^{199}Au , ^{212}Bi , ^{213}Bi , ^{75}Br , ^{76}Br , ^{11}C , ^{13}C , ^{55}Co , ^{62}Cu , ^{64}Cu , ^{67}Cu , ^{165}Dy , ^{166}Dy , ^{169}Er , ^{18}F , ^{19}F , ^{52}Fe , ^{59}Fe , ^{66}Ga , ^{67}Ga , ^{68}Ga , ^{72}Ga , $^{154-158}\text{Gd}$, ^{157}Gd , ^{159}Gd , ^{166}Ho , ^{120}I , ^{121}I , ^{123}I , ^{124}I , ^{125}I , ^{131}I , ^{110}In , ^{111}In , $^{113\text{m}}\text{In}$, ^{194}Ir , $^{81\text{m}}\text{Kr}$, ^{177}Lu , ^{51}Mn , ^{52}Mn , ^{99}Mo , ^{13}N , ^{15}N , ^{15}O , ^{17}O , ^{32}P , ^{33}P , ^{211}Pb , ^{212}Pb , ^{109}Pd , ^{149}Pm , ^{151}Pm , ^{142}Pr , ^{143}Pr , ^{191}Pt , $^{193\text{m}}\text{Pt}$, $^{195\text{m}}\text{Pt}$, ^{223}Ra , ^{142}Rb , ^{186}Re , ^{188}Re ,

¹⁸⁹Re, ¹⁰⁵Rh, ⁴⁷Sc, ⁷⁵Se, ¹⁵³Sm, ^{117m}Sn, ¹²¹Sn, ⁸³Sr, ⁸⁹Sr, ¹⁶¹Tb, ⁹⁴Tc, ⁹⁹Tc, ^{99m}Tc, ²²⁷Th, ²⁰¹Tl, ¹⁷²Tm, ¹²⁷Te, ⁹⁰Y, ¹⁶⁹Yb, ¹⁷⁵Yb, ¹³³X, and ⁸⁹Zr.

In certain embodiments, a radioisotope is conjugated to the antibody or fusion protein via a chelator, for example, a bifunctional chelator. A bifunctional chelator may contain a metal chelating moiety that binds the radioisotope in a stable coordination complex and a reactive functional group that is covalently linked to a targeting moiety, such as any of the antibodies or fusion proteins of the present disclosure, so that the radioisotope may be properly directed to the desirable molecular target *in vivo*. Non-limiting examples of bifunctional chelators that may be employed to conjugate an antibody or fusion protein of the present disclosure to a radioisotope include p-SCN-Bn-DOTA and p-SCN-Bn-deferoxamine. Additional examples of bifunctional chelators that may be employed to conjugate an antibody or fusion protein of the present disclosure to a radioisotope include those described in Price & Orvig (2014) *Chem. Soc. Rev.* 43:260; and Brechbiel (2008) *Q J Nucl Med Mol Imaging* 52(2):166-173.

According to some embodiments, the radioisotope is a therapeutic radioisotope. In certain embodiments, the radioisotope is an alpha emitting radioisotope, e.g., ²²⁵Ac, ²¹¹At, ²¹²Bi/²¹²Pb, ²¹³Bi, ²²³Ra, or ²²⁷Th. In other embodiments, the radioisotope is a beta minus emitting radioisotope, e.g., ³²P, ³³P, ⁶⁷Cu, ⁹⁰Y, ¹³¹I or ¹⁷⁷Lu.

According to some embodiments, the agent is a labeling agent. By "labeling agent" (or "detectable label") is meant the agent detectably labels the antibody or fusion protein, such that the antibody or fusion protein may be detected in an application of interest (e.g., *in vitro* and/or *in vivo* research and/or clinical applications). Detectable labels of interest include radioisotopes (e.g., gamma or positron emitters), enzymes that generate a detectable product (e.g., horseradish peroxidase, alkaline phosphatase, luciferase, etc.), fluorescent proteins, paramagnetic atoms, and the like. In certain aspects, the antibody or fusion protein is conjugated to a specific binding partner of detectable label, e.g., conjugated to biotin such that detection may occur via a detectable label that includes avidin/streptavidin.

In certain embodiments, the agent is a labeling agent that finds use in *in vivo* imaging, such as near-infrared (NIR) optical imaging, single-photon emission computed tomography (SPECT) ± CT imaging, positron emission tomography (PET) ± CT imaging, nuclear magnetic resonance (NMR) spectroscopy, or the like. Labeling agents that find use in such applications include, but are not limited to, fluorescent labels, radioisotopes, and the like. In certain aspects, the labeling agent is a multi-modal *in vivo* imaging agent that permits *in vivo* imaging

using two or more imaging approaches (e.g., see Thorp-Greenwood and Coogan (2011) *Dalton Trans.* 40:6129-6143).

In certain embodiments, the labeling agent is an *in vivo* imaging agent that finds use in near-infrared (NIR) imaging applications. Such agents include, but are not limited to, a
5 Kodak X-SIGHT dye, Pz 247, DyLight 750 and 800 Fluors, Cy 5.5 and 7 Fluors, Alexa Fluor 680 and 750 Dyes, IRDye 680 and 800CW Fluors. According to some embodiments, the labeling agent is an *in vivo* imaging agent that finds use in SPECT imaging applications, non-limiting examples of which include ^{99m}Tc , ^{111}In , ^{123}I , ^{201}Tl , and ^{133}Xe . In certain embodiments, the labeling agent is an *in vivo* imaging agent that finds use in PET imaging applications, e.g.,
10 ^{11}C , ^{13}N , ^{15}O , ^{18}F , ^{64}Cu , ^{62}Cu , ^{124}I , ^{76}Br , ^{82}Rb , ^{68}Ga , or the like.

For half-life extension, the antibodies and fusion proteins of the present disclosure may be conjugated to an agent that provides for an improved pharmacokinetic profile (e.g., by PEGylation, hyperglycosylation, and the like). Modifications that can enhance serum half-life are of interest. A subject antibody or fusion protein may be “PEGylated”, as containing
15 one or more poly(ethylene glycol) (PEG) moieties. Methods and reagents suitable for PEGylation of a protein are well known in the art and may be found, e.g., in US Pat. No. 5,849,860. PEG suitable for conjugation to a protein is generally soluble in water at room temperature and has the general formula $\text{R}(\text{O}-\text{CH}_2-\text{CH}_2)_n\text{O}-\text{R}$, where R is hydrogen or a protective group such as an alkyl or an alkanol group, and where n is an integer from 1 to
20 1000. Where R is a protective group, it generally has from 1 to 8 carbons. The PEG conjugated to the subject antibody or fusion protein can be linear. The PEG conjugated to the subject antibody or fusion protein may also be branched. Branched PEG derivatives such as those described in U.S. Pat. No. 5,643,575, “star-PEGs” and multi-armed PEGs. Star PEGs are described in the art including, e.g., in U.S. Patent No. 6,046,305.

Where the subject antibody or fusion protein is to be isolated from a source, the
25 antibody or fusion protein may be conjugated to one or more moieties that facilitate purification, such as members of specific binding pairs, e.g., biotin (member of biotin-avidin specific binding pair), a lectin, and the like. The antibody can also be bound to (e.g., immobilized onto) a solid support, including, but not limited to, polystyrene plates or beads,
30 magnetic beads, test strips, membranes, and the like.

Where the antibodies or fusion proteins are to be detected in an assay, the antibodies or fusion proteins may contain a detectable label, e.g., a radioisotope (e.g., ^{89}Zr , ^{111}In , and

the like), an enzyme which generates a detectable product (e.g., luciferase, β -galactosidase, horse radish peroxidase, alkaline phosphatase, and the like), a fluorescent protein, a chromogenic protein, dye (e.g., fluorescein isothiocyanate, rhodamine, phycoerythrin, and the like); fluorescence emitting metals, e.g., ^{152}Eu , or others of the lanthanide series, attached to the protein through metal chelating groups such as EDTA; chemiluminescent compounds, e.g., luminol, isoluminol, acridinium salts, and the like; bioluminescent compounds, e.g., luciferin; fluorescent proteins; and the like. Indirect labels include antibodies specific for a subject protein, wherein the antibody may be detected via a secondary antibody; and members of specific binding pairs, e.g., biotin-avidin, and the like.

Any of the above agents may be conjugated to the antibody or fusion protein via a linker. If present, the linker molecule(s) may be of sufficient length to permit the antibody or fusion protein and the linked agent to allow some flexible movement between the antibody or fusion protein and the linked agent. Linker molecules may be, e.g., about 6-50 atoms long. Linker molecules may also be, e.g., aryl acetylene, ethylene glycol oligomers containing 2-10 monomer units, diamines, diacids, amino acids, or combinations thereof.

Where the linkers are peptides, the linkers can be of any suitable length, such as from 1 amino acid (e.g., Gly) to 20 or more amino acids, from 2 amino acids to 15 amino acids, from 3 amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acids to 9 amino acids, 6 amino acids to 8 amino acids, or 7 amino acids to 8 amino acids, and may be 1, 2, 3, 4, 5, 6, or 7 amino acids in length.

Flexible linkers include glycine polymers $(\text{G})_n$, glycine-serine polymers, glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art. Glycine and glycine-serine polymers may be used where relatively unstructured amino acids are of interest, and may serve as a neutral tether between components. The ordinarily skilled artisan will recognize that design of an antibody or fusion protein conjugated to any agents described above can include linkers that are all or partially flexible, such that the linker can include a flexible linker as well as one or more portions that confer a less flexible structure.

According to some embodiments, the antibody or fusion protein is conjugated to the agent via a non-cleavable linker. Non-cleavable linkers of interest include, but are not limited to, thioether linkers. An example of a thioether linker that may be employed includes a succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) linker.

In certain embodiments, the antibody is conjugated to the agent via a cleavable linker. According to some embodiments, the linker is a chemically-labile linker, such as an acid-cleavable linker that is stable at neutral pH (bloodstream pH 7.3-7.5) but undergoes hydrolysis upon internalization into the mildly acidic endosomes (pH 5.0-6.5) and lysosomes (pH 4.5-5.0) of a target cell (e.g., a cancer cell). Chemically-labile linkers include, but are not limited to, hydrazone-based linkers, oxime-based linkers, carbonate-based linkers, ester-based linkers, etc. In certain embodiments, the linker is an enzyme-labile linker, such as an enzyme-labile linker that is stable in the bloodstream but undergoes enzymatic cleavage upon internalization into a target cell, e.g., by a lysosomal protease (such as cathepsin or plasmin) in a lysosome of the target cell (e.g., a cancer cell). Enzyme-labile linkers include, but are not limited to, linkers that include peptidic bonds, e.g., dipeptide-based linkers such as valine-citrulline (VC) linkers, such as a maleimidocaproyl-valine-citrulline-*p*-aminobenzyl (MC-vc-PAB) linker, a valyl-alanyl-*para*-aminobenzyloxy (Val-Ala-PAB) linker, and the like. Chemically-labile linkers, enzyme-labile, and non-cleavable linkers are known and described in detail, e.g., in Ducry & Stump (2010) *Bioconjugate Chem.* 21:5-13; Nolting, B. (2013) *Methods Mol Biol.* 1045:71-100; Tsuchikama and An (2018) *Protein & Cell* 9(1):33-46; and elsewhere.

Numerous strategies are available for linking agents to an antibody or fusion protein directly, or indirectly via a linker. For example, the agent may be derivatized by covalently attaching a linker to the agent, where the linker has a functional group capable of reacting with a "chemical handle" on the antibody or fusion protein. The functional group on the linker may vary and may be selected based on compatibility with the chemical handle on the antibody or fusion protein. According to one embodiment, the chemical handle on the antibody or fusion protein is provided by incorporation of an unnatural amino acid having the chemical handle into the antibody or fusion protein. Unnatural amino acids which find use for preparing the conjugates of the present disclosure include those having a functional group selected from an azide, alkyne, alkene, amino-oxy, hydrazine, aldehyde (e.g., formylglycine, e.g., SMARTag™ technology from Catalent Pharma Solutions), nitron, nitrile oxide, cyclopropene, norbornene, iso-cyanide, aryl halide, and boronic acid functional group. Unnatural amino acids which may be incorporated into an antibody of a conjugate of the present disclosure, which unnatural amino acid may be selected to provide a functional group of interest, are known and described in, e.g., Maza et al. (2015) *Bioconjug. Chem.* 26(9):1884-

9; Patterson et al. (2014) *ACS Chem. Biol.* 9:592–605; Adumeau et al. (2016) *Mol. Imaging Biol.* (2):153-65; and elsewhere. An unnatural amino acid may be incorporated into an antibody or fusion protein via chemical synthesis or recombinant approaches, e.g., using a suitable orthogonal amino acyl tRNA synthetase-tRNA pair for incorporation of the unnatural amino acid during translation of the antibody or fusion protein in a host cell.

The functional group of an unnatural amino acid present in the antibody or fusion protein may be an azide, alkyne, alkene, amino-oxy, hydrazine, aldehyde, asaldehyde, nitron, nitrile oxide, cyclopropene, norbornene, iso-cyanide, aryl halide, boronic acid, diazo, tetrazine, tetrazole, quadrocyclane, iodobenzene, or other suitable functional group, and the functional group on the linker is selected to react with the functional group of the unnatural amino acid (or vice versa). As just one example, an azide-bearing unnatural amino acid (e.g., 5-azido-L-norvaline, or the like) may be incorporated into the antibody or fusion protein and the linker portion of a linker-agent moiety may include an alkyne functional group, such that the antibody or fusion protein and linker-agent moiety are covalently conjugated via azide-alkyne cycloaddition. Conjugation may be carried out using, e.g., a copper-catalyzed azide-alkyne cycloaddition reaction.

In certain embodiments, the chemical handle on the antibody or fusion protein does not involve an unnatural amino acid. An antibody containing no unnatural amino acids may be conjugated to the agent by utilizing, e.g., nucleophilic functional groups of the antibody or fusion protein (such as the N-terminal amine or the primary amine of lysine, or any other nucleophilic amino acid residue) as a nucleophile in a substitution reaction with a moiety bearing a reactive leaving group or other electrophilic group. An example would be to prepare an agent-linker moiety bearing an N-hydroxysuccinimidyl (NHS) ester and allow it to react with the antibody or fusion protein under aqueous conditions at elevated pH (~10) or in polar organic solvents such as DMSO with an added non-nucleophilic base, such as N,N-diisopropylethylamine.

It will be appreciated that the particular approach for attaching a linker, agent and/or antibody or fusion protein to each other may vary depending upon the particular linker, agent and/or antibody or fusion protein and functional groups selected and employed for conjugating the various components to each other.

Methods of Producing Antibodies

Using the information provided herein, the anti-VV A56 and anti-VV B5 antibodies and fusion proteins of the present disclosure may be prepared using standard techniques well known to those of skill in the art. For example, a nucleic acid sequence(s) encoding the amino acid sequence of an antibody or fusion protein of the present disclosure can be used to express the antibodies or fusion proteins. The polypeptide sequences provided herein (see, e.g., Tables 1, 3, 5-11) can be used to determine appropriate nucleic acid sequences encoding the antibodies or fusion proteins and the nucleic acids sequences then used to express one or more antibodies or fusion proteins specific for VV A56 or VV B5. The nucleic acid sequence(s) can be optimized to reflect particular codon "preferences" for various expression systems according to standard methods well known to those of skill in the art. Using the sequence information provided, the nucleic acids may be synthesized according to a number of standard methods known to those of skill in the art.

Once a nucleic acid(s) encoding a subject antibody is synthesized, it can be amplified and/or cloned according to standard methods. Molecular cloning techniques to achieve these ends are known in the art. A wide variety of cloning and *in vitro* amplification methods suitable for the construction of recombinant nucleic acids are known to persons of skill in the art and are the subjects of numerous textbooks and laboratory manuals.

Expression of natural or synthetic nucleic acids encoding the antibodies and fusion proteins of the present disclosure can be achieved by operably linking a nucleic acid encoding the antibody or fusion protein to a promoter (which is either constitutive or inducible), and incorporating the construct into an expression vector to generate a recombinant expression vector. The vectors can be suitable for replication and integration in prokaryotes, eukaryotes, or both. Typical cloning vectors contain functionally appropriately oriented transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the nucleic acid encoding the antibody. The vectors optionally contain generic expression cassettes containing at least one independent terminator sequence, sequences permitting replication of the cassette in both eukaryotes and prokaryotes, e.g., as found in shuttle vectors, and selection markers for both prokaryotic and eukaryotic systems.

To obtain high levels of expression of a cloned nucleic acid it is common to construct expression plasmids which typically contain a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator,

each in functional orientation to each other and to the protein-encoding sequence. Examples of regulatory regions suitable for this purpose in *E. coli* are the promoter and operator region of the *E. coli* tryptophan biosynthetic pathway, the leftward promoter of phage lambda (P_L), and the L-arabinose (*araBAD*) operon. The inclusion of selection markers in DNA vectors transformed in *E. coli* is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol. Expression systems for expressing antibodies are available using, for example, *E. coli*, *Bacillus sp.* and *Salmonella*. *E. coli* systems may also be used.

The antibody gene(s) may also be subcloned into an expression vector that allows for the addition of a tag (e.g., FLAG, hexahistidine, and the like) at the C-terminal end or the N-terminal end of the antibody (e.g., IgG, Fab, scFv, etc.) to facilitate purification. Methods of transfecting and expressing genes in mammalian cells are known in the art. Transducing cells with nucleic acids can involve, for example, incubating lipidic microparticles containing nucleic acids with cells or incubating viral vectors containing nucleic acids with cells within the host range of the vector. The culture of cells used in the present disclosure, including cell lines and cultured cells from tissue (e.g., tumor) or blood samples is well known in the art.

Once the nucleic acid encoding a subject antibody is isolated and cloned, one can express the nucleic acid in a variety of recombinantly engineered cells known to those of skill in the art. Examples of such cells include bacteria, yeast, filamentous fungi, insect (e.g. those employing baculoviral vectors), and mammalian cells.

Isolation and purification of a subject antibody can be accomplished according to methods known in the art. For example, a protein can be isolated from a lysate of cells genetically modified to express the protein constitutively and/or upon induction, or from a synthetic reaction mixture, by immunoaffinity purification (or precipitation using Protein L or A), washing to remove non-specifically bound material, and eluting the specifically bound antibody. The isolated antibody can be further purified by dialysis and other methods normally employed in protein purification methods. In one embodiment, the antibody may be isolated using metal chelate chromatography methods. Antibodies of the present disclosure may contain modifications to facilitate isolation, as discussed above.

The antibodies may be prepared in substantially pure or isolated form (e.g., free from other polypeptides). The protein can be present in a composition that is enriched for the polypeptide relative to other components that may be present (e.g., other polypeptides or

other host cell components). Purified antibodies may be provided such that the antibody is present in a composition that is substantially free of other expressed proteins, e.g., less than 90%, usually less than 60% and more usually less than 50% of the composition is made up of other expressed proteins.

5 The antibodies produced by prokaryotic cells may require exposure to chaotropic agents for proper folding. During purification from *E. coli*, for example, the expressed protein can be optionally denatured and then renatured. This can be accomplished, e.g., by solubilizing the bacterially produced antibodies in a chaotropic agent such as guanidine HCl. The antibody is then renatured, either by slow dialysis or by gel filtration. Alternatively, nucleic
10 acid encoding the antibodies may be operably linked to a secretion signal sequence such as *pelB* so that the antibodies are secreted into the periplasm in correctly-folded form.

 The present disclosure also provides cells that produce the antibodies of the present disclosure, where suitable cells include eukaryotic cells, e.g., mammalian cells. The cells can be a hybrid cell or “hybridoma” that is capable of reproducing antibodies *in vitro* (e.g.
15 monoclonal antibodies, such as IgG). For example, the present disclosure provides a recombinant host cell (also referred to herein as a “genetically modified host cell”) that is genetically modified with one or more nucleic acids comprising a nucleotide sequence encoding a heavy and/or light chain of an antibody of the present disclosure.

 Techniques for creating recombinant DNA versions of the antigen-binding regions of
20 antibody molecules which bypass the generation of hybridomas are also contemplated herein. DNA is cloned into a bacterial (e.g., bacteriophage), yeast (e.g. *Saccharomyces* or *Pichia*), insect or mammalian expression system, for example. One example of a suitable technique uses a bacteriophage lambda vector system having a leader sequence that causes the expressed antibody (e.g. Fab or scFv) to migrate to the periplasmic space (between the
25 bacterial cell membrane and the cell wall) or to be secreted. One can rapidly generate great numbers of functional fragments (e.g. Fab or scFv) for those which bind the antigen of interest.

 Antibodies that specifically bind VV A56 and VV B5 can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, phage
30 display technologies, Selected Lymphocyte Antibody Method (SLAM) (1), or a combination thereof. For example, an antibody may be made and isolated using methods of phage display. Phage display is used for the high-throughput screening of protein interactions. Phages may

be utilized to display antigen-binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds VV A56 or VV B5 can be selected or identified with VV A56 or VV B5, e.g., using labeled VV A56 or VV B5 bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv (individual Fv region from light or heavy chains) or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. The production of high affinity human antibodies by chain shuffling is known, as are combinatorial infection and *in vivo* recombination as a strategy for constructing large phage libraries. In another embodiment, ribosomal display can be used to replace bacteriophage as the display platform. Cell surface libraries may be screened for antibodies. Such procedures provide alternatives to traditional hybridoma techniques for the isolation and subsequent cloning of monoclonal antibodies.

After phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria. For example, techniques to recombinantly produce Fv, scFv, Fab, F(ab')₂, and Fab' fragments may be employed using methods known in the art.

Nucleic Acids, Expression Vectors and Cells

In view of the section above regarding methods of producing the antibodies and fusion proteins of the present disclosure, it will be appreciated that the present disclosure also provides nucleic acids, expression vectors and cells.

In certain embodiments, provided is a nucleic acid encoding a variable heavy chain (V_H) polypeptide, a variable light chain (V_L) polypeptide, or both, of an antibody or fusion protein of the present disclosure, including any of the anti-VV A56 and anti-VV B5 antibodies of the present disclosure, e.g., any of such antibodies described hereinabove. According to some embodiments, the antibody is a single chain antibody (e.g., an scFv), and the nucleic acid encodes the single chain antibody.

According to some embodiments, provided are nucleic acids that encode the variable heavy chain (V_H) polypeptide, the variable light chain (V_L) polypeptide, or both, of the anti-VV A56 antibodies A047/A057, A049/A059/A056, A050, or A054. Examples of such nucleotide

sequences are provided in Table 12 below. Sequences that encode framework regions and CDRs are shown in upper case and lower case, respectively.

Table 12 – Nucleotide Sequences Encoding Example Anti-VV A56 Antibodies

A047/A057 V _H (SEQ ID NO:50)	CAGGAGCAACTGGAGGAGTCCGGGGGAGACCTGGTCAAGCC TGAGGGATCCCTGACACTCACCTGCACAGCCTCTGGATTCTC CTTCAGTagcagctactggatatgcTGGGTCCGCCAGGCTCCAGGGA AGGGGCTGGAGTGGATCGCAtgcatattatgctggtagtggtgtagcacttact acgcgacctgggcgaaaggcCGATTCACCATCTCCAAAACCTCGTCGA CCACGGTGACTCTGCAAATGACCAGTCTGACAGCCGCGGACA CGGCCAGCTATTTCTGTGTCCGCgcatatagtgatagaagtgggtggttactc atttaatttgTGGGGCCCAGGCACCCTGGTCACCGTCTCTTCA
A047/A057 V _L (SEQ ID NO:51)	CAAGTGCTGACCCAGACTGCATCCCCCGTGTCTGCGGCTGTT GGAGGCACAGTCACCATCAATTGCcaggccagtcagagtgttgataataa caactacttagccTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAA CAACTGATCTATtctgcatccagctctggcatctGGGGTCCCATCGCGGTT CAAAGGCAGTGGATCTGGGACACAGTTCACCTCTCACCATCAG CGACGTGCAGTGTGACGATGCTGCCACTTACTACTGTctaggca gttatgattgtagtgatgctgattgttatgctTTCGGCGGAGGGACCGAGGTGG TGGTCAAA
A049/A059/A056 V _H (SEQ ID NO:52)	CAGTCCTTGGAGGAGTCCGGGGGAGACCTGGTCAAGCCTGG GGCATCCCTGACACTCACCTGCACAGCCTCTGGAATCGACTT CAGTgacatttattacatatctTGGGTCCGCCAGGCTCCAGGGAAGGG GCTGGAGTGGATCGCAtgcaacttatgctggttagtagtgtagcacttactacgcg acctgggcgaaaggcCGATTCACCATCTCCAAAGCCTCGTCGACCA CGGTGACTCTGCAAATGACCAGTCTGACAGCCGCGGACACG GCCACCTATTTCTGTGCGAGAgatcggttatcctggtactagtggttaggggtctac ggcatggacctcTGGGGCCCAGGGACCCTCGTCACCGTCTCTTCA
A049/A059/A056 V _L (SEQ ID NO:53)	GTTGTGATGACCCAGACTCCATCCTCCGTGTCTGAACCTGTG GGAGGCACAGTCACCATCAAGTGcaggccagtcagagcattagcgacc tcttatccTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCC TGATCTATtctgcatccactctggcatctGGGGTCTCATCGCGGTTCAAA GGCAGTGGATCTGGGACAGAATTCACCTCTCACCATCAGCGAC CTGGAGTGTGCCGATGCTGCCACTTACTACTGTcaatgtaattattat

	agtcctacttatgggaatgggTTCGGCGGAGGGACCGAGGTGGTGGTCA AA
A050 V _H (SEQ ID NO:54)	CAGTCATTGGAGGAGTCCGGGGGAGACCTGGTCAAGCCTGG GGCATCCCTGACACTCACCTGCACAGCCTCTGGATTCTCCTT CAGTagcagctattggctatgcTGGGCCCCGCCAGGCTCCAGGGAAGG GGCCTGAGTGGATCGCAtgcatttataatggatggcagcacacactacgcga gctgggcgaaaggcCGATTACCATCTCCAAATCCTCGTCGACCAC GGTGACTCTGCAAATGACCAGTCTGACAGCCGCGGACACGG CCACCTATTTCTGTGCGAGAgattatactataattttatacttatggtttaatttg TGGGGCCCAGGCACCCTGGTCACCGTCTCTTCA
A050 V _L (SEQ ID NO:55)	TTCGAATTGACCCAGACTCCATCCTCCGTGGAGGCAGCTGTG GGAGGCACAGTCACCATCAACTGCCaggccagtcagagcgtgaatatttg ggcatccTGGTACCAGCAGAAACCAGGGCAGCCTCCCAAGCTCC TGATCTACaaggcatccactctggcatctGGGGTCCCATCGCGGTTCAA AGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCGA CCTGGAGTGTGCCGATGCTGCCACTTACTACTGTcaaggcggttat cctagtagtagtagtggtgggctTTCGGCGGAGGGACCGAGGTGGTGGT CAAA
A054 V _H (SEQ ID NO:56)	CAGGAGCAGGTGGTGGAGTCCGGGGGAGGCCTGGTCAAGCC TGGGGCATCCCTGACACTCACCTGCACAGCCTCTGGATTCAC CCTCAGTagtagttattggatgcTGGGTCCGCCAGGCTCCAGGGAA GGGGCCTGAGTGGATCGCAtgcatctataatggatggcagcacacactac gcgagctgggcgaaaggcCGATTACCATCTCCAAATCCTCGTCGAC CACGGTGACTCTGCAAATGACCAGTCTGACAGCCGCGGACAC GGCCACCTATTTCTGTGCGAGAgattatactgatgcttttatacttatggtttaa ttgTGGGGCCCAGGCACCCTGGTCACCGTCTCTTCA
A054 V _L (SEQ ID NO:57)	GACATTGTGATGACCCAGACTCCAGCCTCCGTGTCTGAACCT GTGGGAGGCACAGTCACCATCAAGTGCCaggccagtcagagcactagt agctacttagccTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGC TCCTGATCTACagggcatccagtcctggcatctGGGGTCCCATCGCGGTT CAAAGGCAGTGGATCTGCGACAGAGTTCACTCTCACCATCAG CGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTcaaactg gttttatggtagtagtgggcactactTTCGGCGGAGGGACCGAGGTGGTGG TCAAA

A56-CAR-01 V _L (SEQ ID NO:186)	GACGTTGTAATGACTCAGACGCCATCCTCCGTTAGCGAACCA GTCGGAGGTACAGTGACCATAAAGTGCcaagcctctcagtctatatctga cctgttgagtTGGTATCAACAGAAACCGGGACAACCCCCAAAGTTG CTCATCTACtctgctcaacactcgcatcaGGCGTCTCAAGCAGATTCA AAGGGAGTGGGTCCGGTACGGAATTTACTCTTACCATAAGTG ACCTTGAGTGCGCTGACGCTGCTACTTATTATTGcagtgtaactac tattctccgacctacggaaatgggTTCGGAGGCGGAACTGAGGTAGTGG TTAAAAAG
A56-CAR-029 V _L (SEQ ID NO:187)	GACGTTGTAATGACTCAGACGCCATCCTCCGTTAGCGAACCA GTCGGAGGTACAGTGACCATAAAGTGCcaagcctctcagtctatatctga cctgttgagtTGGTATCAACAGAAACCGGGACAACCCCCAAAGTTG CTCATCTACtctgctcaacactcgcatcaGGCGTCTCAAGCAGATTCA AAGGGAGTGGGTCCGGTACGGAATTTACTCTTACCATAAGTG ACCTTGAGTGCGCTGACGCTGCTACTTATTATTGcagtgtaactac tattctccgacctacggaaatgggTTCGGAGGCGGAACTGAGGTAGTGG TTAAA

According to some embodiments, provided are nucleic acids that encode the variable heavy chain (V_H) polypeptide, the variable light chain (V_L) polypeptide, or both, of the anti-VV B5 antibodies A048/A058/A073 or A051. Examples of such nucleotide sequences are provided in Table 13 below. Sequences that encode framework regions and CDRs are shown in upper case and lower case, respectively.

Table 13 – Nucleotide Sequences Encoding Example Anti-VV B5 Antibodies

A048/A058/A073 V _H (SEQ ID NO:58)	CAGGAGCAGCTGGAGGAGTCCGGGGGAGGCCTGGTCAAGCC TGAGGGATCCCTGACACTCACCTGCACAGCTTCTGGATTCTC CTTCAGTagcagctactacatgtgcTGGGTCCGCCAGGCTCCAGGGA GGGGGCTGGAGTGGATCGCAtgcatattatactagtagtggtagcgttactacg cgaactgggcgaaaggcCGATTACCATCTCCAGAACCTCGTCGACC ACGGTGACTCTGCAAATGACCCGTCTGACAGCCGCGGACACG GCCACCTATTTCTGTGTGAGAAacgctgttgggagtagttattttgtattgT GGGGCCCAGGCACCCTGGTCACCGTCTCCTCA
A048/A058/A073 V _L (SEQ ID NO:59)	CAAGTGCTGACCCAGACTCCATCCCCTGTGTCTGCAGCTGTG GGAGGCACAGTCACCATCAGTTGCcaggccagtcagagtgttgctggttaa

	caactacttatccTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAC CTCTTGATCTATtctgtatccactctggcctctGGGGTCCCATCGCGGTT CAAAGGCAGTGGATCTGGGACACAGTTCACCTCTCACCATCAG CGACCTGGAGTGTGACGATGCTGCCACTTACTACTGTcaaggct attataatgatggaatttgggctTTCGGCGGAGGGACCGAGGTGGTGGTC AAA
A051 V _H (SEQ ID NO:60)	CAGGAGCAGGTGGAGGAGTCCGGGGGAGGCCTGGCCAAGC CTGGGGCATCTTTGACACTCACCTGCGAAGCCTCTGGATTCA CCCTCAGTagttactggatgtgcTGGGTCCGCCAGGCTCCAGGGAAG GGGCTGGAGTGGATCGCATgcatttatggtgggagtagtgtagcacttactact cgaactgggcgaaaggcCGATTCACCATCTCCAAAACCTCGTCGACC ACGGTGACTCTGCAAATGACCAGTCTGACAGCCGCGGACACG GCCACCTATTTCTGTGCGAGAgatggtagtacctgggactactttaggttgTG GGGCCCAGGCACCCTGGTCACCGTCTCTTCA
A051 V _L (SEQ ID NO:61)	TATGATATGACCCAGACTCCATCCTCCGTGGAGGCAGCTGTG GGAGGCACAGTCACCATCAAGTGccaggccagtcagagtattaataactaa ctacttatccTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTC CTGATCTACcaggcatccactctggaatctGGGGTCCCATCGCGGTTCA AAGGCAGTGGATCTGGGACAGAGTACACTCTCACCATCAGCG ACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTcaaggctattat actgttgagaatattggaatcctTTCGGCGGAGGGACCGAGGTGGTGGT CAAA

According to some embodiments, provided is a nucleic acid that encodes a CAR of the present disclosure, e.g., a CAR comprising: a single chain antibody comprising a V_H polypeptide and a V_L polypeptide of an anti-VV A56 or anti-VV B5 antibody of the present disclosure; a transmembrane domain; and an intracellular signaling domain. Examples of such single chain antibodies, transmembrane domains, and intracellular signaling domains are described in detail above.

An example nucleotide sequence that encodes A56-CAR-01 described herein is set forth in SEQ ID NO:155. An example nucleotide sequence that encodes A56-CAR-02 described herein is set forth in SEQ ID NO:156. An example nucleotide sequence that encodes A56-CAR-05 described herein is set forth in SEQ ID NO:157. An example nucleotide sequence that encodes A56-CAR-06 described herein is set forth in SEQ ID NO:158. An

example nucleotide sequence that encodes A56-CAR-07 described herein is set forth in SEQ ID NO:159. An example nucleotide sequence that encodes A56-CAR-08 described herein is set forth in SEQ ID NO:160. An example nucleotide sequence that encodes A56-CAR-010 described herein is set forth in SEQ ID NO:161. An example nucleotide sequence that encodes A56-CAR-020 described herein is set forth in SEQ ID NO:162. An example nucleotide sequence that encodes A56-CAR-021 described herein is set forth in SEQ ID NO:163. An example nucleotide sequence that encodes A56-CAR-027 described herein is set forth in SEQ ID NO:164. An example nucleotide sequence that encodes A56-CAR-028 described herein is set forth in SEQ ID NO:165. An example nucleotide sequence that encodes A56-CAR-029 described herein is set forth in SEQ ID NO:166. An example nucleotide sequence that encodes A56-CAR-030 described herein is set forth in SEQ ID NO:167. An example nucleotide sequence that encodes B5-CAR-03 described herein is set forth in SEQ ID NO:168. An example nucleotide sequence that encodes B5-CAR-04 described herein is set forth in SEQ ID NO:169. An example nucleotide sequence that encodes B5-CAR-011 described herein is set forth in SEQ ID NO:170. An example nucleotide sequence that encodes B5-CAR-013 described herein is set forth in SEQ ID NO:171. An example nucleotide sequence that encodes B5-CAR-014 described herein is set forth in SEQ ID NO:172. An example nucleotide sequence that encodes B5-CAR-016 described herein is set forth in SEQ ID NO:173. An example nucleotide sequence that encodes B5-CAR-019 described herein is set forth in SEQ ID NO:174. An example nucleotide sequence that encodes B5-CAR-022 described herein is set forth in SEQ ID NO:175. Examples of nucleotide sequences that encode the murine CARs provided in Table 11 are set forth in SEQ ID NOs:176-179.

Also provided are expression vectors comprising any of the nucleic acids of the present disclosure. Expression of natural or synthetic nucleic acids encoding the antibodies and fusion proteins of the present disclosure can be achieved by operably linking a nucleic acid encoding the antibody or fusion protein to a promoter (which is either constitutive or inducible) and incorporating the construct into an expression vector to generate a recombinant expression vector. The vectors can be suitable for replication and integration in prokaryotes, eukaryotes, or both. Typical cloning vectors contain functionally appropriately oriented transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the nucleic acid encoding the antibody. The vectors

optionally contain generic expression cassettes containing at least one independent terminator sequence, sequences permitting replication of the cassette in both eukaryotes and prokaryotes, e.g., as found in shuttle vectors, and selection markers for both prokaryotic and eukaryotic systems.

5 Cells that comprise any of the nucleic acids and/or expression vectors of the present disclosure are also provided. According to some embodiments, a cell of the present disclosure includes a nucleic acid that encodes the V_H polypeptide of the antibody and the V_L polypeptide of the antibody. In certain such embodiments, the antibody is a single chain antibody (e.g., an scFv), and the nucleic acid encodes the single chain antibody. According
10 to some embodiments, provided is a cell comprising a first nucleic acid encoding a variable heavy chain (V_H) polypeptide of an antibody of the present disclosure, and a second nucleic acid encoding a variable light chain (V_L) polypeptide of the antibody. In certain embodiments, such as cell comprises a first expression vector comprising the first nucleic acid, and a second expression vector comprising the second nucleic acid.

15 Also provided are methods of making an antibody or fusion protein of the present disclosure, the methods including culturing a cell of the present disclosure under conditions suitable for the cell to express the antibody or fusion protein, wherein the antibody or fusion protein is produced. The conditions for culturing the cell such that the antibody or fusion protein is expressed may vary. Such conditions may include culturing the cell in a suitable
20 container (e.g., a cell culture plate or well thereof), in suitable medium (e.g., cell culture medium, such as DMEM, RPMI, MEM, IMDM, DMEM/F-12, or the like) at a suitable temperature (e.g., 32°C - 42°C, such as 37°C) and pH (e.g., pH 7.0 - 7.7, such as pH 7.4) in an environment having a suitable percentage of CO₂, e.g., 3% to 10%, such as 5%).

Chimeric Antigen Receptors that Bind Oncolytic Virus Antigens

25 In addition to the chimeric antigen receptors (CARs) of the present disclosure described in the Fusion Protein section above, aspects of the present disclosure further include anti-oncolytic virus antigen CARs. In certain embodiments, such a CAR comprises an antigen binding domain that specifically binds an oncolytic virus (OV) antigen, a transmembrane domain, and an intracellular signaling domain. Such CARs find a variety of
30 uses. For example, with the benefit of the present disclosure, it will be appreciated that such CARs find use in methods that comprise administering a pharmaceutical composition

comprising an anti-OV antigen CAR to an individual having cancer, wherein cancer cells in the individual are infected with OV and express the OV antigen on their surface, thereby targeting the CAR to the cancer cells to treat the individual's cancer.

5 As used herein, an "oncolytic virus antigen" or "OV antigen" is an antigen encoded by the genome of an oncolytic virus (OV). In some embodiments, the OV antigen is a native OV antigen, whereby "native" is meant the antigen is a protein encoded by the wild-type genome of the OV.

10 In some embodiments, the OV antigen is an antigen encoded by the wild-type genome of a virus from the Poxviridae, Herpesviridae, Adenoviridae, Paramyxoviridae, Rhabdoviridae, Reoviridae, Picornaviridae, Parvoviridae, or Coronaviridae family of viruses. Such an OV antigen may be native or heterologous to the OV.

15 In certain embodiments, the OV antigen is an antigen encoded by the wild-type genome of a virus from a family set forth in Table 14 below, where Table 14 further includes non-limiting examples of virus species/strains within such families as well as non-limiting examples of such antigens.

Table 14 – Example OV Antigens

Family	Virus Species and/or Strain	Genome	Example Antigens
Poxviridae	Vaccinia Virus	dsDNA	A33, A34, A36, A56, B5, F12, F13
Herpesviridae	Herpes simplex virus type 1/2	dsDNA	gB, gC, gD, gH, gL
Adenoviridae	Adenovirus	dsDNA	Fiber, Penton, Hexon, IX, IIIa, VI, VII
Paramyxoviridae	Measles	ssRNA (-)	Hemagglutinin glycoprotein, Fusion glycoprotein
	Newcastle Disease Virus	ssRNA (-)	Hemagglutinin-neuraminidase, Fusion glycoprotein
Rhabdoviridae	Vesicular stomatitis virus	ssRNA (-)	Glycoprotein G
	Maraba	ssRNA (-)	Glycoprotein G
Reoviridae	Reovirus	dsRNA	$\mu 1$, $\sigma 3$, $\sigma 1$, $\lambda 2$, $\lambda 1$
Picornaviridae	Seneca Valley Virus	ssRNA (+)	VP1, VP2, VP3, VP4
	Poliovirus	ssRNA (+)	VP1, VP2, VP3, VP4
	Coxsackievirus	ssRNA (+)	VP1, VP2, VP3, VP4
Parvoviridae	Human Parvovirus	ssDNA	VP2, VP1
Coronaviridae	SARS coronavirus 2	ssRNA (+)	Spike (S), Envelope (E), Nucleoprotein(N), Membrane (M), ORF3a, ORF7a

According to some embodiments, the OV antigen is an antigen encoded by the wild-type genome of a virus from the Poxviridae family selected from Amsacta moorei entomopoxvirus, Chironomus luridus entomopoxvirus, Fowlpox virus, Melolontha melolontha entomopoxvirus, Mollusca contagiosum virus, Mule deerpox virus, Myxoma virus, Nile crocodilepox virus, Orf virus, Sheeppox virus, Swinepox virus, Vaccinia virus, Yaba monkey tumor virus, Yokapox virus, Acrobasis zelleri entomopoxvirus, Adoxophyes honmai

entomopoxvirus, *Aedes aegypti* entomopoxvirus, *Anomala cuprea* entomopoxvirus, *Aphodius tasmaniae* entomopoxvirus, *Arphia conspersa* entomopoxvirus, Bovine papular stomatitis virus, Camelpox virus, *Camptochironomus tentans* entomopoxvirus, Canarypox virus, *Chironomus attenuatus* entomopoxvirus, *Chironomus plumosus* entomopoxvirus, 5 *Choristoneura biennis* entomopoxvirus, *Choristoneura conflictata* entomopoxvirus, *Choristoneura diversum* entomopoxvirus, *Choristoneura fumiferana* entomopoxvirus, *Choristoneura rosaceana* entomopoxvirus, *Chorizagrotis auxiliaris* entomopoxvirus, Cowpox virus, *Demodema bonariensis* entomopoxvirus, *Dermolepida albobirtum* entomopoxvirus, *Diachasmimorpha* entomopoxvirus, *Ectromelia* virus, *Figulus sublaevis* entomopoxvirus, 10 *Geotrupes sylvaticus* entomopoxvirus, Goatpox virus, *Goeldichironomus holoprasinus* entomopoxvirus, Hare fibroma virus, *Heliothis armigera* entomopoxvirus, Juncopox virus, *Locusta migratoria* entomopoxvirus, Lumpy skin disease virus, *Melanoplus sanguinipes* entomopoxvirus, Monkeypox virus, Mynahpox virus, *Mythimna separata* entomopoxvirus, *Oedaleus senegalensis* entomopoxvirus, *Operophtera brumata* entomopoxvirus, 15 Parapoxvirus of red deer in New Zealand, Pigeonpox virus, Pseudocowpox virus, Psittacinepox virus, Pteropox virus, Quailpox virus, Rabbit fibroma virus, Raccoonpox virus, *Schistocerca gregaria* entomopoxvirus, Skunkpox virus, Sparrowpox virus, Squirrel fibroma virus, Squirrelepox virus, Starlingpox virus, Tanapox virus, Taterapox virus, Turkeypox virus, Variola virus, and Volepox virus. Such an OV antigen may be native or heterologous to the 20 OV.

In certain embodiments, the OV antigen is an antigen encoded by the wild-type genome of a virus from the Herpesviridae family selected from Gallid alphaherpesvirus 1, Psittacid alphaherpesvirus 1, Gallid alphaherpesvirus 2, Anatid alphaherpesvirus 1, Columbidae alphaherpesvirus 1, Gallid alphaherpesvirus 3, Meleagrid alphaherpesvirus 1, Chelonid 25 alphaherpesvirus 5, Human alphaherpesvirus 1, Ateline alphaherpesvirus 1, Bovine alphaherpesvirus 2, Cercopithecine alphaherpesvirus 2, Human alphaherpesvirus 2, Leporid alphaherpesvirus 4, Macacine alphaherpesvirus 1, Macropodid alphaherpesvirus 1, Macropodid alphaherpesvirus 2, Panine alphaherpesvirus 3, Papiine alphaherpesvirus 2, Saimiriine alphaherpesvirus 1, Human betaherpesvirus 5, Aotine betaherpesvirus 1, Cebine 30 betaherpesvirus 1, Cercopithecine betaherpesvirus 5, Macacine betaherpesvirus 3, Panine betaherpesvirus 2, Papiine betaherpesvirus 3, Saimiriine betaherpesvirus 4, Murid betaherpesvirus 1, Murid betaherpesvirus 2, Murid betaherpesvirus 8, Human

betaherpesvirus 6A, Human betaherpesvirus 6B, Human betaherpesvirus 7, Elephantid
 betaherpesvirus 1, Human gammaherpesvirus 4, Callitrichine gammaherpesvirus 3,
 Cercopithecine gammaherpesvirus 14, Gorilline gammaherpesvirus 1, Macacine
 gammaherpesvirus 4, Panine gammaherpesvirus 1, Papiine gammaherpesvirus 1, Pongine
 5 gammaherpesvirus 2, Saimiriine gammaherpesvirus 2, Ateline gammaherpesvirus 2, Ateline
 gammaherpesvirus 3, Bovine gammaherpesvirus 4, Cricetid gammaherpesvirus 2, Human
 gammaherpesvirus 8, Macacine gammaherpesvirus 5, Murid gammaherpesvirus 4, Murid
 gammaherpesvirus 7, Alcelaphine gammaherpesvirus 1, Alcelaphine gammaherpesvirus 2,
 Bovine gammaherpesvirus 6, Caprine gammaherpesvirus 2, Hippotragine
 10 gammaherpesvirus 1, Ovine gammaherpesvirus 2, Suid gammaherpesvirus 3, Suid
 gammaherpesvirus 4, Suid gammaherpesvirus 5, Equid gammaherpesvirus 2, Equid
 gammaherpesvirus 5, and Mustelid gammaherpesvirus 1. Such an OV antigen may be native
 or heterologous to the OV.

According to some embodiments, the OV antigen is an antigen encoded by the wild-
 15 type genome of a virus from the Adenoviridae family selected from Fowl aviadenovirus A,
 Frog siadenovirus A, Human mastadenovirus C, Ovine atadenovirus D, Sturgeon
 ichtadenovirus A, Bat mastadenovirus A, Bat mastadenovirus B, Bat mastadenovirus C, Bat
 mastadenovirus D, Bat mastadenovirus E, Bat mastadenovirus F, Bat mastadenovirus G,
 Bovine atadenovirus D, Bovine mastadenovirus A, Bovine mastadenovirus B, Bovine
 20 mastadenovirus C, Canine mastadenovirus A, Deer atadenovirus A, Deer mastadenovirus B,
 Dolphin mastadenovirus A, Dolphin mastadenovirus B, Duck atadenovirus A, Duck
 aviadenovirus B, Equine mastadenovirus A, Equine mastadenovirus B, Falcon aviadenovirus
 A, Fowl aviadenovirus B, Fowl aviadenovirus C, Fowl aviadenovirus D, Fowl aviadenovirus
 E, Goose aviadenovirus A, Great tit siadenovirus A, Human mastadenovirus A, Human
 25 mastadenovirus B, Human mastadenovirus D, Human mastadenovirus E, Human
 mastadenovirus F, Human mastadenovirus G, Lizard atadenovirus A, Murine mastadenovirus
 A, Murine mastadenovirus B, Murine mastadenovirus C, Ovine mastadenovirus A, Ovine
 mastadenovirus B, Penguin siadenovirus A, Pigeon aviadenovirus A, Pigeon aviadenovirus
 B, Platyrrhini mastadenovirus A, Porcine mastadenovirus A, Porcine mastadenovirus B,
 30 Porcine mastadenovirus C, Possum atadenovirus A, Psittacine atadenovirus A, Psittacine
 aviadenovirus B, Raptor siadenovirus A, Sea lion mastadenovirus A, Simian mastadenovirus
 A, Simian mastadenovirus B, Simian mastadenovirus C, Simian mastadenovirus D, Simian

mastadenovirus E, Simian mastadenovirus F, Simian mastadenovirus G, Simian mastadenovirus H, Simian mastadenovirus I, Skua siadenovirus A, Skunk mastadenovirus A, Snake atadenovirus A, Squirrel mastadenovirus A, Tree shrew mastadenovirus A, Turkey aviadenovirus B, Turkey aviadenovirus C, Turkey aviadenovirus D, and Turkey siadenovirus A. Such an OV antigen may be native or heterologous to the OV.

In certain embodiments, the OV antigen is an antigen encoded by the wild-type genome of a virus from the Paramyxoviridae family selected from Avian avulavirus 1, Hendra henipavirus, Measles morbillivirus, Mumps rubulavirus, Murine respirovirus, Reptilian ferlavirus, Salmon aquaparamyxovirus, Achimota rubulavirus 1, Achimota rubulavirus 2, Avian avulavirus 10, Avian avulavirus 11, Avian avulavirus 12, Avian avulavirus 13, Avian avulavirus 14, Avian avulavirus 15, Avian avulavirus 16, Avian avulavirus 17, Avian avulavirus 18, Avian avulavirus 19, Avian avulavirus 2, Avian avulavirus 3, Avian avulavirus 4, Avian avulavirus 5, Avian avulavirus 6, Avian avulavirus 7, Avian avulavirus 8, Avian avulavirus 9, Bat mumps rubulavirus, Bovine respirovirus 3, Canine morbillivirus, Cedar henipavirus, Cetacean morbillivirus, Feline morbillivirus, Ghanaian bat henipavirus, Human respirovirus 1, Human respirovirus 3, Human rubulavirus 2, Human rubulavirus 4, Mammalian rubulavirus 5, Mapuera rubulavirus, Menangle rubulavirus, Mojiang henipavirus, Nipah henipavirus, Phocine morbillivirus, Porcine respirovirus 1, Porcine rubulavirus, Rinderpest morbillivirus, Simian rubulavirus, Small ruminant morbillivirus, Sosuga rubulavirus, Teviot rubulavirus, Tioman rubulavirus, Tuhoko rubulavirus 1, Tuhoko rubulavirus 2, and Tuhoko rubulavirus 3. Such an OV antigen may be native or heterologous to the OV.

According to some embodiments, the OV antigen is an antigen encoded by the wild-type genome of a virus from the Rhabdoviridae family selected from Bovine fever ephemerovirus, Carp sprivivirus, Curionopolis curiovirus, Drosophila melanogaster sigmavirus, Durham tupavirus, Flanders hapavirus, Indiana vesiculovirus, Le Dantec ledantevirus, Lettuce big-vein associated varicosavirus, Lettuce necrotic yellows cytorhabdovirus, Niakha sripuvirus, Orchid fleck dichorhavirus, Perch perhabdovirus, Potato yellow dwarf nucleorhabdovirus, Puerto Almendras almendravirus, Rabies lyssavirus, Salmonid novirhabdovirus, Tibrogargan tibrovirus, Adelaide River ephemerovirus, Alagoas vesiculovirus, Alfalfa dwarf cytorhabdovirus, Almpiwar sripuvirus, American bat vesiculovirus, Anguillid perhabdovirus, Aravan lyssavirus, Arboretum almendravirus, Australian bat lyssavirus, Balsa almendravirus, Barley yellow striate mosaic cytorhabdovirus, Barur

ledantavirus, Bas-Congo tibrovirus, Beatrice Hill tibrovirus, Berrimah ephemerovirus, Bokeloh bat lyssavirus, Broccoli necrotic yellows cytorhabdovirus, Carajas vesiculovirus, Chaco sripuvirus, Chandipura vesiculovirus, Coastal Plains tibrovirus, Cocal vesiculovirus, Coffee ringspot dichorhavirus, Colocasia bobone disease-associated cytorhabdovirus, Coot Bay

5 almedravirus, Datura yellow vein nucleorhabdovirus, Drosophila affinis sigmavirus, Drosophila ananassae sigmavirus, Drosophila immigrans sigmavirus, Drosophila obscura sigmavirus, Drosophila tristis sigmavirus, Duvenhage lyssavirus, Eggplant mottled dwarf nucleorhabdovirus, Ekpoma 1 tibrovirus, Ekpoma 2 tibrovirus, European bat 1 lyssavirus, European bat 2 lyssavirus, Festuca leaf streak cytorhabdovirus, Fikirini ledantavirus, Fukuoka

10 ledantavirus, Gannoruwa bat lyssavirus, Gray Lodge hapavirus, Hart Park hapavirus, Hirame novirhabdovirus, Ikoma lyssavirus, Iriri curiovirus, Irkut lyssavirus, Isfahan vesiculovirus, Itacaiunas curiovirus, Joinjakaka hapavirus, Jurona vesiculovirus, Kamese hapavirus, Kanyawara ledantavirus, Kern Canyon ledantavirus, Keuraliba ledantavirus, Khujand lyssavirus, Kimberley ephemerovirus, Klamath tupavirus, Kolente ledantavirus, Koolpinyah

15 ephemerovirus, Kotonkan ephemerovirus, Kumasi ledantavirus, La Joya hapavirus, Lagos bat lyssavirus, Landjia hapavirus, Lettuce yellow mottle cytorhabdovirus, Lleida bat lyssavirus, Maize Iranian mosaic nucleorhabdovirus, Maize fine streak nucleorhabdovirus, Maize mosaic nucleorhabdovirus, Malpais Spring vesiculovirus, Manitoba hapavirus, Maraba vesiculovirus, Marco hapavirus, Mokola lyssavirus, Morreton vesiculovirus, Mosqueiro

20 hapavirus, Mossuril hapavirus, Mount Elgon bat ledantavirus, Moussa virus, Muscina stabulans sigmavirus, New Jersey vesiculovirus, Ngaingan hapavirus, Nishimuro ledantavirus, Nkolbisson ledantavirus, Northern cereal mosaic cytorhabdovirus, Obodhiang ephemerovirus, Oita ledantavirus, Ord River hapavirus, Parry Creek hapavirus, Perinet vesiculovirus, Pike fry sprivivirus, Piry vesiculovirus, Piscine novirhabdovirus, Radi

25 vesiculovirus, Rice yellow stunt nucleorhabdovirus, Rio Chico almedravirus, Rochambeau curiovirus, Sea trout perhabdovirus, Sena Madureira sripuvirus, Shimoni bat lyssavirus, Snakehead novirhabdovirus, Sonchus cytorhabdovirus 1, Sonchus yellow net nucleorhabdovirus, Sowthistle yellow vein nucleorhabdovirus, Sripur sripuvirus, Strawberry crinkle cytorhabdovirus, Sweetwater Branch tibrovirus, Taro vein chlorosis

30 nucleorhabdovirus, Tupaia tupavirus, West Caucasian bat lyssavirus, Wheat American striate mosaic cytorhabdovirus, Wongabel hapavirus, Wuhan ledantavirus, Yata ephemerovirus, Yongjia ledantavirus, and Yug Bogdanovac vesiculovirus. Such an OV antigen may be native or heterologous to the OV.

In certain embodiments, the OV antigen is an antigen encoded by the wild-type genome of a virus from the Reoviridae family selected from Aedes pseudoscutellaris reovirus, Aquareovirus A, Banna virus, Bluetongue virus, Colorado tick fever virus, Cypovirus 1, Eriocheir sinensis reovirus, Fiji disease virus, Idnoreovirus 1, Mammalian orthoreovirus, 5 Micromonas pusilla reovirus, Mycoreovirus 1, Rice ragged stunt virus, Rotavirus A, Wound tumor virus, African horse sickness virus, Aquareovirus B, Aquareovirus C, Aquareovirus D, Aquareovirus E, Aquareovirus F, Aquareovirus G, Avian orthoreovirus, Baboon orthoreovirus, Changuinola virus, Chenuda virus, Chobar Gorge virus, Corriparta virus, Cypovirus 10, Cypovirus 11, Cypovirus 12, Cypovirus 13, Cypovirus 14, Cypovirus 15, Cypovirus 16, 10 Cypovirus 2, Cypovirus 3, Cypovirus 4, Cypovirus 5, Cypovirus 6, Cypovirus 7, Cypovirus 8, Cypovirus 9, Echinochloa ragged stunt virus, Epizootic hemorrhagic disease virus, Equine encephalosis virus, Eubenangee virus, Eyach virus, Garlic dwarf virus, Great Island virus, Idnoreovirus 2, Idnoreovirus 3, Idnoreovirus 4, Idnoreovirus 5, Ieri virus, Kadipiro virus, Lebombo virus, Liao ning virus, Mahlapitsi orthoreovirus, Maize rough dwarf virus, Mal de Rio 15 Cuarto virus, Mycoreovirus 2, Mycoreovirus 3, Nelson Bay orthoreovirus, Nilaparvata lugens reovirus, Oat sterile dwarf virus, Orungo virus, Palyam virus, Pangola stunt virus, Peruvian horse sickness virus, Piscine orthoreovirus, Reptilian orthoreovirus, Rice black streaked dwarf virus, Rice dwarf virus, Rice gall dwarf virus, Rotavirus B, Rotavirus C, Rotavirus D, Rotavirus E, Rotavirus F, Rotavirus G, Rotavirus H, Rotavirus I, Southern rice black-streaked 20 dwarf virus, St Croix River virus, Umatilla virus, Wad Medani virus, Wallal virus, Warrego virus, Wongorr virus, and Yunnan orbivirus. Such an OV antigen may be native or heterologous to the OV.

According to some embodiments, the OV antigen is an antigen encoded by the wild-type genome of a virus from the Picornaviridae family selected from Aalivirus A, Aichivirus A, 25 Ampivirus A, Aquamavirus A, Avihepatovirus A, Avisivirus A, Bopivirus A, Cadivirus A, Cardiovirus A, Cosavirus A, Crohivirus B, Enterovirus C, Erbovirus A, Foot-and-mouth disease virus, Gallivirus A, Harkavirus A, Hepatovirus A, Hunnivirus A, Kunsagivirus A, Limnipivirus A, Megrivirus A, Mischivirus A, Mosavirus A, Orivirus A, Oscivirus A, Parechovirus A, Pasivirus A, Passerivirus A, Potamipivirus A, Rabovirus A, Rosavirus A, 30 Sakobuvirus A, Salivirus A, Sapelovirus A, Senecavirus A, Shanbavirus A, Sicinivirus A, Teschovirus A, Torchivirus A, Tremovirus A, Aichivirus B, Aichivirus C, Aichivirus D, Aichivirus E, Aichivirus F, Avian sapelovirus, Avisivirus B, Avisivirus C, Bovine rhinitis A virus, Bovine

rhinitis B virus, Cardiovirus B, Cardiovirus C, Cosavirus B, Cosavirus D, Cosavirus E, Cosavirus F, Crohivirus A, Enterovirus A, Enterovirus B, Enterovirus D, Enterovirus E, Enterovirus F, Enterovirus G, Enterovirus H, Enterovirus I, Enterovirus J, Enterovirus K, Enterovirus L, Equine rhinitis A virus, Hepatovirus B, Hepatovirus C, Hepatovirus D, Hepatovirus E, Hepatovirus F, Hepatovirus G, Hepatovirus H, Hepatovirus I, Kunsagivirus B, Kunsagivirus C, Limnipivirus B, Limnipivirus C, Megrivirus B, Megrivirus C, Megrivirus D, Megrivirus E, Mischivirus B, Mischivirus C, Parechovirus B, Parechovirus C, Parechovirus D, Rhinovirus A, Rhinovirus B, Rhinovirus C, and Sapelovirus B. Such an OV antigen may be native or heterologous to the OV.

In certain embodiments, the OV antigen is an antigen encoded by the wild-type genome of a virus from the Parvoviridae family selected from Adeno-associated dependoparvovirus A, Carnivore amdoparvovirus 1, Decapod hepadensovirus 1, Decapod penstyldensovirus 1, Dipteran brevidensovirus 1, Galliform aveparvovirus 1, Lepidopteran ambidensovirus 1, Lepidopteran iteradensovirus 1, Primate erythroparvovirus 1, Primate tetraparvovirus 1, Rodent protoparvovirus 1, Ungulate bocaparvovirus 1, Ungulate copiparvovirus 1, Adeno-associated dependoparvovirus B, Anseriform dependoparvovirus 1, Asteroid ambidensovirus 1, Avian dependoparvovirus 1, Blattodean ambidensovirus 1, Blattodean ambidensovirus 2, Carnivore amdoparvovirus 2, Carnivore amdoparvovirus 3, Carnivore amdoparvovirus 4, Carnivore bocaparvovirus 1, Carnivore bocaparvovirus 2, Carnivore bocaparvovirus 3, Carnivore bocaparvovirus 4, Carnivore bocaparvovirus 5, Carnivore bocaparvovirus 6, Carnivore protoparvovirus 1, Chiropteran bocaparvovirus 1, Chiropteran bocaparvovirus 2, Chiropteran bocaparvovirus 3, Chiropteran bocaparvovirus 4, Chiropteran dependoparvovirus 1, Chiropteran protoparvovirus 1, Chiropteran tetraparvovirus 1, Decapod ambidensovirus 1, Dipteran ambidensovirus 1, Dipteran brevidensovirus 2, Eulipotyphla protoparvovirus 1, Hemipteran ambidensovirus 1, Hemipteran ambidensovirus 2, Hemipteran ambidensovirus 3, Hymenopteran ambidensovirus 1, Lagomorph bocaparvovirus 1, Lepidopteran iteradensovirus 2, Lepidopteran iteradensovirus 3, Lepidopteran iteradensovirus 4, Lepidopteran iteradensovirus 5, Orthopteran ambidensovirus 1, Orthopteran densovirus 1, Pinniped bocaparvovirus 1, Pinniped bocaparvovirus 2, Pinniped dependoparvovirus 1, Primate bocaparvovirus 1, Primate bocaparvovirus 2, Primate erythroparvovirus 2, Primate erythroparvovirus 3, Primate erythroparvovirus 4, Primate protoparvovirus 1, Primate

protoparvovirus 2, Primate protoparvovirus 3, Rodent erythroparvovirus 1, Rodent
 protoparvovirus 2, Rodent protoparvovirus 3, Squamate dependoparvovirus 1, Ungulate
 bocaparvovirus 2, Ungulate bocaparvovirus 3, Ungulate bocaparvovirus 4, Ungulate
 bocaparvovirus 5, Ungulate bocaparvovirus 6, Ungulate copiparvovirus 2, Ungulate
 5 erythroparvovirus 1, Ungulate protoparvovirus 1, Ungulate protoparvovirus 2, Ungulate
 tetraparvovirus 1, Ungulate tetraparvovirus 2, Ungulate tetraparvovirus 3, and Ungulate
 tetraparvovirus 4. Such an OV antigen may be native or heterologous to the OV.

According to some embodiments, the OV antigen is an antigen encoded by the wild-
 type genome of a virus from the Coronaviridae family selected from Alphacoronavirus 1,
 10 Avian coronavirus, Bulbul coronavirus HKU11, Equine torovirus, Murine coronavirus, White
 bream virus, Ball python nidovirus 1, Bat coronavirus CDPHE15, Bat coronavirus HKU10,
 Beluga whale coronavirus SW1, Betacoronavirus 1, Bovine nidovirus 1, Bovine torovirus,
 Chinook salmon nidovirus 1, Common moorhen coronavirus HKU21, Coronavirus HKU15,
 Fathead minnow nidovirus 1, Hedgehog coronavirus 1, Human coronavirus 229E, Human
 15 coronavirus HKU1, Human coronavirus NL63, Human torovirus, Middle East respiratory
 syndrome-related coronavirus, Miniopterus bat coronavirus 1, Miniopterus bat coronavirus
 HKU8, Mink coronavirus 1, Munia coronavirus HKU13, Night heron coronavirus HKU19,
 Pipistrellus bat coronavirus HKU5, Porcine epidemic diarrhea virus, Porcine torovirus,
 Rhinolophus bat coronavirus HKU2, Rousettus bat coronavirus HKU9, SARS coronavirus 2,
 20 Scotophilus bat coronavirus 512, Severe acute respiratory syndrome-related coronavirus,
 Thrush coronavirus HKU12, Tylonycteris bat coronavirus HKU4, White-eye coronavirus
 HKU16, Wigeon coronavirus HKU20, and SARS-CoV-2. Such an OV antigen may be native
 or heterologous to the OV.

In certain embodiments, the OV antigen is an antigen encoded by the genome of a
 25 Vaccinia Virus (e.g., antigen A33, A34, A36, A56, B5, F12, F13, or the like, e.g., from a
 modified VV strain, JX-594, GL-ONC1, or a VV strain selected from Western Reserve, Wyeth,
 Lister, Copenhagen, Temple of Heaven, Patwadangar, and Modified Vaccinia Virus Ankara,
 and the like), adenovirus, HSV, reovirus, vesicular stomatitis virus, New Castle Disease virus,
 Seneca Valley virus, poliovirus, measles virus, Cocksackie virus, and Maraba virus. Such an
 30 OV antigen may be native or heterologous to the OV.

In certain embodiments, the OV antigen is a modified version (or derivative) of a native
 OV antigen. For example, according to some embodiments, the OV antigen comprises the

same or substantially similar epitope of a native antigen, but is modified/engineered to confer a desirable property, e.g., improved infectivity of the virus, or the like. In certain embodiments, the OV antigen is modified/engineered to have a different epitope relative to a native antigen, e.g., such that an existing antibody (e.g., an antibody approved for therapeutic use) binds to the modified/engineered OV antigen whereas the antibody does not bind to the native antigen.

According to some embodiments, the genome of the OV may be modified to encode and express one or more proteins not encoded by the wild-type genome of the OV, where such proteins may be referred to herein as OV antigens “heterologous” or “non-native” to the OV. The genome of an OV may be modified to encode and express any heterologous OV antigen of interest. In certain embodiments, the heterologous OV antigen is a viral antigen (e.g., an antigen encoded by the wild-type genome of any of the viruses described elsewhere herein) heterologous to the OV that expresses the antigen. According to some embodiments, the heterologous OV antigen is a tumor antigen, non-limiting examples of which include 5T4, AXL receptor tyrosine kinase (AXL), B-cell maturation antigen (BCMA), c-MET, C4.4a, carbonic anhydrase 6 (CA6), carbonic anhydrase 9 (CA9), Cadherin-6, CD19, CD20, CD22, CD25, CD27L, CD30, CD33, CD37, CD44v6, CD56, CD70, CD74, CD79b, CD123, CD138, carcinoembryonic antigen (CEA), cKit, Cripto protein, CS1, delta-like canonical Notch ligand 3 (DLL3), endothelin receptor type B (EDNRB), ephrin A4 (EFNA4), epidermal growth factor receptor (EGFR), EGFRvIII, ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3), EPH receptor A2 (EPHA2), fibroblast growth factor receptor 2 (FGFR2), fibroblast growth factor receptor 3 (FGFR3), FMS-like tyrosine kinase 3 (FLT3), folate receptor 1 (FOLR1), glycoprotein non-metastatic B (GPNMB), guanylate cyclase 2C (GUCY2C), human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), Integrin alpha, lysosomal-associated membrane protein 1 (LAMP-1), Lewis Y, LIV-1, leucine rich repeat containing 15 (LRRC15), mesothelin (MSLN), mucin 1 (MUC1), mucin 16 (MUC16), sodium-dependent phosphate transport protein 2B (NaPi2b), Nectin-4, NMB, NOTCH3, p-cadherin (p-CAD), prostate-specific membrane antigen (PSMA), protein tyrosine kinase 7 (PTK7), solute carrier family 44 member 4 (SLC44A4), SLIT like family member 6 (SLITRK6), STEAP family member 1 (STEAP1), tissue factor (TF), T cell immunoglobulin and mucin protein-1 (TIM-1), and trophoblast cell-surface antigen (TROP-2).

Non-limiting examples of antigen-binding domains that specifically bind to tumor antigens which an OV genome may be modified to encode and express, and which antigen-binding domains may be employed in an anti-OV CAR or anti-OV conjugate of the present disclosure, include the antigen-binding domains of the following antibodies: Adecatumumab, 5 Ascrinvacumab, Cixutumumab, Conatumumab, Daratumumab, Drozitumab, Duligotumab, Durvalumab, Dusigitumab, Enfortumab, Enoticumab, Figitumumab, Ganitumab, Glembatumumab, Intetumumab, Ipilimumab, Iratumumab, Icrucumab, Lexatumumab, Lucatumumab, Mapatumumab, Narnatumab, Necitumumab, Nesvacumab, Ofatumumab, Olaratumab, Panitumumab, Patritumab, Pritumumab, Radretumab, Ramucirumab, 10 Rilotumumab, Robatumumab, Seribantumab, Tarextumab, Teprotumumab, Tovetumab, Vantictumab, Vesencumab, Votumumab, Zalutumumab, Flanvotumab, Altumomab, Anatumomab, Arcitumomab, Bectumomab, Blinatumomab, Detumomab, Ibritumomab, Minretumomab, Mitumomab, Moxetumomab, Naptumomab, Nofetumomab, Pemtumomab, Pintumomab, Racotumomab, Satumomab, Solitomab, Taplitumomab, Tenatumomab, 15 Tositumomab, Tremelimumab, Abagovomab, Igovomab, Oregovomab, Capromab, Edrecolomab, Nacolomab, Amatuximab, Bavituximab, Brentuximab, Cetuximab, Derlotuximab, Dinutuximab, Ensituximab, Futuximab, Girentuximab, Indatuximab, Isatuximab, Margetuximab, Rituximab, Siltuximab, Ublituximab, Echromeximab, Abituzumab, Alemtuzumab, Bevacizumab, Bivatuzumab, Brontictuzumab, Cantuzumab, Cantuzumab, 20 Citatuzumab, Clivatuzumab, Dacetuzumab, Demcizumab, Dalotuzumab, Denintuzumab, Elotuzumab, Emactuzumab, Emibetuzumab, Enoblituzumab, Etaracizumab, Farletuzumab, Ficlatuzumab, Gemtuzumab, Imgatuzumab, Inotuzumab, Labetuzumab, Lifestuzumab, Lintuzumab, Lorvotuzumab, Lumretuzumab, Matuzumab, Milatuzumab, Nimotuzumab, Obinutuzumab, Ocaratuzumab, Otlertuzumab, Onartuzumab, Oportuzumab, Parsatuzumab, 25 Pertuzumab, Pinatuzumab, Polatuzumab, Sibrotuzumab, Simtuzumab, Tacatuzumab, Tigatuzumab, Trastuzumab, Tucotuzumab, Vandortuzumab, Vanucizumab, Veltuzumab, Vorsetuzumab, Sofituzumab, Catumaxomab, Ertumaxomab, Depatuxizumab, Ontuxizumab, Blontuvmab, Tamtuvmab, or a tumor antigen-binding variant thereof. As used herein, “variant” is meant the antigen binding domain specifically binds to the particular antigen (e.g., 30 HER2 for Trastuzumab) but has fewer or more amino acids than the parental antibody (e.g., is a fragment (e.g., scFv) of the parental antibody), has one or more amino acid substitutions relative to the parental antibody, or a combination thereof.

In some embodiments, the antigen-binding domain of an anti-OV antigen CAR or anti-OV antigen conjugate of the present disclosure is from an antibody approved by the United States Food and Drug Administration and/or the European Medicines Agency (EMA) for use as a therapeutic antibody (e.g., for targeting certain disease-associated cells in a patient, etc.), or a fragment thereof (e.g., a single-chain version of such an antibody, such as an scFv version of the antibody) that retains the ability to specifically bind the target antigen.

The antigen binding domain of a CAR of the present disclosure may be any suitable format, e.g., scFv, or the like. Any suitable transmembrane and intracellular signaling domains may be employed, including any of the transmembrane and intracellular signaling domains, as well as costimulatory domains, linker sequences/spacer domains, etc. described in the Fusion Protein section above.

A CAR of the present disclosure may be provided by a single peptide, or may be provided by two or more polypeptides. When the CAR is provided by two or more polypeptides, the CAR may be provided in any useful multi-polypeptide format, including any such multi-peptide formats described above in the Fusion Protein section of the present disclosure.

Also provided are nucleic acids encoding any of the anti-OV antigen CARs of the present disclosure, expression vectors comprising such nucleic acids, and cells comprising such nucleic acids and expression vectors.

According to some embodiments, provided is a cell that expresses an anti-OV antigen CAR on its surface. Cells of interest include, but are not limited to, immune cells. In certain embodiments, the immune cell is an immune effector cell. Non-limiting examples of immune effector cells that may express an anti-OV antigen CAR of the present disclosure on its surface include T cells (that is – the cell may be a CAR T cell), NK cells, NKT cells, macrophages, and the like. Also provided are pharmaceutical compositions comprising any of the cells of the present disclosure that express an anti-OV antigen CAR on its surface. Such compositions may comprise the cells and a pharmaceutically acceptable carrier. Examples of suitable pharmaceutically acceptable carriers are described in detail below.

Conjugates that Bind Oncolytic Virus Antigens

In addition to the anti-VV A56 and anti-VV B5 antibody and fusion protein conjugates of the present disclosure described in the Conjugates section above, aspects of the present

disclosure further include anti-oncolytic virus antigen antibody conjugates. In certain embodiments, such a conjugate comprises an antibody that specifically binds an oncolytic virus (OV) antigen, and an agent conjugated to the antibody. According to some embodiments, the agent conjugated to the antibody is selected from a chemotherapeutic agent, a toxin, a radiation sensitizing agent, and a radioactive isotope (e.g., a therapeutic radioactive isotope). The agent may be any of such agents described in the Conjugates section above.

The anti-OV antibody conjugates of the present disclosure find a variety of uses. For example, with the benefit of the present disclosure, it will be appreciated that such conjugates find use in methods that comprise administering a pharmaceutical composition comprising an anti-OV antigen conjugate to an individual having cancer, wherein cancer cells in the individual are infected with OV and express the OV antigen on their surface, thereby targeting the conjugate to the cancer cells to treat the individual's cancer.

The antibody (or fusion protein comprising same) may be selected such that the conjugate specifically binds an OV antigen of interest. The OV antigen may be a native OV antigen. For example, the antibody portion of the conjugate may specifically bind a native antigen encoded by an OV selected from Vaccinia Virus (e.g., antigen A33, A34, A36, A56, B5, F12, F13, or the like, e.g., from JX-594, GL-ONC1, or a VV strain selected from Western Reserve, Wyeth, Lister, Copenhagen, Temple of Heaven, Patwadangar, and Modified Vaccinia Virus Ankara, and the like), adenovirus, HSV, reovirus, vesicular stomatitis virus, New Castle Disease virus, Seneca Valley virus, poliovirus, measles virus, Coxsackie virus, and Maraba virus.

In certain embodiments, the OV antigen is heterologous to the OV. For example, the antibody (or fusion protein comprising the antibody) may be selected such that the antibody portion of the conjugate specifically binds any of the heterologous OV antigens described in the CAR section above.

The antibody portion of an anti-OV antibody conjugate of the present disclosure may be provided in any desired format, e.g., tetrameric format, single chain (e.g., scFv) format, etc. as described in the sections above relating to the antibodies, and anti-VV A56 and anti-VV B5 antibody and fusion protein conjugates, of the present disclosure.

An anti-OV antibody conjugate of the present disclosure may include the agent conjugated to the antibody (or fusion protein comprising the antibody) via a linker, e.g., any

of the non-cleavable or cleavable linkers described in the section above relating to the anti-VV A56 and anti-VV B5 antibody and fusion protein conjugates of the present disclosure.

Also provided are pharmaceutical compositions comprising any of the anti-OV antibody conjugates of the present disclosure. Such compositions may comprise the conjugates and a pharmaceutically acceptable carrier. Examples of suitable pharmaceutically acceptable carriers are described in detail below.

COMPOSITIONS

As summarized above, the present disclosure also provides compositions. According to some embodiments, a composition of the present disclosure includes an antibody, fusion protein, or conjugate of the present disclosure. For example, the antibody, fusion protein, or conjugate may be any of the antibodies, fusion proteins, or conjugates described in the Antibodies section hereinabove, which descriptions are incorporated but not reiterated herein for purposes of brevity.

In certain aspects, a composition of the present disclosure includes the antibody, fusion protein, or conjugate present in a liquid medium. The liquid medium may be an aqueous liquid medium, such as water, a buffered solution, or the like. One or more additives such as a salt (e.g., NaCl, MgCl₂, KCl, MgSO₄), a buffering agent (a Tris buffer, N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), 2-(N-Morpholino)ethanesulfonic acid (MES), 2-(N-Morpholino)ethanesulfonic acid sodium salt (MES), 3-(N-Morpholino)propanesulfonic acid (MOPS), N-tris[Hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS), etc.), a solubilizing agent, a detergent (e.g., a non-ionic detergent such as Tween-20, etc.), a nuclease inhibitor, a protease inhibitor, glycerol, a chelating agent, and the like may be present in such compositions.

Aspects of the present disclosure further include pharmaceutical compositions. In some embodiments, a pharmaceutical composition of the present disclosure includes an anti-VV A56 antibody or anti-VV B5 antibody of the present disclosure (or conjugate or fusion protein comprising same), and a pharmaceutically acceptable carrier.

The antibodies, fusion proteins, or conjugates can be incorporated into a variety of formulations for therapeutic administration. More particularly, the antibodies, fusion proteins, or conjugates can be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable excipients or diluents, and may be formulated into

preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, injections, inhalants and aerosols.

Formulations of the antibodies, fusion proteins, or conjugates for administration to an individual (e.g., suitable for human administration) are generally sterile and may further be free of detectable pyrogens or other contaminants contraindicated for administration to a patient according to a selected route of administration.

In pharmaceutical dosage forms, the antibodies, fusion proteins, or conjugates can be administered in the form of their pharmaceutically acceptable salts, or they may also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds. The following methods and carriers/excipients are merely examples and are in no way limiting.

For oral preparations, the antibodies, fusion proteins, or conjugates can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.

The antibodies, fusion proteins, or conjugates can be formulated for parenteral (e.g., intravenous, intra-arterial, intraosseous, intramuscular, intracerebral, intracerebroventricular, intrathecal, subcutaneous, etc.) administration. In certain aspects, the antibodies, fusion proteins, or conjugates are formulated for injection by dissolving, suspending or emulsifying the antibodies, fusion proteins, or conjugates in an aqueous or non-aqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.

Pharmaceutical compositions that include the antibodies, fusion proteins, or conjugates may be prepared by mixing the antibodies, fusion proteins, or conjugates having the desired degree of purity with optional physiologically acceptable carriers, excipients, stabilizers, surfactants, buffers and/or tonicity agents. Acceptable carriers, excipients and/or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including

ascorbic acid, glutathione, cysteine, methionine and citric acid; preservatives (such as ethanol, benzyl alcohol, phenol, m-cresol, p-chlor-m-cresol, methyl or propyl parabens, benzalkonium chloride, or combinations thereof); amino acids such as arginine, glycine, ornithine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophan, methionine, serine, proline and combinations thereof; monosaccharides, disaccharides and other carbohydrates; low molecular weight (less than about 10 residues) polypeptides; proteins, such as gelatin or serum albumin; chelating agents such as EDTA; sugars such as trehalose, sucrose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, raffinose, glucosamine, N-methylglucosamine, galactosamine, and neuraminic acid; and/or non-ionic surfactants such as Tween, Brij Pluronics, Triton-X, or polyethylene glycol (PEG).

The pharmaceutical composition may be in a liquid form, a lyophilized form or a liquid form reconstituted from a lyophilized form, wherein the lyophilized preparation is to be reconstituted with a sterile solution prior to administration. The standard procedure for reconstituting a lyophilized composition is to add back a volume of pure water (typically equivalent to the volume removed during lyophilization); however solutions comprising antibacterial agents may be used for the production of pharmaceutical compositions for parenteral administration.

An aqueous formulation of the antibodies, fusion proteins, or conjugates may be prepared in a pH-buffered solution, e.g., at pH ranging from about 4.0 to about 7.0, or from about 5.0 to about 6.0, or alternatively about 5.5. Examples of buffers that are suitable for a pH within this range include phosphate-, histidine-, citrate-, succinate-, acetate-buffers and other organic acid buffers. The buffer concentration can be from about 1 mM to about 100 mM, or from about 5 mM to about 50 mM, depending, e.g., on the buffer and the desired tonicity of the formulation.

A tonicity agent may be included to modulate the tonicity of the formulation. Example tonicity agents include sodium chloride, potassium chloride, glycerin and any component from the group of amino acids, sugars as well as combinations thereof. In some embodiments, the aqueous formulation is isotonic, although hypertonic or hypotonic solutions may be suitable. The term "isotonic" denotes a solution having the same tonicity as some other solution with which it is compared, such as physiological salt solution or serum. Tonicity agents may be

used in an amount of about 5 mM to about 350 mM, e.g., in an amount of 100 mM to 350 mM.

A surfactant may also be added to the formulation to reduce aggregation and/or minimize the formation of particulates in the formulation and/or reduce adsorption. Example surfactants include polyoxyethylensorbitan fatty acid esters (Tween), polyoxyethylene alkyl ethers (Brij), alkylphenylpolyoxyethylene ethers (Triton-X), polyoxyethylene-polyoxypropylene copolymer (Poloxamer, Pluronic), and sodium dodecyl sulfate (SDS). Examples of suitable polyoxyethylenesorbitan-fatty acid esters are polysorbate 20, (sold under the trademark Tween 20™) and polysorbate 80 (sold under the trademark Tween 80™). Examples of suitable polyethylene-polypropylene copolymers are those sold under the names Pluronic® F68 or Poloxamer 188™. Examples of suitable Polyoxyethylene alkyl ethers are those sold under the trademark Brij™. Example concentrations of surfactant may range from about 0.001% to about 1% w/v.

A lyoprotectant may also be added in order to protect the antibody and/or T cell activator against destabilizing conditions during a lyophilization process. For example, known lyoprotectants include sugars (including glucose and sucrose); polyols (including mannitol, sorbitol and glycerol); and amino acids (including alanine, glycine and glutamic acid). Lyoprotectants can be included, e.g., in an amount of about 10 mM to 500 nM.

In some embodiments, the pharmaceutical composition includes the antibody, fusion protein, or conjugate, and one or more of the above-identified components (e.g., a surfactant, a buffer, a stabilizer, a tonicity agent) and is essentially free of one or more preservatives, such as ethanol, benzyl alcohol, phenol, m-cresol, p-chlor-m-cresol, methyl or propyl parabens, benzalkonium chloride, and combinations thereof. In other embodiments, a preservative is included in the formulation, e.g., at concentrations ranging from about 0.001 to about 2% (w/v).

KITS

Aspects of the present disclosure further include kits. In certain embodiments, the kits find use in practicing the methods of the present disclosure, e.g., methods comprising administering a pharmaceutical composition of the present disclosure to an individual to target the antibody, fusion protein (e.g., CAR) or conjugate to oncolytic virus (e.g. VV)-infected cancer cells in the individual.

Accordingly, in certain embodiments, a kit of the present disclosure comprises any of the pharmaceutical compositions of the present disclosure, and instructions for administering the pharmaceutical composition to an individual in need thereof. The pharmaceutical composition included in the kit may include any of the antibodies, fusion proteins, and/or conjugates of the present disclosure, e.g., any of the antibodies, fusion proteins, and/or conjugates described hereinabove. As will be appreciated, the kits of the present disclosure may include any of the agents and features described above in the sections relating to the subject antibodies, fusion proteins, conjugates and compositions, which are not reiterated herein for purposes of brevity.

The kits of the present disclosure may include a quantity of the compositions, present in unit dosages, e.g., ampoules, or a multi-dosage format. As such, in certain embodiments, the kits may include one or more (e.g., two or more) unit dosages (e.g., ampoules) of a composition that includes an antibody, fusion protein, and/or conjugate of the present disclosure. The term "unit dosage", as used herein, refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of the composition calculated in an amount sufficient to produce the desired effect. The amount of the unit dosage depends on various factors, such as the particular antibody, fusion protein, and/or conjugate employed, the effect to be achieved, and the pharmacodynamics associated with the antibody, fusion protein, and/or conjugate, in the individual. In yet other embodiments, the kits may include a single multi dosage amount of the composition.

In certain embodiments, a kit of the present disclosure includes instructions for targeting the antibody, fusion protein or conjugate present in the pharmaceutical composition to VV-infected cancer cells in an individual having cancer (e.g., to treat the cancer of the individual), e.g., by administering the pharmaceutical composition to the individual, wherein the individual comprises cancer cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cancer cells by VV antigens expressed on the surface of the infected cancer cells.

According to some embodiments, a kit of the present disclosure may further include pharmaceutical composition comprising VV (e.g., JX-594, GL-ONC1, a strain of VV selected from Western Reserve, Wyeth, Lister, Copenhagen, Temple of Heaven, Patwadangar, and Modified Vaccinia Virus Ankara, etc.). Such a kit may further include instructions for

administering to an individual having cancer the pharmaceutical composition comprising VV in an amount effective to infect cancer cells in the individual, e.g., prior to administration of a pharmaceutical composition comprising an antibody, fusion protein or conjugate of the present disclosure.

5 The instructions (e.g., instructions for use (IFU)) included in the kits may be recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or sub-packaging) etc. In other embodiments, the instructions
10 are present as an electronic storage data file present on a suitable computer readable storage medium, e.g., portable flash drive, DVD, CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the
15 instructions can be downloaded. As with the instructions, the means for obtaining the instructions is recorded on a suitable substrate.

METHODS

Aspects of the present disclosure include methods of using the antibodies, fusion proteins (e.g., CARs), and conjugates of the present disclosure. The methods are useful in
20 a variety of contexts, including *in vitro* and/or *in vivo* research and/or clinical applications.

In certain aspects, provided are methods that comprise administering an effective amount of a pharmaceutical composition comprising any of the anti-VV A56 or anti-VV B5 antibodies of the present disclosure (including any of the fusion proteins or conjugates comprising such antibodies) to an individual having cancer, where the individual comprises
25 cancer cells infected with OV that encode the VV A56 or VV B5 antigen to which the antibodies bind (where the VV A56 or VV B5 antigen may be native or heterologous to the OV), and where the antibody, fusion protein or conjugate is targeted to the infected cancer cells by VV antigens expressed on the surface of the infected cancer cells. According to some embodiments, such methods further comprise, prior to administering the
30 pharmaceutical composition to the individual, infecting the cancer cells by administering an

effective amount of the OV to the individual. Such methods find use, e.g., in treating the cancer of the individual.

In certain embodiments, the pharmaceutical composition comprises any of the anti-VV A56 or anti-VV B5 antibody conjugates of the present disclosure. For example, the pharmaceutical composition may comprise a conjugate, where the anti-VV A56 or anti-VV B5 antibody is conjugated to a detectable label or radioactive isotope which is an *in vivo* imaging agent. Such methods may further comprise imaging the infected cancer cells in the individual using the *in vivo* imaging agent. The methods in which a conjugate comprising a detectable label or radioactive isotope is administered to the individual find use in imaging the cancer cells in the individual, e.g., for diagnostic, prognostic, and/or anti-cancer therapy monitoring purposes.

According to some aspects, provided are methods of targeting an antibody that specifically binds an oncolytic virus (OV) antigen to cancer cells in an individual. Such methods comprise administering to the individual an effective amount of a pharmaceutical composition comprising an antibody (or fusion protein or conjugate comprising an antibody) that specifically binds the OV antigen, where the cancer cells in the individual are infected with OV and express the OV antigen on their surface. The OV antigen may be any of the OV antigens described elsewhere herein. In certain embodiments, the OV antigen is a native OV antigen. For example, the OV may be any of the viruses described above in the section entitled "Chimeric Antigen Receptors that Bind Oncolytic Virus Antigens", or an engineered variant thereof (e.g., an engineered variant having one or more of the OV modifications described hereinbelow – e.g., transgenic for human GM-CSF, deletion of the thymidine kinase gene, and/or the like), and the OV antigen is native to the OV. According to some embodiments, the OV antigen is heterologous to the OV, e.g., a viral antigen heterologous to the OV (e.g., any of the viral OV antigens described above in the section entitled "Chimeric Antigen Receptors that Bind Oncolytic Virus Antigens"), a tumor antigen, or any other heterologous OV antigens described elsewhere herein. According to some embodiments, such methods further comprise, prior to administering the pharmaceutical composition to the individual, infecting the cancer cells by administering an effective amount of the OV to the individual. Such methods find use, e.g., in treating the cancer of the individual.

When bound on the cancer cell surface, the antibody (or fusion protein) may induce cytotoxicity, e.g., via antibody-dependent cellular cytotoxicity (ADCC), by recruiting

complement in complement dependent cytotoxicity (CDC), via antibody-dependent cellular phagocytosis (ADCP), via epitope spreading, or by some other mechanism. The antibodies may be modified in the Fc region to provide desired or enhanced effector functions. This may be achieved by introducing one or more amino acid substitutions in an Fc region of the antibody. Alternatively, where it is desirable to eliminate or reduce effector function, so as to minimize side effects or therapeutic complications, certain other Fc regions may be used.

In certain embodiments, the pharmaceutical composition may comprise a conjugate, where the anti-VV A56 or anti-VV B5 antibody is conjugated to an agent selected from a chemotherapeutic agent, a toxin, a radiation sensitizing agent, a therapeutic radioactive isotope, and a radioisotope that permits *in vivo* imaging of the antibody. The agent may be any such agents described in the Conjugates section above.

The antibody (or fusion protein comprising same) may be selected such that the conjugate specifically binds an OV antigen of interest. OV antigens of interest include, but are not limited to, any of the native or heterologous OV antigens described elsewhere herein.

In certain embodiments, the OV antigen is a native OV antigen. For example, the OV may be any of the viruses described above in the section entitled "Chimeric Antigen Receptors that Bind Oncolytic Virus Antigens", or an engineered variant thereof (e.g., an engineered variant having one or more of the OV modifications described hereinbelow – e.g., transgenic for human GM-CSF, deletion of the thymidine kinase gene, and/or the like), and the OV antigen is native to the OV. According to some embodiments, the OV antigen is heterologous to the OV, e.g., a viral antigen heterologous to the OV (e.g., any of the viral OV antigens described above in the section entitled "Chimeric Antigen Receptors that Bind Oncolytic Virus Antigens"), a tumor antigen, or any other heterologous OV antigens described elsewhere herein. In some embodiments, the antigen is a native or heterologous OV antigen the expression of which is under exclusive control of the wild-type transcription regulatory elements of the OV for the antigen. That is, according to such embodiments, the transcription regulatory elements of the OV for the antigen are not modified relative to the wild-type OV. In certain embodiments, the antigen is a native OV antigen the expression levels of which are altered (e.g., increased) relative to expression by the wild-type OV by modification (e.g., replacement, duplication, etc.) of one or more wild-type transcription regulatory elements of the OV. By way of example, the antigen may be a native OV antigen (e.g., native A56, native B5, or any other native OV antigen of interest) the expression of which is increased relative

to expression by the wild-type OV by operably coupling the coding region of the native OV antigen to one or more heterologous regulatory elements (e.g., promoter, such as a human promoter) that results in higher expression levels as compared to the wild-type transcription regulatory elements of the OV. Such an OV may be a modified OV, e.g., an OV that includes
5 one or more of the OV modifications described hereinbelow.

In certain embodiments, the OV antigen is heterologous to the OV. For example, the antibody may be selected such that the antibody portion of the conjugate specifically binds any of the heterologous OV antigens described elsewhere herein, e.g., viral antigens heterologous to the OV, tumor antigens, or the like.

10 The antibody may be provided in any desired format, e.g., tetrameric format, single chain (e.g., scFv) format, etc. as described in the preceding sections of the present disclosure. According to some embodiments, the pharmaceutical composition comprises the antibody conjugated to a detectable label or radioactive isotope. In certain embodiments, the detectable label or radioactive isotope is an *in vivo* imaging agent. The methods in which the
15 antibody is conjugated to an *in vivo* imaging agent may further comprise detecting the *in vivo* imaging agent to image the cancer cells in the individual *in vivo*, e.g., for diagnostic, prognostic, and/or anti-cancer therapy monitoring purposes.

According to some aspects, provided are methods of targeting a CAR that specifically binds an oncolytic virus (OV) antigen to cancer cells in an individual. Such methods comprise
20 administering to the individual an effective amount of a pharmaceutical composition comprising a CAR comprising an antigen binding domain that specifically binds the OV antigen, where the cancer cells in the individual are infected with OV and express the OV antigen on their surface. The CAR may be expressed on the surface of a cell, e.g., an immune cell, such as an immune effector cell, e.g., a T cell, an NK cell, an NKT cell, a macrophage,
25 or the like. For example, the CAR may be present on the surface of T cells, where the method is a method of targeting CAR T cells to the infected cancer cells in the individual. According to some embodiments, such methods further comprise, prior to administering the pharmaceutical composition to the individual, infecting the cancer cells by administering an effective amount of the OV to the individual. Such methods find use, e.g., in treating the
30 cancer of the individual.

The antigen binding domain of the CAR specifically binds an OV antigen of interest. OV antigens of interest include, but are not limited to, any of the native or heterologous OV

antigens described elsewhere herein. In certain embodiments, the OV antigen is a native OV antigen. For example, the OV may be any of the viruses described above in the section entitled "Chimeric Antigen Receptors that Bind Oncolytic Virus Antigens", or an engineered variant thereof (e.g., an engineered variant having one or more of the OV modifications described hereinbelow – e.g., transgenic for human GM-CSF, deletion of the thymidine kinase gene, and/or the like), and the OV antigen is native to the OV. According to some embodiments, the OV antigen is heterologous to the OV, e.g., a viral antigen heterologous to the OV (e.g., any of the viral OV antigens described above in the section entitled "Chimeric Antigen Receptors that Bind Oncolytic Virus Antigens"), a tumor antigen, or any other heterologous OV antigens described elsewhere herein.

A pharmaceutical composition comprising cells that express a CAR on their surface may be prepared by a variety of methods. In some embodiments, a cell of the present disclosure is produced by transfecting the cell with a viral vector encoding the CAR. In some embodiments, the cell is a T cell, such that provided are methods of producing a CAR T cell. In some embodiments, such methods include activating a population of T cells (e.g., T cells obtained from an individual to whom a CAR T cell therapy will be administered), stimulating the population of T cells to proliferate, and transducing the T cell with a viral vector encoding the CAR. In some embodiments, the T cells are transduced with a retroviral vector, e.g., a gamma retroviral vector, encoding the CAR. In some embodiments, the T cells are transduced with a lentiviral vector encoding the CAR.

Cells of the present disclosure may be autologous/autogeneic ("self") or non-autologous ("non-self," e.g., allogeneic, syngeneic or xenogeneic). "Autologous" as used herein, refers to cells from the same individual. "Allogeneic" as used herein refers to cells of the same species that differ genetically from the cell in comparison. "Syngeneic," as used herein, refers to cells of a different individual that are genetically identical to the cell in comparison. In some embodiments, the cells are T cells obtained from a mammal. In some embodiments, the mammal is a primate. In some embodiments, the primate is a human.

T cells may be obtained from a number of sources including, but not limited to, peripheral blood, peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In certain embodiments, T cells can be obtained from a unit of blood collected

from an individual using any number of known techniques such as sedimentation, e.g., FICOLL™ separation.

In some embodiments, an isolated or purified population of T cells is used. In some embodiments, T_{CTL} and T_H lymphocytes are purified from PBMCs. In some embodiments, the
5 T_{CTL} and T_H lymphocytes are sorted into naïve (T_N), memory (T_{MEM}), and effector (T_{EFF}) T cell subpopulations either before or after activation, expansion, and/or genetic modification. Suitable approaches for such sorting are known and include, e.g., magnetic-activated cell sorting (MACS), where T_N are CD45RA⁺ CD62L⁺ CD95⁻; TSCM are CD45RA⁺ CD62L⁺ CD95⁺; TCM are CD45RO⁺ CD62L⁺ CD95⁺; and TEM are CD45RO⁺ CD62L⁻ CD95⁺. An
10 example approach for such sorting is described in Wang et al. (2016) *Blood* 127(24):2980-90.

In some embodiments, a specific subpopulation of T cells expressing one or more of the following markers: CD3, CD4, CD8, CD28, CD45RA, CD45RO, CD62, CD127, and HLA-DR can be further isolated by positive or negative selection techniques. In some
15 embodiments, a specific subpopulation of T cells, expressing one or more of the markers selected from the group consisting of CD62L, CCR7, CD28, CD27, CD122, CD127, CD197; or CD38 or CD62L, CD127, CD197, and CD38, is further isolated by positive or negative selection techniques. In some embodiments, the manufactured T cell compositions do not express one or more of the following markers: CD57, CD244, CD 160, PD-1, CTLA4, TIM3,
20 and LAG3. In some embodiments, the manufactured T cell compositions do not substantially express one or more of the following markers: CD57, CD244, CD 160, PD-1, CTLA4, TIM3, and LAG3.

In order to achieve therapeutically effective doses of T cell compositions, the T cells may be subjected to one or more rounds of stimulation, activation and/or expansion. T cells
25 can be activated and expanded generally using methods as described, for example, in U.S. Patents 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; and 6,867,041, each of which is incorporated herein by reference in its entirety for all purposes. In some embodiments, T cells are activated and expanded for about 1 to 21 days,
30 e.g., about 5 to 21 days. In some embodiments, T cells are activated and expanded for about 1 day to about 4 days, about 1 day to about 3 days, about 1 day to about 2 days, about 2 days to about 3 days, about 2 days to about 4 days, about 3 days to about 4 days, or about

1 day, about 2 days, about 3 days, or about 4 days prior to introduction of a nucleic acid (e.g., expression vector) encoding the CAR into the T cells.

In some embodiments, T cells are activated and expanded for about 6 hours, about 12 hours, about 18 hours or about 24 hours prior to introduction of a nucleic acid (e.g., expression vector) encoding the CAR into the T cells. In some embodiments, T cells are activated at the same time that a nucleic acid (e.g., an expression vector) encoding the CAR is introduced into the T cells.

In some embodiments, conditions appropriate for T cell culture include an appropriate media (e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 15, (Lonza)) and one or more factors necessary for proliferation and viability including, but not limited to serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN- γ , IL-4, IL-7, IL-21, GM-CSF, IL-10, IL-12, IL-15, TGF β , and TNF- α or any other additives suitable for the growth of cells known to the skilled artisan. Further illustrative examples of cell culture media include, but are not limited to RPMI 1640, Clicks, AEVI-V, DMEM, MEM, a-MEM, F-12, X-Vivo 15, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells.

In some embodiments, the nucleic acid (e.g., an expression vector) encoding the CAR is introduced into the cell (e.g., a T cell) by microinjection, transfection, lipofection, heat-shock, electroporation, transduction, gene gun, microinjection, DEAE-dextran-mediated transfer, and the like. In some embodiments, the nucleic acid (e.g., expression vector) encoding the CAR is introduced into the cell (e.g., a T cell) by AAV transduction. The AAV vector may comprise ITRs from AAV2, and a serotype from any one of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV 10. In some embodiments, the AAV vector comprises ITRs from AAV2 and a serotype from AAV6. In some embodiments, the nucleic acid (e.g., expression vector) encoding the CAR is introduced into the cell (e.g., a T cell) by lentiviral or retroviral transduction. The lentiviral vector backbone may be derived from HIV-1, HIV-2, visna-maedi virus (VMV) virus, caprine arthritis-encephalitis virus (CAEV), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), bovine immune deficiency virus (BIV), or simian immunodeficiency virus (SIV). The lentiviral vector may be integration competent or an integrase deficient lentiviral vector (TDLV). In one embodiment,

IDLV vectors including an HIV-based vector backbone (i.e., HIV cis-acting sequence elements) are employed.

In certain aspects, provided are methods of targeting a conjugate that comprises an antibody that specifically binds an oncolytic virus (OV) antigen to cancer cells in an individual.

5 Such methods comprise administering to the individual an effective amount of a pharmaceutical composition comprising an antibody that specifically binds the OV antigen, where the cancer cells in the individual are infected with OV and express the OV antigen on their surface. According to some embodiments, such methods further comprise, prior to administering the pharmaceutical composition to the individual, infecting the cancer cells by
10 administering an effective amount of the OV to the individual. Such methods find use, e.g., in treating the cancer of the individual.

The antibody of the conjugate specifically binds an OV antigen of interest, including but not limited to any of the OV antigens described elsewhere herein. In certain embodiments, the OV antigen is a native OV antigen. For example, the OV may be any of
15 the viruses described above in the section entitled "Chimeric Antigen Receptors that Bind Oncolytic Virus Antigens", or an engineered variant thereof (e.g., an engineered variant having one or more of the OV modifications described hereinbelow – e.g., transgenic for human GM-CSF, deletion of the thymidine kinase gene, and/or the like), and the OV antigen is native to the OV. According to some embodiments, the OV antigen is heterologous to the
20 OV, e.g., a viral antigen heterologous to the OV (e.g., any of the viral OV antigens described above in the section entitled "Chimeric Antigen Receptors that Bind Oncolytic Virus Antigens"), a tumor antigen, or any other heterologous OV antigens described elsewhere herein.

An OV administered to an individual according to the present disclosure may be a
25 wild-type OV or a modified OV. According to some embodiments, the OV is a modified OV, where the modified OV is a chimeric OV comprising two or more domains from different viruses. In some embodiments, the OV is a modified OV (e.g., a non-chimeric or chimeric OV) that includes one or more modifications in one or more of the following functional categories: infection, replication, tropism, improved safety, reporter genes for imaging,
30 thwarting the host anti-viral immune response, enhancing the host anti-tumor immune response, etc. According to some embodiments, the OV is modified to: encode and express human GM-CSF; have a deletion of the thymidine kinase gene (limiting or substantially

limiting viral replication to cells with high levels of thymidine kinase, typically seen in cancer cells with a mutated RAS or p53 gene); encode and express a reporter gene (e.g., Lac Z, luciferase, and/or the like); alter one or more genes encoding ribonucleotide reductase (RR); disrupt the F2L gene (which encodes the viral dUTPase involved in both maintaining the fidelity of DNA replication and providing the precursor for the production of TMP by thymidylate synthase); express a therapeutic protein (e.g., a suicide gene – that is, a gene coding for a protein able to convert a precursor of a drug into a cytotoxic compound, including but not limited to TK, cytosine deaminase, purine nucleoside phosphorylase, uracil phosphoribosyl transferase, thymidylate kinase, and the like); express an immunostimulatory protein, where "immunostimulatory protein" refers to a protein which has the ability to stimulate the immune system, in a specific or non-specific way, including cytokines, chemokines, growth factors, etc.; and any combinations thereof. Any of the modified OV described above may encode any of the OV antigens described elsewhere herein. For example, the modified OV may be modified from any of the viruses described above in the section entitled "Chimeric Antigen Receptors that Bind Oncolytic Virus Antigens", and the OV antigen is native to the OV. According to some embodiments, the OV antigen is heterologous to the modified OV, e.g., a viral antigen heterologous to the modified OV (e.g., any of the viral OV antigens described above in the section entitled "Chimeric Antigen Receptors that Bind Oncolytic Virus Antigens"), a tumor antigen, or any other heterologous OV antigens described elsewhere herein.

In certain aspects, provided are methods comprising administering a pharmaceutical composition comprising cells (e.g., cancer cells) infected with OV. The pharmaceutical composition may further include an antibody, conjugate, or fusion protein that specifically binds an OV antigen expressed by the infected cells, e.g., cancer cells. The cells (e.g., cancer cells) may have been removed from the individual during surgery. The cells (e.g., cancer cells) may have been altered (and killed) in the lab to make them more likely to be attacked by the immune system when administered back into the patient. The patient's immune system then attacks the cells and any similar cells still in the body. The antibody, conjugate, or fusion protein of the present disclosure may be employed according to this approach to promote uptake of tumor particles/antigens by Fc receptors on professional APC, leading to an enhanced immune response against the tumor.

The pharmaceutical compositions may be administered to any of a variety of individuals. In certain aspects, the individual is a “mammal” or “mammalian,” where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys). In some embodiments, the individual is a human. In certain aspects, the individual is an animal model (e.g., a mouse model, a primate model, or the like) of a cellular proliferative disorder, e.g., cancer.

The individual in need thereof may have a cell proliferative disorder. By “cell proliferative disorder” is meant a disorder wherein unwanted cell proliferation of one or more subset(s) of cells in a multicellular organism occurs, resulting in harm, for example, pain or decreased life expectancy to the organism. Cell proliferative disorders include, but are not limited to, cancer, pre-cancer, benign tumors, blood vessel proliferative disorders (e.g., arthritis, restenosis, and the like), fibrotic disorders (e.g., hepatic cirrhosis, atherosclerosis, and the like), psoriasis, epidermic and dermoid cysts, lipomas, adenomas, capillary and cutaneous hemangiomas, lymphangiomas, nevi lesions, teratomas, nephromas, myofibromatosis, osteoplastic tumors, dysplastic masses, mesangial cell proliferative disorders, and the like.

In some embodiments, the individual has cancer. The subject methods may be employed for the treatment of a large variety of cancers. “Tumor”, as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms “cancer” and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation. Examples of cancers that may be treated using the subject methods include, but are not limited to, carcinoma, lymphoma, blastoma, and sarcoma. More particular examples of such cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bile duct cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, various types of head and neck cancer, and the like. In certain embodiments, the individual has a cancer selected from a solid tumor, recurrent glioblastoma multiforme (GBM),

non-small cell lung cancer, metastatic melanoma, melanoma, peritoneal cancer, epithelial ovarian cancer, glioblastoma multiforme (GBM), metastatic colorectal cancer, colorectal cancer, pancreatic ductal adenocarcinoma, squamous cell carcinoma, esophageal cancer, gastric cancer, neuroblastoma, fallopian tube cancer, bladder cancer, metastatic breast
5 cancer, pancreatic cancer, soft tissue sarcoma, recurrent head and neck cancer squamous cell carcinoma, head and neck cancer, anaplastic astrocytoma, malignant pleural mesothelioma, breast cancer, squamous non-small cell lung cancer, rhabdomyosarcoma, metastatic renal cell carcinoma, basal cell carcinoma (basal cell epithelioma), and gliosarcoma. In certain aspects, the individual has a cancer selected from melanoma,
10 Hodgkin lymphoma, renal cell carcinoma (RCC), bladder cancer, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC).

The antibodies, fusion proteins and conjugates of the present disclosure may be administered via a route of administration selected from oral (e.g., in tablet form, capsule form, liquid form, or the like), parenteral (e.g., by intravenous, intra-arterial, subcutaneous,
15 intramuscular, or epidural injection), topical, intra-nasal, or intra-tumoral administration.

The antibodies, fusion proteins and conjugates of the present disclosure may be administered in a pharmaceutical composition in a therapeutically effective amount. By “therapeutically effective amount” is meant a dosage sufficient to produce a desired result, e.g., an amount sufficient to effect beneficial or desired therapeutic (including preventative)
20 results, such as a reduction in a symptom of a cancer, as compared to a control. With respect to cancer, in some embodiments, the therapeutically effective amount is sufficient to slow the growth of a tumor, reduce the size of a tumor, and/or the like. An effective amount can be administered in one or more administrations.

As described above, aspects of the present disclosure include methods for treating a
25 cancer of an individual. By treatment is meant at least an amelioration of one or more symptoms associated with the cancer of the individual, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g. symptom, associated with the cancer being treated. As such, treatment also includes situations where the cancer, or at least one or more symptoms associated therewith, are completely inhibited,
30 e.g., prevented from happening, or stopped, e.g., terminated, such that the individual no longer suffers from the cancer, or at least the symptoms that characterize the cancer.

An antibody, fusion protein, or conjugate of the present disclosure may be administered to the individual alone or in combination with a second agent. Second agents of interest include, but are not limited to, agents approved by the United States Food and Drug Administration and/or the European Medicines Agency (EMA) for use in treating cancer.

5 In some embodiments, the second agent is an immune checkpoint inhibitor. Immune checkpoint inhibitors of interest include, but are not limited to, a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, a programmed cell death-1 (PD-1) inhibitor, a programmed cell death ligand-1 (PD-L1) inhibitor, a lymphocyte activation gene-3 (LAG-3) inhibitor, a T-cell immunoglobulin domain and mucin domain 3 (TIM-3) inhibitor, an
10 indoleamine (2,3)-dioxygenase (IDO) inhibitor, a T cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibitor, a V-domain Ig suppressor of T cell activation (VISTA) inhibitor, a B7-H3 inhibitor, and any combination thereof.

When an antibody, fusion protein, or conjugate of the present disclosure is administered with a second agent, the antibody, fusion protein, or conjugate and the second
15 agent may be administered to the individual according to any suitable administration regimen. According to certain embodiments, the antibody, fusion protein, or conjugate and the second agent are administered according to a dosing regimen approved for individual use. In some embodiments, the administration of the antibody, fusion protein, or conjugate permits the second agent to be administered according to a dosing regimen that involves one or more
20 lower and/or less frequent doses, and/or a reduced number of cycles as compared with that utilized when the second agent is administered without administration of the antibody, fusion protein, or conjugate. In certain aspects, the administration of the second agent permits the antibody, fusion protein, or conjugate to be administered according to a dosing regimen that involves one or more lower and/or less frequent doses, and/or a reduced number of cycles
25 as compared with that utilized when the antibody, fusion protein, or conjugate is administered without administration of the second agent.

In some embodiments, one or more doses of the antibody, fusion protein, or conjugate and the second agent are administered concurrently to the individual. By “concurrently” is meant the antibody, fusion protein, or conjugate and the second agent are either present in
30 the same pharmaceutical composition, or the antibody, fusion protein, or conjugate and the second agent are administered as separate pharmaceutical compositions within 1 hour or less, 30 minutes or less, or 15 minutes or less.

In some embodiments, one or more doses of the antibody, fusion protein, or conjugate and the second agent are administered sequentially to the individual.

In some embodiments, the antibody, fusion protein, or conjugate and the second agent are administered to the individual in different compositions and/or at different times. For example, the antibody, fusion protein, or conjugate may be administered prior to administration of the second agent, e.g., in a particular cycle. Alternatively, the second agent may be administered prior to administration of the antibody, fusion protein, or conjugate, e.g., in a particular cycle. The second agent to be administered may be administered a period of time that starts at least 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, or up to 5 days or more after the administration of the first agent to be administered.

In one example, the second agent is administered to the individual for a desirable period of time prior to administration of the antibody, fusion protein, or conjugate. In certain aspects, such a regimen “primes” the cancer cells to potentiate the anti-cancer effect of the antibody, fusion protein, or conjugate. Such a period of time separating a step of administering the second agent from a step of administering the antibody, fusion protein, or conjugate is of sufficient length to permit priming of the cancer cells, desirably so that the anti-cancer effect of the antibody, fusion protein, or conjugate is increased.

In some embodiments, administration of one agent is specifically timed relative to administration of the other agent. For example, in some embodiments, the antibody, fusion protein, or conjugate is administered so that a particular effect is observed (or expected to be observed, for example based on population studies showing a correlation between a given dosing regimen and the particular effect of interest).

In certain aspects, desired relative dosing regimens for agents administered in combination may be assessed or determined empirically, for example using *ex vivo*, *in vivo* and/or *in vitro* models; in some embodiments, such assessment or empirical determination is made *in vivo*, in a patient population (e.g., so that a correlation is established), or alternatively in a particular individual of interest.

In some embodiments, the antibody, fusion protein, or conjugate and the second agent are administered according to an intermittent dosing regimen including at least two cycles. Where two or more agents are administered in combination, and each by such an intermittent, cycling, regimen, individual doses of different agents may be interdigitated with one another. In certain aspects, one or more doses of a second agent is administered a period of time after

a dose of the first agent. In some embodiments, each dose of the second agent is administered a period of time after a dose of the first agent. In certain aspects, each dose of the first agent is followed after a period of time by a dose of the second agent. In some embodiments, two or more doses of the first agent are administered between at least one pair of doses of the second agent; in certain aspects, two or more doses of the second agent are administered between at least one pair of doses of the first agent. In some embodiments, different doses of the same agent are separated by a common interval of time; in some embodiments, the interval of time between different doses of the same agent varies. In certain aspects, different doses of the antibody, fusion protein, or conjugate and the second agent are separated from one another by a common interval of time; in some embodiments, different doses of the different agents are separated from one another by different intervals of time.

One exemplary protocol for interdigitating two intermittent, cycled dosing regimens may include: (a) a first dosing period during which a therapeutically effective amount the antibody, fusion protein, or conjugate is administered to the individual; (b) a first resting period; (c) a second dosing period during which a therapeutically effective amount of the second agent is administered to the individual; and (d) a second resting period. A second exemplary protocol for interdigitating two intermittent, cycled dosing regimens may include: (a) a first dosing period during which a therapeutically effective amount the second agent is administered to the individual; (b) a first resting period; (c) a second dosing period during which a therapeutically effective amount of the antibody, fusion protein, or conjugate is administered to the individual; and (d) a second resting period.

In some embodiments, the first resting period and second resting period may correspond to an identical number of hours or days. Alternatively, in some embodiments, the first resting period and second resting period are different, with either the first resting period being longer than the second one or, vice versa. In some embodiments, each of the resting periods corresponds to 120 hours, 96 hours, 72 hours, 48 hours, 24 hours, 12 hours, 6 hours, 30 hours, 1 hour, or less. In some embodiments, if the second resting period is longer than the first resting period, it can be defined as a number of days or weeks rather than hours (for instance 1 day, 3 days, 5 days, 1 week, 2, weeks, 4 weeks or more).

If the first resting period's length is determined by existence or development of a particular biological or therapeutic event, then the second resting period's length may be

determined on the basis of different factors, separately or in combination. Exemplary such factors may include type and/or stage of a cancer against which the therapy is administered; properties (e.g., pharmacokinetic properties) of the antibody, fusion protein, or conjugate, and/or one or more features of the patient's response to therapy with the antibody, fusion protein, or conjugate. In some embodiments, length of one or both resting periods may be adjusted in light of pharmacokinetic properties (e.g., as assessed via plasma concentration levels) of one or the other of the administered agents. For example, a relevant resting period might be deemed to be completed when plasma concentration of the relevant agent is below a pre-determined level, optionally upon evaluation or other consideration of one or more features of the individual's response.

In certain aspects, the number of cycles for which a particular agent is administered may be determined empirically. Also, in some embodiments, the precise regimen followed (e.g., number of doses, spacing of doses (e.g., relative to each other or to another event such as administration of another therapy), amount of doses, etc.) may be different for one or more cycles as compared with one or more other cycles.

The antibody, fusion protein, or conjugate and the second agent may be administered together or independently via any suitable route of administration. The antibody, fusion protein, or conjugate and the second agent may be administered via a route of administration independently selected from oral, parenteral (e.g., by intravenous, intra-arterial, subcutaneous, intramuscular, or epidural injection), topical, or intra-nasal administration. According to certain embodiments, antibody, fusion protein, or conjugate and the second agent are both administered orally (e.g., in tablet form, capsule form, liquid form, or the like) either concurrently (in the same pharmaceutical composition or separate pharmaceutical compositions) or sequentially.

When the methods further comprise, prior to administering the pharmaceutical composition to the individual, infecting the cancer cells by administering the OV to the individual, any suitable administration regimen may be employed to infect the cancer cells. Poxvirus replication takes place in the cytoplasm, as the virus is sufficiently complex to have acquired all the functions necessary for genome replication. Once in the cell cytoplasm, gene expression is carried out by viral enzymes associated with the core. Expression is divided into 2 phases: early genes: which represent about of 50% genome, and are expressed before genome replication, and late genes, which are expressed after genome replication. The

temporal control of expression is provided by the late promoters, which are dependent on DNA replication for activity. Genome replication is believed to involve self-priming, leading to the formation of high molecular weight concatemers, which are subsequently cleaved and repaired to make virus genomes. Viral assembly occurs in the cytoskeleton and probably involves interactions with the cytoskeletal proteins (e.g., actin-binding proteins). Inclusions form in the cytoplasm that mature into virus particles. Vaccinia virus is unique among DNA viruses as it replicates only in the cytoplasm of the host cell. Therefore, the large genome is required to code for various enzymes and proteins needed for viral DNA replication. During replication, vaccinia produces several infectious forms, which differ in their outer membranes: the intracellular mature virion (IMV), the intracellular enveloped virion (IEV), the cell-associated enveloped virion (CEV), and the extracellular enveloped virion (EEV).

To infect the cancer cells with the OV, the OV is administered using a suitable route of administration. The route of administration may vary with the location and nature of the cancer, and may include, e.g., intradermal, transdermal, parenteral, intravenous, intramuscular, intranasal, subcutaneous, regional (e.g., in the proximity of a tumor, particularly with the vasculature or adjacent vasculature of a tumor), percutaneous, intratracheal, intraperitoneal, intraarterial, intravesical, intratumoral, inhalation, perfusion, lavage, and oral administration and formulation. Intratumoral injection, or injection directly into the tumor vasculature is specifically contemplated for discrete, solid, accessible tumors. Local, regional or systemic administration also may be appropriate. The viral particles may advantageously be contacted by administering multiple injections to the tumor, spaced, for example, at approximately 1 cm intervals. Continuous administration also may be applied where appropriate, for example, by implanting a catheter into a tumor or into tumor vasculature. Such continuous perfusion may take place, for example, for a period of from about 1-2 hours, to about 2-6 hours, to about 6-12 hours, or about 12-24 hours following the initiation of administration. Administration regimens may vary, and often depend on tumor type, tumor location, disease progression, and health and age of the patient. Certain types of tumor will require more aggressive treatment, while at the same time, certain patients cannot tolerate more taxing protocols. The clinician will be best suited to make such decisions.

Injection of nucleic acid constructs may be delivered by syringe or any other method used for injection of a solution, so long as the expression construct can pass through the particular gauge of needle required for injection. An exemplary needleless injection system

that may be used for the administration of OV is exemplified in U.S. Pat. No. 5,846,233. This system features a nozzle defining an ampule chamber for holding the solution and an energy device for pushing the solution out of the nozzle to the site of delivery. Another exemplary syringe system is one that permits multiple injections of predetermined quantities of a solution precisely at any depth (U.S. Pat. No. 5,846,225). Mixtures of OV particles or nucleic acids encoding same may be prepared in water suitably mixed with one or more excipients, carriers, or diluents. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils.

A physician may start prescribing doses of OV vector at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. Alternatively, a physician may begin a treatment regimen by administering a dose of OV vector and subsequently administer progressively lower doses until a therapeutic effect is achieved, e.g., a reduction in the volume of one or more tumors.

The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

Example 1 – Antibody Generation

Stable CHO cell lines were generated expressing either vaccinia virus A56 (CHO-A56) or B5 capsid protein (CHO-B5), using A56 or B5 sequence from a Wyeth VV strain (SEQ ID NO:180 and SEQ ID NO:181, respectively). Antibodies were raised in New Zealand White Rabbits by sequential semi-monthly subcutaneous immunization with a mix of CHO-A56 and CHO-B5 cells (30 million per cell type for first injection, 45 million for subsequent injections)—mixed with aluminum hydroxide (5 mg/injection) and CpG (Cat# ODN1826, 20 µg/injection). One week following the 10th injection, the rabbit was euthanized and the spleen was harvested (Cedarlane). B cells were cultured and isolated as per Babcook et al. (1). Antibodies were identified by screening the B-cell supernatants for binding to OVCAR3 cells (ATCC, Cat# HTB-161) infected with VV Western Reserve strain VVdd(eGFP) (gift from Dr. John Bell, Ottawa Hospital Research Institute (OHRI), SEQ ID NOs:182 and 183), by flow cytometry (data not shown). In order to clone the antibody from cultured B cells, the frozen cells were thawed and analyzed by A56.hFc or B5.hFc hemolytic plaque assay. The human Fc fusion proteins were generated in-house using A56 or B5 sequence from the Wyeth VV

strain as set out in Tables 2 and 4. Isolated single B cells were lysed and antibody V-genes were amplified by RT-PCR. PCR products corresponding to matched antibody heavy and light chains were then cloned into human IgG1 constant region and Igk constant region constructs (pTT5/IgG1, pTT5/Igk). To produce recombinant antibody, VH and VL chain plasmids were transfected into HEK293-6E cells using 293fectin (Thermo, Cat# 12347019). After 96 hours of secretion, the antibody-containing supernatant was cleared of cells by centrifugation and sterile filtration (0.22 µm). Antibodies were purified using HiTrap Mab Select SuRe column (GE, Cat#: 11003495) and HiPrep 26/10 Desalting column (GE, Cat# 17508701) on an AKTA Express system. The purity of the antibodies was tested by SDS-PAGE, UPLC-SEC, and LC-MS. The sequences of the antibodies generated are shown in Tables 1 and 3. The antibody ID and formats are set out in Table 15 below.

Table 15 – Antibody ID and Format

Antibody	ID	Fc
Anti-B5 Rabbit Antibody	A048	hIgG1
	A058	muIgG2a
	A073	RbIgG
Anti-A56 Rabbit Antibody	A049	hIgG1
	A059	muIgG2a
	A056	RbIgG
Anti-A56 Rabbit Antibody	A047	hIgG1
	A057	muIgG2a
Anti-B5 Rabbit Antibody	A051	hIgG1
Anti-A56 Rabbit Antibody	A050	hIgG1
Anti-A56 Rabbit Antibody	A054	hIgG1

Example 2 – Antibody Binding to A56 and B5 Antigens

Stable cell lines were generated using Lenti-x293T (Clontech, Cat# 632181) cells, resulting in HEK-A56(GFP) and HEK-B5(GFP) cells which express the antigens A56 (Wyeth VV sequence) or B5 (Wyeth VV sequence) on the cell surface. A549 (ATCC, Cat# CCL-185) and CaOv3 (ATCC, Cat# HTB-75) tumor cells were grown to 80-90% confluence in

appropriate media (A549 - F-12K Nutrient Mixture (Gibco, Cat# 21127-022); CaOV3 -DMEM (Gibco, Cat# 11995-040) supplemented with 10% FBS (Corning, Cat# 35-015-CV)). Cells were infected with VVdd(eGFP) at a multiplicity of infection of 0.5 in serum free RPMI (Gibco, Cat# A10491-01) and incubated for 6.5 h, at 37°C in 5% CO₂. Wells were supplemented with growth media 1:2, and further incubated overnight. A549 cells were trypsinized, and plated, alongside the CaOV3 cells, at approximately 1×10^5 cells per well, in 96-well v-bottom plates (Sarstedt, Cat# 82.1583.001). Corresponding uninfected A549 and CaOV3 cells, and HEK-A56(GFP) and HEK-B5(GFP) and HEK-WT cell lines were also plated at 4×10^4 cells per well. Anti-Vaccinia Virus rabbit polyclonal antibody (CedarLane, Cat# LS-C103289) was used as a positive control.

Anti-A56 antibodies (A047, A049, A050, or A054), anti-B5 antibodies (A048 or A051), and human IgG isotype control (Sigma, Cat# I5154) were added to cells and incubated for 25 min on ice. Cells were washed twice with PBS, centrifuged at 450 G for 4 min and incubated with 1:100 AlexaFluor 647 conjugated anti-rabbit IgG (Jackson, Cat# 115-605-046) or AlexaFluor 647 conjugated anti-human IgG (Jackson, Cat# 109-605-098), with 1:1000 fixable viability dye eFluor 780 (eBioscience, Cat# 65-0865-14) for 15 min at room temperature (RT). Following two washes with PBS, cells were fixed in IC fixation buffer (eBioscience, Cat# 00-8222-49) for 10 min, washed twice with PBS, resuspended in 1% FBS in PBS, and analyzed by flow cytometry on a BD LSRFortessa X-20 HTS system, and data processed with FlowJo V 10.5.3 Software. The data shows binding of antibodies to VV VVdd(eGFP) infected cells (FIG. 1). The anti-A56 antibodies bind HEK-A56(GFP) cells, and the anti-B5 antibodies bind HEK-B5(GFP) cells, specifically (FIG. 2). No binding was observed to negative controls – HEK parental cells, uninfected A549 or CaOV3 cells, and an irrelevant VV antigen A33, also expressed in HEK cells (data not shown). Isotype control hIgG showed no binding to cells.

A commercially available anti-B5 antibody (Immunotech, Cat#IT-012-009M1, raised using a VV Western Reserve immunogen) was tested for binding to B5 antigens. By flow cytometry, a dilution series of the anti-Vaccinia rabbit polyclonal antibody was compared to the Immunotech anti-B5 antibody ('IT anti-B5 IgG'), as well as isotype controls, with similar assay conditions as above. For mouse antibody detection of IT anti-B5 IgG and mouse isotype control, a goat anti-mouse A647 (Jackson, Cat #115-005-146) was used. The IT anti-B5 IgG did not bind to the HEK-B5 cells (FIG. 3, top panel). An ELISA to assess binding to the B5.hFc soluble antigen confirmed this antibody does not bind the B5 reagents made

based on the VV Wyeth B5 sequence. In this assay, B5.hFc was coated on a maxisorp plate at 2 µg/ml and incubated overnight at 4°C. Following standard ELISA procedure, the plate was washed, blocked in 5% skim milk powder, the primary antibodies incubated in block for 1h RT, and washed. Secondary detection was with goat anti-mIgG Fc HRP (Jackson, Cat# 115-035-071) or anti-Rb IgG Fc HRP (Jackson ImmunoResearch, Cat# 111-035-046), for 1 h at RT, followed by washing, and addition of 50 µl/well TMB K-Blue (Neogen, #308175), and then 50 µl/well 1N HCl. The IT anti-B5 IgG was negative for binding to the B5.hFc soluble antigen by standard ELISA (FIG. 3, bottom panel).

The IT anti-B5 IgG was also tested for binding to Western Reserve VVddeGFP-infected A549 and HT29 cells. A549 and HT29 cells (ATCC cat# HTB-38, grown in McCoy 5A media (Gibco #16600-082) + 10% FBS) were cultured to 80-90% confluency. Cells were infected with VVdd(eGFP) at a multiplicity of infection of 1 in serum free RPMI. Cells were incubated for 6.5 h at 37°C in 5% CO₂, supplemented with growth media 1:2, and further incubated overnight. The cells were trypsinized, and plated at approximately 1 x 10⁵ cells per well, in 96-well v-bottom plates. Anti-B5 antibodies A048 hIgG1 and IT anti-B5 IgG, and human isotype controls were added to cells and incubated for 25 min on ice. Cells were washed and antibody detected as above, with AlexaFluor 647 conjugated anti-human IgG and anti-murine IgG (Jackson, #115-605-164), followed by 1:1000 fixable viability dye eFluor 780. Following two washes, fixation, and resuspension in 1% FBS in PBS, the samples were analyzed by flow cytometry on a BD LSRFortessa X-20 HTS system. The data show that A048 antibody binds to Western Reserve VVddeGFP-infected A549 and HT29 cells more strongly than IT anti-B5 IgG (FIG. 4). The EC₅₀ for binding of A048 antibody to infected A549 cells and HT29 cells is 6 nM, and 1.1nM respectively. The EC₅₀ for binding of IT anti-B5 IgG to infected A549 and HT29 cells is 78 nM and 15.8 nM, respectively.

Example 3 – Reformatting to Mouse and Rabbit Antibodies

Antibodies were reformatted to full rabbit IgG or chimeric rabbit/mouse IgG2a Fc antibodies, expressed in HEK293 cells, and purified as described previously. A549 cells infected with VVdd(eGFP), as described above, were tested for binding by the antibodies as rabbit IgG, or mouse or human chimeras. Anti-A56 antibodies (A056, A049, A059), and anti-B5 antibodies (A073, A048, A058), as well as rabbit IgG isotype (Jackson, Cat#011-000-003), human IgG isotype (Sigma Aldrich, Cat# I5154), and mouse IgG isotype (R&D Biosystems,

Cat# MAB004) were added to infected cells and incubated for 25 min on ice. Cells were washed, and incubated with 1:100 AlexaFluor 647 conjugated anti-rabbit IgG (Jackson, Cat# 115-605-046), or anti-human IgG (Jackson, Cat# 109-605-098), or anti-mouse IgG (Jackson, Cat# 115-605-164), with 1:1000 DAPI (BioLegend, Cat# 422801) for 15 min at RT. Following washes and fixation, samples were analyzed by flow cytometry. Data confirms binding of all formats to VV VVdd(eGFP)-infected cells with similar EC50s (FIG. 5, Table 16). No binding was observed to uninfected cells, or by isotype controls.

Table 16 – Antibody format and EC50 for binding to VV-infected A549 cells

Antibody	ID	Fc	VVdd (eGFP)-Infected A549 EC50 nM
Anti-B5 Rabbit Antibody	A048	hIgG1	9 nM
	A058	mulgG2a	3 nM
	A073	RbIgG	3 nM
Anti-A56 Rabbit Antibody	A049	hIgG1	14 nM
	A059	mulgG2a	5 nM
	A056	RbIgG	16 nM

Example 4 – Antibody Binding to Virus-infected Tissue

BALB/c female mice were implanted with 1×10^6 MC38 cells on Day 0. For some mice, VVdd(eGFP) was given IT, 2.5×10^7 pfu in 100 μ l, on Day 11 and Day 13 post MC38 implantation, and mice were euthanized on Day 16. A control mouse bearing an MC38 tumor was treated with PBS in place of VVdd(eGFP) and was euthanized Day 12 post implantation. Tumor tissue was collected in 10% neutral buffered formalin (NBF). Tissues were formalin fixed, paraffin embedded, sectioned and stained. H&E stained images were scanned using the Aperio ScanScope AT2 digital slide scanner. Tissues were deparaffinized and rehydrated according to standard protocols. Tissue was autoclaved in antigen retriever (Sigma, Cat# C999-100ML) for 20 min at 121°C, for heat-induced epitope retrieval. After cooling, slides were rinsed twice with PBS, and the section isolated with a PAP pen to create a hydrophobic

barrier. Tissue was kept hydrated with 200 µl wash buffer (0.1% Tween-20, 0.1% BSA in PBS). The tissues were permeabilized at RT for 10 min using 0.2% Triton in PBS, and washed three times. Sections were blocked for 60 min in blocking buffer (5% normal goat serum, 0.05% Tween-20, 0.1% BSA in PBS). Primary antibodies in antibody diluent (1% normal goat serum, 0.05% Tween-20, 0.1% BSA in PBS) were applied to sections, after removal of blocking buffer, and incubated overnight at 4°C. A049 (Anti-A56) hIgG1 was used at 12.5 µg/ml, and a positive control polyclonal rabbit anti-Vaccinia virus antibody (CedarLane, Cat# LS-C103289) was used at 1:100. Human IgG1 (Sigma, Cat# I5154) and rabbit IgG (Jackson ImmunoResearch Laboratories, Cat# 011-000-003) isotype controls were used at 25 µg/ml.

The next day, tissues were washed and secondary antibodies (200 µl) prepped in antibody diluent and incubated for 1.5 h at RT in the dark. Human primary antibody stained tissues were detected with AlexaFluor 549-conjugated goat anti-human IgG (Jackson, Cat# 109-585-003,) at 1:100, and rabbit primary antibodies were detected with AlexaFluor Plus 488 Goat anti-rabbit IgG (H+L) antibody (Thermo, Cat# A32731) at 10 µg/ml. Following incubation, slides were washed three times, 5 min each. Hoechst stain (Sigma, Cat# B2261) was added to tissues at 1 µg/ml, incubated for 10 min and then excess removed. Cover slips were added with Fluoromont-G (Southern Biotech, Cat# 0100-01) and imaged using a Leica SP5 X Laser Scanning Confocal Microscope. Data confirms binding of A049 to VV VVdd(eGFP) infected tumor tissue, with no binding observed to uninfected tumor tissue (FIG. 6). Polyclonal rabbit anti-Vaccinia virus antibody shows non-specific binding to uninfected tumor tissue.

Example 5 – Antibody Affinity to B5 and A56 Protein

Antibody affinity was assessed using a Biacore T200. On a Series S CM5 chip, A048 was immobilized on FC2, and A051 was immobilized on FC3, with FC1 blank immobilized. The sensor surface was activated by injecting EDC and NHS. Ligands were immobilized as follows: anti-B5 A048 hIgG1 (12 µg/mL) prepared in 200 µL sodium acetate, pH 4.5, and A051 (12 µg/mL) in 200 µl sodium acetate pH 5.0. The remaining activated groups were blocked by injecting ethanolamine. Finally, the chip was washed with 50 mM NaOH. Approximately 1000 RU of each antibody was amine coupled, followed by chip equilibration with buffer. All binding studies were performed in freshly prepared and filtered running buffer HBS-EP+ (GE, Cat# BR100188). B5.hFc (MW 150 kDa) was flowed over as analyte in increasing concentration of antigen (1.5 nM, 4.6 nM, 13.8 nM, 41.4 nM and 124 nM) for 200s at 30 µl/min association, followed by a single 30 min dissociation. At the end of each cycle,

the IgG capture surfaces were regenerated by injecting pH 1.5, 10 mM glycine for 60s at 30 μ l/min. Running buffer without analyte was injected for double reference subtraction. Curves were fit using 1:1 Langmuir binding.

Similar experimental conditions were set up for the A56 antibodies except different concentrations of A56.hFc were flowed over the sensor (0.6 nM, 1.9 nM, 5.6 nM, 16.7 nM, and 50 nM). Apparent KD is listed, as due to use of bivalent antigens B5.hFc and A56.hFc, the interaction with the antibody may not be a simple 1:1 binding (Table 17). Affinity of A051 could not be determined under these conditions, as it was reaching the limits of detection of the Biacore T200.

Table 17 – Affinity of Antibodies to A56 or B5 proteins

	k_a (1/Ms)	k_d (1/s)	Apparent KD (nM)
A047 (A56)	1.92×10^4	4.50×10^{-5}	2.34 nM
A049 (A56)	3.95×10^5	2.27×10^{-5}	≤ 0.1 nM*
A050 (A56)	9.98×10^4	5.07×10^{-5}	0.507 nM
A054 (A56)	9.25×10^5	1.41×10^{-2}	15.32 nM
A048 (B5)	2.967×10^4	2.209×10^{-5}	0.745 nM

* Approaching limits of detection

Antibodies were assessed for affinity to A56.hFc or B5.hFc.

Example 6 – Epitope Binning

Antibodies were biotinylated using EZ-Link Sulfo-NHS-LC-Biotin (Thermo, Cat# 21343) using a 20:1 ratio according to manufacturer's protocols. A549 cells were infected at a MOI of 0.5 using VVdd(eGFP), and fixed on the day before the assay. On the day of the assay, virus-infected A549 cells were pre-incubated with 25 μ g/mL of non-biotinylated antibodies and incubated for 1h. The biotinylated antibodies (10 μ g/ml) were then spiked into wells in a 96-well v-bottom plate to a final concentration of 5 μ g/ml and allowed incubate for 1h. Finally, detection was performed using streptavidin-Alexa647(Jackson, Cat# 016-600-084) to detect the bound biotinylated antibodies. Samples were acquired on the Intellicyt HTFC high throughput flow cytometer. An anti-ovalbumin antibody (in-house Centre for Drug Research and Development (CDRD)) was used as an irrelevant control IgG. The data indicates that the anti-A56 antibodies appear to bind different epitopes on A56, as similar binding to the first antibody tested is observed when a 2nd antibody is added to the VAVC coated plate. Similarly, the data indicates that the anti-B5 antibodies appear to bind different epitopes on B5 (FIG. 7).

Example 7 – Antibody Binding to Virus Particles

A 96-well plate (Corning, Cat# 3368) was coated with 9×10^6 pfu/mL VVdd(eGFP) in sodium bicarbonate buffer (pH 9.6), 50 μ l/well. After overnight incubation at 4°C, the coated wells were washed three times with PBS, and fixation buffer was added and incubated for 10 min. The coated wells were then washed four times with distilled water. The wells were blocked for 1h at RT with 5% skim milk powder in PBS. Antibodies (A049, A047, A050, A054, A048, A051) were diluted and titrated 1:4 in blocking buffer, from a starting concentration of 20 μ g/ml. NKp30, an NK cell cytotoxicity receptor, has been shown to bind VV A56 (2). NKp30-His(in-house) soluble protein was tested at 20 μ g/mL or 1 μ g /ml as a positive control, and hlgG1 as a negative control. The wells were washed four times with water, and 50 μ l/well of antibody was added and incubated for 1h at RT. Subsequently, the wells were washed with water, and 0.2 μ g/mL HRP-conjugated goat anti-hlgG Fc (Jackson, Cat# 109-035-098) in blocking buffer was added and incubated for 1h at RT. After washing, 50 μ l/well of TMB (Neogen, Cat # 308177) was added and the plate incubated for 30 min at RT. The color development was stopped with 1 M HCl, 50 μ l. Absorbance was measured at 450 nm using Spectromax plate reader and data was processed using SoftMaxPro. Data shows all antibodies tested except A054 bind to virus particles of VVdd(eGFP) (FIG. 8).

Example 8 – Effect of Antibodies on Virus Infection

A549 cells were seeded at 5×10^4 cells per well in 96-well flat bottom plate (Flacon, Cat#353075) and adhered overnight at 37°C, 5% CO₂. VVdd(eGFP) at different MOIs (1.5×10^6 pfu/mL (MOI 1), 1.5×10^5 pfu/mL (MOI 0.1) and 1.5×10^4 pfu/mL (MOI 0.01)) was incubated with equal volume of 20 μ g/mL A047, A048, A049, A050, A051, A054, hlgG (Sigma, Cat# I5154) or 1:100 vaccinia virus polyclonal antibody (Cedarlane, Cat# LS-C103289) in serum-free F-12K Nutrient Mixture (Gibco, Cat# 21127-022), for 15 min at RT. Cells were infected with the VVdd(eGFP)/antibody mixture for 6.5 h at 37°C, 5% CO₂ followed by addition of F-12K Nutrient Mixture (Gibco, Cat# 21127-022), supplemented with 10% FBS (Corning 35-015-CV Lot 35015124), at 1:2 dilution and cultured overnight. After incubation, adherent cells were trypsinized and plated alongside non-adherent cells transferred to a 96-well v-bottom plate (Sarstedt, Cat# 82.1583.001). Cells were centrifuged at 450 G for 4 min, resuspended in 1:1000 fixable viability dye eFluor 780 (eBioscience, Cat# 65-0865-14) and incubated for 15 min, RT. Cells were then washed with PBS, fixed with IC fixation buffer

(eBioscience, Cat# 00-8222-49) for 10 min RT, washed with PBS, and finally resuspended in 1x PBS with 6000 beads per well of CountBright absolute counting beads (Invitrogen, Cat# C36950). Samples were analyzed by flow cytometry on a BD LSRFortessa X-20 HTS system, and data processed with FlowJo V 10.5.3 Software. Data indicates that addition of these antibodies does not inhibit or reduce VVdd(eGFP) infection of tumor cells (FIG. 9).

Example 9 – Antibody Thermal Stability

Denaturing temperatures (T_m) of antibodies were determined from differential scanning fluorimetry (DSF) using Protein Thermo Shift Dye Kit™ (ThermoFisher, Cat#: 4461146). Briefly, 31 $\mu\text{g/mL}$ of antibody was used in each reaction. Melting curves of the antibodies were generated using an Applied Biosystems QuantStudio 7 Flex Real-Time PCR System with the recommended settings stated in the kit manual. The T_m 's of the antibodies (Table 18) were then determined by using the ThermoFisher Protein Thermal Shift software (v.1.3). T_{m1} of the antibodies was determined by DSF.

Table 18 – Antibody Thermal Stability

Antibody	T_{m1}
A047	71.6 $\pm$ 0.2 °C
A048	70.7 $\pm$ 0.1 °C
A049	73.8 $\pm$ 0.4 °C
A050	70.8 $\pm$ 0.2 °C
A051	71.2 $\pm$ 0.2 °C
A054	68.0 $\pm$ 0.9 °C

Example 10 – Antibody Binding to Murine Cell Lines Infected with Vaccinia Copenhagen

B16F10 (ATCC, Cat# CRL-6475), CT26LacZ (ATCC, Cat# CRL-2639), and MC38 (gift from Dr. John Bell, OHRI) tumor cells were grown to 80-90% confluence in 10 cm tissue culture plates (Thermo Scientific, Cat# 12-556-002) in appropriate media (B16F10 – DMEM (Gibco, Cat# 11995-040); MC38 - DMEM (Gibco, Cat# 11995-040); CT26LacZ – RPMI1640 (Gibco, Cat#11875-093) supplemented with 10% FBS (Gibco, Cat# 12483020). Cells were infected with VVcopenhagen (YFP) (gift from Dr. John Bell, OHRI) at a multiplicity of infection

of 0.5 in serum-free DMEM (Gibco, Cat# 11995-040) and incubated for 6.5 h, at 37°C in 5% CO₂. Plates were supplemented with growth media at a 1:2 ratio, and further incubated overnight (~16hs). B16F10 cells were trypsinized (TrypLE, Cat# 12604021) and plated alongside the CT26LacZ and MC38 cells at approximately 1 x 10⁵ cells per well, in 96-well U-bottom plates (Sarstedt, Cat# 83.3925). Corresponding uninfected B16F10, CT26LacZ, and MC38 cells were also plated at 1 x 10⁵ cells per well. Cells were washed twice with PBS 3% FBS (FACs Buffer) with centrifugation at 1800 rpm for 3 min. Cells were resuspended in PBS and incubated with 1:3000 fixable viability dye Zombie NIR (Biolegend, Cat# 423106) for 15 min at RT. Following two washes with FACS buffer, cells were resuspended in FACS buffer with mouse Fc block (BD, Cat# 553141) and incubated for 5 min at RT. Without further washing, cells were stained directly with either anti-A56-PE (A056, Rb IgG) at 1:100, anti-B5-PE (A073, Rb IgG) at 1:100, or anti-Vaccinia Virus rabbit polyclonal antibody (CedarLane, Cat# LS-C103289) at 1:100 (which served as a positive control) and incubated for 30 min at 4°C. Cells were washed twice with FACS buffer and resuspended. Wells that received anti-vaccinia virus primary antibody were then stained with anti-rabbit IgG-PE (Biolegend, Cat# 406421) at 1:100 and incubated for an additional 20 min at 4°C. Following an additional wash with FACs buffer, cells were fixed in IC fixation buffer (eBioscience, Cat# 00-8222-49) for 10 min, washed twice with PBS, resuspended in FACS buffer, and analyzed by flow cytometry on a Cytex Aurora flow cytometer. Data was processed using FlowJo V 10.5.3 Software. The data shows percent YFP expression in each infected cell line, indicating the proportion of cells infected with VVcopenhagen (YFP) (FIG. 10A). The anti-A56-PE and anti-B5-PE antibodies were found to bind B16F10, CT26LacZ, and MC38 cells that, according to their YFP positivity, were infected with VVcopenhagen (YFP) (FIG. 10B). As expected, the anti-Vaccinia Virus rabbit polyclonal antibody also bound to infected (YFP-positive) cells. No binding was observed to uninfected negative control cells.

Example 11 – Immunohistochemistry Detection of Vaccinia A56 and B5

HEK-B5(GFP) cell lines were grown to 90% confluence in ten 15 cm tissue culture plates (Corning, Cat#353025) in appropriate media (HEK - DMEM (Gibco, Cat# 11995-040) supplemented with 10% FBS (Gibco, Cat#12483020)). Additionally, U2OS cells (a gift from Dr. John Bell, OHRI) were grown to 90% confluence and infected with VVcopenhagen (YFP) at a multiplicity of infection of 0.025 and incubated for 72h at 37°C in 5% CO₂. HEK-A56, HEK-B5, HEK-WT and U2OS cells were trypsinized (TrypLE, Cat# 12604021), counted, and

resuspended to a concentration of 2×10^8 cells/ml in 15 ml polypropylene tubes (FroggaBio, Cat#TB15-500). Cells were centrifuged at 1500 RPM for 5 min, resuspended in 1 ml of molten histogel (Thermo Scientific, Cat#HG-4000-012), and placed on ice for 10 min to allow the histogel to solidify. Histogel pellets were transferred to 10 ml 10% neutral buffered formalin (Sigma, Cat#HT501128) and left at RT for 24h. For immunohistochemistry (IHC), histogel sections (4 μ m) were incubated overnight at 37°C, deparaffinized, rehydrated using xylene and an ethanol gradient, and subjected to antigen retrieval with Diva decloaker reagent (Biocare, Cat#DV2004) in a Biocare decloaking chamber (110°C for 15 min), and loaded into an Intellipath FLX Autostainer. Brightfield IHC was performed at room temperature with Biocare reagents. Slides were treated with Peroxidase-1 (Biocare, Cat#PX968) for 5 min and Background Sniper (Biocare, Cat#BS966) for 10 min. Primary antibodies diluted in DaVinci Green (Biocare, Cat#PD900) were applied for 30 min followed by Mach2 HRP Polymer (either mouse or rabbit, based on the species of the primary antibody) (Biocare, Cat#RHRP520 & MHRP520) for 30 min. DAB horseradish peroxidase (Biocare, Cat#IPK5010G80) chromogen substrate was added to the slides. CAT hematoxylin (Biocare, Cat#CATHE) diluted 1:5 with dH₂O was added for 5 min at RT. Stained slides were washed with water, air-dried and cover-slipped using Ecomount (Biocare, Cat#EM897L). Antibody dilutions were as follows: A058 anti-B5, Rb/Mu IgG2a, 1/280 (10 μ g/mL); A059 anti-A56, Rb/Mu IgG2a, 1/540 (10 μ g/mL); A056 anti-A56, Rb IgG, 1/840 (10 μ g/mL); A073 anti-B5, Rb IgG, 1/550 (10 μ g/mL). Antibodies specific for A56 or B5 were able to specifically detect target antigen on stably transfected HEK-A56 and HEK-B5 cells, respectively (FIG. 11). No cross reactivity against alternative antigen or HEK-WT cells was observed. Both anti-A56 and anti-B5 antibodies were able to detect protein expression on infected U2OS cells, and no background staining was detected on uninfected U2OS cells (FIG. 11).

Example 12 – Immunohistochemical detection of A56 and B5 from VV treated tumors

C57BL/6 wild type mice (Jackson Laboratory, Cat#000664) were implanted with 1×10^6 B16F10 (ATCC, Cat# CRL-6475) tumor cells subcutaneously on the rear right flank. Mice were grouped as follows: 1 dose VVcopenhagen (YFP), 2 doses VVcopenhagen (YFP), PBS, and Vesticular stomatitis Virus (VSV) (gift from Dr. John Bell, OHRI). All injections were at a dose of 1×10^7 PFU in 100 μ l volume and delivered intratumorally when tumors reached a size of 35-40 mm². Animals were euthanized either 1, 2, 3, or 7 days following their first

injection. Tumors were collected and fixed in 10% neutral buffered formalin for 24h. Following fixation tumors were embedded in paraffin wax and 1-5 2 mm tumor punches were taken from each resected tumor. Tumor punches were arrayed to create a tumor tissue microarray (TMA) and sectioned onto glass slides. For IHC, TMA sections (4 μ m) were incubated overnight at 37°C, deparaffinized, rehydrated using xylene and an ethanol gradient, and subjected to antigen retrieval with Diva decloaker reagent (Biocare, Cat#DV2004) in a Biocare decloaking chamber (110°C for 15 minutes), and loaded into an Intellipath FLX Autostainer. Brightfield IHC was performed at RT with Biocare reagents. Slides were treated with Peroxidized-1 (Biocare, Cat#PX968) for 5 min and Background Sniper (Biocare, Cat#BS966) for 10 min. Primary antibodies diluted in DaVinci Green (Biocare, Cat#PD900) were applied for 30 min followed by Mach2 HRP Polymer (either murine or rabbit, based on species of primary antibody) (Biocare, Cat#RHRP520 & MHRP520) for 30 min. DAB horseradish peroxidase (Biocare, Cat#IPK5010G80) chromogen substrate was added to the slides. CAT hematoxylin (Biocare, Cat#CATHE) diluted 1/5 with dH₂O was added for 5 min at RT. Stained slides were washed with water, air-dried and cover-slipped using Ecomount (Biocare, Cat#EM897L). Slides were stained with either Anti-A56 (A056) or Anti-B5 (A073) Rb IgG and detected with an anti-rabbit secondary antibody. Antibody dilutions were as follows: A056 anti-A56, Rb IgG, 1/840 (10 μ g/mL); A073 anti-B5, Rb IgG, 1/550 (10 μ g/mL). DAB staining (dark grey) indicates positive protein detection (FIG. 12). Antibodies for A56 or B5 were able to specifically detect target antigen on the majority of cores taken from treated tumors. Increased protein detection was evident on tumors that received multiple VVcopenhagen (YFP) doses. No cross reactivity against PBS or VSV treated tumors was evident. These findings demonstrate the specific detection and extent of virally derived A56 and B5 protein expression following intratumoral delivery of vaccinia virus.

Example 13 – VV Chimeric Antigen Receptor (CAR) design and detection following lentiviral transduction

The human VV-CAR constructs all contain a GM-CSFR α leader sequence followed by the A56 or B5 scFv (derived from A56: A049, B5: A048), a human CD8 α hinge and transmembrane domain, a human 4-1BB intracellular signaling domain, and a human CD3 ζ intracellular signaling domain (Fig. 13A) (3). Some CAR constructs included a reporter protein (e.g. eGFP) separated by a T2A ribosomal skip sequence. The amino acid sequences of the CARs are provided in Table 7.

Gene fragments encoding A56-CAR-01, A56-CAR-02, B5-CAR-03, B5-CAR-04 or A56-CAR-06 were synthesized by Twist Biosciences. Gene fragments were cloned into a 2nd generation transfer plasmid (gift from Dr. Robert Holt, BC Cancer). Lentivirus encoding VV-CAR constructs were generated using a standard calcium phosphate transfection protocol (4) and 2nd generation packaging vectors (gift from Dr. Rob Holt BC Cancer). Jurkat T cells (ATCC, Cat# TIB-152) were transduced with 500 µl supernatant from each lentivirus transfection. Jurkat cells were then expanded for 1 week and 1 x 10⁶ CAR positive cells were sorted based on goat anti-Rb IgG F(ab')₂ -Alexa Fluor 647 detection (Jackson Laboratories, Cat#111-605-047). Enriched Jurkat CAR-positive populations were expanded for an additional week and plated in a co-culture assay with HEK-A56, HEK-B5 or HEK-WT cells. Cells were cultured overnight (16 h) at a 1:1 Effector:Target (E:T) ratio (1 x 10⁵ total cells). The following day cells were washed with PBS, blocked with normal goat serum (Jackson Laboratories, Cat# 005-000-001), and stained for CD45 v450 (BD, Cat# 560367), CD69 PE-Cy7 (Biolegend, Cat# 310912), anti-Rb IgG Alexa Fluor 647. A56-CAR-01, A56-CAR-02, and A56-CAR-06 exhibited downregulation of cell surface CAR molecules when cultured with the target HEK-A56 line; such downregulation of cell surface CAR molecules is indicative of CAR activation (FIG. 14). Similarly, B5-specific CARs, B5-CAR-03, and B5-CAR-04, exhibited downregulation of surface CAR when cultured with the target HEK-B5 line. No CAR downregulation was present when CAR-T cells were cultured with HEK WT lines or irrelevant target antigens. These data demonstrate that effector T cells transduced to express A56- or B5-specific CARs undergo activation (as evidenced by downregulation of cell surface CAR expression) upon encounter with target cells bearing the appropriate antigen (A56 or B5, respectively).

Example 14 – CAR and eGFP expression on activated A56-CAR-06 positive Jurkat T cells

Jurkat A56-CAR-06 lines co-expressing eGFP were cultured with HEK-A56 lines overnight (16 h), and as expected from the results of Example 13, CAR expression was observed to be reduced (FIG. 15). However, within the CAR “negative” population, an eGFP-positive population was observed. Furthermore, the eGFP-positive population exhibited increased expression of CD69, a T cell activation marker, whereas the eGFP-negative population exhibited minimal CD69 expression. CD69 upregulation is indicative of CAR-T cell recognition of target cells bearing the appropriate antigen (A56 in this case). These results show that following encounter with target cells bearing an appropriate antigen (A56 in this

case), CAR-T cells exhibit downregulation of cell surface CAR expression yet can still be identified by eGFP and CD69 expression, the latter providing independent evidence of target cell recognition via the CAR.

5 Example 15 – Jurkat T cells expressing VV-CARs show specific activation when co-cultured with HEK cell lines bearing the appropriate target antigen

Jurkat T cells expressing either A56-CAR-01, A56-CAR-02, B5-CAR-03, B5-CAR-04 or A56-CAR-06 were co-cultured in triplicate with HEK-WT, HEK-A56, or HEK-B5 stable lines at a 1:1 E:T ratio, 1×10^5 total cells per condition. Cells were cultured overnight (16 h) at 37°C
10 in 5% CO₂. The following day cells were washed with PBS, blocked in normal goat serum, and stained for CD45, CD69, anti-RB IgG. CD45+ Jurkat populations were then assessed for CD69 expression. All CARs tested showed increased expression of CD69 when co-cultured with cells expressing the appropriate target antigen but minimal expression of CD69 when co-cultured with HEK WT cells or HEK cells expressing an irrelevant target antigen (FIG. 16).
15 These findings demonstrate that A56- and B5-directed CAR-T cells exhibit specific recognition of target cells expressing the appropriate antigens (A56 and B5, respectively) and show minimal cross-reactivity and/or constitutive activity (tonic signalling).

20 Example 16 – Primary healthy donor T cells transduced and enriched for A56-CAR-06 expression

CD4+ and CD8+ T cell populations were isolated from healthy donor PBMC samples. 5×10^5 healthy donor T cells were activated with Miltenyi TransAct™ (Miltenyi Biotec, Cat# 130-111-160) and grown in Miltenyi TexMACS GMP (Miltenyi Biotec, Cat# 170-076-309) media supplemented with 3% human serum (Sigma, Cat#H4522), gentamicin sulfate
25 (Sandoz, DIN:02268531) and human interleukin-7 (Miltenyi Biotec, Cat# 130-095-367) and interleukin-15 (Miltenyi Biotec, Cat# 130-095-764) (10 µg/ml). 24h after activation, T cells were transduced with A56-CAR-06 lentivirus at an MOI of 0.25. Cells were expanded for the following 12 days at a density less than 1×10^6 cells per ml. Following expansion a fraction of A56-CAR-06 transduced T cells were sorted on eGFP positivity using a flow cytometer. 2
30 $\times 10^5$ cells were sorted for high purity and plated in a single well of a 96-well round bottom plate. The sorted population was activated as described above and expanded for an additional 12 days, maintaining a cell density below 1×10^6 cells/ml. The final expanded enriched population was > 95% CAR positive by flow cytometry (FIG. 17). These findings

show that primary PBMC-derived human T cells can be readily transduced to express VV-CAR constructs and can be enriched and expanded post-transduction.

Example 17 – Human T cells expressing A56-CAR-06 show specific activation when co-cultured with A56-expressing HEK293T lines

Human T cells expressing A56-CAR-06 were co-cultured in triplicate overnight (16 h) with HEK-WT, HEK-A56, or HEK-B5 lines at a 1:1 E:T ratio with 1×10^5 cells total per condition. The following day cells were washed with PBS, blocked with normal goat serum, and stained to detect expression of CD3 BV510 (Biolegend, Cat# 317332), CD45, CD69, CD137 BV650 (Biolegend, Cat# 564092), anti-RB IgG. CD3+ eGFP+ T cell populations were assessed by flow cytometry for CD69 and CD137 expression. The A56-CAR-06 transduced T cells showed increased expression of CD69 and CD137 when co-cultured with cells expressing the A56 target antigen but minimal expression of CD69 and CD137 when co-cultured with HEK-WT cells or HEK cells expressing an irrelevant antigen (FIG. 18). These findings demonstrate that primary T cells transduced to express A56-CAR-06 exhibit specific activation when cultured with target cells expressing the A56 antigen on their surface.

Example 18 – Human T cells expressing A56-CAR-06 induce morphological signs of cell death in A56-expressing target cells

HEK-WT, HEK-A56, or HEK-B5 cells (2×10^5 each) were seeded in a 24-well tissue culture plate and left overnight to adhere. The following day 1×10^5 A56-CAR-06 T cells were added to each well, and cells were cultured for an additional 48 h. Images depict distinct morphological changes to the HEK-A56 target cell line when co-cultured with A56-CAR-06-positive T cells, indicative of direct tumor cell killing. In contrast, HEK-WT and HEK-B5 lines remained fully confluent with no morphological changes (FIG. 19). These findings show destruction HEK-A56 cell monolayers following co-culture with A56-CAR-06 T cells, providing evidence of a direct cytopathic effect.

Example 19 – Human T cells expressing B5-CAR-011 demonstrate cytotoxicity against B5-expressing target cells

A mammalian expression transfer plasmid encoding firefly luciferase, pCCL Luc Puromycin (gift from Dr. Jonathan Bramson, McMaster University) was used to generate lentivirus, as described previously in Example 13. HEK-WT, A56, and B5 lines were

transduced with this luciferase-encoding lentivirus and selected over 2 weeks for resistance to puromycin (1.5 µg/ml, Sigma, Cat#P8833). Puromycin-resistant cell cultures were expanded and used as target populations for VV-CAR killing assays. Luciferase-expressing target HEK lines were seeded at 2×10^4 cells, 100 µl per well in a 96-well plate (Corning, Cat# 3917) and incubated overnight to adhere. A sorted population of previously expanded primary human B5-CAR-011 T cells was plated (100 µl per well) in triplicate in a 96-well plate and split over a 2-fold dilution series to achieve a range of E:T ratios from 10:1 to 0.625:1. The diluted T cell suspensions were then transferred to the adherent HEK cells to achieve a total volume of 200 µl. Additionally, 3 wells of target cells alone and 3 wells of media only were plated to determine maximal and minimal relative luminescence units (RLU). Cells were cultured for 24 h at 37°C in 5% CO₂. The following day, each well received 22 µl 10X stock of Xenolight™ D-Luciferin (Perkin Elmer, Cat#122799) and incubated for 10 min at RT in the dark. Plates were then scanned on a luminescence plate reader (Perkin Elmer Wallac Envision 2104 Multilabel Reader). FIG. 20A depicts average RLU from triplicate wells at each E:T ratio at 24 h. Triplicate wells were averaged, and the percent specific cytotoxicity was determined by the following equation: percent specific cytotoxicity = $100 \times (\text{Max Luminescence RLU} - \text{Test Luminescence RLU}) / (\text{Min Luminescence RLU} - \text{Max Luminescence RLU})$. B5-CAR-011 T cells exhibited high percent specific cytotoxicity at multiple E:T ratios (FIG. 20B). Moreover, B5-expressing target cells co-cultured with B5-CAR-011 T cells showed clear morphological signs of cell death at 24 h, whereas B5-CAR-011 T cells showed no signs of cytotoxicity against HEK293 WT or HEK293 A56 cells (FIG. 20C). The results show that B5-CAR-011 T cells efficiently and specifically kill HEK-B5 tumor cells. (FIG. 20). By targeting OV antigens expressed on the surface of tumor cells, target cells can be made susceptible to OV-CAR mediated destruction.

Example 20 – Radiolabeled anti-A56 antibody enables clear visualization of A56-expressing tumor cells in vivo by Positron Emission Tomography

Anti-A56 antibody (A049) was selected and radiolabeled with Zirconium-89 (⁸⁹Zr) for biodistribution studies and microPET imaging, which allows deep tissue imaging in live mice with high sensitivity and high spatial resolution (5, 6). ⁸⁹Zr is well suited for use with mAbs due to its long half-life (78 h) and favourable decay properties (6, 7). Two milligrams of A049 were conjugated with p-SCN-Bn-deferoxamine (1-(4-isothiocyanatophenyl)-3-[6,17-

dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)- 6,11,17, 22-tetraazaheptaecosine] thiourea, DFO, Macrocyclics, Plano, TX, USA) with a chelator:mAb molecular ratio of 3:1. The reaction was performed at 37°C for 1h in PBS pH 9 with a final concentration of 2 mg/mL of antibody. Conjugated antibody (DFO-A049) was then purified
5 from the unconjugated deferoxamine using centrifugal filter units with a 50 kDa molecular weight cutoff (Amicon ultracentrifuge filters, Ultracel-50: regenerated cellulose, Millipore Corp., Billerica, MA, USA) and washed once with 5 mg/mL 2,5-dihydroxybenzoic acid in 0.25 M sodium acetate solution (Sigma-Aldrich, Oakville, Ontario, Canada). The concentration of the purified immunoconjugate solution was determined by a Bradford assay according to the
10 manufacturer's recommendations (Sigma-Aldrich).

Immunoconjugate radiolabeling with ^{89}Zr

^{89}Zr was produced via proton irradiation on an yttrium-89 disk (American Elements, Los Angeles, CA, USA) in an ACSI (Richmond, Canada) TR-19 cyclotron at 13 MeV as previously described (8). After irradiation, the disc was dissolved in HCl (10 mL, 2 M), and
15 purified using a hydroxamate-based ZR resin supplied by Triskem (Bruz, France). Briefly, the disk solution was loaded on the resin, washed with 10 mL of 2 M HCl solution followed by 10 mL of water, and then eluted off with 0.5 mL of oxalic acid (0.05 M).

For radiolabeling, the immunoconjugate DFO-A049 (0.4 mg) and ^{89}Zr solution (0.4 mL, pH 7, 232 MBq) were added to PBS (final volume: 1 mL, pH 7), and the resulting solution was
20 incubated for 1 h at room temperature. The radiochemical yield (RCY) was determined using instant thin layer chromatography silica gel (iTLC-SG, Agilent technologies, Santa Clara, California, USA) with 50 mM DTPA pH 7 as a solvent (Sigma-Aldrich). The R_f values of ^{89}Zr -labeled antibody and free ^{89}Zr were 0 and 1, respectively. Efficient labeling was observed with a RCY of 96%. ^{89}Zr -labeled antibodies were then separated from free ^{89}Zr by a PD-10
25 desalting column (GE Healthcare, London, United Kingdom), and concentrated using a 50 kDa molecular weight cut off filter (Millipore Corp.). The specific activity of ^{89}Zr -DFO-A049 was determined using a size-exclusion HPLC column (BioSep-SEC-s3000, Phenomenex, Torrance, California, USA) on an Agilent HPLC system (Santa Clara, CA, USA) equipped with a model 1200 quaternary pump, a model 1200 UV absorbance detector, and a Bioscan
30 (Washington DC, USA) NaI scintillation detector. The HPLC buffer was an isocratic gradient of 0.1 M sodium phosphate monobasic dihydrate, 0.1 M sodium phosphate dibasic dodecahydrate, 0.1 M sodium azide and 0.15 M sodium chloride (pH 6.2–7.0). A specific

activity of 0.1 MBq/ μ g was obtained and was sufficient for *in vivo* characterization of the radioimmunoconjugate. Final radiochemical purity was determined using iTLC-SG as previously described and was >99.9%.

Antibody immunoreactivity

5 The immunoreactivity fraction of ^{89}Zr -DFO-A049 was estimated according to the Lindmo cell-binding method using HEK-293 cells stably modified to express the A56 antigen (Wyeth VV sequence) (HEK-A56). Briefly, HEK-A56 cells were suspended at different concentrations from 1.0 to 24.6×10^6 cells/mL in PBS pH 7.4. The remaining procedure was performed as previously described (9). Results showed that 52% of the ^{89}Zr -DFO-A049 is still
10 efficient to bind to A56 protein.

Animal tumor models and antibody injection

 All animal experiments were performed at the Animal Resource Centre of the BC Cancer Research Centre in accordance with the institutional guidelines of the University of British Columbia Animal Care Committee (Vancouver, British Columbia, Canada) and under
15 the supervision of authorized investigators. Twelve week old female immunodeficient NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mice (obtained from an in-house breeding colony) were subcutaneously injected with HEK-A56 cells on the left shoulder or parental non expressing A56 HEK-293 cells on the right shoulder (n=8 mice). For both cell lines, 5×10^6 cells were injected in matrigel (1:1 ratio, BD Bioscience, Mississauga, Ontario, Canada).

20 Positron emission tomography (PET)

 When tumors reached imaging size ($\sim 100 \text{ mm}^3$), the mice were anesthetized with 2% isoflurane in oxygen and intravenously injected with ^{89}Zr -DFO-A049 ($40.9 \pm 1.5 \mu\text{g}$, $4.1 \pm 0.2 \text{ MBq}$). PET images were acquired for one mouse 1, 3 and 5 days post-injection using a Siemens (Knoxville, TN, USA) Inveon microPET/CT scanner. The mouse underwent a CT
25 scan for attenuation correction followed by a 20 min static PET acquisition at day 1 and 3, and 30 min scan at day 5. Images were reconstructed using the 3-dimensional ordered-subsets expectation maximization (OSEM3D, 2 iterations) followed by a fast maximum *a priori* algorithm (FastMAP: 18 iterations). Maximum intensity projection images show expected accumulation in normal organs such as liver and spleen due to antibody processing and
30 metabolism, in addition to bone uptake resulting from known demetalation of ^{89}Zr -DFO

conjugates in mice (especially in high bone remodeling regions such as long bone epiphysis) (10). More importantly, PET images show higher tumor uptake and tumor-to-background ratios for the HEK-A56 tumor compared to the negative control one (HEK-293), indicating specific and efficient tumor uptake of the ^{89}Zr -DFO-A049 antibody (FIG. 21).

5 Assessment of ^{89}Zr -DFO-A049 biodistribution

At day 5, all mice were euthanized and organs of interest were collected for biodistribution studies as described previously (9). Results are shown in Table 19 for ^{89}Zr -DFO-A049.

10 Table 19 – Biodistribution of ^{89}Zr -DFO-A049 at day 5 in A56-expressing HEK (HEK-A56) and non-expressing HEK-293 tumor-bearing mice. The values are expressed as mean $\pm$ SD percent injected dose per gram of tissue (%ID/g); n = 8 per time point. Statistical difference between HEK-A56 and HEK is shown (**, $p < 0.05$, t-test).

Organs	Day 5	
Blood	0.32 $\pm$ 0.13	
Fat	0.19 $\pm$ 0.07	
Uterus	3.76 $\pm$ 1.11	
Ovaries	3.47 $\pm$ 1.27	
Intestine	1.13 $\pm$ 0.16	
Spleen	16.98 $\pm$ 2.05	
Liver	3.52 $\pm$ 0.39	
Pancreas	0.51 $\pm$ 0.10	
Stomach	0.61 $\pm$ 0.09	
Adrenal glands	1.98 $\pm$ 0.82	
Kidney	2.02 $\pm$ 0.27	
Lungs	3.17 $\pm$ 0.76	
Heart	0.58 $\pm$ 0.08	
HEK-A56	7.71 $\pm$ 4.52	**
HEK-293	1.44 $\pm$ 0.25	
Muscle	0.27 $\pm$ 0.04	
Bone	4.78 $\pm$ 0.53	
Brain	0.22 $\pm$ 0.39	

15 Biodistribution results confirm PET image observations with expected radioimmunoconjugate biodistribution in normal organs. Concerning tumors, a higher uptake of 7.71 $\pm$ 4.52 %ID/g was obtained in the A56-expressing HEK tumors as compared to 1.44 $\pm$ 0.25 %ID/g in the non-expressing one (n=8, $p < 0.05$). These *in vivo* results (PET imaging

and biodistribution study) therefore establish that ^{89}Zr -DFO-A049 can be effectively and selectively delivered to A56-expressing tumors.

Antibodies targeting oncolytic virus encoded proteins expressed on the surface of OV-infected tumor cells can be used to allow for diagnostic, therapeutic and theranostic applications when labeled with radionuclides, for example, in *in vivo* imaging of OV infection by PET imaging and localized delivery of therapeutic radioactive isotopes by radioimmunotherapy to kill OV-infected cells and also non-infected neighbouring tumor cells (11,12).

10 References

1. Babcook, J.S., Leslie, K.B., Olsen, O.A., Salmon, R.A., Schrader, J.W. (1996) A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. *Proc Natl Acad Sci U S A* **93** (15): p. 7843-8.
- 15 2. Jarahian, M., Fiedler, M., Cohnen, A., Djandji, D., Hammerling, G. J., Gati, C., Cerwenka, A., Turner, P. C., Moyer, R. W., Watzl, C., Hengel, H., and Momburg, F. (2011) Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. *PLoS Pathog* **7**, e1002195.
3. S. Guedan, H. Calderon, A.D. Posey, M. V Maus, Engineering and Design of Chimeric Antigen Receptors, *Mol. Ther. Methods Clin. Dev.* **12** (2019) 145–156. <https://doi.org/10.1016/j.omtm.2018.12.009>.
- 20 4. *Molecular Cloning: A Laboratory Manual* 3rd edition (eds. Sambrook, J. & Russell, D.W.) (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA, 2001).
- 25 5. Kim JS. Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET. *Nuclear medicine and molecular imaging*. 2016;50(2):104-11.
6. van de Watering FC, Rijpkema M, Perk L, Brinkmann U, Oyen WJ, Boerman OC. Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. *BioMed research international*. 2014;2014:203601.
- 30 7. Zhang Y, Hong H, Cai W. PET tracers based on Zirconium-89. *Current radiopharmaceuticals*. 2011;4(2):131-9.

8. Dias GM, Ramogida CF, Rousseau J, Zacchia NA, Hoehr C, Schaffer P, Lin K-S, Bénard F. ^{89}Zr for antibody labeling and in vivo studies - A comparison between liquid and solid target production. *Nucl Med Biol.* 2018 Mar;58:1-7.
- 5 9. Rousseau J, Zhang Z, Wang X, Zhang C, Lau J, Rousseau E, et al. Synthesis and evaluation of bifunctional tetrahydroxamate chelators for labeling antibodies with (89)Zr for imaging with positron emission tomography. *Bioorg Med Chem Lett.* 2018;28(5):899-905.
- 10 10. Rousseau J, Zhang Z, Dias GM, Zhang C, Colpo N, Bénard F, Lin K-S. Design, synthesis and evaluation of novel bifunctional tetrahydroxamate chelators for PET imaging of ^{89}Zr -labeled antibodies. *Bioorg Med Chem Lett.* 2017;27(4):708-712.
11. Makvandi M., et al. Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations. *Target Oncol.* 2018 Apr;13(2):189-203.
- 15 12. Kraeber-Bodere F, Bodet-Milin C, Rousseau C, Eugene T, Pallardy A, Frampas E, et al. Radioimmunoconjugates for the treatment of cancer. *Seminars in oncology.* 2014;41(5):613-22.

Accordingly, the preceding merely illustrates the principles of the present disclosure. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and
20 conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and
25 embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein.

WHAT IS CLAIMED IS:

1. An antibody that specifically binds to Vaccinia Virus A56 antigen (VV A56) and competes for binding to VV A56 with an antibody comprising:

a variable heavy chain (V_H) polypeptide comprising

5 a V_H CDR1 comprising the amino acid sequence SSYWIC (SEQ ID NO:3),

a V_H CDR2 comprising the amino acid sequence CIYAGSGGSTYYATWAKG (SEQ ID NO:4), and

a V_H CDR3 comprising the amino acid sequence AYSDRSGGYSFNL (SEQ ID NO:5); and

10 a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSVDNNNYLA (SEQ ID NO:6),

a V_L CDR2 comprising the amino acid sequence SASSLAS (SEQ ID NO:7), and

15 a V_L CDR3 comprising the amino acid sequence LGSYDCSDADCYA (SEQ ID NO:8);

a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence DIYYIS (SEQ ID NO:11),

a V_H CDR2 comprising the amino acid sequence CTYAGSSGSTYYATWAKG (SEQ ID NO:12), and

20 a V_H CDR3 comprising the amino acid sequence DRYPGTSGRVYGM DL (SEQ ID NO:13); and

a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSISDLLS (SEQ ID NO:14),

a V_L CDR2 comprising the amino acid sequence SASTLAS (SEQ ID NO:15), and

25 a V_L CDR3 comprising the amino acid sequence QCNYYSPTYGNG (SEQ ID NO:16);

a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence SSYWLC (SEQ ID NO:19),

a V_H CDR2 comprising the amino acid sequence CIYNGDGSTHYASWAKG (SEQ ID NO:20), and

30 a V_H CDR3 comprising the amino acid sequence DYTYNFYTYGFNL (SEQ ID NO:21); and

a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSVNIWAS (SEQ ID NO:22),
 a V_L CDR2 comprising the amino acid sequence KASTLAS (SEQ ID NO:23), and
 a V_L CDR3 comprising the amino acid sequence QGGYPSSSSGWA (SEQ ID
 NO:24); or

5 a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence SSYWIC (SEQ ID NO:27),

a V_H CDR2 comprising the amino acid sequence CTYNGDGSTHYASWAKG (SEQ
 ID NO:28), and

10 a V_H CDR3 comprising the amino acid sequence DYTDAFYTYGFNL (SEQ ID
 NO:29); and

a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSTSSYLA (SEQ ID NO:30),

a V_L CDR2 comprising the amino acid sequence RASSLAS (SEQ ID NO:31), and

15 a V_L CDR3 comprising the amino acid sequence QTGFYGSSGHT (SEQ ID NO:32).

2. The antibody of claim 1, wherein the antibody comprises:

a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence SSYWIC (SEQ ID NO:3),

20 a V_H CDR2 comprising the amino acid sequence CIYAGSGGSTYYATWAKG (SEQ
 ID NO:4), and

a V_H CDR3 comprising the amino acid sequence AYSDRSGGYSFNL (SEQ ID
 NO:5); and

a variable light chain (V_L) polypeptide comprising

25 a V_L CDR1 comprising the amino acid sequence QASQSVDNNNYLA (SEQ ID
 NO:6),

a V_L CDR2 comprising the amino acid sequence SASSLAS (SEQ ID NO:7), and

a V_L CDR3 comprising the amino acid sequence LGSYDCSDADCYA (SEQ ID
 NO:8);

a variable heavy chain (V_H) polypeptide comprising

30 a V_H CDR1 comprising the amino acid sequence DIYYIS (SEQ ID NO:11),

a V_H CDR2 comprising the amino acid sequence CTYAGSSGSTYYATWAKG (SEQ
 ID NO:12), and

a V_H CDR3 comprising the amino acid sequence DRYPGTSGRVYGM DL (SEQ ID NO:13); and

a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSIDLLS (SEQ ID NO:14),

a V_L CDR2 comprising the amino acid sequence SASTLAS (SEQ ID NO:15), and

a V_L CDR3 comprising the amino acid sequence QCNYYSPTYGNG (SEQ ID NO:16);

a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence SSYWLC (SEQ ID NO:19),

a V_H CDR2 comprising the amino acid sequence CIYNGDGSTHYASWAKG (SEQ ID NO:20), and

a V_H CDR3 comprising the amino acid sequence DYTYNFYTYGFNL (SEQ ID NO:21); and

a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSVNIWAS (SEQ ID NO:22),

a V_L CDR2 comprising the amino acid sequence KASTLAS (SEQ ID NO:23), and

a V_L CDR3 comprising the amino acid sequence QGGYPSSSSGWA (SEQ ID NO:24); or

a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence SSYWIC (SEQ ID NO:27),

a V_H CDR2 comprising the amino acid sequence CTYNGDGSTHYASWAKG (SEQ ID NO:28), and

a V_H CDR3 comprising the amino acid sequence DYTDAFYTYGFNL (SEQ ID NO:29); and

a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSTSSYLA (SEQ ID NO:30),

a V_L CDR2 comprising the amino acid sequence RASSLAS (SEQ ID NO:31), and

a V_L CDR3 comprising the amino acid sequence QTGFYGSSGHT (SEQ ID NO:32).

3. The antibody of claim 1 or claim 2, wherein the antibody comprises:

a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater identity to the amino acid sequence set forth in SEQ ID NO:1; and

a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater identity to the amino acid sequence set forth in SEQ ID NO:2.

4. The antibody of claim 1 or claim 2, wherein the antibody comprises:

a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater identity to the amino acid sequence set forth in SEQ ID NO:9; and

a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater identity to the amino acid sequence set forth in SEQ ID NO:10.

5. The antibody of claim 1 or claim 2, wherein the antibody comprises:

a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater identity to the amino acid sequence set forth in SEQ ID NO:17; and

a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater identity to the amino acid sequence set forth in SEQ ID NO:18.

6. The antibody of claim 1 or claim 2, wherein the antibody comprises:

a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater identity to the amino acid sequence set forth in SEQ ID NO:25; and

a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater identity to the amino acid sequence set forth in SEQ ID NO:26.

7. The antibody of claim 1 or claim 2, wherein the antibody comprises:

a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater identity to the amino acid sequence set forth in SEQ ID NO:9; and

a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater identity to the amino acid sequence set forth in SEQ ID NO:62.

8. The antibody of claim 1 or claim 2, wherein the antibody comprises:

a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70% or greater identity to the amino acid sequence set forth in SEQ ID NO:9; and

a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70% or greater identity to the amino acid sequence set forth in SEQ ID NO:63.

9. An antibody that specifically binds to Vaccinia Virus B5 antigen (VV B5) and competes for binding to VV B5 with an antibody comprising:

a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence SSYYMC (SEQ ID NO:35),

a V_H CDR2 comprising the amino acid sequence CIYTSSGSAYYANWAKG (SEQ ID NO:36), and

a V_H CDR3 comprising the amino acid sequence NAVGSSYYLYL (SEQ ID NO:37); and

a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSVAGNNYLS (SEQ ID NO:38),

a V_L CDR2 comprising the amino acid sequence SVSTLAS (SEQ ID NO:39), and

a V_L CDR3 comprising the amino acid sequence QGYNDGIWA (SEQ ID NO:40); or

a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence SYWMC (SEQ ID NO:43),

a V_H CDR2 comprising the amino acid sequence CIYGGSSGSTYYSNWAKG (SEQ ID NO:44), and

a V_H CDR3 comprising the amino acid sequence DGSTWDYFRL (SEQ ID NO:45); and

a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSINTNYLS (SEQ ID NO:46),

a V_L CDR2 comprising the amino acid sequence QASTLES (SEQ ID NO:47), and

a V_L CDR3 comprising the amino acid sequence QGYTVENIGNP (SEQ ID NO:48).

10. The antibody of claim 9, wherein the antibody comprises:

a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence SSYYMC (SEQ ID NO:35),

a V_H CDR2 comprising the amino acid sequence CIYTSSGSAYYANWAKG (SEQ ID NO:36), and

a V_H CDR3 comprising the amino acid sequence NAVGSSYYLYL (SEQ ID NO:37); and

a variable light chain (V_L) polypeptide comprising

a V_L CDR1 comprising the amino acid sequence QASQSVAGNNYLS (SEQ ID NO:38),

a V_L CDR2 comprising the amino acid sequence SVSTLAS (SEQ ID NO:39), and
a V_L CDR3 comprising the amino acid sequence QGYNDGIWA (SEQ ID NO:40); or

a variable heavy chain (V_H) polypeptide comprising

a V_H CDR1 comprising the amino acid sequence SYWMC (SEQ ID NO:43),

5 a V_H CDR2 comprising the amino acid sequence CIYGGSSGSTYYSNWAKG (SEQ
ID NO:44), and

a V_H CDR3 comprising the amino acid sequence DGSTWDYFRL (SEQ ID NO:45);
and

a variable light chain (V_L) polypeptide comprising

10 a V_L CDR1 comprising the amino acid sequence QASQSINTNYLS (SEQ ID NO:46),

a V_L CDR2 comprising the amino acid sequence QASTLES (SEQ ID NO:47), and

a V_L CDR3 comprising the amino acid sequence QGYTVENIGNP (SEQ ID NO:48).

11. The antibody of claim 9 or claim 10, wherein the antibody comprises:

15 a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70%
or greater identity to the amino acid sequence set forth in SEQ ID NO:33; and

a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70%
or greater identity to the amino acid sequence set forth in SEQ ID NO:34.

20 12. The antibody of claim 9 or claim 10, wherein the antibody comprises:

a variable heavy chain (V_H) polypeptide comprising an amino acid sequence having 70%
or greater identity to the amino acid sequence set forth in SEQ ID NO:41; and

a variable light chain (V_L) polypeptide comprising an amino acid sequence having 70%
or greater identity to the amino acid sequence set forth in SEQ ID NO:42.

25 13. The antibody of any one of claims 1 to 12, wherein the antibody is a monoclonal
antibody.

14. The antibody of any one of claims 1 to 13, wherein the antibody is a humanized
30 antibody.

15. The antibody of any one of claims 1 to 14, wherein the antibody is an IgG.

16. The antibody of claim 15, wherein the antibody comprises a human Fc domain.

17. The antibody of claim 16, wherein the antibody is a human IgG1.
18. The antibody of any one of claims 1 to 14, wherein the antibody is selected from the
5 group consisting of: a Fab, a F(ab')₂, and a F(ab').
19. The antibody of any one of claims 1 to 14, wherein the antibody is a single chain antibody.
- 10 20. The antibody of claim 19, wherein the single chain antibody is an scFv.
21. The antibody of any one of claims 1 to 20, wherein the antibody is a bispecific antibody comprising a first antigen-binding domain comprising a V_H polypeptide-V_L polypeptide pair as defined in any one of claims 1 to 12.
15
22. The antibody of claim 21, wherein the bispecific antibody comprises a second antigen-binding domain that specifically binds an antigen other than a Vaccinia Virus antigen.
23. The antibody of claim 22, wherein the antigen other than a Vaccinia Virus antigen is an
20 immune cell surface antigen.
24. The antibody of claim 23, wherein the immune cell surface antigen is an immune effector cell surface antigen.
- 25 25. The antibody of claim 24, wherein the immune cell surface antigen is a T cell surface antigen.
26. The antibody of claim 25, wherein the antigen is a T cell stimulatory molecule.
- 30 27. The antibody of claim 26, wherein the T cell stimulatory molecule is CD3 or CD28.
28. The antibody of claim 24, wherein the immune cell surface antigen is a natural killer (NK) cell surface antigen.

29. The antibody of claim 24, wherein the immune cell surface antigen is a macrophage cell surface antigen.

30. A fusion protein, comprising:

5 a chain of an antibody of any one of claims 1 to 29 fused to a heterologous sequence of amino acids.

31. The fusion protein of claim 30, wherein the heterologous sequence of amino acids is fused to the C-terminus of the chain of the antibody.

10

32. The fusion protein of claim 30 or claim 31, wherein the antibody is the single chain antibody of claim 19 or 20.

33. The fusion protein of claim 32, wherein the fusion protein is a chimeric antigen receptor (CAR) comprising:

15

the single chain antibody;
a transmembrane domain; and
an intracellular signaling domain.

34. A conjugate, comprising:

20

an antibody of any one of claims 1 to 29 or a fusion protein of any one of claims 30 to 33; and
an agent conjugated to the antibody or fusion protein.

35. The conjugate of claim 34, wherein the agent is selected from the group consisting of: a chemotherapeutic agent, a toxin, a radiation sensitizing agent, a radioactive isotope, a detectable label, and a half-life extending moiety.

25

36. The conjugate of claim 35, wherein the radioactive isotope is a therapeutic radioactive isotope.

30

37. The conjugate of claim 35, wherein the detectable label is a radiolabel.

38. The conjugate of claim 37, wherein the radiolabel is Zirconium-89 (⁸⁹Zr).

39. The conjugate of any one of claims 34 to 38, wherein the agent is conjugated to the antibody or fusion protein via a non-cleavable linker.
- 5 40. The conjugate of any one of claims 34 to 38, wherein the agent is conjugated to the antibody or fusion protein via a cleavable linker.
41. The conjugate of claim 40, wherein the cleavable linker is an enzyme-cleavable linker.
- 10 42. The conjugate of claim 41, wherein the linker is cleavable by a lysosomal protease.
43. The conjugate of claim 42, wherein the linker is cleavable by cathepsin or plasmin.
44. A nucleic acid encoding a variable heavy chain (V_H) polypeptide, a variable light chain
15 (V_L) polypeptide, or both, of an antibody of any one of claims 1 to 29.
45. A nucleic acid encoding the fusion protein of any one of claims 30 to 33.
46. An expression vector comprising the nucleic acid of claim 44 or claim 45.
- 20 47. A cell comprising:
the nucleic acid of claim 44 or claim 45; or
the expression vector of claim 46.
- 25 48. A cell comprising:
a first nucleic acid encoding the variable heavy chain (V_H) polypeptide of an antibody of
any one of claims 1 to 18; and
a second nucleic acid encoding the variable light chain (V_L) polypeptide of the antibody.
- 30 49. The cell of claim 48, comprising:
a first expression vector comprising the first nucleic acid; and
a second expression vector comprising the second nucleic acid.

50. A method of producing the antibody of any one of claims 1 to 28, comprising culturing the cell of any one of claims 47 to 49 under conditions suitable for the cell to express the antibody, wherein the antibody is produced.
- 5 51. A pharmaceutical composition, comprising:
the antibody of any one of claims 1 to 28; and
a pharmaceutically acceptable carrier.
- 10 52. A pharmaceutical composition, comprising:
the fusion protein of any one of claims 30 to 33; and
a pharmaceutically acceptable carrier.
- 15 53. A pharmaceutical composition, comprising:
the conjugate of any one of claims 34 to 43; and
a pharmaceutically acceptable carrier.
- 20 54. A kit, comprising:
the pharmaceutical composition of any one of claims 51 to 53; and
instructions for administering the pharmaceutical composition to an individual in need thereof.
- 25 55. The kit of claim 54, wherein the pharmaceutical composition is present in one or more unit dosages.
- 30 56. The kit of claim 54, wherein the pharmaceutical composition is present in two or more unit dosages.
57. A method, comprising:
administering the pharmaceutical composition of any one of claims 51 to 53 to an individual having cancer, wherein the individual comprises cancer cells infected with Vaccinia Virus (VV), and wherein the antibody, fusion protein or conjugate is targeted to the infected cancer cells by VV antigens expressed on the surface of the infected cancer cells.

58. The method according to claim 57, further comprising, prior to administering the pharmaceutical composition to the individual, infecting the cancer cells by administering VV to the individual.

5 59. The method according to claim 57 or 58, wherein the method is a method of treating the cancer of the individual.

60. The method according to any one of claims 57 to 59, wherein the pharmaceutical composition of claim 53 is administered to the individual, wherein the conjugate comprises the
10 antibody conjugated to a detectable label or radioactive isotope which is an *in vivo* imaging agent, and wherein the method comprises imaging the infected cancer cells in the individual using the *in vivo* imaging agent.

61. A method of targeting an antibody that specifically binds an oncolytic virus (OV) antigen
15 to cancer cells in an individual, comprising:
administering to the individual a pharmaceutical composition comprising an antibody that specifically binds the OV antigen, wherein the cancer cells in the individual are infected with OV and express the OV antigen on their surface.

20 62. The method according to claim 61, further comprising, prior to administering the pharmaceutical composition to the individual, infecting the cancer cells by administering the OV to the individual.

63. The method according to claim 61 or claim 62, wherein the OV antigen is native to the
25 OV.

64. The method according to claim 61 or claim 62, wherein the OV antigen is heterologous to the OV.

30 65. The method according to any one of claims 61 to 64, wherein the OV is selected from the group consisting of: Vaccinia Virus, adenovirus, Herpes Simplex Virus (HSV), reovirus, vesicular stomatitis virus, New Castle Disease virus, Seneca Valley virus, poliovirus, measles virus, Coxsackie virus, and Maraba virus.

66. The method according to any one of claims 61 to 64, wherein the OV is Vaccinia Virus (VV).
- 5 67. The method according to claim 66, wherein the VV is JX-594 or GL-ONC1.
68. The method according to claim 66, wherein the strain of VV is selected from the group consisting of: Western Reserve, Wyeth, Lister, Copenhagen, Temple of Heaven, Patwadangar, and Modified Vaccinia Virus Ankara.
- 10 69. The method according to any one of claims 61 to 68, wherein the antibody is a monoclonal antibody.
70. The method according to any one of claims 61 to 69, wherein the antibody is a humanized antibody.
- 15 71. The method according to any one of claims 61 to 70, wherein the antibody is an IgG.
72. The method according to claim 71, wherein the antibody comprises a human Fc domain.
- 20 73. The method according to claim 72, wherein the antibody is a human IgG1.
74. The method according to any one of claims 61 to 70, wherein the antibody is selected from the group consisting of: a Fab, a F(ab')₂, and a F(ab').
- 25 75. The method according to any one of claims 61 to 70, wherein the antibody is a single chain antibody.
76. The method according to claim 75, wherein the single chain antibody is an scFv.
- 30 77. The method according to any one of claims 66 to 76, wherein the OV antigen is a VV A56 antigen.
78. The method according to claim 77, wherein the pharmaceutical composition comprises an antibody of any one of claims 1 to 8.

79. The method according to any one of claims 66 to 76, wherein the OV antigen is a VV B5 antigen.

5 80. The method according to claim 79, wherein the pharmaceutical composition comprises an antibody of any one of claims 9 to 12.

81. The method according to any one of claims 57 to 80, wherein the pharmaceutical composition comprises the antibody conjugated to a detectable label or radioactive isotope.

10 82. The method according to claim 81, wherein the detectable label or radioactive isotope is an *in vivo* imaging agent.

83. The method according to claim 82, comprising detecting the *in vivo* imaging agent to
15 image the cancer cells *in vivo*.

84. The method according to any one of claims 61 to 83, wherein the method is a method of treating the cancer of the individual.

20 85. A chimeric antigen receptor (CAR) comprising:
an antigen binding domain that specifically binds an oncolytic virus (OV) antigen;
a transmembrane domain; and
an intracellular signaling domain.

25 86. The CAR of claim 85, wherein the OV antigen is native to the OV.

87. The CAR of claim 85, wherein the OV antigen is heterologous to the OV.

30 88. The CAR of any one of claims 85 to 87, wherein the OV is selected from the group consisting of: Vaccinia Virus, adenovirus, Herpes Simplex Virus (HSV), reovirus, vesicular stomatitis virus, New Castle Disease virus, Seneca Valley virus, poliovirus, measles virus, and Maraba virus.

89. The CAR of any one of claims 85 to 87, wherein the OV antigen is an antigen encoded by a Vaccinia Virus (VV).

90. The CAR of claim 89, wherein the VV is JX-594 or GL-ONC1.

5

91. The CAR of claim 89, wherein the strain of VV is selected from the group consisting of: Western Reserve, Wyeth, Lister, Copenhagen, Temple of Heaven, Patwadangar, and Modified Vaccinia Virus Ankara.

10 92. The CAR of claim 89, wherein the OV antigen is a VV A56 antigen.

93. The CAR of claim 92, wherein the antigen binding domain comprises a V_H polypeptide-V_L polypeptide pair of an antibody of any one of claims 1 to 8.

15 94. The CAR of claim 89, wherein the OV antigen is a VV B5 antigen.

95. The CAR of claim 94, wherein the antigen binding domain comprises a V_H polypeptide-V_L polypeptide pair of an antibody of any one of claims 9 to 12.

20 96. The CAR of any one of claims 85 to 95, wherein the antigen-binding domain comprises an scFv.

97. The CAR of any one of 85 to 96, wherein the CAR is provided by a single polypeptide.

25 98. The CAR of any one of 85 to 96, wherein the CAR is provided by two or more polypeptides.

99. A nucleic acid encoding the CAR of any one of claims 85 to 98.

30 100. A cell comprising the nucleic acid of claim 99.

101. The cell of claim 100, wherein the cell expresses the CAR on its surface.

102. The cell of claim 100 or 101, wherein the cell is an immune cell.

103. The cell of claim 102, wherein the cell is an immune effector cell.

104. The cell of claim 103, wherein the cell is a T cell.

5

105. The cell of claim 103, wherein the cell is an NK cell.

106. The cell of claim 103, wherein the cell is a macrophage.

10 107. A pharmaceutical composition comprising the cell of any one of claims 100 to 105.

108. A method of targeting a CAR that specifically binds an oncolytic virus (OV) antigen to cancer cells in an individual, comprising:

15 administering to the individual the pharmaceutical composition of claim 107, wherein the cancer cells in the individual are infected with OV and express the OV antigen on their surface.

20 109. The method according to claim 108, further comprising, prior to administering the pharmaceutical composition to the individual, infecting the cancer cells by administering the OV to the individual.

110. The method according to claim 108 or claim 109, wherein the method is a method of treating the cancer of the individual.

25 111. A conjugate, comprising:
an antibody that specifically binds an oncolytic virus (OV) antigen; and
an agent conjugated to the antibody, wherein the agent is selected from the group consisting of: a chemotherapeutic agent, a toxin, a radiation sensitizing agent, and a radioactive isotope.

30

112. The conjugate of claim 111, wherein the radioactive isotope is a therapeutic radioactive isotope.

113. The conjugate of claim 111 or claim 112, wherein the OV antigen is native to the OV.

114. The conjugate of claim 111 or claim 112, wherein the OV antigen is heterologous to the OV.

5 115. The conjugate of any one of claims 111 to 114, wherein the OV antigen is an antigen encoded by an OV selected from the group consisting of: Vaccinia Virus, adenovirus, HSV, reovirus, vesicular stomatitis virus, New Castle Disease virus, Seneca Valley virus, poliovirus, measles virus, Coxsackie virus, and Maraba virus.

10 116. The conjugate of any one of claims 111 to 114, wherein the OV antigen is an antigen encoded by a Vaccinia Virus (VV).

117. The conjugate of claim 116, wherein the VV is JX-594 or GL-ONC1.

15 118. The conjugate of claim 116, wherein the strain of VV is selected from the group consisting of: Western Reserve, Wyeth, Lister, Copenhagen, Temple of Heaven, Patwadangar, and Modified Vaccinia Virus Ankara.

119. The conjugate of claim 116, wherein the OV antigen is a VV A56 antigen.

20 120. The conjugate of claim 119, wherein the antibody is an antibody of any one of claims 1 to 8.

121. The conjugate of claim 116, wherein the OV antigen is a VV B5 antigen.

25 122. The conjugate of claim 121, wherein the antibody is an antibody of any one of claims 9 to 12.

30 123. The conjugate of any one of claims 111 to 122, wherein the antibody is a monoclonal antibody.

124. The conjugate of any one of claims 111 to 123, wherein the antibody is a humanized antibody.

125. The conjugate of any one of claims 111 to 124, wherein the antibody is an IgG.
126. The conjugate of claim 125, wherein the antibody comprises a human Fc domain.
- 5 127. The conjugate of claim 126, wherein the antibody is a human IgG1.
128. The conjugate of any one of claims 111 to 124, wherein the antibody is selected from the group consisting of: a Fab, a F(ab')₂, and a F(ab').
- 10 129. The conjugate of any one of claims 111 to 124, wherein the antibody is a single chain antibody.
130. The conjugate of claim 129, wherein the single chain antibody is an scFv.
- 15 131. The conjugate of any one of claims 111 to 130, wherein the agent is conjugated to the antibody via a non-cleavable linker.
132. The conjugate of any one of claims 111 to 130, wherein the agent is conjugated to the antibody via a cleavable linker.
- 20 133. The conjugate of claim 132, wherein the cleavable linker is an enzyme-cleavable linker.
134. The conjugate of claim 133, wherein the linker is cleavable by a lysosomal protease.
- 25 135. The conjugate of claim 134, wherein the linker is cleavable by cathepsin or plasmin.
136. A pharmaceutical composition comprising the conjugate of any one of claims 111 to 135.
137. A method of targeting a conjugate that comprises an antibody that specifically binds an
30 oncolytic virus (OV) antigen to cancer cells in an individual, comprising:
administering to the individual the pharmaceutical composition of claim 136, wherein the
cancer cells in the individual are infected with OV and express the OV antigen on
their surface.

138. The method according to claim 137, further comprising, prior to administering the pharmaceutical composition to the individual, infecting the cancer cells by administering the OV to the individual.

5

139. The method according to claim 137 or claim 138, wherein the method is a method of treating the cancer of the individual.

FIG. 1




FIG. 2




FIG. 3




FIG. 4






FIG. 5








FIG. 7






FIG. 8



10/29

FIG. 9





FIG. 10A



11/29

FIG. 10B




FIG. 11





















FIG. 12A

B16F10 PBS & VSV	B16F10 WV D1	B16F10 WV D2	B16F10 WV D3	B16F10 WV D7	B16F10 WVx2 D3	B16F10 WVx2 D7
F1 PBS  F2 PBS  F3 PBS  F5 PBS  F4 VSV D3 						
F1 WVD1  F2 WVD1  F3 WVD1 						
F1 WVD2  F2 WVD2 						
F1 WVD3  F3 WVD3  F5 WVD3 						
F1 WVD7  F4 WVD7  F3 WVD7 						
F5 WVx2 D3  F4 WVx2 D3  F4 WVx2 D3 						
F2 WVx2 D7  F5 WVx2 D7  F3 WVx2 D7 						

A56 Stain

FIG. 12B

B16F10 PBS & VSV	B16F10 W D1	B16F10 W D2	B16F10 W D3	B16F10 W D7	B16F10 WX2 D3	B16F10 WX2 D7
F1 PBS F2 PBS F3 PBS F5 PBS F4 VSV D3	F1 WVD1 F2 WVD1 F3 WVD1	F1 WVD2 F2 WVD2	F1 WVD3 F3 WVD3 F5 WVD3	F1 WVD7 F4 WVD7 F3 WVD7	F5 Wx2 D3 F2 Wx2 D3 F4 Wx2 D3	F2 vx2 D7 F5 vx2 D7 F3 vx2 D7
B5 Stain						

FIG. 12C




FIG. 13A




FIG. 13B




FIG. 14

A56-CAR-01




FIG. 14 (Cont.)




FIG. 14 (Cont.)




FIG. 14 (Cont.)

B5-CAR-04






FIG. 14 (Cont.)








FIG. 16




FIG. 17




FIG. 18






FIG. 19

A56-CAR-06 : HEK WT



A56-CAR-06 : HEK B5



A56-CAR-06 : HEK A56




FIG. 20A




FIG. 20B




FIG. 20C





FIG. 21

⁸⁹Zr-DFO-A049



SEQUENCE LISTING

<110> Centre for Drug Research and Development
 Provincial Health Services Authority
 Cummins, Emma J.
 Bergqvist, Jan Peter
 Nelson, Brad
 Twumasi-Boateng, Kwame
 Eunice Kwok, Yin Yu
 Smazynski, Julian
 Benard, Francois
 Rousseau, Julie Marie
 Lin, Kuo-Shyan

<120> ANTI-ONCOLYTIC VIRUS ANTIGEN ANTIBODIES AND METHODS OF USING SAME

<130> 0081436-203/87167535

<150> US 62/900,303

<151> 2019-09-13

<160> 187

<170> PatentIn version 3.5

<210> 1

<211> 123

<212> PRT

<213> Oryctolagus cuniculus

<400> 1

Gln	Glu	Gln	Leu	Glu	Glu	Ser	Gly	Gly	Asp	Leu	Val	Lys	Pro	Glu	Gly
1				5					10					15	

Ser	Leu	Thr	Leu	Thr	Cys	Thr	Ala	Ser	Gly	Phe	Ser	Phe	Ser	Ser	Ser
			20					25					30		

Tyr	Trp	Ile	Cys	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp
		35					40					45			

Ile	Ala	Cys	Ile	Tyr	Ala	Gly	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Thr
	50					55					60				

Trp	Ala	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Lys	Thr	Ser	Ser	Thr	Thr	Val
65					70					75					80

Thr	Leu	Gln	Met	Thr	Ser	Leu	Thr	Ala	Ala	Asp	Thr	Ala	Ser	Tyr	Phe
			85					90						95	

Cys	Val	Arg	Ala	Tyr	Ser	Asp	Arg	Ser	Gly	Gly	Tyr	Ser	Phe	Asn	Leu
			100					105					110		

Trp	Gly	Pro	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser
		115					120			

<210> 2

<211> 112

<212> PRT

<213> Oryctolagus cuniculus

<400> 2

Gln Val Leu Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ser Val Asp Asn Asn Asn
20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Gln Leu
35 40 45

Ile Tyr Ser Ala Ser Ser Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val Gln
65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Ser Tyr Asp Cys Ser
85 90 95

Asp Ala Asp Cys Tyr Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 3

<211> 6

<212> PRT

<213> Oryctolagus cuniculus

<400> 3

Ser Ser Tyr Trp Ile Cys
1 5

<210> 4

<211> 18

<212> PRT

<213> Oryctolagus cuniculus

<400> 4

Cys Ile Tyr Ala Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Thr Trp Ala
1 5 10 15

Lys Gly

<210> 5

<211> 13

<212> PRT

<213> Oryctolagus cuniculus

<400> 5

Ala Tyr Ser Asp Arg Ser Gly Gly Tyr Ser Phe Asn Leu
1 5 10

<210> 6

<211> 13
<212> PRT
<213> Oryctolagus cuniculus

<400> 6

Gln Ala Ser Gln Ser Val Asp Asn Asn Asn Tyr Leu Ala
1 5 10

<210> 7
<211> 7
<212> PRT
<213> Oryctolagus cuniculus

<400> 7

Ser Ala Ser Ser Leu Ala Ser
1 5

<210> 8
<211> 13
<212> PRT
<213> Oryctolagus cuniculus

<400> 8

Leu Gly Ser Tyr Asp Cys Ser Asp Ala Asp Cys Tyr Ala
1 5 10

<210> 9
<211> 124
<212> PRT
<213> Oryctolagus cuniculus

<400> 9

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr
20 25 30

Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp
100 105 110

Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 10
<211> 109
<212> PRT
<213> *Oryctolagus cuniculus*

<400> 10

Val Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly Gly
1 5 10 15

Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu Leu
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
35 40 45

Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr Tyr
85 90 95

Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 11
<211> 6
<212> PRT
<213> *Oryctolagus cuniculus*

<400> 11

Asp Ile Tyr Tyr Ile Ser
1 5

<210> 12
<211> 18
<212> PRT
<213> *Oryctolagus cuniculus*

<400> 12

Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp Ala
1 5 10 15

Lys Gly

<210> 13
<211> 15
<212> PRT
<213> *Oryctolagus cuniculus*

<400> 13

Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp Leu
1 5 10 15

<210> 14
<211> 11
<212> PRT
<213> Oryctolagus cuniculus

<400> 14

Gln Ala Ser Gln Ser Ile Ser Asp Leu Leu Ser
1 5 10

<210> 15
<211> 7
<212> PRT
<213> Oryctolagus cuniculus

<400> 15

Ser Ala Ser Thr Leu Ala Ser
1 5

<210> 16
<211> 12
<212> PRT
<213> Oryctolagus cuniculus

<400> 16

Gln Cys Asn Tyr Tyr Ser Pro Thr Tyr Gly Asn Gly
1 5 10

<210> 17
<211> 121
<212> PRT
<213> Oryctolagus cuniculus

<400> 17

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser Tyr
20 25 30

Trp Leu Cys Trp Ala Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Ile
35 40 45

Ala Cys Ile Tyr Asn Gly Asp Gly Ser Thr His Tyr Ala Ser Trp Ala
50 55 60

Lys Gly Arg Phe Thr Ile Ser Lys Ser Ser Ser Thr Thr Val Thr Leu
65 70 75 80

Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala
85 90 95

Arg Asp Tyr Thr Tyr Asn Phe Tyr Thr Tyr Gly Phe Asn Leu Trp Gly
100 105 110

Pro Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 18
<211> 109
<212> PRT
<213> Oryctolagus cuniculus

<400> 18

Phe Glu Leu Thr Gln Thr Pro Ser Ser Val Glu Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ser Val Asn Ile Trp Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
35 40 45

Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Gly Tyr Pro Ser Ser Ser Ser
85 90 95

Gly Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 19
<211> 6
<212> PRT
<213> Oryctolagus cuniculus

<400> 19

Ser Ser Tyr Trp Leu Cys
1 5

<210> 20
<211> 17
<212> PRT
<213> Oryctolagus cuniculus

<400> 20

Cys Ile Tyr Asn Gly Asp Gly Ser Thr His Tyr Ala Ser Trp Ala Lys
1 5 10 15

Gly

<210> 21
<211> 13
<212> PRT
<213> Oryctolagus cuniculus

<400> 21

Asp Tyr Thr Tyr Asn Phe Tyr Thr Tyr Gly Phe Asn Leu
1 5 10

<210> 22
<211> 11
<212> PRT
<213> Oryctolagus cuniculus

<400> 22

Gln Ala Ser Gln Ser Val Asn Ile Trp Ala Ser
1 5 10

<210> 23
<211> 7
<212> PRT
<213> Oryctolagus cuniculus

<400> 23

Lys Ala Ser Thr Leu Ala Ser
1 5

<210> 24
<211> 12
<212> PRT
<213> Oryctolagus cuniculus

<400> 24

Gln Gly Gly Tyr Pro Ser Ser Ser Ser Gly Trp Ala
1 5 10

<210> 25
<211> 122
<212> PRT
<213> Oryctolagus cuniculus

<400> 25

Gln Glu Gln Val Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Thr Leu Ser Ser Ser
20 25 30

Tyr Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp
35 40 45

Ile Ala Cys Thr Tyr Asn Gly Asp Gly Ser Thr His Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Ser Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Asp Tyr Thr Asp Ala Phe Tyr Thr Tyr Gly Phe Asn Leu Trp
100 105 110

Gly Pro Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 26
<211> 109
<212> PRT
<213> Oryctolagus cuniculus

<400> 26

Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Ser Glu Pro Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Thr Ser Ser Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45

Tyr Arg Ala Ser Ser Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Ala Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Thr Gly Phe Tyr Gly Ser Ser
85 90 95

Gly His Thr Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 27
<211> 6
<212> PRT
<213> Oryctolagus cuniculus

<400> 27

Ser Ser Tyr Trp Ile Cys
1 5

<210> 28
<211> 17
<212> PRT
<213> Oryctolagus cuniculus

<400> 28

Cys Thr Tyr Asn Gly Asp Gly Ser Thr His Tyr Ala Ser Trp Ala Lys
1 5 10 15

Gly

<210> 29
<211> 13
<212> PRT
<213> Oryctolagus cuniculus

<400> 29

Asp Tyr Thr Asp Ala Phe Tyr Thr Tyr Gly Phe Asn Leu
1 5 10

<210> 30
<211> 11
<212> PRT
<213> Oryctolagus cuniculus

<400> 30

Gln Ala Ser Gln Ser Thr Ser Ser Tyr Leu Ala
1 5 10

<210> 31
<211> 7
<212> PRT
<213> Oryctolagus cuniculus

<400> 31

Arg Ala Ser Ser Leu Ala Ser
1 5

<210> 32
<211> 11
<212> PRT
<213> Oryctolagus cuniculus

<400> 32

Gln Thr Gly Phe Tyr Gly Ser Ser Gly His Thr
1 5 10

<210> 33
<211> 120
<212> PRT
<213> Oryctolagus cuniculus

<400> 33

Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser
20 25 30

Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser Ala Tyr Tyr Ala Asn Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Arg Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr Leu Tyr Leu Trp Gly Pro
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 34
<211> 109
<212> PRT
<213> Oryctolagus cuniculus

<400> 34

Gln Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Ser Cys Gln Ala Ser Gln Ser Val Ala Gly Asn Asn
20 25 30

Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu
35 40 45

Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu
65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly
85 90 95

Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 35
<211> 6
<212> PRT
<213> Oryctolagus cuniculus

<400> 35

Ser Ser Tyr Tyr Met Cys
1 5

<210> 36
<211> 17
<212> PRT

<213> Oryctolagus cuniculus

<400> 36

Cys Ile Tyr Thr Ser Ser Gly Ser Ala Tyr Tyr Ala Asn Trp Ala Lys
1 5 10 15

Gly

<210> 37

<211> 11

<212> PRT

<213> Oryctolagus cuniculus

<400> 37

Asn Ala Val Gly Ser Ser Tyr Tyr Leu Tyr Leu
1 5 10

<210> 38

<211> 13

<212> PRT

<213> Oryctolagus cuniculus

<400> 38

Gln Ala Ser Gln Ser Val Ala Gly Asn Asn Tyr Leu Ser
1 5 10

<210> 39

<211> 7

<212> PRT

<213> Oryctolagus cuniculus

<400> 39

Ser Val Ser Thr Leu Ala Ser
1 5

<210> 40

<211> 10

<212> PRT

<213> Oryctolagus cuniculus

<400> 40

Gln Gly Tyr Tyr Asn Asp Gly Ile Trp Ala
1 5 10

<210> 41

<211> 119

<212> PRT

<213> Oryctolagus cuniculus

<400> 41

Gln Glu Gln Val Glu Glu Ser Gly Gly Gly Leu Ala Lys Pro Gly Ala
1 5 10 15

Ser Leu Thr Leu Thr Cys Glu Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20 25 30

Trp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile Tyr Gly Gly Ser Ser Gly Ser Thr Tyr Tyr Ser Asn Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Asp Gly Ser Thr Trp Asp Tyr Phe Arg Leu Trp Gly Pro Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

<210> 42
<211> 110
<212> PRT
<213> Oryctolagus cuniculus

<400> 42

Tyr Asp Met Thr Gln Thr Pro Ser Ser Val Glu Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Asn Thr Asn Tyr
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45

Tyr Gln Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Tyr Tyr Thr Val Glu Asn
85 90 95

Ile Gly Asn Pro Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 43
<211> 5
<212> PRT
<213> Oryctolagus cuniculus

<400> 43

Ser Tyr Trp Met Cys

1 5

<210> 44
<211> 18
<212> PRT
<213> Oryctolagus cuniculus

<400> 44

Cys Ile Tyr Gly Gly Ser Ser Gly Ser Thr Tyr Tyr Ser Asn Trp Ala
1 5 10 15

Lys Gly

<210> 45
<211> 10
<212> PRT
<213> Oryctolagus cuniculus

<400> 45

Asp Gly Ser Thr Trp Asp Tyr Phe Arg Leu
1 5 10

<210> 46
<211> 12
<212> PRT
<213> Oryctolagus cuniculus

<400> 46

Gln Ala Ser Gln Ser Ile Asn Thr Asn Tyr Leu Ser
1 5 10

<210> 47
<211> 7
<212> PRT
<213> Oryctolagus cuniculus

<400> 47

Gln Ala Ser Thr Leu Glu Ser
1 5

<210> 48
<211> 12
<212> PRT
<213> Oryctolagus cuniculus

<400> 48

Gln Gly Tyr Tyr Thr Val Glu Asn Ile Gly Asn Pro
1 5 10

<210> 49
<211> 15
<212> PRT
<213> Oryctolagus cuniculus

<400> 49

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
 1 5 10 15

<210> 50
 <211> 369
 <212> DNA
 <213> *Oryctolagus cuniculus*

<400> 50
 caggagcaac tggaggagtc cgggggagac ctggtcaagc ctgagggatc cctgacactc 60
 acctgcacag cctctggatt ctcttcagtc agcagctact ggatatgctg ggtccgccag 120
 gctccaggga aggggctgga gtggatcgca tgcatttatg ctggtagtgg tggtagcact 180
 tactacgcga cctgggcgaa aggccgattc accatctcca aaacctcgtc gaccacggtg 240
 actctgcaaa tgaccagtct gacagccgcg gacacggcca gctatttctg tgtccgcgca 300
 tatagtgata gaagtggtag ttactcattt aatttgtggg gccagggcac cctggtcacc 360
 gtctcttca 369

<210> 51
 <211> 336
 <212> DNA
 <213> *Oryctolagus cuniculus*

<400> 51
 caagtgtga cccagactgc atccccgtg tctgaggctg ttggaggcac agtcaccatc 60
 aattgccagg ccagtcagag tgttgataat aacaactact tagcctggta tcagcagaaa 120
 ccagggcagc ctcccaaaca actgatctat tctgcatcca gtctggcatc tggggtcca 180
 tcgcggttca aaggcagtgg atctgggaca cagttcactc tcaccatcag cgacgtgcag 240
 tgtgacgatg ctgccactta ctactgtcta ggcagttatg attgtagtga tgctgattgt 300
 tatgctttcg gcggaggggac cgaggtgggtg gtcaaa 336

<210> 52
 <211> 372
 <212> DNA
 <213> *Oryctolagus cuniculus*

<400> 52
 cagtccttgg aggagtccgg gggagacctg gtcaagcctg gggcatccct gacactcacc 60
 tgcacagcct ctggaatcga ctctcagtcac atttattaca tatcttgggt ccgccaggct 120
 ccagggaagg ggctggagtg gatcgcatgc acttatgctg gtagtagtgg tagcacttac 180
 tacgcgacct gggcgaaagg ccgattcacc atctccaaag cctcgtcgac cacggtgact 240
 ctgcaaatga ccagtctgac agccgcggac acggccacct atttctgtgc gagagatcgt 300
 tatcctggta ctagtggttag ggtctacggc atggacctct ggggcccagg gaccctcgtc 360
 accgtctctt ca 372

<210> 53
 <211> 327
 <212> DNA
 <213> *Oryctolagus cuniculus*

<400> 53
gttgtgatga cccagactcc atcctccgtg tctgaacctg tgggaggcac agtcaccatc 60
aagtgccagg ccagtcagag cattagcgac ctcttattcct ggtatcagca gaaaccaggg 120
cagcctccca agctcctgat ctattctgca tccactctgg catctgggggt ctcatcgcg 180
ttcaaaggca gtggatctgg gacagaattc actctcacca tcagcgacct ggagtgtgcc 240
gatgctgcca cttactactg tcaatgtaat tattatagtc ctacttatgg gaatggtttc 300
ggcggaggga ccgaggtggt ggtcaaa 327

<210> 54
<211> 363
<212> DNA
<213> *Oryctolagus cuniculus*

<400> 54
cagtcattgg aggagtccgg gggagacctg gtcaagcctg gggcatccct gacactcacc 60
tgcacagcct ctggattctc cttcagtagc agctattggc tatgctgggc ccgccaggct 120
ccaggaagg ggctgagtg gatcgcatgc atttataatg gtgatggcag cacacactac 180
gcgagctggg cgaaaggccg attcaccatc tccaaatcct cgctgaccac ggtgactctg 240
caaatgacca gtctgacagc cgcgacacg gccacctatt tctgtgcgag agattatact 300
tataatTTTT atacttatgg ttttaatttg tggggcccag gcaccctggt caccgtctct 360
tca 363

<210> 55
<211> 327
<212> DNA
<213> *Oryctolagus cuniculus*

<400> 55
ttcgaattga cccagactcc atcctccgtg gaggcagctg tgggaggcac agtcaccatc 60
aactgccagg ccagtcagag cgtgaatatt tgggcatcct ggtaccagca gaaaccaggg 120
cagcctccca agctcctgat ctacaaggca tccactctgg catctgggggt cccatcgcg 180
ttcaaaggca gtggatctgg gacagagttc actctcacca tcagcgacct ggagtgtgcc 240
gatgctgcca cttactactg tcaaggcgggt tatcctagta gtagtagtgg ttgggctttc 300
ggcggaggga ccgaggtggt ggtcaaa 327

<210> 56
<211> 366
<212> DNA
<213> *Oryctolagus cuniculus*

<400> 56
caggagcagg tggaggagtc cgggggaggc ctggtcaagc ctggggcatc cctgacactc 60
acctgcacag cctctggatt caccctcagt agtagttatt ggatatgctg ggtccgccag 120
gctccaggga aggggcctga gtggatcgca tgcacttata atggtgatgg cagcacacac 180
tacgcgagct gggcgaaagg ccgattcacc atctccaaat cctcgtcgac caggtgact 240

ctgcaaatga ccagtctgac agccgcggac acggccacct atttctgtgc gagagattat	300
actgatgctt ttatactta tggttttaat ttgtggggcc caggcacct ggtcaccgtc	360
tcttca	366

<210> 57
 <211> 327
 <212> DNA
 <213> *Oryctolagus cuniculus*

<400> 57 gacattgtga tgaccagac tccagcctcc gtgtctgaac ctgtgggagg cacagtcacc	60
atcaagtgcc aggccagtca gagcactagt agctacttag cctggatatca gcagaaacca	120
gggcagcctc ccaagctcct gatctacagg gcatccagtc tggcatctgg ggtcccatcg	180
cggttcaaag gcagtggatc tgcgacagag ttcactctca ccatcagcga cctggagtgt	240
gccgatgctg ccacttacta ctgtcaaact ggtttttatg gtagtagtgg gcatactttc	300
ggcggaggga ccgaggtggt ggtcaaa	327

<210> 58
 <211> 360
 <212> DNA
 <213> *Oryctolagus cuniculus*

<400> 58 caggagcagc tggaggagtc cgggggaggc ctggtcaagc ctgagggatc cctgacactc	60
acctgcacag cttctggatt ctcttcagt agcagctact acatgtgctg ggtccgccag	120
gctccaggga gggggctgga tgggatcgca tgcatttata ctagtagtgg tagcgcttac	180
tacgcgaact gggcgaaagg ccgattcacc atctccagaa cctcgtcgac cacggtgact	240
ctgcaaatga cccgtctgac agccgcggac acggccacct atttctgtgt gagaaacgt	300
gttgggagta gttattattt gtatttgtgg ggcccaggca ccctggtcac cgtctctca	360

<210> 59
 <211> 327
 <212> DNA
 <213> *Oryctolagus cuniculus*

<400> 59 caagtgtga cccagactcc atcccctgtg tctgcagctg tgggaggcac agtcaccatc	60
agttgccagg ccagtcagag gtgtgctggt aacaactact tatcctggta tcagcagaaa	120
ccagggcagc ctccaacct cttgatctat tctgtatcca ctctggcctc tggggtcca	180
tcgcggttca aaggcagtgg atctgggaca cagttcactc tcaccatcag cgacctggag	240
tgtgacgatg ctgccactta ctactgtcaa ggctattata atgatggaat ttgggctttc	300
ggcggaggga ccgaggtggt ggtcaaa	327

<210> 60
 <211> 357
 <212> DNA
 <213> *Oryctolagus cuniculus*

<400> 60
caggagcagg tggaggagtc cgggggaggc ctggccaagc ctggggcatc tttgacactc 60
acctgcgaag cctctggatt caccctcagt agttactgga tgtgctgggt ccgccaggct 120
ccaggggaagg ggctggagtg gatcgcatgc atttatgggt ggagtagtgg tagcacttac 180
tactcgaact gggcgaaagg ccgattcacc atctccaaaa cctcgtcgac cacggtgact 240
ctgcaaatga ccagtctgac agccgcggac acggccacct atttctgtgc gagagatggt 300
agtacctggg actacttttag gttgtggggc ccaggcaccc tggtcaccgt ctcttca 357

<210> 61
<211> 330
<212> DNA
<213> Oryctolagus cuniculus

<400> 61
tatgatatga cccagactcc atcctccgtg gaggcagctg tgggaggcac agtcaccatc 60
aagtgccagg ccagtcagag tattaatact aactacttat cctggtatca gcagaaacca 120
gggcagcctc ccaagctcct gatctaccag gcatccactc tggaatctgg ggtcccatcg 180
cggttcaaag gcagtggatc tgggacagag tacactctca ccatcagcga cctggagtgt 240
gccgatgctg ccacttacta ctgtcaaggc tattatactg ttgagaatat tggtaatcct 300
ttcggcggag ggaccgaggt ggtggtcaaa 330

<210> 62
<211> 111
<212> PRT
<213> Oryctolagus cuniculus

<400> 62

Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr
85 90 95

Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys Lys
100 105 110

<210> 63

<211> 110
<212> PRT
<213> *Oryctolagus cuniculus*

<400> 63

Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr
85 90 95

Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 64
<211> 253
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 64

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr
20 25 30

Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp

100

105

110

Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser
 115 120 125

Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Asp Val
 130 135 140

Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly Gly Thr
 145 150 155 160

Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu Leu Ser
 165 170 175

Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ser
 180 185 190

Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly Ser Gly
 195 200 205

Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp
 210 215 220

Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr Tyr Gly
 225 230 235 240

Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys Lys
 245 250

<210> 65

<211> 253

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 65

Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly
 1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu
 20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
 35 40 45

Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
 65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr
85 90 95

Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys Lys Gly
100 105 110

Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys
115 120 125

Gly Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala
130 135 140

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile
145 150 155 160

Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
165 170 175

Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr
180 185 190

Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val
195 200 205

Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe
210 215 220

Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met
225 230 235 240

Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser
245 250

<210> 66
<211> 251
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 66

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr
20 25 30

Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp
100 105 110

Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser
115 120 125

Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Val Val
130 135 140

Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly Gly Thr Val
145 150 155 160

Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu Leu Ser Trp
165 170 175

Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ser Ala
180 185 190

Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly Ser Gly Ser
195 200 205

Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp Ala
210 215 220

Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr Tyr Gly Asn
225 230 235 240

Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys
245 250

<210> 67
<211> 251
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 67

Val Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly Gly
1 5 10 15

Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu Leu
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
35 40 45

Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr Tyr
85 90 95

Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys Gly Ser Thr
100 105 110

Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln
115 120 125

Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser Leu
130 135 140

Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr Tyr
145 150 155 160

Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala
165 170 175

Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp Ala
180 185 190

Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr Leu
195 200 205

Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala
210 215 220

Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp Leu
225 230 235 240

Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser
245 250

<210> 68
<211> 252
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 68

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr

20

25

30

Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp
 50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr
 65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
 85 90 95

Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp
 100 105 110

Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser
 115 120 125

Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Asp Val
 130 135 140

Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly Gly Thr
 145 150 155 160

Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu Leu Ser
 165 170 175

Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ser
 180 185 190

Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly Ser Gly
 195 200 205

Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp
 210 215 220

Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr Tyr Gly
 225 230 235 240

Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys
 245 250

<210> 69

<211> 252

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 69

Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr
85 90 95

Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys Gly Ser
100 105 110

Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly
115 120 125

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
130 135 140

Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr
145 150 155 160

Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
165 170 175

Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp
180 185 190

Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr
195 200 205

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
210 215 220

Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp
225 230 235 240

Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser
245 250

<210> 70

<211> 247

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 70

Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser
20 25 30

Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser Ala Tyr Tyr Ala Asn Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Arg Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr Leu Tyr Leu Trp Gly Pro
100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys
115 120 125

Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Leu Thr Gln Thr
130 135 140

Pro Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys
145 150 155 160

Gln Ala Ser Gln Ser Val Ala Gly Asn Asn Tyr Leu Ser Trp Tyr Gln
165 170 175

Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu Ile Tyr Ser Val Ser Thr
180 185 190

Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr
195 200 205

Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr
210 215 220

Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly Ile Trp Ala Phe Gly Gly
225 230 235 240

Gly Thr Glu Val Val Val Lys
245

<210> 71
<211> 247
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 71

Gln Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Ser Cys Gln Ala Ser Gln Ser Val Ala Gly Asn Asn
20 25 30

Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu
35 40 45

Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu
65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly
85 90 95

Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys Gly Ser Thr
100 105 110

Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln
115 120 125

Glu Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly Ser
130 135 140

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser Tyr
145 150 155 160

Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Ile
165 170 175

Ala Cys Ile Tyr Thr Ser Ser Gly Ser Ala Tyr Tyr Ala Asn Trp Ala
180 185 190

Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Thr Leu
195 200 205

Gln Met Thr Arg Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Val
210 215 220

Arg Asn Ala Val Gly Ser Ser Tyr Tyr Leu Tyr Leu Trp Gly Pro Gly
225 230 235 240

Thr Leu Val Thr Val Ser Ser
245

<210> 72
<211> 498
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 72

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu
20 25 30

Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile
35 40 45

Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly
50 55 60

Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser
65 70 75 80

Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly
115 120 125

Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val
130 135 140

Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly
145 150 155 160

Ser Thr Lys Gly Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser
165 170 175

Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser
180 185 190

Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
195 200 205

Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser
210 215 220

Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
225 230 235 240

Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr
245 250 255

Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val
260 265 270

Val Lys Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro
275 280 285

Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro
290 295 300

Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp
305 310 315 320

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu
325 330 335

Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu
340 345 350

Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu
355 360 365

Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys
370 375 380

Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
385 390 395 400

Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
405 410 415

Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
420 425 430

Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
435 440 445

Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
450 455 460

Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
465 470 475 480

Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
485 490 495

Pro Arg

<210> 73
<211> 515
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 73

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu
20 25 30

Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile
35 40 45

Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly
50 55 60

Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser
65 70 75 80

Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly
115 120 125

Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val
130 135 140

Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly
145 150 155 160

Ser Thr Lys Gly Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser
165 170 175

Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser
180 185 190

Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
195 200 205

Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser
210 215 220

Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
225 230 235 240

Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr
245 250 255

Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val
260 265 270

Val Lys Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
275 280 285

Gly Ser Gly Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala
290 295 300

Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg
305 310 315 320

Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys
325 330 335

Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu
340 345 350

Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu
355 360 365

Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln
370 375 380

Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly
385 390 395 400

Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
405 410 415

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
420 425 430

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
435 440 445

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
450 455 460

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
465 470 475 480

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
485 490 495

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
500 505 510

Pro Pro Arg
515

<210> 74
<211> 495
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 74

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu
20 25 30

Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile
35 40 45

Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly
50 55 60

Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser
65 70 75 80

Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly
115 120 125

Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val
130 135 140

Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly
145 150 155 160

Ser Thr Lys Gly Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser
165 170 175

Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser
180 185 190

Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
195 200 205

Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser
 210 215 220

Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
 225 230 235 240

Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr
 245 250 255

Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val
 260 265 270

Val Lys Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu
 275 280 285

Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
 290 295 300

Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
 305 310 315 320

Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
 325 330 335

Ile Ile Phe Trp Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe
 340 345 350

Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly
 355 360 365

Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg
 370 375 380

Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
 385 390 395 400

Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
 405 410 415

Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
 420 425 430

Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
 435 440 445

Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
 450 455 460

Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
 465 470 475 480

Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490 495

<210> 75
<211> 498
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 75

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Asp Val Val Met Thr Gln Thr Pro Ser Ser
20 25 30

Val Ser Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser
35 40 45

Gln Ser Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln
50 55 60

Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val
65 70 75 80

Ser Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
85 90 95

Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys
100 105 110

Asn Tyr Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu
115 120 125

Val Val Val Lys Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser
130 135 140

Gly Glu Gly Ser Thr Lys Gly Gln Ser Leu Glu Glu Ser Gly Gly Asp
145 150 155 160

Leu Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly
165 170 175

Ile Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro
180 185 190

Gly Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly
195 200 205

Ser Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys
210 215 220

Ala Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala
225 230 235 240

Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser
245 250 255

Gly Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr
260 265 270

Val Ser Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro
275 280 285

Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro
290 295 300

Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp
305 310 315 320

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu
325 330 335

Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu
340 345 350

Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu
355 360 365

Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys
370 375 380

Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
385 390 395 400

Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
405 410 415

Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
420 425 430

Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
435 440 445

Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
450 455 460

Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
465 470 475 480

Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
485 490 495

Pro Arg

<210> 76
<211> 515
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 76

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Asp Val Val Met Thr Gln Thr Pro Ser Ser
20 25 30

Val Ser Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser
35 40 45

Gln Ser Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln
50 55 60

Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val
65 70 75 80

Ser Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
85 90 95

Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys
100 105 110

Asn Tyr Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu
115 120 125

Val Val Val Lys Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser
130 135 140

Gly Glu Gly Ser Thr Lys Gly Gln Ser Leu Glu Glu Ser Gly Gly Asp
145 150 155 160

Leu Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly
165 170 175

Ile Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro
180 185 190

Gly Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly
195 200 205

Ser Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys
210 215 220

Ala Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala
225 230 235 240

Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser
245 250 255

Gly Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr
260 265 270

Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
275 280 285

Gly Ser Gly Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala
290 295 300

Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg
305 310 315 320

Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys
325 330 335

Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu
340 345 350

Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu
355 360 365

Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln
370 375 380

Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly
385 390 395 400

Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
405 410 415

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
420 425 430

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
435 440 445

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
450 455 460

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
465 470 475 480

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
485 490 495

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
500 505 510

Pro Pro Arg
515

<210> 77
<211> 496
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 77

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu
20 25 30

Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile
35 40 45

Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly
50 55 60

Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser
65 70 75 80

Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly
115 120 125

Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val
130 135 140

Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly
145 150 155 160

Ser Thr Lys Gly Val Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu
165 170 175

Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile
180 185 190

Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys
195 200 205

Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg
 210 215 220

Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp
 225 230 235 240

Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr
 245 250 255

Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val
 260 265 270

Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile
 275 280 285

Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala
 290 295 300

Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr
 305 310 315 320

Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu
 325 330 335

Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile
 340 345 350

Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp
 355 360 365

Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
 370 375 380

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
 385 390 395 400

Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
 405 410 415

Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
 420 425 430

Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
 435 440 445

Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
 450 455 460

Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
 465 470 475 480

Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490 495

<210> 78
<211> 496
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 78

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Val Val Met Thr Gln Thr Pro Ser Ser Val
20 25 30

Ser Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln
35 40 45

Ser Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro
50 55 60

Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser
65 70 75 80

Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
85 90 95

Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn
100 105 110

Tyr Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val
115 120 125

Val Val Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu
130 135 140

Gly Ser Thr Lys Gly Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val
145 150 155 160

Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp
165 170 175

Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys
180 185 190

Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr
195 200 205

Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser
210 215 220

Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr
 225 230 235 240

Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg
 245 250 255

Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser
 260 265 270

Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile
 275 280 285

Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala
 290 295 300

Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr
 305 310 315 320

Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu
 325 330 335

Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile
 340 345 350

Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp
 355 360 365

Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
 370 375 380

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
 385 390 395 400

Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
 405 410 415

Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
 420 425 430

Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
 435 440 445

Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
 450 455 460

Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
 465 470 475 480

Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
 485 490 495

<210> 79
<211> 497
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 79

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu
20 25 30

Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile
35 40 45

Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly
50 55 60

Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser
65 70 75 80

Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly
115 120 125

Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val
130 135 140

Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly
145 150 155 160

Ser Thr Lys Gly Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser
165 170 175

Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser
180 185 190

Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
195 200 205

Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser
210 215 220

Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
225 230 235 240

Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr
 245 250 255

Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val
 260 265 270

Val Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr
 275 280 285

Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala
 290 295 300

Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile
 305 310 315 320

Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser
 325 330 335

Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr
 340 345 350

Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu
 355 360 365

Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu
 370 375 380

Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln
 385 390 395 400

Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu
 405 410 415

Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly
 420 425 430

Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
 435 440 445

Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu
 450 455 460

Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr
 465 470 475 480

Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro
 485 490 495

Arg

<210> 80
<211> 497
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 80

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Asp Val Val Met Thr Gln Thr Pro Ser Ser
20 25 30

Val Ser Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser
35 40 45

Gln Ser Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln
50 55 60

Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val
65 70 75 80

Ser Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
85 90 95

Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys
100 105 110

Asn Tyr Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu
115 120 125

Val Val Val Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly
130 135 140

Glu Gly Ser Thr Lys Gly Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu
145 150 155 160

Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile
165 170 175

Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly
180 185 190

Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser
195 200 205

Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala
210 215 220

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp
225 230 235 240

Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly
 245 250 255
 Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val
 260 265 270
 Ser Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr
 275 280 285
 Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala
 290 295 300
 Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile
 305 310 315 320
 Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser
 325 330 335
 Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr
 340 345 350
 Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu
 355 360 365
 Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu
 370 375 380
 Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln
 385 390 395 400
 Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu
 405 410 415
 Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly
 420 425 430
 Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
 435 440 445
 Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu
 450 455 460
 Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr
 465 470 475 480
 Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro
 485 490 495

Arg

<210> 81
<211> 492
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 81

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly
20 25 30

Leu Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly
35 40 45

Phe Ser Phe Ser Ser Ser Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro
50 55 60

Gly Arg Gly Leu Glu Trp Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser
65 70 75 80

Ala Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Arg Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr
115 120 125

Leu Tyr Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser
130 135 140

Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly
145 150 155 160

Gln Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
165 170 175

Thr Val Thr Ile Ser Cys Gln Ala Ser Gln Ser Val Ala Gly Asn Asn
180 185 190

Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu
195 200 205

Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
210 215 220

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu
225 230 235 240

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly
 245 250 255
 Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys Thr Thr Thr
 260 265 270
 Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro
 275 280 285
 Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val
 290 295 300
 His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro
 305 310 315 320
 Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu
 325 330 335
 Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro
 340 345 350
 Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys
 355 360 365
 Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe
 370 375 380
 Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
 385 390 395 400
 Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
 405 410 415
 Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
 420 425 430
 Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
 435 440 445
 Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
 450 455 460
 Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
 465 470 475 480
 Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
 485 490

<210> 82
 <211> 509
 <212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 82

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly
20 25 30

Leu Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly
35 40 45

Phe Ser Phe Ser Ser Ser Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro
50 55 60

Gly Arg Gly Leu Glu Trp Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser
65 70 75 80

Ala Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Arg Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr
115 120 125

Leu Tyr Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser
130 135 140

Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly
145 150 155 160

Gln Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
165 170 175

Thr Val Thr Ile Ser Cys Gln Ala Ser Gln Ser Val Ala Gly Asn Asn
180 185 190

Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu
195 200 205

Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
210 215 220

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu
225 230 235 240

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly
245 250 255

Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys Gly Gly Gly
 260 265 270

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Thr Thr
 275 280 285

Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln
 290 295 300

Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala
 305 310 315 320

Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala
 325 330 335

Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr
 340 345 350

Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln
 355 360 365

Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
 370 375 380

Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys
 385 390 395 400

Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
 405 410 415

Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
 420 425 430

Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
 435 440 445

Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
 450 455 460

Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
 465 470 475 480

Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
 485 490 495

Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
 500 505

<210> 83
 <211> 489
 <212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 83

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly
20 25 30

Leu Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly
35 40 45

Phe Ser Phe Ser Ser Ser Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro
50 55 60

Gly Arg Gly Leu Glu Trp Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser
65 70 75 80

Ala Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Arg Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr
115 120 125

Leu Tyr Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser
130 135 140

Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly
145 150 155 160

Gln Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
165 170 175

Thr Val Thr Ile Ser Cys Gln Ala Ser Gln Ser Val Ala Gly Asn Asn
180 185 190

Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu
195 200 205

Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
210 215 220

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu
225 230 235 240

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly
245 250 255

Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys Ile Glu Val
 260 265 270

Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile
 275 280 285

Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly
 290 295 300

Pro Ser Lys Pro Phe Trp Val Leu Val Val Gly Gly Val Leu Ala
 305 310 315 320

Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Lys
 325 330 335

Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg
 340 345 350

Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro
 355 360 365

Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser
 370 375 380

Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
 385 390 395 400

Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
 405 410 415

Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
 420 425 430

Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
 435 440 445

Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
 450 455 460

Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
 465 470 475 480

Leu His Met Gln Ala Leu Pro Pro Arg
 485

<210> 84
 <211> 492
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 84

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Val Leu Thr Gln Thr Pro Ser Pro Val
20 25 30

Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ala Ser Gln
35 40 45

Ser Val Ala Gly Asn Asn Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly
50 55 60

Gln Pro Pro Asn Leu Leu Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly
65 70 75 80

Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu
85 90 95

Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln
100 105 110

Gly Tyr Tyr Asn Asp Gly Ile Trp Ala Phe Gly Gly Gly Thr Glu Val
115 120 125

Val Val Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu
130 135 140

Gly Ser Thr Lys Gly Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly Leu
145 150 155 160

Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe
165 170 175

Ser Phe Ser Ser Ser Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly
180 185 190

Arg Gly Leu Glu Trp Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser Ala
195 200 205

Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser
210 215 220

Ser Thr Thr Val Thr Leu Gln Met Thr Arg Leu Thr Ala Ala Asp Thr
225 230 235 240

Ala Thr Tyr Phe Cys Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr Leu
245 250 255

Tyr Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Thr Thr Thr
260 265 270

Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro
275 280 285

Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val
290 295 300

His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro
305 310 315 320

Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu
325 330 335

Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro
340 345 350

Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys
355 360 365

Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe
370 375 380

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
385 390 395 400

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
405 410 415

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
420 425 430

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
435 440 445

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
450 455 460

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
465 470 475 480

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490

<210> 85
<211> 509
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 85

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro

1	5							10							15						
Ala	Phe	Leu	Leu	Ile	Pro	Gln	Val	Leu	Thr	Gln	Thr	Pro	Ser	Pro	Val						
		20						25				30									
Ser	Ala	Ala	Val	Gly	Gly	Thr	Val	Thr	Ile	Ser	Cys	Gln	Ala	Ser	Gln						
		35				40						45									
Ser	Val	Ala	Gly	Asn	Asn	Tyr	Leu	Ser	Trp	Tyr	Gln	Gln	Lys	Pro	Gly						
50						55				60											
Gln	Pro	Pro	Asn	Leu	Leu	Ile	Tyr	Ser	Val	Ser	Thr	Leu	Ala	Ser	Gly						
65					70				75						80						
Val	Pro	Ser	Arg	Phe	Lys	Gly	Ser	Gly	Ser	Gly	Thr	Gln	Phe	Thr	Leu						
				85				90						95							
Thr	Ile	Ser	Asp	Leu	Glu	Cys	Asp	Asp	Ala	Ala	Thr	Tyr	Tyr	Cys	Gln						
		100						105				110									
Gly	Tyr	Tyr	Asn	Asp	Gly	Ile	Trp	Ala	Phe	Gly	Gly	Gly	Thr	Glu	Val						
		115				120						125									
Val	Val	Lys	Gly	Ser	Thr	Ser	Gly	Ser	Gly	Lys	Pro	Gly	Ser	Gly	Glu						
130						135				140											
Gly	Ser	Thr	Lys	Gly	Gln	Glu	Gln	Leu	Glu	Glu	Ser	Gly	Gly	Gly	Leu						
145					150				155						160						
Val	Lys	Pro	Glu	Gly	Ser	Leu	Thr	Leu	Thr	Cys	Thr	Ala	Ser	Gly	Phe						
				165				170						175							
Ser	Phe	Ser	Ser	Ser	Tyr	Tyr	Met	Cys	Trp	Val	Arg	Gln	Ala	Pro	Gly						
		180						185				190									
Arg	Gly	Leu	Glu	Trp	Ile	Ala	Cys	Ile	Tyr	Thr	Ser	Ser	Gly	Ser	Ala						
		195				200						205									
Tyr	Tyr	Ala	Asn	Trp	Ala	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Thr	Ser						
210						215				220											
Ser	Thr	Thr	Val	Thr	Leu	Gln	Met	Thr	Arg	Leu	Thr	Ala	Ala	Asp	Thr						
225					230				235						240						
Ala	Thr	Tyr	Phe	Cys	Val	Arg	Asn	Ala	Val	Gly	Ser	Ser	Tyr	Tyr	Leu						
				245				250						255							
Tyr	Leu	Trp	Gly	Pro	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly						
		260						265				270									
Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Thr	Thr						
		275				280						285									

Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln
290 295 300

Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala
305 310 315 320

Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala
325 330 335

Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Ser Leu Val Ile Thr
340 345 350

Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln
355 360 365

Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
370 375 380

Cys Arg Phe Pro Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys
385 390 395 400

Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
405 410 415

Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
420 425 430

Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
435 440 445

Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
450 455 460

Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
465 470 475 480

Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
485 490 495

Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
500 505

<210> 86
<211> 476
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 86

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser

1	5	10	15																
Leu	Thr	Leu	Thr	Cys	Thr	Ala	Ser	Gly	Ile	Asp	Phe	Ser	Asp	Ile	Tyr				
		20						25					30						
Tyr	Ile	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Ile				
		35					40					45							
Ala	Cys	Thr	Tyr	Ala	Gly	Ser	Ser	Gly	Ser	Thr	Tyr	Tyr	Ala	Thr	Trp				
	50					55					60								
Ala	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Lys	Ala	Ser	Ser	Thr	Thr	Val	Thr				
65					70					75					80				
Leu	Gln	Met	Thr	Ser	Leu	Thr	Ala	Ala	Asp	Thr	Ala	Thr	Tyr	Phe	Cys				
				85					90					95					
Ala	Arg	Asp	Arg	Tyr	Pro	Gly	Thr	Ser	Gly	Arg	Val	Tyr	Gly	Met	Asp				
			100					105					110						
Leu	Trp	Gly	Pro	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Gly	Ser	Thr	Ser				
		115					120					125							
Gly	Ser	Gly	Lys	Pro	Gly	Ser	Gly	Glu	Gly	Ser	Thr	Lys	Gly	Asp	Val				
	130					135					140								
Val	Met	Thr	Gln	Thr	Pro	Ser	Ser	Val	Ser	Glu	Pro	Val	Gly	Gly	Thr				
145					150					155					160				
Val	Thr	Ile	Lys	Cys	Gln	Ala	Ser	Gln	Ser	Ile	Ser	Asp	Leu	Leu	Ser				
				165					170					175					
Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Pro	Pro	Lys	Leu	Leu	Ile	Tyr	Ser				
			180					185					190						
Ala	Ser	Thr	Leu	Ala	Ser	Gly	Val	Ser	Ser	Arg	Phe	Lys	Gly	Ser	Gly				
		195					200					205							
Ser	Gly	Thr	Glu	Phe	Thr	Leu	Thr	Ile	Ser	Asp	Leu	Glu	Cys	Ala	Asp				
	210					215					220								
Ala	Ala	Thr	Tyr	Tyr	Cys	Gln	Cys	Asn	Tyr	Tyr	Ser	Pro	Thr	Tyr	Gly				
225					230					235					240				
Asn	Gly	Phe	Gly	Gly	Gly	Thr	Glu	Val	Val	Val	Lys	Lys	Thr	Thr	Thr				
			245						250					255					
Pro	Ala	Pro	Arg	Pro	Pro	Thr	Pro	Ala	Pro	Thr	Ile	Ala	Ser	Gln	Pro				
			260					265					270						
Leu	Ser	Leu	Arg	Pro	Glu	Ala	Cys	Arg	Pro	Ala	Ala	Gly	Gly	Ala	Val				
		275					280					285							

His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro
290 295 300

Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu
305 310 315 320

Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro
325 330 335

Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys
340 345 350

Arg Phe Pro Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe
355 360 365

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
370 375 380

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
385 390 395 400

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
405 410 415

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
420 425 430

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
435 440 445

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
450 455 460

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475

<210> 87
<211> 493
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 87

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr
20 25 30

Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile

35

40

45

Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp
100 105 110

Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser
115 120 125

Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Asp Val
130 135 140

Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly Gly Thr
145 150 155 160

Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu Leu Ser
165 170 175

Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ser
180 185 190

Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly Ser Gly
195 200 205

Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp
210 215 220

Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr Tyr Gly
225 230 235 240

Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys Lys Gly Gly Gly
245 250 255

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Thr Thr
260 265 270

Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln
275 280 285

Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala
290 295 300

Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala
305 310 315 320

Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr
325 330 335

Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln
340 345 350

Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
355 360 365

Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys
370 375 380

Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
385 390 395 400

Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
405 410 415

Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
420 425 430

Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
435 440 445

Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
450 455 460

Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
465 470 475 480

Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490

<210> 88
<211> 473
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 88

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr
20 25 30

Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp

50	55	60															
Ala 65	Lys	Gly	Arg	Phe	Thr 70	Ile	Ser	Lys	Ala	Ser 75	Ser	Thr	Thr	Val	Thr 80		
Leu	Gln	Met	Thr	Ser 85	Leu	Thr	Ala	Ala	Asp 90	Thr	Ala	Thr	Tyr	Phe	Cys 95		
Ala	Arg	Asp	Arg 100	Tyr	Pro	Gly	Thr	Ser 105	Gly	Arg	Val	Tyr	Gly 110	Met	Asp		
Leu	Trp	Gly 115	Pro	Gly	Thr	Leu	Val 120	Thr	Val	Ser	Ser	Gly 125	Ser	Thr	Ser		
Gly 130	Ser	Gly	Lys	Pro	Gly	Ser 135	Gly	Glu	Gly	Ser	Thr 140	Lys	Gly	Asp	Val		
Val 145	Met	Thr	Gln	Thr	Pro	Ser 150	Ser	Val	Ser	Glu 155	Pro	Val	Gly	Gly	Thr 160		
Val	Thr	Ile	Lys	Cys 165	Gln	Ala	Ser	Gln	Ser 170	Ile	Ser	Asp	Leu	Leu 175	Ser		
Trp	Tyr	Gln	Gln 180	Lys	Pro	Gly	Gln	Pro 185	Pro	Lys	Leu	Leu	Ile 190	Tyr	Ser		
Ala	Ser	Thr 195	Leu	Ala	Ser	Gly	Val 200	Ser	Ser	Arg	Phe	Lys 205	Gly	Ser	Gly		
Ser	Gly 210	Thr	Glu	Phe	Thr	Leu	Thr 215	Ile	Ser	Asp	Leu 220	Glu	Cys	Ala	Asp		
Ala 225	Ala	Thr	Tyr	Tyr	Cys 230	Gln	Cys	Asn	Tyr	Tyr 235	Ser	Pro	Thr	Tyr	Gly 240		
Asn	Gly	Phe	Gly	Gly 245	Gly	Thr	Glu	Val	Val 250	Val	Lys	Lys	Ile	Glu 255	Val		
Met	Tyr	Pro	Pro 260	Pro	Tyr	Leu	Asp	Asn 265	Glu	Lys	Ser	Asn	Gly 270	Thr	Ile		
Ile	His	Val 275	Lys	Gly	Lys	His	Leu 280	Cys	Pro	Ser	Pro	Leu	Phe 285	Pro	Gly		
Pro	Ser 290	Lys	Pro	Phe	Trp	Val 295	Leu	Val	Val	Val	Gly 300	Gly	Val	Leu	Ala		
Cys 305	Tyr	Ser	Leu	Leu	Val 310	Thr	Val	Ala	Phe	Ile 315	Ile	Phe	Trp	Val	Lys 320		
Arg	Gly	Arg	Lys	Lys 325	Leu	Leu	Tyr	Ile	Phe	Lys 330	Gln	Pro	Phe	Met 335	Arg		

Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro
340 345 350

Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser
355 360 365

Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
370 375 380

Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
385 390 395 400

Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
405 410 415

Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
420 425 430

Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
435 440 445

Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
450 455 460

Leu His Met Gln Ala Leu Pro Pro Arg
465 470

<210> 89
<211> 476
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 89

Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr

85

90

95

Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys Lys Gly
 100 105 110

Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys
 115 120 125

Gly Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala
 130 135 140

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile
 145 150 155 160

Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
 165 170 175

Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr
 180 185 190

Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val
 195 200 205

Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe
 210 215 220

Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met
 225 230 235 240

Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Thr Thr Thr
 245 250 255

Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro
 260 265 270

Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val
 275 280 285

His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro
 290 295 300

Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu
 305 310 315 320

Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro
 325 330 335

Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys
 340 345 350

Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe
 355 360 365

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
370 375 380

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
385 390 395 400

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
405 410 415

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
420 425 430

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
435 440 445

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
450 455 460

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470 475

<210> 90
<211> 493
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 90

Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr
85 90 95

Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys Lys Gly
100 105 110

Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys

115

120

125

Gly Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala
 130 135 140

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile
 145 150 155 160

Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
 165 170 175

Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr
 180 185 190

Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val
 195 200 205

Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe
 210 215 220

Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met
 225 230 235 240

Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
 245 250 255

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Thr Thr
 260 265 270

Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln
 275 280 285

Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala
 290 295 300

Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala
 305 310 315 320

Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr
 325 330 335

Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln
 340 345 350

Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
 355 360 365

Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys
 370 375 380

Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
 385 390 395 400

Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
405 410 415

Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
420 425 430

Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
435 440 445

Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
450 455 460

Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
465 470 475 480

Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
485 490

<210> 91
<211> 474
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 91

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr
20 25 30

Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp
100 105 110

Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser
115 120 125

Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Val Val

130				135				140							
Met 145	Thr	Gln	Thr	Pro	Ser 150	Ser	Val	Ser	Glu	Pro 155	Val	Gly	Gly	Thr	Val 160
Thr	Ile	Lys	Cys	Gln 165	Ala	Ser	Gln	Ser	Ile 170	Ser	Asp	Leu	Leu	Ser 175	Trp
Tyr	Gln	Gln	Lys 180	Pro	Gly	Gln	Pro	Pro 185	Lys	Leu	Leu	Ile	Tyr 190	Ser	Ala
Ser	Thr	Leu 195	Ala	Ser	Gly	Val	Ser 200	Ser	Arg	Phe	Lys	Gly 205	Ser	Gly	Ser
Gly	Thr 210	Glu	Phe	Thr	Leu	Thr 215	Ile	Ser	Asp	Leu	Glu 220	Cys	Ala	Asp	Ala
Ala 225	Thr	Tyr	Tyr	Cys	Gln 230	Cys	Asn	Tyr	Tyr	Ser 235	Pro	Thr	Tyr	Gly	Asn 240
Gly	Phe	Gly	Gly	Gly 245	Thr	Glu	Val	Val	Val 250	Lys	Thr	Thr	Thr	Pro 255	Ala
Pro	Arg	Pro 260	Pro	Thr	Pro	Ala	Pro 265	Thr	Ile	Ala	Ser	Gln 270	Pro	Leu	Ser
Leu	Arg	Pro 275	Glu	Ala	Cys	Arg	Pro 280	Ala	Ala	Gly	Gly 285	Ala	Val	His	Thr
Arg	Gly 290	Leu	Asp	Phe	Ala	Cys 295	Asp	Ile	Tyr	Ile	Trp 300	Ala	Pro	Leu	Ala
Gly 305	Thr	Cys	Gly	Val	Leu 310	Leu	Leu	Ser	Leu	Val 315	Ile	Thr	Leu	Tyr	Cys 320
Lys	Arg	Gly	Arg	Lys 325	Lys	Leu	Leu	Tyr	Ile 330	Phe	Lys	Gln	Pro	Phe 335	Met
Arg	Pro	Val	Gln 340	Thr	Thr	Gln	Glu	Glu 345	Asp	Gly	Cys	Ser	Cys 350	Arg	Phe
Pro	Glu	Glu 355	Glu	Glu	Gly	Gly	Cys 360	Glu	Leu	Arg	Val	Lys 365	Phe	Ser	Arg
Ser	Ala 370	Asp	Ala	Pro	Ala	Tyr 375	Gln	Gln	Gly	Gln	Asn 380	Gln	Leu	Tyr	Asn
Glu 385	Leu	Asn	Leu	Gly	Arg 390	Arg	Glu	Glu	Tyr	Asp 395	Val	Leu	Asp	Lys	Arg 400
Arg	Gly	Arg	Asp	Pro 405	Glu	Met	Gly	Gly	Lys 410	Pro	Arg	Arg	Lys	Asn 415	Pro

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
420 425 430

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
435 440 445

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
450 455 460

Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470

<210> 92
<211> 474
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 92

Val Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly Gly
1 5 10 15

Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu Leu
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
35 40 45

Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr Tyr
85 90 95

Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys Gly Ser Thr
100 105 110

Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln
115 120 125

Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser Leu
130 135 140

Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr Tyr
145 150 155 160

Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala

165

170

175

Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp Ala
180 185 190

Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr Leu
195 200 205

Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala
210 215 220

Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp Leu
225 230 235 240

Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Thr Thr Thr Pro Ala
245 250 255

Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser
260 265 270

Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr
275 280 285

Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala
290 295 300

Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys
305 310 315 320

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met
325 330 335

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe
340 345 350

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg
355 360 365

Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn
370 375 380

Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg
385 390 395 400

Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro
405 410 415

Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala
420 425 430

Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His
435 440 445

Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp
450 455 460

Ala Leu His Met Gln Ala Leu Pro Pro Arg
465 470

<210> 93
<211> 475
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 93

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr
20 25 30

Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp
100 105 110

Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser
115 120 125

Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Asp Val
130 135 140

Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly Gly Thr
145 150 155 160

Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu Leu Ser
165 170 175

Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ser
180 185 190

Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly Ser Gly

195

200

205

Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp
 210 215 220
 Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr Tyr Gly
 225 230 235 240
 Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys Thr Thr Thr Pro
 245 250 255
 Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu
 260 265 270
 Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His
 275 280 285
 Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu
 290 295 300
 Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr
 305 310 315 320
 Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe
 325 330 335
 Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg
 340 345 350
 Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser
 355 360 365
 Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr
 370 375 380
 Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys
 385 390 395 400
 Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn
 405 410 415
 Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu
 420 425 430
 Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly
 435 440 445
 His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr
 450 455 460
 Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
 465 470 475

<210> 94
<211> 475
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 94

Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr
85 90 95

Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys Gly Ser
100 105 110

Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly
115 120 125

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
130 135 140

Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr
145 150 155 160

Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
165 170 175

Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp
180 185 190

Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr
195 200 205

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
210 215 220

Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp

225		230		235		240
Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Thr Thr Thr Pro						
		245		250		255
Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu						
		260		265		270
Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His						
		275		280		285
Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu						
		290		295		300
Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr						
		305		310		315
Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe						
		325		330		335
Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg						
		340		345		350
Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser						
		355		360		365
Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr						
		370		375		380
Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys						
		385		390		395
Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn						
		405		410		415
Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu						
		420		425		430
Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly						
		435		440		445
His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr						
		450		455		460
Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg						
		465		470		475

<210> 95
 <211> 470
 <212> PRT
 <213> Artificial sequence
 <220>

<223> synthetic sequence

<400> 95

Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser
20 25 30

Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser Ala Tyr Tyr Ala Asn Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Arg Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr Leu Tyr Leu Trp Gly Pro
100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys
115 120 125

Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Leu Thr Gln Thr
130 135 140

Pro Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys
145 150 155 160

Gln Ala Ser Gln Ser Val Ala Gly Asn Asn Tyr Leu Ser Trp Tyr Gln
165 170 175

Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu Ile Tyr Ser Val Ser Thr
180 185 190

Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr
195 200 205

Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr
210 215 220

Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly Ile Trp Ala Phe Gly Gly
225 230 235 240

Gly Thr Glu Val Val Val Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro
245 250 255

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu

260

265

270

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
 275 280 285

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
 290 295 300

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg
 305 310 315 320

Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln
 325 330 335

Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu
 340 345 350

Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala
 355 360 365

Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu
 370 375 380

Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp
 385 390 395 400

Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu
 405 410 415

Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile
 420 425 430

Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr
 435 440 445

Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met
 450 455 460

Gln Ala Leu Pro Pro Arg
 465 470

<210> 96
 <211> 487
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 96

Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly
 1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser
 20 25 30

Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp
 35 40 45

Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser Ala Tyr Tyr Ala Asn Trp
 50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Thr
 65 70 75 80

Leu Gln Met Thr Arg Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
 85 90 95

Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr Leu Tyr Leu Trp Gly Pro
 100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys
 115 120 125

Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Leu Thr Gln Thr
 130 135 140

Pro Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys
 145 150 155 160

Gln Ala Ser Gln Ser Val Ala Gly Asn Asn Tyr Leu Ser Trp Tyr Gln
 165 170 175

Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu Ile Tyr Ser Val Ser Thr
 180 185 190

Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr
 195 200 205

Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr
 210 215 220

Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly Ile Trp Ala Phe Gly Gly
 225 230 235 240

Gly Thr Glu Val Val Val Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly
 245 250 255

Ser Gly Gly Gly Gly Ser Gly Gly Thr Thr Thr Pro Ala Pro Arg Pro
 260 265 270

Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro
 275 280 285

Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu

290

295

300

Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys
 305 310 315 320

Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly
 325 330 335

Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val
 340 345 350

Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu
 355 360 365

Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp
 370 375 380

Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
 385 390 395 400

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
 405 410 415

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
 420 425 430

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
 435 440 445

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
 450 455 460

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
 465 470 475 480

Met Gln Ala Leu Pro Pro Arg
 485

<210> 97
 <211> 467
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 97

Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly
 1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser
 20 25 30

Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser Ala Tyr Tyr Ala Asn Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Arg Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr Leu Tyr Leu Trp Gly Pro
100 105 110

Gly Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys
115 120 125

Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Val Leu Thr Gln Thr
130 135 140

Pro Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys
145 150 155 160

Gln Ala Ser Gln Ser Val Ala Gly Asn Asn Tyr Leu Ser Trp Tyr Gln
165 170 175

Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu Ile Tyr Ser Val Ser Thr
180 185 190

Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr
195 200 205

Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr
210 215 220

Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly Ile Trp Ala Phe Gly Gly
225 230 235 240

Gly Thr Glu Val Val Val Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr
245 250 255

Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys
260 265 270

His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp
275 280 285

Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val
290 295 300

Thr Val Ala Phe Ile Ile Phe Trp Val Lys Arg Gly Arg Lys Lys Leu

305 310 315 320

Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln
325 330 335

Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly
340 345 350

Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
355 360 365

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
370 375 380

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
385 390 395 400

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
405 410 415

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
420 425 430

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
435 440 445

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
450 455 460

Pro Pro Arg
465

<210> 98
<211> 470
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 98

Gln Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Ser Cys Gln Ala Ser Gln Ser Val Ala Gly Asn Asn
20 25 30

Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu
35 40 45

Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu
65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly
85 90 95

Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys Gly Ser Thr
100 105 110

Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln
115 120 125

Glu Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly Ser
130 135 140

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser Tyr
145 150 155 160

Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Ile
165 170 175

Ala Cys Ile Tyr Thr Ser Ser Gly Ser Ala Tyr Tyr Ala Asn Trp Ala
180 185 190

Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Thr Leu
195 200 205

Gln Met Thr Arg Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Val
210 215 220

Arg Asn Ala Val Gly Ser Ser Tyr Tyr Leu Tyr Leu Trp Gly Pro Gly
225 230 235 240

Thr Leu Val Thr Val Ser Ser Thr Thr Thr Pro Ala Pro Arg Pro Pro
245 250 255

Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu
260 265 270

Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp
275 280 285

Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly
290 295 300

Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg
305 310 315 320

Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln
325 330 335

Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu

340

345

350

Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala
 355 360 365

Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu
 370 375 380

Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp
 385 390 395 400

Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu
 405 410 415

Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile
 420 425 430

Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr
 435 440 445

Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met
 450 455 460

Gln Ala Leu Pro Pro Arg
 465 470

<210> 99
 <211> 487
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 99

Gln Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
 1 5 10 15

Thr Val Thr Ile Ser Cys Gln Ala Ser Gln Ser Val Ala Gly Asn Asn
 20 25 30

Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu
 35 40 45

Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
 50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu
 65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly
 85 90 95

Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys Gly Ser Thr
 100 105 110

Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln
 115 120 125

Glu Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly Ser
 130 135 140

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser Tyr
 145 150 155 160

Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Ile
 165 170 175

Ala Cys Ile Tyr Thr Ser Ser Gly Ser Ala Tyr Tyr Ala Asn Trp Ala
 180 185 190

Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Thr Leu
 195 200 205

Gln Met Thr Arg Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Val
 210 215 220

Arg Asn Ala Val Gly Ser Ser Tyr Tyr Leu Tyr Leu Trp Gly Pro Gly
 225 230 235 240

Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
 245 250 255

Ser Gly Gly Gly Gly Ser Gly Gly Thr Thr Thr Pro Ala Pro Arg Pro
 260 265 270

Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro
 275 280 285

Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu
 290 295 300

Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys
 305 310 315 320

Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly
 325 330 335

Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val
 340 345 350

Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu
 355 360 365

Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp

370

375

380

Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn
385 390 395 400

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg
405 410 415

Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly
420 425 430

Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu
435 440 445

Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu
450 455 460

Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His
465 470 475 480

Met Gln Ala Leu Pro Pro Arg
485

<210> 100

<211> 755

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 100

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu
20 25 30

Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile
35 40 45

Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly
50 55 60

Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser
65 70 75 80

Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly
115 120 125

Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val
130 135 140

Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly
145 150 155 160

Ser Thr Lys Gly Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser
165 170 175

Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser
180 185 190

Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
195 200 205

Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser
210 215 220

Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
225 230 235 240

Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr
245 250 255

Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val
260 265 270

Val Lys Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro
275 280 285

Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro
290 295 300

Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp
305 310 315 320

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu
325 330 335

Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu
340 345 350

Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu
355 360 365

Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys
370 375 380

Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln

385		390		395		400
Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu						
		405		410		415
Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly						
		420		425		430
Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu						
		435		440		445
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly						
		450		455		460
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser						
		465		470		475
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro						
		485		490		495
Pro Arg Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp						
		500		505		510
Val Glu Glu Asn Pro Gly Pro Met Val Ser Lys Gly Glu Glu Asp Asn						
		515		520		525
Met Ala Ile Ile Lys Glu Phe Met Arg Phe Lys Val His Met Glu Gly						
		530		535		540
Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg						
		545		550		555
Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys Val Thr Lys Gly Gly						
		565		570		575
Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr Gly						
		580		585		590
Ser Lys Ala Tyr Val Lys His Pro Ala Asp Ile Pro Asp Tyr Leu Lys						
		595		600		605
Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val Met Asn Phe Glu						
		610		615		620
Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser Leu Gln Asp Gly						
		625		630		635
Glu Phe Ile Tyr Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Ser Asp						
		645		650		655
Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu Ala Ser Ser Glu						
		660		665		670

Arg Met Tyr Pro Glu Asp Gly Ala Leu Lys Gly Glu Ile Lys Gln Arg
675 680 685

Leu Lys Leu Lys Asp Gly Gly His Tyr Asp Ala Glu Val Lys Thr Thr
690 695 700

Tyr Lys Ala Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr Asn Val Asn
705 710 715 720

Ile Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr Thr Ile Val Glu
725 730 735

Gln Tyr Glu Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Asp Glu
740 745 750

Leu Tyr Lys
755

<210> 101
<211> 763
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 101

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu
20 25 30

Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile
35 40 45

Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly
50 55 60

Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser
65 70 75 80

Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly
115 120 125

Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val

130					135					140					
Ser 145	Ser	Gly	Ser	Thr	Ser 150	Gly	Ser	Gly	Lys	Pro 155	Gly	Ser	Gly	Glu	Gly 160
Ser	Thr	Lys	Gly	Asp 165	Val	Val	Met	Thr	Gln 170	Thr	Pro	Ser	Ser	Val 175	Ser
Glu	Pro	Val	Gly 180	Gly	Thr	Val	Thr	Ile 185	Lys	Cys	Gln	Ala	Ser 190	Gln	Ser
Ile	Ser	Asp 195	Leu	Leu	Ser	Trp	Tyr 200	Gln	Gln	Lys	Pro	Gly 205	Gln	Pro	Pro
Lys	Leu 210	Leu	Ile	Tyr	Ser	Ala 215	Ser	Thr	Leu	Ala	Ser 220	Gly	Val	Ser	Ser
Arg 225	Phe	Lys	Gly	Ser	Gly 230	Ser	Gly	Thr	Glu	Phe 235	Thr	Leu	Thr	Ile	Ser 240
Asp	Leu	Glu	Cys	Ala 245	Asp	Ala	Ala	Thr	Tyr 250	Tyr	Cys	Gln	Cys	Asn 255	Tyr
Tyr	Ser	Pro	Thr 260	Tyr	Gly	Asn	Gly	Phe 265	Gly	Gly	Gly	Thr	Glu 270	Val	Val
Val	Lys	Lys 275	Thr	Thr	Thr	Pro	Ala 280	Pro	Arg	Pro	Pro	Thr 285	Pro	Ala	Pro
Thr	Ile 290	Ala	Ser	Gln	Pro	Leu 295	Ser	Leu	Arg	Pro	Glu 300	Ala	Cys	Arg	Pro
Ala 305	Ala	Gly	Gly	Ala	Val 310	His	Thr	Arg	Gly	Leu 315	Asp	Phe	Ala	Cys	Asp 320
Ile	Tyr	Ile	Trp	Ala 325	Pro	Leu	Ala	Gly	Thr 330	Cys	Gly	Val	Leu	Leu 335	Leu
Ser	Leu	Val	Ile 340	Thr	Leu	Tyr	Cys	Lys 345	Arg	Gly	Arg	Lys	Lys 350	Leu	Leu
Tyr	Ile	Phe 355	Lys	Gln	Pro	Phe	Met 360	Arg	Pro	Val	Gln	Thr	Thr	Gln	Glu
Glu	Asp 370	Gly	Cys	Ser	Cys	Arg 375	Phe	Pro	Glu	Glu	Glu 380	Glu	Gly	Gly	Cys
Glu 385	Leu	Arg	Val	Lys	Phe 390	Ser	Arg	Ser	Ala	Asp 395	Ala	Pro	Ala	Tyr	Gln 400
Gln	Gly	Gln	Asn 405	Gln	Leu	Tyr	Asn	Glu	Leu 410	Asn	Leu	Gly	Arg	Arg 415	Glu

Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
 420 425 430

Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
 435 440 445

Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
 450 455 460

Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
 465 470 475 480

Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
 485 490 495

Pro Arg Leu Ile Asn Gly Ser Gly Gln Cys Thr Asn Tyr Ala Leu Leu
 500 505 510

Lys Leu Ala Gly Asp Val Glu Ser Asn Pro Gly Pro Met Val Ser Lys
 515 520 525

Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu Leu Asp
 530 535 540

Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu Gly Glu Gly
 545 550 555 560

Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr Thr Gly
 565 570 575

Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu Thr Tyr Gly
 580 585 590

Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln His Asp Phe
 595 600 605

Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr Ile Phe
 610 615 620

Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys Phe Glu
 625 630 635 640

Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp Phe Lys
 645 650 655

Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr Asn Ser
 660 665 670

His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile Lys Val
 675 680 685

Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln Leu Ala
690 695 700

Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu
705 710 715 720

Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp Pro
725 730 735

Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr Ala Ala
740 745 750

Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
755 760

<210> 102
<211> 758
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 102

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu
20 25 30

Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile
35 40 45

Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly
50 55 60

Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser
65 70 75 80

Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly
115 120 125

Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val
130 135 140

Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly
145 150 155 160

Ser Thr Lys Gly Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser
 165 170 175

Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser
 180 185 190

Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 195 200 205

Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser
 210 215 220

Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
 225 230 235 240

Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr
 245 250 255

Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val
 260 265 270

Val Lys Lys Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro
 275 280 285

Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro
 290 295 300

Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp
 305 310 315 320

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu
 325 330 335

Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu
 340 345 350

Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu
 355 360 365

Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys
 370 375 380

Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln
 385 390 395 400

Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu
 405 410 415

Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly
 420 425 430

Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu
435 440 445

Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly
450 455 460

Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser
465 470 475 480

Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro
485 490 495

Pro Arg Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp
500 505 510

Val Glu Glu Asn Pro Gly Pro Met Val Ser Lys Gly Glu Glu Leu Phe
515 520 525

Thr Gly Val Val Pro Ile Leu Val Glu Leu Asp Gly Asp Val Asn Gly
530 535 540

His Lys Phe Ser Val Ser Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly
545 550 555 560

Lys Leu Thr Leu Lys Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro
565 570 575

Trp Pro Thr Leu Val Thr Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser
580 585 590

Arg Tyr Pro Asp His Met Lys Gln His Asp Phe Phe Lys Ser Ala Met
595 600 605

Pro Glu Gly Tyr Val Gln Glu Arg Thr Ile Phe Phe Lys Asp Asp Gly
610 615 620

Asn Tyr Lys Thr Arg Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val
625 630 635 640

Asn Arg Ile Glu Leu Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile
645 650 655

Leu Gly His Lys Leu Glu Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile
660 665 670

Met Ala Asp Lys Gln Lys Asn Gly Ile Lys Val Asn Phe Lys Ile Arg
675 680 685

His Asn Ile Glu Asp Gly Ser Val Gln Leu Ala Asp His Tyr Gln Gln
690 695 700

Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu Pro Asp Asn His Tyr
705 710 715 720

Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp
725 730 735

His Met Val Leu Leu Glu Phe Val Thr Ala Ala Gly Ile Thr Leu Gly
740 745 750

Met Asp Glu Leu Tyr Lys
755

<210> 103
<211> 772
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 103

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu
20 25 30

Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile
35 40 45

Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly
50 55 60

Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser
65 70 75 80

Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly
115 120 125

Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val
130 135 140

Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly
145 150 155 160

Ser Thr Lys Gly Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser
165 170 175

Glu	Pro	Val	Gly	Gly	Thr	Val	Thr	Ile	Lys	Cys	Gln	Ala	Ser	Gln	Ser	180	185	190	
Ile	Ser	Asp	Leu	Leu	Ser	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Pro	Pro	195	200	205	
Lys	Leu	Leu	Ile	Tyr	Ser	Ala	Ser	Thr	Leu	Ala	Ser	Gly	Val	Ser	Ser	210	215	220	
Arg	Phe	Lys	Gly	Ser	Gly	Ser	Gly	Thr	Glu	Phe	Thr	Leu	Thr	Ile	Ser	225	230	235	240
Asp	Leu	Glu	Cys	Ala	Asp	Ala	Ala	Thr	Tyr	Tyr	Cys	Gln	Cys	Asn	Tyr	245	250	255	
Tyr	Ser	Pro	Thr	Tyr	Gly	Asn	Gly	Phe	Gly	Gly	Gly	Thr	Glu	Val	Val	260	265	270	
Val	Lys	Lys	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	275	280	285	
Gly	Ser	Gly	Gly	Thr	Thr	Thr	Pro	Ala	Pro	Arg	Pro	Pro	Thr	Pro	Ala	290	295	300	
Pro	Thr	Ile	Ala	Ser	Gln	Pro	Leu	Ser	Leu	Arg	Pro	Glu	Ala	Cys	Arg	305	310	315	320
Pro	Ala	Ala	Gly	Gly	Ala	Val	His	Thr	Arg	Gly	Leu	Asp	Phe	Ala	Cys	325	330	335	
Asp	Ile	Tyr	Ile	Trp	Ala	Pro	Leu	Ala	Gly	Thr	Cys	Gly	Val	Leu	Leu	340	345	350	
Leu	Ser	Leu	Val	Ile	Thr	Leu	Tyr	Cys	Lys	Arg	Gly	Arg	Lys	Lys	Leu	355	360	365	
Leu	Tyr	Ile	Phe	Lys	Gln	Pro	Phe	Met	Arg	Pro	Val	Gln	Thr	Thr	Gln	370	375	380	
Glu	Glu	Asp	Gly	Cys	Ser	Cys	Arg	Phe	Pro	Glu	Glu	Glu	Glu	Gly	Gly	385	390	395	400
Cys	Glu	Leu	Arg	Val	Lys	Phe	Ser	Arg	Ser	Ala	Asp	Ala	Pro	Ala	Tyr	405	410	415	
Gln	Gln	Gly	Gln	Asn	Gln	Leu	Tyr	Asn	Glu	Leu	Asn	Leu	Gly	Arg	Arg	420	425	430	
Glu	Glu	Tyr	Asp	Val	Leu	Asp	Lys	Arg	Arg	Gly	Arg	Asp	Pro	Glu	Met	435	440	445	

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
450 455 460

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
465 470 475 480

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
485 490 495

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
500 505 510

Pro Pro Arg Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly
515 520 525

Asp Val Glu Glu Asn Pro Gly Pro Met Val Ser Lys Gly Glu Glu Asp
530 535 540

Asn Met Ala Ile Ile Lys Glu Phe Met Arg Phe Lys Val His Met Glu
545 550 555 560

Gly Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly
565 570 575

Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys Val Thr Lys Gly
580 585 590

Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr
595 600 605

Gly Ser Lys Ala Tyr Val Lys His Pro Ala Asp Ile Pro Asp Tyr Leu
610 615 620

Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val Met Asn Phe
625 630 635 640

Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser Leu Gln Asp
645 650 655

Gly Glu Phe Ile Tyr Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Ser
660 665 670

Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu Ala Ser Ser
675 680 685

Glu Arg Met Tyr Pro Glu Asp Gly Ala Leu Lys Gly Glu Ile Lys Gln
690 695 700

Arg Leu Lys Leu Lys Asp Gly Gly His Tyr Asp Ala Glu Val Lys Thr
705 710 715 720

Thr Tyr Lys Ala Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr Asn Val

725

730

735

Asn Ile Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr Thr Ile Val
 740 745 750

Glu Gln Tyr Glu Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Asp
 755 760 765

Glu Leu Tyr Lys
 770

<210> 104

<211> 752

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 104

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
 1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu
 20 25 30

Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Ile
 35 40 45

Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro Gly
 50 55 60

Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly Ser
 65 70 75 80

Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Ala
 85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp
 100 105 110

Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser Gly
 115 120 125

Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val
 130 135 140

Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly
 145 150 155 160

Ser Thr Lys Gly Asp Val Val Met Thr Gln Thr Pro Ser Ser Val Ser
 165 170 175

Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser
 180 185 190

Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 195 200 205

Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Ser Ser
 210 215 220

Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
 225 230 235 240

Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Asn Tyr
 245 250 255

Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu Val Val
 260 265 270

Val Lys Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu
 275 280 285

Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro
 290 295 300

Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val
 305 310 315 320

Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe
 325 330 335

Ile Ile Phe Trp Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe
 340 345 350

Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly
 355 360 365

Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg
 370 375 380

Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln
 385 390 395 400

Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp
 405 410 415

Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro
 420 425 430

Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
 435 440 445

Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg

450				455				460							
Arg 465	Gly	Lys	Gly	His	Asp 470	Gly	Leu	Tyr	Gln	Gly 475	Leu	Ser	Thr	Ala	Thr 480
Lys	Asp	Thr	Tyr	Asp 485	Ala	Leu	His	Met	Gln 490	Ala	Leu	Pro	Pro	Arg	Gly 495
Ser	Gly	Glu	Gly 500	Arg	Gly	Ser	Leu	Leu 505	Thr	Cys	Gly	Asp	Val 510	Glu	Glu
Asn	Pro	Gly 515	Pro	Met	Val	Ser	Lys 520	Gly	Glu	Glu	Asp	Asn 525	Met	Ala	Ile
Ile	Lys 530	Glu	Phe	Met	Arg	Phe 535	Lys	Val	His	Met	Glu 540	Gly	Ser	Val	Asn
Gly 545	His	Glu	Phe	Glu	Ile 550	Glu	Gly	Glu	Gly	Glu 555	Gly	Arg	Pro	Tyr	Glu 560
Gly	Thr	Gln	Thr	Ala 565	Lys	Leu	Lys	Val	Thr 570	Lys	Gly	Gly	Pro	Leu 575	Pro
Phe	Ala	Trp	Asp 580	Ile	Leu	Ser	Pro	Gln 585	Phe	Met	Tyr	Gly	Ser 590	Lys	Ala
Tyr	Val	Lys 595	His	Pro	Ala	Asp	Ile 600	Pro	Asp	Tyr	Leu	Lys 605	Leu	Ser	Phe
Pro	Glu 610	Gly	Phe	Lys	Trp	Glu 615	Arg	Val	Met	Asn	Phe 620	Glu	Asp	Gly	Gly
Val 625	Val	Thr	Val	Thr	Gln 630	Asp	Ser	Ser	Leu	Gln 635	Asp	Gly	Glu	Phe	Ile 640
Tyr	Lys	Val	Lys	Leu 645	Arg	Gly	Thr	Asn	Phe 650	Pro	Ser	Asp	Gly	Pro 655	Val
Met	Gln	Lys	Lys 660	Thr	Met	Gly	Trp	Glu 665	Ala	Ser	Ser	Glu	Arg 670	Met	Tyr
Pro	Glu	Asp 675	Gly	Ala	Leu	Lys	Gly 680	Glu	Ile	Lys	Gln	Arg 685	Leu	Lys	Leu
Lys	Asp 690	Gly	Gly	His	Tyr	Asp 695	Ala	Glu	Val	Lys	Thr 700	Thr	Tyr	Lys	Ala
Lys 705	Lys	Pro	Val	Gln 710	Leu	Pro	Gly	Ala	Tyr	Asn 715	Val	Asn	Ile	Lys	Leu 720
Asp	Ile	Thr	Ser	His 725	Asn	Glu	Asp	Tyr	Thr 730	Ile	Val	Glu	Gln	Tyr 735	Glu

Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys
740 745 750

<210> 105
<211> 755
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 105

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Asp Val Val Met Thr Gln Thr Pro Ser Ser
20 25 30

Val Ser Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser
35 40 45

Gln Ser Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln
50 55 60

Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val
65 70 75 80

Ser Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
85 90 95

Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys
100 105 110

Asn Tyr Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu
115 120 125

Val Val Val Lys Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser
130 135 140

Gly Glu Gly Ser Thr Lys Gly Gln Ser Leu Glu Glu Ser Gly Gly Asp
145 150 155 160

Leu Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly
165 170 175

Ile Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro
180 185 190

Gly Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly
195 200 205

Ser Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys

210					215					220					
Ala 225	Ser	Ser	Thr	Thr	Val 230	Thr	Leu	Gln	Met	Thr 235	Ser	Leu	Thr	Ala 240	Ala
Asp	Thr	Ala	Thr	Tyr 245	Phe	Cys	Ala	Arg	Asp 250	Arg	Tyr	Pro	Gly	Thr 255	Ser
Gly	Arg	Val	Tyr 260	Gly	Met	Asp	Leu	Trp 265	Gly	Pro	Gly	Thr	Leu 270	Val	Thr
Val	Ser	Ser 275	Thr	Thr	Thr	Pro	Ala 280	Pro	Arg	Pro	Pro	Thr 285	Pro	Ala	Pro
Thr	Ile 290	Ala	Ser	Gln	Pro	Leu 295	Ser	Leu	Arg	Pro	Glu 300	Ala	Cys	Arg	Pro
Ala 305	Ala	Gly	Gly	Ala	Val 310	His	Thr	Arg	Gly	Leu 315	Asp	Phe	Ala	Cys	Asp 320
Ile	Tyr	Ile	Trp	Ala 325	Pro	Leu	Ala	Gly	Thr 330	Cys	Gly	Val	Leu	Leu 335	Leu
Ser	Leu	Val	Ile 340	Thr	Leu	Tyr	Cys	Lys 345	Arg	Gly	Arg	Lys	Lys 350	Leu	Leu
Tyr	Ile 355	Phe	Lys	Gln	Pro	Phe	Met 360	Arg	Pro	Val	Gln 365	Thr	Thr	Gln	Glu
Glu 370	Asp	Gly	Cys	Ser	Cys	Arg 375	Phe	Pro	Glu	Glu	Glu 380	Glu	Gly	Gly	Cys
Glu 385	Leu	Arg	Val	Lys	Phe 390	Ser	Arg	Ser	Ala	Asp 395	Ala	Pro	Ala	Tyr	Gln 400
Gln	Gly	Gln	Asn	Gln 405	Leu	Tyr	Asn	Glu	Leu 410	Asn	Leu	Gly	Arg	Arg 415	Glu
Glu	Tyr	Asp	Val 420	Leu	Asp	Lys	Arg	Arg 425	Gly	Arg	Asp	Pro	Glu 430	Met	Gly
Gly	Lys	Pro	Arg	Arg	Lys	Asn 440	Pro	Gln	Glu	Gly	Leu	Tyr 445	Asn	Glu	Leu
Gln 450	Lys	Asp	Lys	Met	Ala	Glu 455	Ala	Tyr	Ser	Glu	Ile 460	Gly	Met	Lys	Gly
Glu 465	Arg	Arg	Arg	Gly	Lys 470	Gly	His	Asp	Gly	Leu 475	Tyr	Gln	Gly	Leu	Ser 480
Thr	Ala	Thr	Lys	Asp 485	Thr	Tyr	Asp	Ala	Leu 490	His	Met	Gln	Ala	Leu 495	Pro

Pro Arg Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp
500 505 510

Val Glu Glu Asn Pro Gly Pro Met Val Ser Lys Gly Glu Glu Asp Asn
515 520 525

Met Ala Ile Ile Lys Glu Phe Met Arg Phe Lys Val His Met Glu Gly
530 535 540

Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg
545 550 555 560

Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys Val Thr Lys Gly Gly
565 570 575

Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr Gly
580 585 590

Ser Lys Ala Tyr Val Lys His Pro Ala Asp Ile Pro Asp Tyr Leu Lys
595 600 605

Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val Met Asn Phe Glu
610 615 620

Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser Leu Gln Asp Gly
625 630 635 640

Glu Phe Ile Tyr Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Ser Asp
645 650 655

Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu Ala Ser Ser Glu
660 665 670

Arg Met Tyr Pro Glu Asp Gly Ala Leu Lys Gly Glu Ile Lys Gln Arg
675 680 685

Leu Lys Leu Lys Asp Gly Gly His Tyr Asp Ala Glu Val Lys Thr Thr
690 695 700

Tyr Lys Ala Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr Asn Val Asn
705 710 715 720

Ile Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr Thr Ile Val Glu
725 730 735

Gln Tyr Glu Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Asp Glu
740 745 750

Leu Tyr Lys
755

<210> 106
<211> 772
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 106

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Asp Val Val Met Thr Gln Thr Pro Ser Ser
20 25 30

Val Ser Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser
35 40 45

Gln Ser Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln
50 55 60

Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val
65 70 75 80

Ser Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
85 90 95

Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Cys
100 105 110

Asn Tyr Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly Thr Glu
115 120 125

Val Val Val Lys Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser
130 135 140

Gly Glu Gly Ser Thr Lys Gly Gln Ser Leu Glu Glu Ser Gly Gly Asp
145 150 155 160

Leu Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly
165 170 175

Ile Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg Gln Ala Pro
180 185 190

Gly Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly Ser Ser Gly
195 200 205

Ser Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys
210 215 220

Ala Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala
225 230 235 240

Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro Gly Thr Ser
 245 250 255

Gly Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr Leu Val Thr
 260 265 270

Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
 275 280 285

Gly Ser Gly Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala
 290 295 300

Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg
 305 310 315 320

Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys
 325 330 335

Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu
 340 345 350

Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu
 355 360 365

Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln
 370 375 380

Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly
 385 390 395 400

Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr
 405 410 415

Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
 420 425 430

Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met
 435 440 445

Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu
 450 455 460

Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys
 465 470 475 480

Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu
 485 490 495

Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu
 500 505 510

Pro Pro Arg Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly
 515 520 525

Asp Val Glu Glu Asn Pro Gly Pro Met Val Ser Lys Gly Glu Glu Asp
 530 535 540

Asn Met Ala Ile Ile Lys Glu Phe Met Arg Phe Lys Val His Met Glu
 545 550 555 560

Gly Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly
 565 570 575

Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys Val Thr Lys Gly
 580 585 590

Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr
 595 600 605

Gly Ser Lys Ala Tyr Val Lys His Pro Ala Asp Ile Pro Asp Tyr Leu
 610 615 620

Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val Met Asn Phe
 625 630 635 640

Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser Leu Gln Asp
 645 650 655

Gly Glu Phe Ile Tyr Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Ser
 660 665 670

Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu Ala Ser Ser
 675 680 685

Glu Arg Met Tyr Pro Glu Asp Gly Ala Leu Lys Gly Glu Ile Lys Gln
 690 695 700

Arg Leu Lys Leu Lys Asp Gly Gly His Tyr Asp Ala Glu Val Lys Thr
 705 710 715 720

Thr Tyr Lys Ala Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr Asn Val
 725 730 735

Asn Ile Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr Thr Ile Val
 740 745 750

Glu Gln Tyr Glu Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Asp
 755 760 765

Glu Leu Tyr Lys
 770

<210> 107
<211> 749
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 107

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly
20 25 30

Leu Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly
35 40 45

Phe Ser Phe Ser Ser Ser Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro
50 55 60

Gly Arg Gly Leu Glu Trp Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser
65 70 75 80

Ala Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Arg Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr
115 120 125

Leu Tyr Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser
130 135 140

Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly
145 150 155 160

Gln Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
165 170 175

Thr Val Thr Ile Ser Cys Gln Ala Ser Gln Ser Val Ala Gly Asn Asn
180 185 190

Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu
195 200 205

Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
210 215 220

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu
225 230 235 240

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly
245 250 255

Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys Thr Thr Thr
260 265 270

Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro
275 280 285

Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val
290 295 300

His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro
305 310 315 320

Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu
325 330 335

Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro
340 345 350

Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys
355 360 365

Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe
370 375 380

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
385 390 395 400

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
405 410 415

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
420 425 430

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
435 440 445

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
450 455 460

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
465 470 475 480

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg Gly Ser Gly Glu
485 490 495

Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro Gly
500 505 510

Pro Met Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu
515 520 525

Phe Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu
530 535 540

Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln
545 550 555 560

Thr Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp
565 570 575

Asp Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys
580 585 590

His Pro Ala Asp Ile Pro Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly
595 600 605

Phe Lys Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Val Val Thr
610 615 620

Val Thr Gln Asp Ser Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val
625 630 635 640

Lys Leu Arg Gly Thr Asn Phe Pro Ser Asp Gly Pro Val Met Gln Lys
645 650 655

Lys Thr Met Gly Trp Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu Asp
660 665 670

Gly Ala Leu Lys Gly Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp Gly
675 680 685

Gly His Tyr Asp Ala Glu Val Lys Thr Thr Tyr Lys Ala Lys Lys Pro
690 695 700

Val Gln Leu Pro Gly Ala Tyr Asn Val Asn Ile Lys Leu Asp Ile Thr
705 710 715 720

Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu
725 730 735

Gly Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys
740 745

<210> 108
<211> 752
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 108

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
 1 5 10 15
 Ala Phe Leu Leu Ile Pro Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly
 20 25 30
 Leu Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly
 35 40 45
 Phe Ser Phe Ser Ser Ser Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro
 50 55 60
 Gly Arg Gly Leu Glu Trp Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser
 65 70 75 80
 Ala Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr
 85 90 95
 Ser Ser Thr Thr Val Thr Leu Gln Met Thr Arg Leu Thr Ala Ala Asp
 100 105 110
 Thr Ala Thr Tyr Phe Cys Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr
 115 120 125
 Leu Tyr Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser
 130 135 140
 Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly
 145 150 155 160
 Gln Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
 165 170 175
 Thr Val Thr Ile Ser Cys Gln Ala Ser Gln Ser Val Ala Gly Asn Asn
 180 185 190
 Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu
 195 200 205
 Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
 210 215 220
 Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu
 225 230 235 240
 Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly
 245 250 255
 Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys Thr Thr Thr
 260 265 270

Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro
275 280 285

Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val
290 295 300

His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro
305 310 315 320

Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu
325 330 335

Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro
340 345 350

Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys
355 360 365

Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe
370 375 380

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
385 390 395 400

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
405 410 415

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
420 425 430

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
435 440 445

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
450 455 460

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
465 470 475 480

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg Gly Ser Gly Glu
485 490 495

Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro Gly
500 505 510

Pro Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile
515 520 525

Leu Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser
530 535 540

Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe

545		550		555		560
Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr						
	565			570		575
Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met						
	580			585		590
Lys Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln						
	595			600		605
Glu Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala						
	610			615		620
Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys						
	625			630		635
Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu						
	645			650		655
Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys						
	660			665		670
Asn Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly						
	675			680		685
Ser Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp						
	690			695		700
Gly Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala						
	705			710		715
Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu						
	725			730		735
Phe Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys						
	740			745		750

<210> 109
 <211> 766
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 109

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly
20 25 30

Leu Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly
35 40 45

Phe Ser Phe Ser Ser Ser Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro
50 55 60

Gly Arg Gly Leu Glu Trp Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser
65 70 75 80

Ala Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Arg Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr
115 120 125

Leu Tyr Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser
130 135 140

Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly
145 150 155 160

Gln Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
165 170 175

Thr Val Thr Ile Ser Cys Gln Ala Ser Gln Ser Val Ala Gly Asn Asn
180 185 190

Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu
195 200 205

Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
210 215 220

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu
225 230 235 240

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly
245 250 255

Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys Gly Gly Gly
260 265 270

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Thr Thr
275 280 285

Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln
290 295 300

Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala

305		310		315		320
Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala						
		325		330		335
Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr						
		340		345		350
Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln						
		355		360		365
Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser						
		370		375		380
Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys						
		385		390		395
						400
Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln						
		405		410		415
Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu						
		420		425		430
Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg						
		435		440		445
Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met						
		450		455		460
Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly						
		465		470		475
						480
Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp						
		485		490		495
Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg Gly Ser Gly						
		500		505		510
Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro						
		515		520		525
Gly Pro Met Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys						
		530		535		540
Glu Phe Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His						
		545		550		555
						560
Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr						
		565		570		575
Gln Thr Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala						
		580		585		590

Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val
595 600 605

Lys His Pro Ala Asp Ile Pro Asp Tyr Leu Lys Leu Ser Phe Pro Glu
610 615 620

Gly Phe Lys Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Val Val
625 630 635 640

Thr Val Thr Gln Asp Ser Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys
645 650 655

Val Lys Leu Arg Gly Thr Asn Phe Pro Ser Asp Gly Pro Val Met Gln
660 665 670

Lys Lys Thr Met Gly Trp Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu
675 680 685

Asp Gly Ala Leu Lys Gly Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp
690 695 700

Gly Gly His Tyr Asp Ala Glu Val Lys Thr Thr Tyr Lys Ala Lys Lys
705 710 715 720

Pro Val Gln Leu Pro Gly Ala Tyr Asn Val Asn Ile Lys Leu Asp Ile
725 730 735

Thr Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln Tyr Glu Arg Ala
740 745 750

Glu Gly Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys
755 760 765

<210> 110
<211> 746
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 110

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly
20 25 30

Leu Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly
35 40 45

Phe Ser Phe Ser Ser Ser Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro

50

55

60

Gly Arg Gly Leu Glu Trp Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser
65 70 75 80

Ala Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr
85 90 95

Ser Ser Thr Thr Val Thr Leu Gln Met Thr Arg Leu Thr Ala Ala Asp
100 105 110

Thr Ala Thr Tyr Phe Cys Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr
115 120 125

Leu Tyr Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Ser
130 135 140

Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly
145 150 155 160

Gln Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
165 170 175

Thr Val Thr Ile Ser Cys Gln Ala Ser Gln Ser Val Ala Gly Asn Asn
180 185 190

Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu
195 200 205

Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
210 215 220

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu
225 230 235 240

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly
245 250 255

Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys Ile Glu Val
260 265 270

Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile
275 280 285

Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly
290 295 300

Pro Ser Lys Pro Phe Trp Val Leu Val Val Gly Gly Val Leu Ala
305 310 315 320

Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Lys
325 330 335

Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg
 340 345 350

Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro
 355 360 365

Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser
 370 375 380

Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu
 385 390 395 400

Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg
 405 410 415

Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln
 420 425 430

Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr
 435 440 445

Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp
 450 455 460

Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala
 465 470 475 480

Leu His Met Gln Ala Leu Pro Pro Arg Gly Ser Gly Glu Gly Arg Gly
 485 490 495

Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro Gly Pro Met Val
 500 505 510

Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe Met Arg
 515 520 525

Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu Phe Glu Ile
 530 535 540

Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys
 545 550 555 560

Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu
 565 570 575

Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys His Pro Ala
 580 585 590

Asp Ile Pro Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp
 595 600 605

Glu Arg Val Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln
610 615 620

Asp Ser Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val Lys Leu Arg
625 630 635 640

Gly Thr Asn Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met
645 650 655

Gly Trp Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu Asp Gly Ala Leu
660 665 670

Lys Gly Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp Gly Gly His Tyr
675 680 685

Asp Ala Glu Val Lys Thr Thr Tyr Lys Ala Lys Lys Pro Val Gln Leu
690 695 700

Pro Gly Ala Tyr Asn Val Asn Ile Lys Leu Asp Ile Thr Ser His Asn
705 710 715 720

Glu Asp Tyr Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu Gly Arg His
725 730 735

Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys
740 745

<210> 111
<211> 749
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 111

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Val Leu Thr Gln Thr Pro Ser Pro Val
20 25 30

Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ala Ser Gln
35 40 45

Ser Val Ala Gly Asn Asn Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly
50 55 60

Gln Pro Pro Asn Leu Leu Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly
65 70 75 80

Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu
85 90 95

Thr	Ile	Ser	Asp	Leu	Glu	Cys	Asp	Asp	Ala	Ala	Thr	Tyr	Tyr	Cys	Gln	100	105	110	
Gly	Tyr	Tyr	Asn	Asp	Gly	Ile	Trp	Ala	Phe	Gly	Gly	Gly	Thr	Glu	Val	115	120	125	
Val	Val	Lys	Gly	Ser	Thr	Ser	Gly	Ser	Gly	Lys	Pro	Gly	Ser	Gly	Glu	130	135	140	
Gly	Ser	Thr	Lys	Gly	Gln	Glu	Gln	Leu	Glu	Glu	Ser	Gly	Gly	Gly	Leu	145	150	155	160
Val	Lys	Pro	Glu	Gly	Ser	Leu	Thr	Leu	Thr	Cys	Thr	Ala	Ser	Gly	Phe	165	170	175	
Ser	Phe	Ser	Ser	Ser	Tyr	Tyr	Met	Cys	Trp	Val	Arg	Gln	Ala	Pro	Gly	180	185	190	
Arg	Gly	Leu	Glu	Trp	Ile	Ala	Cys	Ile	Tyr	Thr	Ser	Ser	Gly	Ser	Ala	195	200	205	
Tyr	Tyr	Ala	Asn	Trp	Ala	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Thr	Ser	210	215	220	
Ser	Thr	Thr	Val	Thr	Leu	Gln	Met	Thr	Arg	Leu	Thr	Ala	Ala	Asp	Thr	225	230	235	240
Ala	Thr	Tyr	Phe	Cys	Val	Arg	Asn	Ala	Val	Gly	Ser	Ser	Tyr	Tyr	Leu	245	250	255	
Tyr	Leu	Trp	Gly	Pro	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Thr	Thr	Thr	260	265	270	
Pro	Ala	Pro	Arg	Pro	Pro	Thr	Pro	Ala	Pro	Thr	Ile	Ala	Ser	Gln	Pro	275	280	285	
Leu	Ser	Leu	Arg	Pro	Glu	Ala	Cys	Arg	Pro	Ala	Ala	Gly	Gly	Ala	Val	290	295	300	
His	Thr	Arg	Gly	Leu	Asp	Phe	Ala	Cys	Asp	Ile	Tyr	Ile	Trp	Ala	Pro	305	310	315	320
Leu	Ala	Gly	Thr	Cys	Gly	Val	Leu	Leu	Leu	Ser	Leu	Val	Ile	Thr	Leu	325	330	335	
Tyr	Cys	Lys	Arg	Gly	Arg	Lys	Lys	Leu	Leu	Tyr	Ile	Phe	Lys	Gln	Pro	340	345	350	
Phe	Met	Arg	Pro	Val	Gln	Thr	Thr	Gln	Glu	Glu	Asp	Gly	Cys	Ser	Cys	355	360	365	

Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe
370 375 380

Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu
385 390 395 400

Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp
405 410 415

Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys
420 425 430

Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala
435 440 445

Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys
450 455 460

Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr
465 470 475 480

Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg Gly Ser Gly Glu
485 490 495

Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro Gly
500 505 510

Pro Met Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu
515 520 525

Phe Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu
530 535 540

Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln
545 550 555 560

Thr Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp
565 570 575

Asp Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys
580 585 590

His Pro Ala Asp Ile Pro Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly
595 600 605

Phe Lys Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Val Val Thr
610 615 620

Val Thr Gln Asp Ser Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val
625 630 635 640

Lys Leu Arg Gly Thr Asn Phe Pro Ser Asp Gly Pro Val Met Gln Lys
645 650 655

Lys Thr Met Gly Trp Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu Asp
660 665 670

Gly Ala Leu Lys Gly Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp Gly
675 680 685

Gly His Tyr Asp Ala Glu Val Lys Thr Thr Tyr Lys Ala Lys Lys Pro
690 695 700

Val Gln Leu Pro Gly Ala Tyr Asn Val Asn Ile Lys Leu Asp Ile Thr
705 710 715 720

Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu
725 730 735

Gly Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys
740 745

<210> 112
<211> 766
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 112

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
1 5 10 15

Ala Phe Leu Leu Ile Pro Gln Val Leu Thr Gln Thr Pro Ser Pro Val
20 25 30

Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ala Ser Gln
35 40 45

Ser Val Ala Gly Asn Asn Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly
50 55 60

Gln Pro Pro Asn Leu Leu Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly
65 70 75 80

Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu
85 90 95

Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln
100 105 110

Gly Tyr Tyr Asn Asp Gly Ile Trp Ala Phe Gly Gly Gly Thr Glu Val
115 120 125

Val Val Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu
130 135 140

Gly Ser Thr Lys Gly Gln Glu Gln Leu Glu Glu Ser Gly Gly Gly Leu
145 150 155 160

Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe
165 170 175

Ser Phe Ser Ser Ser Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly
180 185 190

Arg Gly Leu Glu Trp Ile Ala Cys Ile Tyr Thr Ser Ser Gly Ser Ala
195 200 205

Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Thr Ser
210 215 220

Ser Thr Thr Val Thr Leu Gln Met Thr Arg Leu Thr Ala Ala Asp Thr
225 230 235 240

Ala Thr Tyr Phe Cys Val Arg Asn Ala Val Gly Ser Ser Tyr Tyr Leu
245 250 255

Tyr Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly
260 265 270

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Thr Thr
275 280 285

Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln
290 295 300

Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala
305 310 315 320

Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala
325 330 335

Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr
340 345 350

Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln
355 360 365

Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser
370 375 380

Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys
385 390 395 400

Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln
405 410 415

Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu
420 425 430

Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg
435 440 445

Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met
450 455 460

Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly
465 470 475 480

Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp
485 490 495

Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg Gly Ser Gly
500 505 510

Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro
515 520 525

Gly Pro Met Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys
530 535 540

Glu Phe Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His
545 550 555 560

Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr
565 570 575

Gln Thr Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala
580 585 590

Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val
595 600 605

Lys His Pro Ala Asp Ile Pro Asp Tyr Leu Lys Leu Ser Phe Pro Glu
610 615 620

Gly Phe Lys Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Val Val
625 630 635 640

Thr Val Thr Gln Asp Ser Ser Leu Gln Asp Gly Glu Phe Ile Tyr Lys
645 650 655

Val Lys Leu Arg Gly Thr Asn Phe Pro Ser Asp Gly Pro Val Met Gln
660 665 670

Lys Lys Thr Met Gly Trp Glu Ala Ser Ser Glu Arg Met Tyr Pro Glu

675

680

685

Asp Gly Ala Leu Lys Gly Glu Ile Lys Gln Arg Leu Lys Leu Lys Asp
 690 695 700

Gly Gly His Tyr Asp Ala Glu Val Lys Thr Thr Tyr Lys Ala Lys Lys
 705 710 715 720

Pro Val Gln Leu Pro Gly Ala Tyr Asn Val Asn Ile Lys Leu Asp Ile
 725 730 735

Thr Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln Tyr Glu Arg Ala
 740 745 750

Glu Gly Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys
 755 760 765

<210> 113
 <211> 22
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 113

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro
 1 5 10 15

Ala Phe Leu Leu Ile Pro
 20

<210> 114
 <211> 18
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 114

Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
 1 5 10 15

Lys Gly

<210> 115
 <211> 45
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 115

Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala
1 5 10 15

Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly
20 25 30

Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp
35 40 45

<210> 116
<211> 48
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 116

Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro
1 5 10 15

Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro
20 25 30

Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp
35 40 45

<210> 117
<211> 62
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 117

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5 10 15

Gly Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile
20 25 30

Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala
35 40 45

Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp
50 55 60

<210> 118
<211> 39
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 118

Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn
1 5 10 15

Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu
20 25 30

Phe Pro Gly Pro Ser Lys Pro
35

<210> 119
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 119

Gly Gly Gly Ser Ser Gly Gly Gly Ser Gly
1 5 10

<210> 120
<211> 12
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 120

Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro
1 5 10

<210> 121
<211> 106
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 121

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu
1 5 10 15

Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
20 25 30

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
35 40 45

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
50 55 60

Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly
65 70 75 80

Asn Val Phe Ser Cys Val Met His Glu Ala Leu His Asn His Tyr Thr
85 90 95

Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
100 105

<210> 122
<211> 229
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 122

Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe
1 5 10 15

Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
20 25 30

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
35 40 45

Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val
50 55 60

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser
65 70 75 80

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
85 90 95

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser
100 105 110

Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
115 120 125

Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln
130 135 140

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
145 150 155 160

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
165 170 175

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu
180 185 190

Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser

195

200

205

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
210 215 220

Leu Ser Leu Gly Lys
225

<210> 123
<211> 24
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 123

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu
1 5 10 15

Ser Leu Val Ile Thr Leu Tyr Cys
20

<210> 124
<211> 23
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 124

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu
1 5 10 15

Ser Leu Val Ile Thr Leu Tyr
20

<210> 125
<211> 22
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 125

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu
1 5 10 15

Ser Leu Val Ile Thr Leu
20

<210> 126
<211> 27
<212> PRT
<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 126

Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
1 5 10 15

Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
20 25

<210> 127

<211> 28

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 127

Met Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser
1 5 10 15

Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val
20 25

<210> 128

<211> 21

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 128

Leu Cys Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu
1 5 10 15

Thr Ala Leu Phe Leu
20

<210> 129

<211> 22

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 129

Met Ala Leu Ile Val Leu Gly Gly Val Ala Gly Leu Leu Leu Phe Ile
1 5 10 15

Gly Leu Gly Ile Phe Phe
20

<210> 130

<211> 27
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 130

Ile Ile Ser Phe Phe Leu Ala Leu Thr Ser Thr Ala Leu Leu Phe Leu
1 5 10 15

Leu Phe Phe Leu Thr Leu Arg Phe Ser Val Val
20 25

<210> 131
<211> 42
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 131

Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met
1 5 10 15

Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe
20 25 30

Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
35 40

<210> 132
<211> 41
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 132

Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr
1 5 10 15

Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
20 25 30

Pro Arg Asp Phe Ala Ala Tyr Arg Ser
35 40

<210> 133
<211> 41
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 133

Arg Ser Lys Arg Ser Arg Gly Gly His Ser Asp Tyr Met Asn Met Thr
1 5 10 15

Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro
20 25 30

Pro Arg Asp Phe Ala Ala Tyr Arg Ser
35 40

<210> 134

<211> 42

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 134

Ala Leu Tyr Leu Leu Arg Arg Asp Gln Arg Leu Pro Pro Asp Ala His
1 5 10 15

Lys Pro Pro Gly Gly Gly Ser Phe Arg Thr Pro Ile Gln Glu Glu Gln
20 25 30

Ala Asp Ala His Ser Thr Leu Ala Lys Ile
35 40

<210> 135

<211> 112

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 135

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
1 5 10 15

Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
20 25 30

Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
35 40 45

Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
50 55 60

Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
65 70 75 80

Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
85 90 95

Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
100 105 110

<210> 136
<211> 23
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 136

Gly Ser Gly Gln Cys Thr Asn Tyr Ala Leu Leu Lys Leu Ala Gly Asp
1 5 10 15

Val Glu Ser Asn Pro Gly Pro
20

<210> 137
<211> 21
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 137

Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu
1 5 10 15

Glu Asn Pro Gly Pro
20

<210> 138
<211> 239
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 138

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
1 5 10 15

Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly
20 25 30

Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
35 40 45

Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
50 55 60

Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys
65 70 75 80

Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
85 90 95

Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
100 105 110

Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
115 120 125

Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
130 135 140

Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn
145 150 155 160

Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
165 170 175

Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
180 185 190

Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu
195 200 205

Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
210 215 220

Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
225 230 235

<210> 139
<211> 236
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 139

Met Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe
1 5 10 15

Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu Phe
20 25 30

Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr
35 40 45

Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp
50 55 60

Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys His

65		70		75		80									
Pro	Ala	Asp	Ile	Pro	Asp	Tyr	Leu	Lys	Leu	Ser	Phe	Pro	Glu	Gly	Phe
			85					90						95	
Lys	Trp	Glu	Arg	Val	Met	Asn	Phe	Glu	Asp	Gly	Gly	Val	Val	Thr	Val
			100					105					110		
Thr	Gln	Asp	Ser	Ser	Leu	Gln	Asp	Gly	Glu	Phe	Ile	Tyr	Lys	Val	Lys
		115					120					125			
Leu	Arg	Gly	Thr	Asn	Phe	Pro	Ser	Asp	Gly	Pro	Val	Met	Gln	Lys	Lys
	130					135					140				
Thr	Met	Gly	Trp	Glu	Ala	Ser	Ser	Glu	Arg	Met	Tyr	Pro	Glu	Asp	Gly
145					150				155						160
Ala	Leu	Lys	Gly	Glu	Ile	Lys	Gln	Arg	Leu	Lys	Leu	Lys	Asp	Gly	Gly
				165					170					175	
His	Tyr	Asp	Ala	Glu	Val	Lys	Thr	Thr	Tyr	Lys	Ala	Lys	Lys	Pro	Val
			180					185					190		
Gln	Leu	Pro	Gly	Ala	Tyr	Asn	Val	Asn	Ile	Lys	Leu	Asp	Ile	Thr	Ser
		195					200					205			
His	Asn	Glu	Asp	Tyr	Thr	Ile	Val	Glu	Gln	Tyr	Glu	Arg	Ala	Glu	Gly
	210					215					220				
Arg	His	Ser	Thr	Gly	Gly	Met	Asp	Glu	Leu	Tyr	Lys				
225					230					235					
<210>	140														
<211>	683														
<212>	PRT														
<213>	Artificial sequence														
<220>															
<223>	synthetic sequence														
<400>	140														
Met	Ala	Ser	Pro	Leu	Thr	Arg	Phe	Leu	Ser	Leu	Asn	Leu	Leu	Leu	Leu
1				5					10				15		
Gly	Glu	Ser	Ile	Ile	Leu	Gly	Ser	Gly	Glu	Ala	Gln	Glu	Gln	Leu	Glu
			20					25					30		
Glu	Ser	Gly	Gly	Gly	Leu	Val	Lys	Pro	Glu	Gly	Ser	Leu	Thr	Leu	Thr
		35					40					45			
Cys	Thr	Ala	Ser	Gly	Phe	Ser	Phe	Ser	Ser	Ser	Tyr	Tyr	Met	Cys	Trp
50					55						60				

Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Ile Ala Cys Ile Tyr
65 70 75 80

Thr Ser Ser Gly Ser Ala Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe
85 90 95

Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Thr Leu Gln Met Thr Arg
100 105 110

Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Val Arg Asn Ala Val
115 120 125

Gly Ser Ser Tyr Tyr Leu Tyr Leu Trp Gly Pro Gly Thr Leu Val Thr
130 135 140

Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu
145 150 155 160

Gly Ser Thr Lys Gly Gln Val Leu Thr Gln Thr Pro Ser Pro Val Ser
165 170 175

Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ala Ser Gln Ser
180 185 190

Val Ala Gly Asn Asn Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln
195 200 205

Pro Pro Asn Leu Leu Ile Tyr Ser Val Ser Thr Leu Ala Ser Gly Val
210 215 220

Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr
225 230 235 240

Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly
245 250 255

Tyr Tyr Asn Asp Gly Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val
260 265 270

Val Lys Thr Thr Lys Pro Val Leu Arg Thr Pro Ser Pro Val His Pro
275 280 285

Thr Gly Thr Ser Gln Pro Gln Arg Pro Glu Asp Cys Arg Pro Arg Gly
290 295 300

Ser Val Lys Gly Thr Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp
305 310 315 320

Ala Pro Leu Ala Gly Ile Cys Val Ala Leu Leu Leu Ser Leu Ile Ile
325 330 335

Thr Leu Ile Cys Tyr His Lys Trp Ile Arg Lys Lys Phe Pro His Ile

340

345

350

Phe Lys Gln Pro Phe Lys Lys Thr Thr Gly Ala Ala Gln Glu Glu Asp
 355 360 365

Ala Cys Ser Cys Arg Cys Pro Gln Glu Glu Glu Gly Gly Gly Gly Gly
 370 375 380

Tyr Glu Leu Arg Ala Lys Phe Ser Arg Ser Ala Glu Thr Ala Ala Asn
 385 390 395 400

Leu Gln Asp Pro Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg
 405 410 415

Glu Glu Tyr Asp Val Leu Glu Lys Lys Arg Ala Arg Asp Pro Glu Met
 420 425 430

Gly Gly Lys Gln Gln Arg Arg Arg Asn Pro Gln Glu Gly Val Tyr Asn
 435 440 445

Ala Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Thr
 450 455 460

Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly
 465 470 475 480

Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Thr
 485 490 495

Leu Ala Pro Arg Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys
 500 505 510

Gly Asp Val Glu Glu Asn Pro Gly Pro Met Asn Pro Ala Ile Ser Val
 515 520 525

Ala Leu Leu Leu Ser Val Leu Gln Val Ser Arg Gly Gln Lys Val Thr
 530 535 540

Ser Leu Thr Ala Cys Leu Val Asn Gln Asn Leu Arg Leu Asp Cys Arg
 545 550 555 560

His Glu Asn Asn Thr Lys Asp Asn Ser Ile Gln His Glu Phe Ser Leu
 565 570 575

Thr Arg Glu Lys Arg Lys His Val Leu Ser Gly Thr Leu Gly Ile Pro
 580 585 590

Glu His Thr Tyr Arg Ser Arg Val Thr Leu Ser Asn Gln Pro Tyr Ile
 595 600 605

Lys Val Leu Thr Leu Ala Asn Phe Thr Thr Lys Asp Glu Gly Asp Tyr
 610 615 620

Phe Cys Glu Leu Arg Val Ser Gly Ala Asn Pro Met Ser Ser Asn Lys
625 630 635 640

Ser Ile Ser Val Tyr Arg Asp Lys Leu Val Lys Cys Gly Gly Ile Ser
645 650 655

Leu Leu Val Gln Asn Thr Ser Trp Met Leu Leu Leu Leu Leu Ser Leu
660 665 670

Ser Leu Leu Gln Ala Leu Asp Phe Ile Ser Leu
675 680

<210> 141
<211> 683
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 141

Met Ala Ser Pro Leu Thr Arg Phe Leu Ser Leu Asn Leu Leu Leu Leu
1 5 10 15

Gly Glu Ser Ile Ile Leu Gly Ser Gly Glu Ala Gln Val Leu Thr Gln
20 25 30

Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser
35 40 45

Cys Gln Ala Ser Gln Ser Val Ala Gly Asn Asn Tyr Leu Ser Trp Tyr
50 55 60

Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu Ile Tyr Ser Val Ser
65 70 75 80

Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly
85 90 95

Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala
100 105 110

Thr Tyr Tyr Cys Gln Gly Tyr Tyr Asn Asp Gly Ile Trp Ala Phe Gly
115 120 125

Gly Gly Thr Glu Val Val Val Lys Gly Ser Thr Ser Gly Ser Gly Lys
130 135 140

Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Glu Gln Leu Glu Glu
145 150 155 160

Ser Gly Gly Gly Leu Val Lys Pro Glu Gly Ser Leu Thr Leu Thr Cys

165

170

175

Thr	Ala	Ser	Gly	Phe	Ser	Phe	Ser	Ser	Ser	Tyr	Tyr	Met	Cys	Trp	Val
			180					185					190		
Arg	Gln	Ala	Pro	Gly	Arg	Gly	Leu	Glu	Trp	Ile	Ala	Cys	Ile	Tyr	Thr
		195					200					205			
Ser	Ser	Gly	Ser	Ala	Tyr	Tyr	Ala	Asn	Trp	Ala	Lys	Gly	Arg	Phe	Thr
	210					215					220				
Ile	Ser	Arg	Thr	Ser	Ser	Thr	Thr	Val	Thr	Leu	Gln	Met	Thr	Arg	Leu
225					230					235					240
Thr	Ala	Ala	Asp	Thr	Ala	Thr	Tyr	Phe	Cys	Val	Arg	Asn	Ala	Val	Gly
				245					250					255	
Ser	Ser	Tyr	Tyr	Leu	Tyr	Leu	Trp	Gly	Pro	Gly	Thr	Leu	Val	Thr	Val
			260					265					270		
Ser	Ser	Thr	Thr	Lys	Pro	Val	Leu	Arg	Thr	Pro	Ser	Pro	Val	His	Pro
		275					280					285			
Thr	Gly	Thr	Ser	Gln	Pro	Gln	Arg	Pro	Glu	Asp	Cys	Arg	Pro	Arg	Gly
	290					295					300				
Ser	Val	Lys	Gly	Thr	Gly	Leu	Asp	Phe	Ala	Cys	Asp	Ile	Tyr	Ile	Trp
305					310					315					320
Ala	Pro	Leu	Ala	Gly	Ile	Cys	Val	Ala	Leu	Leu	Leu	Ser	Leu	Ile	Ile
				325					330					335	
Thr	Leu	Ile	Cys	Tyr	His	Lys	Trp	Ile	Arg	Lys	Lys	Phe	Pro	His	Ile
			340					345					350		
Phe	Lys	Gln	Pro	Phe	Lys	Lys	Thr	Thr	Gly	Ala	Ala	Gln	Glu	Glu	Asp
		355					360					365			
Ala	Cys	Ser	Cys	Arg	Cys	Pro	Gln	Glu	Glu	Glu	Gly	Gly	Gly	Gly	Gly
	370					375					380				
Tyr	Glu	Leu	Arg	Ala	Lys	Phe	Ser	Arg	Ser	Ala	Glu	Thr	Ala	Ala	Asn
385					390					395					400
Leu	Gln	Asp	Pro	Asn	Gln	Leu	Tyr	Asn	Glu	Leu	Asn	Leu	Gly	Arg	Arg
				405					410					415	
Glu	Glu	Tyr	Asp	Val	Leu	Glu	Lys	Lys	Arg	Ala	Arg	Asp	Pro	Glu	Met
			420					425					430		
Gly	Gly	Lys	Gln	Gln	Arg	Arg	Arg	Asn	Pro	Gln	Glu	Gly	Val	Tyr	Asn
		435					440					445			

Ala Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Thr
 450 455 460
 Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly
 465 470 475 480
 Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Thr
 485 490 495
 Leu Ala Pro Arg Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys
 500 505 510
 Gly Asp Val Glu Glu Asn Pro Gly Pro Met Asn Pro Ala Ile Ser Val
 515 520 525
 Ala Leu Leu Leu Ser Val Leu Gln Val Ser Arg Gly Gln Lys Val Thr
 530 535 540
 Ser Leu Thr Ala Cys Leu Val Asn Gln Asn Leu Arg Leu Asp Cys Arg
 545 550 555 560
 His Glu Asn Asn Thr Lys Asp Asn Ser Ile Gln His Glu Phe Ser Leu
 565 570 575
 Thr Arg Glu Lys Arg Lys His Val Leu Ser Gly Thr Leu Gly Ile Pro
 580 585 590
 Glu His Thr Tyr Arg Ser Arg Val Thr Leu Ser Asn Gln Pro Tyr Ile
 595 600 605
 Lys Val Leu Thr Leu Ala Asn Phe Thr Thr Lys Asp Glu Gly Asp Tyr
 610 615 620
 Phe Cys Glu Leu Arg Val Ser Gly Ala Asn Pro Met Ser Ser Asn Lys
 625 630 635 640
 Ser Ile Ser Val Tyr Arg Asp Lys Leu Val Lys Cys Gly Gly Ile Ser
 645 650 655
 Leu Leu Val Gln Asn Thr Ser Trp Met Leu Leu Leu Leu Leu Ser Leu
 660 665 670
 Ser Leu Leu Gln Ala Leu Asp Phe Ile Ser Leu
 675 680

<210> 142
 <211> 687
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> synthetic sequence

<400> 142

Met Ala Ser Pro Leu Thr Arg Phe Leu Ser Leu Asn Leu Leu Leu Leu
1 5 10 15

Gly Glu Ser Ile Ile Leu Gly Ser Gly Glu Ala Gln Ser Leu Glu Glu
20 25 30

Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys
35 40 45

Thr Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val
50 55 60

Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala
65 70 75 80

Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe
85 90 95

Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser
100 105 110

Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr
115 120 125

Pro Gly Thr Ser Gly Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly
130 135 140

Thr Leu Val Thr Val Ser Ser Gly Ser Thr Ser Gly Ser Gly Lys Pro
145 150 155 160

Gly Ser Gly Glu Gly Ser Thr Lys Gly Val Val Met Thr Gln Thr Pro
165 170 175

Ser Ser Val Ser Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln
180 185 190

Ala Ser Gln Ser Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln Lys Pro
195 200 205

Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser
210 215 220

Gly Val Ser Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr
225 230 235 240

Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys
245 250 255

Gln Cys Asn Tyr Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly Gly Gly
260 265 270

Thr Glu Val Val Val Lys Thr Thr Lys Pro Val Leu Arg Thr Pro Ser
 275 280 285

Pro Val His Pro Thr Gly Thr Ser Gln Pro Gln Arg Pro Glu Asp Cys
 290 295 300

Arg Pro Arg Gly Ser Val Lys Gly Thr Gly Leu Asp Phe Ala Cys Asp
 305 310 315 320

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Ile Cys Val Ala Leu Leu Leu
 325 330 335

Ser Leu Ile Ile Thr Leu Ile Cys Tyr His Lys Trp Ile Arg Lys Lys
 340 345 350

Phe Pro His Ile Phe Lys Gln Pro Phe Lys Lys Thr Thr Gly Ala Ala
 355 360 365

Gln Glu Glu Asp Ala Cys Ser Cys Arg Cys Pro Gln Glu Glu Glu Gly
 370 375 380

Gly Gly Gly Gly Tyr Glu Leu Arg Ala Lys Phe Ser Arg Ser Ala Glu
 385 390 395 400

Thr Ala Ala Asn Leu Gln Asp Pro Asn Gln Leu Tyr Asn Glu Leu Asn
 405 410 415

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Glu Lys Lys Arg Ala Arg
 420 425 430

Asp Pro Glu Met Gly Gly Lys Gln Gln Arg Arg Arg Asn Pro Gln Glu
 435 440 445

Gly Val Tyr Asn Ala Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser
 450 455 460

Glu Ile Gly Thr Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly
 465 470 475 480

Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu
 485 490 495

His Met Gln Thr Leu Ala Pro Arg Gly Ser Gly Glu Gly Arg Gly Ser
 500 505 510

Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro Gly Pro Met Asn Pro
 515 520 525

Ala Ile Ser Val Ala Leu Leu Leu Ser Val Leu Gln Val Ser Arg Gly
 530 535 540

Gln Lys Val Thr Ser Leu Thr Ala Cys Leu Val Asn Gln Asn Leu Arg
545 550 555 560

Leu Asp Cys Arg His Glu Asn Asn Thr Lys Asp Asn Ser Ile Gln His
565 570 575

Glu Phe Ser Leu Thr Arg Glu Lys Arg Lys His Val Leu Ser Gly Thr
580 585 590

Leu Gly Ile Pro Glu His Thr Tyr Arg Ser Arg Val Thr Leu Ser Asn
595 600 605

Gln Pro Tyr Ile Lys Val Leu Thr Leu Ala Asn Phe Thr Thr Lys Asp
610 615 620

Glu Gly Asp Tyr Phe Cys Glu Leu Arg Val Ser Gly Ala Asn Pro Met
625 630 635 640

Ser Ser Asn Lys Ser Ile Ser Val Tyr Arg Asp Lys Leu Val Lys Cys
645 650 655

Gly Gly Ile Ser Leu Leu Val Gln Asn Thr Ser Trp Met Leu Leu Leu
660 665 670

Leu Leu Ser Leu Ser Leu Leu Gln Ala Leu Asp Phe Ile Ser Leu
675 680 685

<210> 143
<211> 687
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 143

Met Ala Ser Pro Leu Thr Arg Phe Leu Ser Leu Asn Leu Leu Leu Leu
1 5 10 15

Gly Glu Ser Ile Ile Leu Gly Ser Gly Glu Ala Val Val Met Thr Gln
20 25 30

Thr Pro Ser Ser Val Ser Glu Pro Val Gly Gly Thr Val Thr Ile Lys
35 40 45

Cys Gln Ala Ser Gln Ser Ile Ser Asp Leu Leu Ser Trp Tyr Gln Gln
50 55 60

Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu
65 70 75 80

Ala Ser Gly Val Ser Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu
85 90 95

Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr
100 105 110

Tyr Cys Gln Cys Asn Tyr Tyr Ser Pro Thr Tyr Gly Asn Gly Phe Gly
115 120 125

Gly Gly Thr Glu Val Val Val Lys Gly Ser Thr Ser Gly Ser Gly Lys
130 135 140

Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Gln Ser Leu Glu Glu Ser
145 150 155 160

Gly Gly Asp Leu Val Lys Pro Gly Ala Ser Leu Thr Leu Thr Cys Thr
165 170 175

Ala Ser Gly Ile Asp Phe Ser Asp Ile Tyr Tyr Ile Ser Trp Val Arg
180 185 190

Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Cys Thr Tyr Ala Gly
195 200 205

Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp Ala Lys Gly Arg Phe Thr
210 215 220

Ile Ser Lys Ala Ser Ser Thr Thr Val Thr Leu Gln Met Thr Ser Leu
225 230 235 240

Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Arg Tyr Pro
245 250 255

Gly Thr Ser Gly Arg Val Tyr Gly Met Asp Leu Trp Gly Pro Gly Thr
260 265 270

Leu Val Thr Val Ser Ser Thr Thr Lys Pro Val Leu Arg Thr Pro Ser
275 280 285

Pro Val His Pro Thr Gly Thr Ser Gln Pro Gln Arg Pro Glu Asp Cys
290 295 300

Arg Pro Arg Gly Ser Val Lys Gly Thr Gly Leu Asp Phe Ala Cys Asp
305 310 315 320

Ile Tyr Ile Trp Ala Pro Leu Ala Gly Ile Cys Val Ala Leu Leu Leu
325 330 335

Ser Leu Ile Ile Thr Leu Ile Cys Tyr His Lys Trp Ile Arg Lys Lys
340 345 350

Phe Pro His Ile Phe Lys Gln Pro Phe Lys Lys Thr Thr Gly Ala Ala
355 360 365

Gln Glu Glu Asp Ala Cys Ser Cys Arg Cys Pro Gln Glu Glu Glu Gly
370 375 380

Gly Gly Gly Gly Tyr Glu Leu Arg Ala Lys Phe Ser Arg Ser Ala Glu
385 390 395 400

Thr Ala Ala Asn Leu Gln Asp Pro Asn Gln Leu Tyr Asn Glu Leu Asn
405 410 415

Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Glu Lys Lys Arg Ala Arg
420 425 430

Asp Pro Glu Met Gly Gly Lys Gln Gln Arg Arg Arg Asn Pro Gln Glu
435 440 445

Gly Val Tyr Asn Ala Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser
450 455 460

Glu Ile Gly Thr Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly
465 470 475 480

Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu
485 490 495

His Met Gln Thr Leu Ala Pro Arg Gly Ser Gly Glu Gly Arg Gly Ser
500 505 510

Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro Gly Pro Met Asn Pro
515 520 525

Ala Ile Ser Val Ala Leu Leu Leu Ser Val Leu Gln Val Ser Arg Gly
530 535 540

Gln Lys Val Thr Ser Leu Thr Ala Cys Leu Val Asn Gln Asn Leu Arg
545 550 555 560

Leu Asp Cys Arg His Glu Asn Asn Thr Lys Asp Asn Ser Ile Gln His
565 570 575

Glu Phe Ser Leu Thr Arg Glu Lys Arg Lys His Val Leu Ser Gly Thr
580 585 590

Leu Gly Ile Pro Glu His Thr Tyr Arg Ser Arg Val Thr Leu Ser Asn
595 600 605

Gln Pro Tyr Ile Lys Val Leu Thr Leu Ala Asn Phe Thr Thr Lys Asp
610 615 620

Glu Gly Asp Tyr Phe Cys Glu Leu Arg Val Ser Gly Ala Asn Pro Met
625 630 635 640

Ser Ser Asn Lys Ser Ile Ser Val Tyr Arg Asp Lys Leu Val Lys Cys
645 650 655

Gly Gly Ile Ser Leu Leu Val Gln Asn Thr Ser Trp Met Leu Leu Leu
660 665 670

Leu Leu Ser Leu Ser Leu Leu Gln Ala Leu Asp Phe Ile Ser Leu
675 680 685

<210> 144
<211> 27
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 144

Met Ala Ser Pro Leu Thr Arg Phe Leu Ser Leu Asn Leu Leu Leu Leu
1 5 10 15

Gly Glu Ser Ile Ile Leu Gly Ser Gly Glu Ala
20 25

<210> 145
<211> 29
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 145

Met Thr Ser Ser His Ala Met Asn Ile Thr Pro Leu Ala Gln Leu Ala
1 5 10 15

Leu Leu Phe Ser Thr Leu Leu Leu Pro Gly Thr Gln Ala
20 25

<210> 146
<211> 44
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 146

Thr Thr Lys Pro Val Leu Arg Thr Pro Ser Pro Val His Pro Thr Gly
1 5 10 15

Thr Ser Gln Pro Gln Arg Pro Glu Asp Cys Arg Pro Arg Gly Ser Val
20 25 30

Lys Gly Thr Gly Leu Asp Phe Ala Cys Asp Ile Tyr
35 40

<210> 147
<211> 39
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 147

Phe Cys Lys Ile Glu Phe Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu
1 5 10 15

Arg Ser Asn Gly Thr Ile Ile His Ile Lys Glu Lys His Leu Cys His
20 25 30

Thr Gln Ser Ser Pro Lys Leu
35

<210> 148
<211> 20
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 148

Ile Trp Ala Pro Leu Ala Gly Ile Cys Val Ala Leu Leu Leu Ser Leu
1 5 10 15

Ile Ile Thr Leu
20

<210> 149
<211> 24
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 149

Ile Trp Ala Pro Leu Ala Gly Ile Cys Val Ala Leu Leu Leu Ser Leu
1 5 10 15

Ile Ile Thr Leu Ile Cys Tyr His
20

<210> 150
<211> 27
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 150

Phe Trp Ala Leu Val Val Val Ala Gly Val Leu Phe Cys Tyr Gly Leu
1 5 10 15

Leu Val Thr Val Ala Leu Cys Val Ile Trp Thr
20 25

<210> 151
<211> 45
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 151

Lys Trp Ile Arg Lys Lys Phe Pro His Ile Phe Lys Gln Pro Phe Lys
1 5 10 15

Lys Thr Thr Gly Ala Ala Gln Glu Glu Asp Ala Cys Ser Cys Arg Cys
20 25 30

Pro Gln Glu Glu Glu Gly Gly Gly Gly Tyr Glu Leu
35 40 45

<210> 152
<211> 41
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 152

Asn Ser Arg Arg Asn Arg Leu Leu Gln Ser Asp Tyr Met Asn Met Thr
1 5 10 15

Pro Arg Arg Pro Gly Leu Thr Arg Lys Pro Tyr Gln Pro Tyr Ala Pro
20 25 30

Ala Arg Asp Phe Ala Ala Tyr Arg Pro
35 40

<210> 153
<211> 113
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 153

Arg Ala Lys Phe Ser Arg Ser Ala Glu Thr Ala Ala Asn Leu Gln Asp
1 5 10 15

Pro Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
20 25 30

Asp Val Leu Glu Lys Lys Arg Ala Arg Asp Pro Glu Met Gly Gly Lys
35 40 45

Gln Gln Arg Arg Arg Asn Pro Gln Glu Gly Val Tyr Asn Ala Leu Gln
50 55 60

Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Thr Lys Gly Glu
65 70 75 80

Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr
85 90 95

Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Thr Leu Ala Pro
100 105 110

Arg

<210> 154
<211> 162
<212> PRT
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 154

Met Asn Pro Ala Ile Ser Val Ala Leu Leu Leu Ser Val Leu Gln Val
1 5 10 15

Ser Arg Gly Gln Lys Val Thr Ser Leu Thr Ala Cys Leu Val Asn Gln
20 25 30

Asn Leu Arg Leu Asp Cys Arg His Glu Asn Asn Thr Lys Asp Asn Ser
35 40 45

Ile Gln His Glu Phe Ser Leu Thr Arg Glu Lys Arg Lys His Val Leu
50 55 60

Ser Gly Thr Leu Gly Ile Pro Glu His Thr Tyr Arg Ser Arg Val Thr
65 70 75 80

Leu Ser Asn Gln Pro Tyr Ile Lys Val Leu Thr Leu Ala Asn Phe Thr
85 90 95

Thr Lys Asp Glu Gly Asp Tyr Phe Cys Glu Leu Arg Val Ser Gly Ala
100 105 110

Asn Pro Met Ser Ser Asn Lys Ser Ile Ser Val Tyr Arg Asp Lys Leu
115 120 125

Val Lys Cys Gly Gly Ile Ser Leu Leu Val Gln Asn Thr Ser Trp Met
130 135 140

Leu Leu Leu Leu Leu Ser Leu Ser Leu Leu Gln Ala Leu Asp Phe Ile
145 150 155 160

Ser Leu

<210> 155
<211> 1497
<212> DNA
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 155
atgcttctcc tggtgacaag ccttctgctc tgtgagttac cacaccagc attcctcctg 60
atcccacaaa gtctggaaga gtctgggggc gaccttgtca agcccgagc ttcactgacc 120
ctgacctgca cggctagtgg aatcgacttc tccgacatat attacatcag ttgggttcgc 180
caagcgcctg ggaagggtct ggaatggata gcgtgtacgt atgccgggag tagcgggtcc 240
acatattacg ctacgtgggc gaaaggtaga ttcacgatct ccaaggctag ttcaacaaca 300
gtaacattgc agatgacttc cctcacagca gccgatacgg ctacatactt ttgtgcgcgg 360
gacaggatatc caggaacctc agggagggta tatggaatgg acttgtgggg accgggcacc 420
ttggttaccg tgagtagcgg gagcacgagt ggaagcggta aaccaggttc tggagaaggg 480
agtacgaaag gagacgttgt aatgactcag acgccatcct ccgttagcga accagtcgga 540
ggtacagtga ccataaagt ccaagcctct cagtctatat ctgacctgtt gaggttggtat 600
caacagaaac cgggacaacc ccaaagtgtg ctcatctact ctgcgtcaac actcgcatca 660
ggcgtctcaa gcagattcaa agggagtgagg tccggtagcg aatttactct taccataagt 720
gaccttgagt gcgctgacgc tgctacttat tattgccagt gtaactacta ttctccgacc 780
tacggaaatg ggttcggagg cggaaactgag gtagtggtta aaaagaccac gacgccagcg 840
ccgcgaccac caacaccggc gccaccatc gcgtcccaac cacttagttt gaggcctgaa 900
gcctgtaggc cagcagctgg tggcgcagtg cacacgaggg ggctggactt cgcctgtgat 960
atctacatct gggcgccctt ggccgggact tgtgggggtcc ttctcctgtc actggttatc 1020
accctttact gcaaacgggg caggaagaag ctgctctaca tctttaagca gcctttcatg 1080
cgccctgtgc agacgactca agaggaagat ggctgtagct gccgatttcc agaagaagaa 1140
gaaggaggat gtgaactgag agtgaagttc agcaggagcg cagacgcccc cgcgtaggag 1200
cagggccaga accagctcta taacgagctc aatctaggac gaagagagga gtacgatgtt 1260
ttggacaaga gacgtggccg ggaccctgag atggggggaa agccgagaag gaagaaccct 1320
caggaaggcc tgtacaatga actgcagaaa gataagatgg cggaggccta cagttagatt 1380
gggatgaaag gcgagcgccg gaggggcaag gggcacgatg gcctttacca gggctctcagt 1440
acagccacca aggacaccta cgacgccctt cacatgcagg ccctgcccc tcgctaa 1497

<210> 156
<211> 1497
<212> DNA
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 156
atgcttctcc tggtgacaag cttctgctc tgtgagttac cacaccagc attcctcctg 60
atcccagacg ttgtaatgac tcagacgcca tcctccgtta gcgaaccagt cggaggtaca 120
gtgaccataa agtgccaagc ctctcagtct atatctgacc tgttgagttg gtatcaacag 180
aaaccgggac aacccccaaa gttgctcatc tactctgcgt caacactcgc atcaggcgctc 240
tcaagcagat tcaaaggag tgggtccggt acggaattta ctcttaccat aagtgacctt 300
gagtgcgctg acgctgctac ttattattgc cagtgttaact actattctcc gacctacgga 360
aatgggttcg gaggcggaac tgaggtagtg gttaaaaagg ggagcacgag tggaagcggc 420
aaaccagggt ctggagaagg gagtacgaaa ggacaaagtc tggaagagtc tgggggcgac 480
cttgtcaagc ccggagcttc actgaccctg acctgcacgg ctagtggaat cgacttctcc 540
gacatatatt acatcagttg ggttcgcaa gcgcctggga agggctctgga atggatagcg 600
tgtacgtatg ccgggagtag cgggtccaca tattacgcta cgtgggcgaa aggtagattc 660
acgatctcca aggctagttc aacaacagta acattgcaga tgacttcctt cacagcagcc 720
gatacggcta catacttttg tgcgcgggac aggtatccag gaacctcagg gagggtatat 780
ggaatggact tgtggggacc gggcaccttg gttaccgtga gtagcaccac gacgccagcg 840
ccgcgaccac caacaccggc gccaccatc gcgtcccaac cacttagttt gaggcctgaa 900
gcctgtaggc cagcagctgg tgggtgcagtg cacacgaggg ggctggactt cgcctgtgat 960
atctacatct gggcgccctt ggccgggact tgtgggggtcc ttctcctgtc actggttatc 1020
accctttact gcaaacgggg caggaagaag ctgctctaca tctttaagca gcctttcatg 1080
cgccctgtgc agacgactca agaggaagat ggctgtagct gccgatttcc agaagaagaa 1140
gaaggaggat gtgaactgag agtgaagttc agcaggagcg cagacgccc cgcgtagcag 1200
cagggccaga accagctcta taacgagctc aatctaggac gaagagagga gtacgatgtt 1260
ttggacaaga gacgtggccg ggaccctgag atggggggaa agccgagaag gaagaaccct 1320
caggaaggcc tgtacaatga actgcagaaa gataagatgg cggaggccta cagttagatt 1380
gggatgaaag gcgagcgccg gaggggcaag gggcacgatg gcctttacca gggctctcagt 1440
acagccacca aggacaccta cgacgccctt cacatgcagg ccctgcccc tcgctaa 1497

<210> 157
<211> 2268
<212> DNA
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 157

atgctgctcc tcgttaccag cttgctcctg tgtgaattgc cacatccagc gtttcttctg	60
ataccgcaat ccctggaaga atccgggtggc gatctctgta agccaggcgc ctctcttacg	120
ctgacatgta cagcatccgg tattgacttc tctgacatct attacatttc ctgggtgaga	180
caagctccgg gtaagggatt ggaatggata gcctgcacgt acgcgggctc ttccgggtca	240
acatactatg caacctgggc aaaaggacgt tttaccatct ccaaagcaag tagcactacc	300
gtcactctcc aaatgacgtc cctgacagct gcggatacag ccacatactt ctgtgccagg	360
gaccgatatc ctggtacttc aggaagggtc tatggaatgg acctgtgggg tcccgggacc	420
ctcgttaccg tctcctctgg gagcacgagc ggatcaggga aacctggcag cggggaaggc	480
tcaaccaagg gagatgtggt tatgactcag acgcctagct ctgtgagtga gcccgtcggc	540
gggacagtta cgatcaagtg tcaagcctca caaagcatct cagatctgct gtcctggtat	600
cagcaaaagc cggggcaacc cccaaaactt cttatctaca gcgcctctac gcttgcatca	660
ggagtatcat ccagatttaa aggttccgga agcgggaccg aattcactct tacaatctcc	720
gatctcgaat gcgctgatgc tgcgacttat tactgtcaat gtaattacta ttccccgacg	780
tatgggaacg gatttggcgg tggcacagag gtcgtctgta agaagaccac tacgcctgcc	840
ccgagaccgc ccactcctgc tcccactatt gcaagccaac ctctgagtct cagaccagaa	900
gcttgccgcc ctgcagcagg tggggcagtg catacaagag ggcttgattt tgcttgcgac	960
atttacatat gggctcccct ggccggcact tgtggtgttc tgctgctttc cctcgtgatt	1020
acactctact gcaagagggg acggaagaaa ctgctctaca tattcaaaca acctttcatg	1080
cgacctgtcc aaacaactca ggaagaggat ggggtgttcct gtagatttcc cgaagaagag	1140
gaaggcgggt gcgaactgag ggtaaaattc agtcgctccg ctgacgcacc cgcatatcag	1200
caaggccaaa accagcttta taatgaattg aacctcgggc ggcgcgagga atacgacgtg	1260
ctggacaaac gccgtggtag ggatccagaa atgggcggca aaccaggcgc caagaatccg	1320
caagaaggcc tgtataatga actgcaaaag gataaaatgg cagaggcata ttcagaaata	1380
ggtatgaagg gcgaacgacg gagaggcaag ggacatgatg gactctacca aggcttgtcc	1440
actgccacta aggacaccta tgacgcgctg catatgcaag cgctgcccc gaggggcagc	1500
ggtgaggggc gcggctcttt gcttacgtgc ggagatgtag aagaaaatcc cgggccgatg	1560
gtgagcaaa gcgaggaaga caatatggcg attatcaagg aattcatgag gtttaaagt	1620
cacatggaag ggtcagtga tggccatgag tttgaaatag aagggtgagg tgaaggccga	1680
ccttacgaag gcacccaaac tgcaaagctc aaghtaaca aaggcgggcc gttgcctttt	1740
gcttgggata tactcagtcc gcaattcatg tatggctcta aagcttatgt gaaacacca	1800
gctgacattc cagattacct taaattgagc tttcccgaag gctttaaatg ggaaagagt	1860
atgaattttg aagatggcgg agtcgtaacc gttactcaag attcaagtct tcaggacggt	1920
gagtttattt acaaagtcaa actccgtggg acaaatctt cttctgatgg gccggtgatg	1980
caaaagaaaa ctatgggctg ggaagccagc tcagagcgaa tgtaccggga agacggcgcg	2040

ctgaaaggag agattaagca gagactcaaa ctgaaggacg gcggacacta cgatgctgaa	2100
gtcaaaacaa cttataaggc caagaagcca gtgcaactgc ctggggcgta taatgtgaat	2160
attaaactgg acatcacttc tcacaacgaa gactatacca ttgttgaaca atacgaacgt	2220
gcagagggta gacatagcac aggcggcatg gatgaactct acaagtga	2268

<210> 158
 <211> 2292
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 158	
atgcttctcc tggtgacaag ctttctgctc tgtgagttac cacaccagc attcctcctg	60
atcccacaaa gtctggaaga gtctgggggc gaccttgtca agcccggagc ttcactgacc	120
ctgacctgca cggtctagtg aatcgacttc tccgacatat attacatcag ttgggttcgc	180
caagcgcctg ggaagggtct ggaatggata gcgtgtacgt atgccgggag tagcgggtcc	240
acatattacg ctacgtgggc gaaaggtaga ttcacgatct ccaaggctag ttcaacaaca	300
gtaacattgc agatgacttc cctcacagca gccgatacgg ctacatactt ttgtgcgcgg	360
gacaggatat caggaacctc agggagggta tatggaatgg acttgtgggg accgggcacc	420
ttggttaccg tgagtagcgg gagcacgagt ggaagcggta aaccaggttc tggagaaggg	480
agtacgaaag gagacgttgt aatgactcag acgccatcct ccgttagcga accagtcgga	540
ggtacagtga ccataaagtg ccaagcctct cagtctatat ctgacctgtt gagttggtat	600
caacagaaac cgggacaacc cccaaagttg ctcatctact ctgcgtcaac actcgcatca	660
ggcgtctcaa gcagattcaa agggagtgagg tccggtagcg aatttactct taccataagt	720
gaccttgagt gcgctgacgc tgctacttat tattgccagt gtaactacta ttctccgacc	780
tacggaaatg ggttcggagg cggaactgag gtagtggtta aaaagaccac gacgccagcg	840
ccgcgaccac caacaccggc gccaccatc gcgtcccaac cacttagttt gaggcctgaa	900
gcctgtaggc cagcagctgg tgggtgcagtg cacacgaggg ggctggactt cgcctgtgat	960
atctacatct gggcgccctt ggccgggact tgtggggtcc ttctcctgtc actggttatc	1020
accctttact gcaaacgggg caggaagaag ctgctctaca tctttaagca gcctttcatg	1080
cgccctgtgc agacgactca agaggaagat ggctgtagct gccgatttcc agaagaagaa	1140
gaaggaggat gtgaactgag agtgaagttc agcaggagcg cagacgcccc cgcgtaccag	1200
cagggccaga accagctcta taacgagctc aatctaggac gaagagagga gtacgatgtt	1260
ttggacaaga gacgtggccg ggaccctgag atggggggaa agccgagaag gaagaaccct	1320
caggaaggcc tgtacaatga actgcagaaa gataagatgg cggaggccta cagtgagatt	1380
gggatgaaag gcgagcgccg gaggggcaag gggcacgatg gcctttacca gggctctcagt	1440
acagccacca aggacaccta cgacgccctt cacatgcagg ccctgcccc tcgcttaatt	1500
aacggaagcg gacagtgtac taattatgct ctcttgaaat tggctggaga tgttgagagc	1560

aaccctggac ctatggtgag caagggcgag gagctgttca ccggggtggt gcccatcctg	1620
gtcgcagctgg acggcgacgt aaacggccac aagttcagcg tgtccggcga gggcgagggc	1680
gatgccacct acggcaagct gacctgaag ttcatctgca ccaccggcaa gctgcccgtg	1740
ccctggccca ccctcgtgac cacctgacc tacggcgtgc agtgcttcag ccgctacccc	1800
gaccacatga agcagcacga cttcttcaag tccgccatgc ccgaaggcta cgtccaggag	1860
cgcaccatct tcttcaagga cgacggcaac tacaagacct gcgccgaggt gaagttcgag	1920
ggcgacaccc tggngaaccg catcgagctg aagggcacgc acttcaagga ggacggcaac	1980
atcctggggc acaagctgga gtacaactac aacagccaca acgtctatat catggccgac	2040
aagcagaaga acggcatcaa ggtgaacttc aagatccgcc acaacatcga ggacggcagc	2100
gtgcagctcg ccgaccacta ccagcagaac acccccatcg gcgacggccc cgtgctgctg	2160
cccgacaacc actacctgag caccagtcg gccctgagca aagaccccaa cgagaagcgc	2220
gatcacatgg tcctgctgga gttcgtgacc gccgccggga tcaactctcg catggacgag	2280
ctgtacaagt aa	2292

<210> 159
 <211> 2319
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 159	
atgctgctgt tggtagacct tctgcttctc tgtgagctgc ctcatccgc ttttctcttg	60
atcccgacga gcttgaaga gtcaggtggt gaccttgtga agcctggcgc atccctcaca	120
ttgacctgta cggcatccgg gatagacttt agcgacattt attacatttc ttgggtaagg	180
caggccccag gcaaagggtc ggaatggatc gcttgactt acgctggctc ttcaggaagt	240
acctattatg ctacttgggc gaagggtcgt ttcacgatca gcaaggcatc tagcaccacc	300
gtgacactcc agatgacttc cctgactgct gccgacaccg ccacgtattt ctgcgccaga	360
gaccgctacc ctgggacctc aggccgagtc tatgggatgg acctgtgggg ccctggcaca	420
ctggtgactg tctcctctgg ctcaactagc ggatcaggca agcccgggtc tggagagggc	480
agcaccaaag gggatgttgt gatgaccag acgcctagct cagtttcaga gcctgtaggt	540
ggcacagtga cgatcaaatg tcaggccagt caatctatta gcgacttgct gagctggtat	600
cagcaaaagc ctggtcagcc ccctaagctg ctgatatact ctgcatccac cctggcctct	660
ggcgtgagca gccgatttaa aggctctgga tctgggaccg aattcacact tacaatctct	720
gaccttgagt gtgccgatgc ggcaacctac tactgtcagt gcaactatta ttctccgact	780
tatggcaatg ggttcggcgg cggaactgag gtagtggtca agaagggcgg cggcggatca	840
ggtggcgggt gatctggcgg aggaggctcc ggtggaacaa ccaccctgc cccacgtccc	900
ccgactcctg caccgacgat tgcacacag cccttgtctc tccgtcctga ggcctgtcgc	960

ccggcagcag gtggcgccgt gcatacgaga ggactcgatt tcgcatgtga tatatatatt	1020
tgggccccac tcgcaggcac ttgcggcgtg ctgcttctga gcctcgttat tacactgtat	1080
tgtaaagcggg gaaggaagaa gctgttgtac atattcaaac aaccattcat gcgaccagt	1140
cagacaaccc aagaggaaga tggctgttca tgcagattcc ccgaggaaga ggaaggcggg	1200
tgtgagctgc gcgtaaaatt tagcagggtcc gcagatgcgc ccgcttatca gcaaggccag	1260
aatcagctct acaatgaact gaatctgggc cgcagagaag aatatgacgt ccttgacaag	1320
aggcgaggta gggaccctga gatgggcgga aagccgagac gcaagaaccc acaagagggt	1380
ctgtacaatg agcttcaaaa ggacaagatg gccgaggcgt actctgagat tggcatgaag	1440
ggtgaacgta ggcgcggtaa ggggcatgac gggctctacc aggggctgtc aacggctacc	1500
aaagatactt acgacgccct gcacatgcag gctctccac cacgcggaag cggcgaagg	1560
cgagggagtc tcctcacatg cggtgatgtg gaagaaaacc caggaccgat ggtagcaaaa	1620
ggggaagagg acaatatggc gataattaaa gagtttatgc gattcaaggt acatatggaa	1680
ggatctgtta atgggcatga atttgagatt gaaggagaag gggaaggacg tccctacgaa	1740
ggcacacaga cagccaaact caaggttacc aaggcgggc ccctgccatt tgcattgggac	1800
atacttagtc cccaattcat gtatggctcc aaggcctatg tcaagcacc tgcagatatt	1860
cctgactatc tgaagctgtc attccctgag ggatttaagt gggaacgggt aatgaacttc	1920
gaagacggcg gcgtgggtgac cgtgacacag gattcttccc tgcaagacgg cgagttcata	1980
tataaggtaa agctgagggg tacgaacttc ccatccgatg gccccgtcat gcagaagaaa	2040
acaatgggat gggaaagcag tagcgaacgc atgtacccc aagatggagc gttgaaagga	2100
gaaattaaac agcgctcaa actgaaagac ggcggacatt acgacgctga ggttaagacc	2160
acataataag ccaagaagcc ggtccaactc ccagggcggt acaatgtcaa catcaaactc	2220
gatatcacia gccataatga agattatact atcgtggagc agtacgaacg agccgagggc	2280
aggcactcca caggcggcat ggatgaactg tataagtaa	2319

<210> 160
 <211> 2268
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 160	
atgctcctgc tcgtgacctc tttgttgctt tgtgagctgc cccatcctgc gttcctgctg	60
attccggatg ttgtgatgac gaaaactcct tccagcgtat ctgaaccggt tggcgggtact	120
gtaaccatca aatgccaggc ctcaaaaagt atctctgac ttctttcttg gtatcaaaaa	180
aagccaggtc aaccgcccc attgctcatt tactcagcca gtacactcgc gagtggggtc	240
agttcccgtc tcaaaggatc tggttctgga acagaattca ccctcacaat atccgatttg	300
gaatgcgcag atgccgtac ttactattgt caatgtaact attattcacc aacttatggg	360
aatggctttg gtgggtggcac cgagggtggt gttaagaagg ggagcacatc cggcagtggc	420

aagccagggt ccggggaagg atcaacaaag ggtcaatcac tggaagaaag cggcggcgac	480
cttgtgaaac cgggagccag cctcacgctc acttgtaccg catcaggtat cgacttttca	540
gacatctact atatctcctg ggtgctcaa gcgccaggta aaggcttgga atggatcgca	600
tgtacttacg caggaagcag tggctctacg tactatgccg catgggcaaa ggggagattt	660
acaataagta aagcatcatc tactacagtt actcttcaaa tgacaagcct gacagcggcc	720
gatactgcta cgtatttctg tgctagagat cgttacccgg ggacttcagg cagagtctac	780
ggcatggacc tctggggacc tggaactttg gtaacagtca gctccacaac gaccccggt	840
ccccggccac caaccccagc acccactata gcatcccaac cattgtctct gagacctgag	900
gcttgacagc cagcagccgg cggcgccgtt cacactaggg gcttgattt tgcattgat	960
atttacattt gggccccact ggccggcact tgtggcgtgc tgcttctcag tctcgtgatt	1020
actttgtact gaaaagagg ccggaagaag ctgctgtata ttttcaaaca accgtttatg	1080
cgccctgttc aaacgacgca agaaggagc ggctgttctt gcagattccc tgaggaagaa	1140
gaagggtgat gcgaactcag ggtaaattc agcaggagt cggacgcgc gccgtatcaa	1200
cagggtcaga atcaacttta caacgagctg aatctgggca gacgggaaga gtatgatgtt	1260
cttgacaagc gcagagggcg cgatccggag atgggtggga aacccggcg aaagaatcca	1320
caagaaggcc tctataacga gtcctaaaag gacaaaatgg cagaagctta tagcgaaatc	1380
ggaatgaaag gggagcggag acgtggtaaa gggcacgacg gcctctatca agggctttct	1440
acagctacca aagacactta tgacgccctt cacatgcaag cgctcccacc aagaggatca	1500
ggcgagggcc ggggttcctt gttgacatgt ggggatgtcg aagaaaacc aggccgatg	1560
gtgtcaaagg gtgaggaaga taatatggcg attatcaaag agttcatgag attcaaggtt	1620
catatggaag gaagtgtcaa tgggcatgaa tttgagattg agggagaagg ggaaggctgc	1680
ccttatgagg gcacccaaac agcaaaactt aaagtcacca agggcgggtc tcttcggtc	1740
gcgtgggaca tcctgtcccc tcaattcatg tacggatcca aagcttatgt taagcaccca	1800
gctgatattc ccgattactt gaaactgtcc ttccccgaag gctttaaatg ggagcgcgtg	1860
atgaattttg aagatggcgg ggtagtaacc gttacacagg actcaagtct gcaagatggg	1920
gaatttatct ataaagtcaa gcttcgaggc accaactttc catcagacgg accggttatg	1980
cagaagaaga ctatgggctg ggaagccagc agtgaacgta tgtaccaga agatggggca	2040
ctgaaggagg agatcaagca aaggttgaag ttgaaagatg gtggacatta cgatgccgag	2100
gttaagacaa cgtataaagc caagaagcct gtccaacttc ccggagcata caacgttaac	2160
atcaagttgg atatcacatc acataatgaa gactatacga tagttgaaca atacgaaagg	2220
gcagagggaa ggcacagtac aggcgggatg gatgagctgt ataaatga	2268

<210> 161

<211> 2319

<212> DNA

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 161

atgttggtgtg	tggtaacatc	tttgcttctg	tgtgagctcc	ctcatccgc	cttcctgctt	60
atacccgatg	tggtaatgac	gcaaaactcct	tcaagtgtca	gtgaacccgt	aggcggaaacg	120
gtcaccatca	agtgtcaggc	gtctcaaagc	attagcgatc	tcctgtcatg	gtatcagcaa	180
aagccaggtc	agccacccaa	gctcctcata	tattcagcga	gcaccctcgc	gtcaggagtt	240
agcagtcgct	tcaaagggtc	aggatccggg	acggaattca	cccttaccat	aagcgacctc	300
gaatgtgccg	atgccgcgac	atattattgc	caatgtaatt	attattcccc	gacatacggg	360
aatggctttg	ggggggggac	agaggtcgtg	gttaagaagg	ggtcacgctc	aggttccggg	420
aagcccggct	ccggtgaggg	gagcactaaa	ggtcagtcac	tcgaggaatc	tggtggagac	480
ctcgtgaagc	caggagcatc	cctgacactc	acctgcacag	cgtcagggat	tgacttctcc	540
gacatatact	acattagttg	gggccgacag	gctccgggga	aaggcttgga	atggatagca	600
tgcacctatg	ccgggagctc	aggcagtaca	tactatgcca	cttgggcgaa	aggccgtttc	660
acgatctcaa	aagctagctc	caccacagtc	actttgcaa	tgacgtctct	caccgccgcc	720
gacacagcca	cgtatttctg	tgccagagat	agatacccg	gaacctctgg	cagagtctat	780
ggatatggatt	tgtgggggtcc	cggtactctg	gtcaccgtaa	gttctggagg	aggcggtagt	840
ggcggcggcg	gttccggtgg	aggcgggtct	ggcggaaaca	caactccggc	ccccaggccg	900
cctacacctg	ctccaactat	cgccagccaa	cccttgtcac	tccgccccga	agcttgacaga	960
cctgccgccg	gtggcgcagt	tcatacgagg	ggacttgact	tcgcctgtga	tatctacata	1020
tgggcgccac	ttgcaggaac	ttgtggcggt	ctccttctct	ctctgggtgat	taccctctat	1080
tgtaaacggg	gccgaagaa	actcctgtat	atcttcaagc	aaccattcat	gaggccagtt	1140
cagaccaccc	aagaagagga	cggtctctct	tgctcggttcc	ctgaggaaga	ggaaggcgga	1200
tgtgaactca	gagtgaatt	ctccagatct	gcagatgctc	cggcctacca	acagggccaa	1260
aaccaactct	ataacgaact	taacttgggg	agacgcgaag	aatacgaatg	gttgataag	1320
cgaagaggtc	gggatccaga	gatgggcgga	aaacctagac	gcaagaatcc	gcaggaaggg	1380
ctgtacaatg	aactccagaa	agacaaaatg	gcagaagcat	acagtgaat	tggaatgaaa	1440
ggagaaagaa	gaagagggaa	aggacacgac	ggactttatc	agggcctctc	aaccgcaaca	1500
aaagacactt	acgacgccct	gcacatgcaa	gctcttcccc	ctcggggctc	cggagaaggc	1560
cggggctccc	tgctgacttg	tggcgacgtg	gaagaaaacc	caggacctat	ggtgagtaaa	1620
ggggaagagg	acaacatggc	cataattaaa	gaatttatga	ggttcaaagt	gcatatggaa	1680
ggttctgtca	atgggcatga	atttgaaatt	gaggggagaag	gggaaggccg	gccttatgag	1740
ggtactcaaa	ccgctaaatt	gaaagtgaca	aagggcggtc	ctctgccgtt	tgcatgggat	1800
atcttgtctc	cgcaattcat	gtacgggtca	aaagcttacg	tcaaacaccc	ggccgatata	1860
ccagactatt	tgaactgtc	attccagag	ggattttaat	gggagagggt	catgaatttt	1920
gaggatggcg	gcgttggttac	ggtaaccag	gattcatcac	tgcaagacgg	ggaattcatt	1980

tataaagtca aactcagagg gacaaatttc cccagcgatg gtcctgtgat gcaaaagaaa	2040
acaatgggct gggaagcctc ttcagaaaga atgtatcctg aggatggagc cctgaaggga	2100
gagattaaac agcggctgaa gctgaaggac ggtggctcatt acgacgctga agtaaagaca	2160
acatataagg caaagaaacc agtccaattg ccgggcgcat ataatgtcaa catcaaactg	2220
gatataacct ctcacaatga agattacaca atcgtcgagc agtacgagcg ggcagaaggg	2280
agacacagta ccggtggcat ggatgagctg tataaatga	2319

<210> 162
 <211> 2277
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 162	
atgttgttgc ttgtcacgtc ctttcttctg tgtgagctcc cccatcctgc atttctcctc	60
atcccacaga gtcttgagga gtcaggcggg gacctggtaa aaccggcg cttcttgacc	120
ctgacctgca cggcaagtgg tattgatttc agcgatatatt attatatctc atgggtgcga	180
caagcacctg gaaaaggcct tgagtggatt gcgtgtactt acgccggtag cagcgggagc	240
acttattacg ctacttgggc aaagggccgc ttcaccattt ccaaggccag tagcacaacc	300
gttactcttc aaatgacctc tctcaccgcc gccgatacgg cgacttattt ctgcgcaaga	360
gatagatacc ctggtacatc aggaagagtc tatggcatgg acctctgggg cccggggaca	420
ctggtcacccg tctcttcagg atccacctca gggagtggaa aaccaggttc tggagagggc	480
tcaacaaaag gggatgtcgt tatgacgcag actccttcca gcgtctcaga gccagtaggt	540
ggcactgtaa cgattaaatg tcaggcatct caatccatta gcgatcttct gtcttggtat	600
caacaaaagc ctggtcagcc ccctaaactc ctcatctata gcgcatctac gttggcatca	660
ggggtgtcat ctcgctttaa aggctccgga agtggaaacc aatttacact tactatcagt	720
gatttggaaat gcgcagacgc cgcaacctat tattgtcaat gcaattatta tagtccaacg	780
tacggcaacg ggttcggggg gggaactgaa gtggttgtca agaagaccac aacccggca	840
ccacgtccac ctacgcctgc accaacaatt gcctctcagc ctcttagcct gcggcctgaa	900
gcatgtcgtc ccgctgccgg tgggtgcagtc cacaccgcg gactggactt cgcctgcgat	960
atttacatat gggctccgct ggctgggacc tgcggagtgc tgctgctcag tcttgtgatc	1020
actctgtact gaaaacgagg ccgtaagaaa ctgttgtata ttttcaagca accgtttatg	1080
cgcccagttc agaccacgca agaggaagac ggatgctctt gtcggtttcc cgaagaggaa	1140
gaaggcggct gtgagcttag agtgaaattt tcaaggctctg cagatgcccc cgcgtaccaa	1200
caaggacaaa atcaactgta caacgagctg aacctggggc ggcgcgagga atatgatgtg	1260
ctcgacaaaa gacgcgggag agaccccgaa atgggcggca aacccggcg caagaatccg	1320
caagaaggtt tgtataatga actccaaaag gataagatgg cagaagcata ctctgaaatt	1380

ggaatgaaag gggagcggcg caggggaaag gggcacgacg gcctgtatca ggggctgtcc	1440
acagctacta aggatacata tgacgcgctg cacatgcagg cgttgccgcc tcggggttct	1500
ggcgagggtta ggggatcact gcttacttgt ggtgacgtgg aagagaatcc tgggtccatg	1560
gtttccaagg gtgaagagtt gttcacaggc gttgtgccga tcctgggtgga gttggatgga	1620
gacgttaatg gacataagtt tagcgtttct ggcgaaggag agggcgacgc aacatacggc	1680
aaactgacct tgaagttcat ttgtacaacc gggaagctgc cagtcccgtg gccaaactc	1740
gtgaccactc tgacttacgg cgtgcaatgc ttttcccgt accctgacca tatgaagcag	1800
cacgatttct ttaagtccgc catgccggaa gggatatgtcc aagagcggac aattttcttt	1860
aaggatgatg gaaactacaa gacgagagct gaagtcaagt ttgaaggaga tacactggtt	1920
aataggatcg agcttaaagg catagatttc aaggaagacg gaaatattct ggggcacaag	1980
ctcgagtaca actataactc acacaacgtg tatatcatgg ctgacaagca aaagaacggc	2040
ataaaagtta attttaagat aagacacaat atcgaagacg ggtctgtgca gcttgctgat	2100
cattatcaac aaaacactcc aataggagat ggaccagttc tccttcccga taatcactat	2160
ctcagcacgc aatcagcgct gagtaaagac cccaacgaga agcgagacca catggtgctc	2220
ctggaatttg tcaactgcagc aggaattacg cttgggatgg atgaactgta caagtga	2277

<210> 163
 <211> 2259
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 163	
atgctcctct tggtgacatc actccttctg tgtgaactcc cacatcctgc ttttctgctt	60
attccacaat cactggaaga atctgggtgg gacctcgtca agccaggtgc gtctctcact	120
ctgacctgca cagctagtgg aattgacttt tcagatatatt attacatttc ctgggtaaga	180
caggccccgg gcaagggctt ggaatggatt gcttgtagat acgcaggttc ctcagggtca	240
acctattatg ctacatgggc taaaggtaga ttactatca gcaaagcatc ttccacgact	300
gttacccttc aaatgaccag cctcacggcg gccgacactg ctacgtactt ttgtgctcgc	360
gacaggatct ctggaaccag cggtcgggtc tacgggatgg acctttgggg tccaggcacc	420
cttgttactg tgtcatccgg ttcaacatcc ggctccggaa agcctgggtc cggggaaggt	480
agcaccaagg gcgatgtgg aatgactcaa actccaagct ctgtctcaga accggtgggc	540
ggtacagtaa caataaatg tcaagcatcc cagagcatct ccgacctgtt gagttggtat	600
cagcaaaagc cagggtcaacc accgaagttg ctcatcttaca gcgctagcac gctcgccagc	660
ggtgtgagca gcaggtttaa aggctccggg tccggaacgg aattcactct gactatcagt	720
gacctggagt gcgccgatgc agctacctat tattgccaat gtaattatta ttcaccact	780
tacggcaatg gtttcggcgg cgggaccgaa gtagtagtga agaaaattga agtgatgtat	840
ccccccctt atctggataa tgagaaaagc aatggtacga tcatccacgt taagggaag	900

cacttgtgcc ccagcccact gtttcccga cccagtaaac ctttctgggt tttggtcgtg	960
gttggcggcg ttcttgcctg ttattccctg cttgtcacgg tggcgtttat catcttctgg	1020
gtcaagcgag gcaggaagaa actcctctat atctttaaac aaccctttat gcggccagta	1080
caaactacac aagaagagga tggctgttca tgccgtttcc ccgaagagga agaaggcggc	1140
tgcgaactgc gggttaagtt ctctagaagt gctgacgcac cagcttatca acaaggacag	1200
aatcaactct ataatgaact gaatctgggc cgacgcgagg aatacgaatg tctggacaag	1260
agacgcggac gcgaccaga gatgggcgga aaaccacgta ggaagaatcc acaagaaggc	1320
ttgtataacg aacttcaaaa ggataaaatg gccgaggcgt attctgaaat aggaatgaag	1380
ggcgagagga gacgcgggaa gggcatgac gggctgtatc aaggctctgtc tacagccacc	1440
aaggacacct acgatgccct gcacatgcaa gcaactccgc cacgcgggag cggatgaagg	1500
cgtggatccc tgctcacttg cggagatgtg gaagaaaacc caggcccgat ggtagcaag	1560
ggcgaagagg ataatatggc cattatcaaa gaatttatgc gttttaaggt ccatatggaa	1620
gggtccgtca acgggcacga gtttgaaatt gaaggggaag gggaaggcg gccttacgag	1680
ggcactcaaa cagcgaagct gaaagtgact aaaggcggcc ctctcccttt tgcttgggat	1740
attctttctc ctcaattcat gtacggaagt aaagcatacg tgaaacatcc tgcagatatc	1800
cctgattacc ttaaactctc attccccgaa gggttcaagt gggaaagagt gatgaatttt	1860
gaggatggcg gcgtcggttac tgtgacgcaa gattctagtc tccaagacgg agagtttata	1920
tataaggtta aactgcgggg caccaacttc ccctcagatg gtcccgtgat gcaaaagaag	1980
actatggggt gggaaagctag ctctgaaagg atgtaccctg aggacggagc cctcaagggt	2040
gaaattaagc aaaggcttaa gctgaaagat ggcggccact acgatgccga agtcaaaaaca	2100
acatacaaag cgaagaaacc agttcagctg cctggagctt ataatgttaa cataaaactg	2160
gatattacct ctcaaacga agactatact atcgtcgaac agtatgagag ggctgaagg	2220
cggcactcta ctggcgggat ggatgaactt tacaagtga	2259

<210> 164
 <211> 1491
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 164	
atgcttctcc tggtgacaag ctttctgctc tgtgagttac cacaccagc attcctcctg	60
atcccacaaa gtctggaaga gtctgggggc gaccttgtca agcccggagc ttcactgacc	120
ctgacctgca cggctagtgg aatcgacttc tccgacatat attacatcag ttgggttcgc	180
caagcgcttg ggaagggtct ggaatggata gcgtgtacgt atgccgggag tagcgggtcc	240
acatattacg ctacgtgggc gaaaggtaga ttcacgatct ccaaggctag ttcaacaaca	300
gtaacattgc agatgacttc cctcacagca gccgatacgg ctacatactt ttgtgcgcgg	360

gacaggtatc caggaacctc agggagggta tatggaatgg acttgtgggg accgggcacc	420
ttggttaccg tgagtagcgg cagtactagt ggtagtgga agcccgaag cggggaaggc	480
tccaccaagg gagttgtaat gactcagacg ccatcctccg ttagcgaacc agtcggaggt	540
acagtgacca taaagtgcc agcctctcag tctatatctg acctgttgag ttggtatcaa	600
cagaaaccgg gacaaccccc aaagttgctc atctactctg cgtcaacact cgcatcaggc	660
gtctcaagca gattcaaagg gagtgggtcc ggtacggaat ttactcttac cataagtac	720
cttgagtgcg ctgacgctgc tacttattat tgccagtgt actactattc tccgacctac	780
ggaaatgggt tcggaggcgg aactgaggta gtggttaaaa ccaccactcc ggctccccga	840
ccacctactc ctgcccctac aatcgctagc cagcctttga gtcttaggcc tgaagcttgt	900
aggcctgccg caggcggggc agtgcacaca aggggccttg acttcgcctg tgatatctac	960
atatgggcac ccctggctgg aacctgcgga gtgctccttt tgagtctcgt gattactctg	1020
tactgcaagc ggggaagaaa gaagctgttg tacattttca agcagccatt catgcgaccc	1080
gtccagacca cacaagagga agacggctgt agttgcaggt ttcctgaaga ggaagagggc	1140
ggatgcgagc tccgcgtgaa attcagtaga tccgcagatg cccctgctta ccagcagggg	1200
caaaaccagc tgtataacga attgaatctg ggacgccgag aggaatacga cgtgctcgac	1260
aagagacgtg ggcgatgatcc agagatgggt ggcaaacccc ggcgtaagaa ccctcaagag	1320
gggctgtaca atgaactcca aaaggataag atggccgaag cttattccga aattggcatg	1380
aaaggggaac gccggcgagg gaaaggccac gacggacttt accagggtct tagcaccgcg	1440
acaaaggaca cctacgacgc attgcatatg caggcactcc caccaggta a	1491

<210> 165
 <211> 1491
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 165	
atgcttctcc tggtgacaag cttctgctc tgtgagttac cacaccagc attcctcctg	60
atcccagttg taatgactca gacgccatcc tccgttagcg aaccagtcgg aggtacagtg	120
accataaagt gccaaacctc tcagtctata tctgacctgt tgagttggta tcaacagaaa	180
ccgggacaac ccccaaagtt gctcatctac tctgcgtcaa cactcgcac aggcgtctca	240
agcagattca aaggagtggt gtccgggtacg gaatttactc ttaccataag tgaccttgag	300
tgcgctgacg ctgctactta ttattgccag tgtaactact attctccgac ctacggaaat	360
gggttcggag gcggaactga ggtagtggtt aaaggcagta ctagtggtag tggaaagccc	420
ggaagcgggg aaggctccac caagggacaa agtctggaag agtctggggg cgacctgtgc	480
aagcccggag cttcactgac cctgacctgc acggctagtg gaatcgactt ctccgacata	540
tattacatca gttgggttcg ccaagcgcct gggaagggtc tggaatggat agcgtgtacg	600
tatgccggga gtagcgggtc cacatattac gctacgtggg cgaaaggtag attcacgac	660

tccaaggcta gttcaacaac agtaacattg cagatgactt ccctcacagc agccgatacg	720
gctacatact tttgtgcgcg ggacaggtat ccaggaacct caggaggagggt atatggaatg	780
gacttgtggg gaccgggcac cttggttacc gtgagtagca ccaccactcc ggctccccga	840
ccacctactc ctgcccctac aatcgctagc cagcctttga gtcttaggcc tgaagcttgt	900
aggcctgccg caggcggggc agtgcacaca aggggccttg acttcgcctg tgatatctac	960
atatgggcac ccctggctgg aacctgcgga gtgctccttt tgagtctcgt gattactctg	1020
tactgcaagc ggggaagaaa gaagctgttg tacattttca agcagccatt catgcgaccc	1080
gtccagacca cacaagagga agacggctgt agttgcaggt ttcctgaaga ggaagagggc	1140
ggatgcgagc tccgcgtgaa attcagtaga tccgcagatg cccctgctta ccagcagggg	1200
caaaaccagc tgtataacga attgaatctg ggacgccgag aggaatacga cgtgctcgac	1260
aagagacgtg ggcgtgatcc agagatgggt ggcaaacccc ggcgtaagaa ccctcaagag	1320
gggctgtaca atgaactcca aaaggataag atggccgaag cttattccga aattggcatg	1380
aaaggggaac gccggcgcg gaaaggccac gacggacttt accagggtct tagcaccgcg	1440
acaaaggaca cctacgacgc attgcatatg caggcactcc caccaggta a	1491

<210> 166
 <211> 1494
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 166	
atgcttctcc tggtgacaag ctttctgctc tgtgagttac cacaccagc attcctcctg	60
atcccacaaa gtctggaaga gtctgggggc gaccttgtca agcccggagc ttcactgacc	120
ctgacctgca cggctagtgg aatcgacttc tccgacatat attacatcag ttgggttcgc	180
caagcgcctg ggaagggtct ggaatggata gcgtgtacgt atgccgggag tagcgggtcc	240
acatattacg ctacgtgggc gaaaggtaga ttcacgatct ccaaggctag ttcaacaaca	300
gtaacattgc agatgacttc cctcacagca gccgatacgg ctacatactt ttgtgcgcg	360
gacaggtatc caggaacctc agggagggta tatggaatgg acttgtgggg accgggcacc	420
ttggttaccg tgagtagcgg cagtactagt ggtagtggaa agcccggaag cggggaaggc	480
tccaccaagg gagacgttgt aatgactcag acgccatcct ccgttagcga accagtcgga	540
ggtacagtga ccataaagtg ccaagcctct cagtctatat ctgacctgtt gagttggtat	600
caacagaaac cgggacaacc cccaaagttg ctcatctact ctgctgcaac actcgcatca	660
ggcgtctcaa gcagattcaa agggagtggg tccggtacgg aatttactct taccataagt	720
gaccttgagt gcgctgacgc tgctacttat tattgccagt gtaactacta ttctccgacc	780
tacggaaatg ggttcggagg cggaactgag gtagtggtta aaaccaccac tccggctccc	840
cgaccaccta ctctgcccc tacaatcgct agccagcctt tgagtcttag gcctgaagct	900

tgtaggcctg ccgcaggcgg ggcagtgac acaaggggcc ttgacttcgc ctgtgatatc	960
tacatatggg caccctggc tggaacctgc ggagtgtcc ttttgagtct cgtgattact	1020
ctgtactgca agcggggaag aaagaagctg ttgtacattt tcaagcagcc attcatgcga	1080
cccgctccaga ccacacaaga ggaagacggc tgtagttgca ggtttcctga agaggaagag	1140
ggcggatgcg agctccgcgt gaaattcagt agatccgcag atgcccctgc ttaccagcag	1200
gggcaaaacc agctgtataa cgaattgaat ctgggacgcc gagaggaata cgacgtgctc	1260
gacaagagac gtgggcgtga tccagagatg ggtggcaaac cccggcgtaa gaacctcaa	1320
gaggggctgt acaatgaact caaaaggat aagatggccg aagcttattc cgaaattggc	1380
atgaaagggg aacgccggcg cgggaaaggc cacgacggac tttaccaggg tcttagcacc	1440
gcgacaaagg acacctacga cgcattgcat atgcaggcac tcccaccag gtaa	1494

<210> 167
 <211> 1494
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 167	
atgcttctcc tggtgacaag cttctgtctc tgtgagttac cacaccagc attcctcctg	60
atcccagacg ttgtaatgac tcagacgcca tcctccgtta gcgaaccagt cggaggtaca	120
gtgaccataa agtgccaagc ctctcagtct atatctgacc tgttgagttg gtatcaacag	180
aaaccgggac aacccccaaa gttgtcatc tactctgcgt caacactcgc atcaggcgctc	240
tcaagcagat tcaaaggag tgggtccggt acggaattta ctcttaccat aagtgcctt	300
gagtgcgctg acgctgtac ttattattgc cagtgttaact actattctcc gacctacgga	360
aatgggttcg gaggcggaac tgaggtagtg gttaaaggca gtactagtgg tagtggaag	420
cccgaagcg gggaaggctc caccaaggga caaagtctgg aagagtctgg gggcgacctt	480
gtcaagcccg gagcttact gacctgacc tgcacggcta gtggaatcga cttctccgac	540
atatattaca tcagttgggt tcgccaagcg cctgggaagg gtctggaatg gatagcgtgt	600
acgtatgccg ggagtagcgg gtccacatat tacgctacgt gggcgaaagg tagattcacg	660
atctccaagg ctagtccaac aacagtaaca ttgcagatga cttccctcac agcagccgat	720
acggctacat acttttgtgc gcgggacagg tatccaggaa cctcaggag ggtatatgga	780
atggacttgt ggggaccggg caccttggtt accgtgagta gcaccaccac tccggctccc	840
cgaccaccta ctctgcccc tacaatcgct agccagcctt tgagtcttag gcctgaagct	900
tgtaggcctg ccgcaggcgg ggcagtgac acaaggggcc ttgacttcgc ctgtgatatc	960
tacatatggg caccctggc tggaacctgc ggagtgtcc ttttgagtct cgtgattact	1020
ctgtactgca agcggggaag aaagaagctg ttgtacattt tcaagcagcc attcatgcga	1080
cccgctccaga ccacacaaga ggaagacggc tgtagttgca ggtttcctga agaggaagag	1140
ggcggatgcg agctccgcgt gaaattcagt agatccgcag atgcccctgc ttaccagcag	1200

gggcaaaacc agctgtataa cgaattgaat ctgggacgcc gagaggaata cgacgtgctc	1260
gacaagagac gtgggcgtga tccagagatg ggtggcaaac cccggcgtaa gaaccctcaa	1320
gaggggctgt acaatgaact ccaaaaggat aagatggccg aagcttattc cgaaattggc	1380
atgaaagggg aacgccggcg cgggaaaggc cagcagggac tttaccaggg tcttagcacc	1440
gcgacaaagg acacctacga cgcattgcat atgcaggcac tcccaccag gtaa	1494

<210> 168
 <211> 1479
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 168	
atgcttctcc tggtgacaag ctttctgctc tgtgagttac cacaccagc attcctcctg	60
atcccacagg aacagttgga agagtcaggt gggggccttg tcaagcctga aggtagtctg	120
acactcacct gcactgcatc agggttttct tttagctcat catattatat gtgctgggtc	180
agacaagcgc cggggagagg actggagtgg attgcgtgca ttatacttc ttctggttca	240
gcctattacg ctaattgggc taaagggcgg ttcacaatat ctggaacttc ttctactact	300
gtgacactcc agatgacgcg cctgacggct gctgatacag caacctactt ctgtgtacga	360
aatgctgttg ggtccagtta ctatttgtac ctgtgggggc ctggaactct cgtgacagta	420
agtagcggga gcacgagtgg aagcggtaaa ccaggttctg gagaaggag tacgaaagga	480
caagtcttga ctcagacccc aagccctgtg tccgcagcgg ttggtggtac agtaacaata	540
tcttgccagg cctcaciaag tgtggcaggc aacaactacc tttcatggta tcaacaaaaa	600
ccagggcagc ccccaaacct cctcatctat agcgtgtcca ccttggcttc cggggttcca	660
tcccggttta agggtagtgg aagtgggtaca caattcacgt tgacaatctc agacttggaa	720
tgtgatgacg cagccacata ttactgccag ggctattaca acgacggcat ctgggctttt	780
ggtggaggaa ctgaggtagt ggttaaaacc acgacgccag cgccgcgacc accaacaccg	840
gcgcccacca tcgctccca accacttagt ttgaggcctg aagcctgtag gccagcagct	900
ggtggtgcag tgcacacgag ggggctggac ttgcctgtg atatctacat ctgggcgccc	960
ttggccggga cttgtggggt ctttctcctg tcactggtta tcacccttta ctgcaaacgg	1020
ggcaggaaga agctgctcta catctttaag cagcctttca tgcgccctgt gcagacgact	1080
caagaggaag atggctgtag ctgccgattt ccagaagaag aagaaggagg atgtgaactg	1140
agagtgaagt tcagcaggag cgcagacgcc cccgcgtacc agcagggcca gaaccagctc	1200
tataacgagc tcaatctagg acgaagagag gagtacgatg ttttgacaa gagacgtggc	1260
cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat	1320
gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc	1380
cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc	1440

tacgacgccc ttcacatgca ggccctgccc cctcgctaa

1479

<210> 169

<211> 1479

<212> DNA

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 169

atgcttctcc tggtgacaag ctttctgctc tgtgagttac cacaccagc attcctcctg	60
atcccacaag tcttgactca gaccccaagc cctgtgtccg cagcggttgg tggtagta	120
acaatatctt gccaggcctc acaaagtgtg gcaggcaaca actaccttc atggtatcaa	180
caaaaaccag ggagccccc aaacctctc atctatagcg tgtccacctt ggcttcggg	240
gttccatccc ggtttaagg tagtggaagt ggtacacaat tcacgttgac aatctcagac	300
ttggaatgtg atgacgcagc cacatattac tgccagggt attacaacga cggcatctgg	360
gcttttggtg gaggaactga ggtagtgtt aaaggagca cgagtgaag cggtaaacca	420
ggttctggag aaggagtag gaaaggacag gaacagttgg aagagtcagg tgggggctt	480
gtcaagcctg aaggtagtct gacactcacc tgcactgcat cagggttttc ttttagctca	540
tcatattata tgtgctgggt cagacaagcg ccggggagag gactggagt gattgcgtgc	600
atttatactt cttctggttc agcctattac gctaattggg ctaaaggcg gttcacaata	660
tctcgaactt cttctactac tgtgacactc cagatgacgc gcctgacggc tgctgataca	720
gcaacctact tctgtgtacg aaatgctgtt ggggtccagtt actatttcta cctgtggggg	780
cctggaactc tcgtgacagt aagtagcacc acgacgccag cgccgcgacc accaacaccg	840
gcgcccacca tcgctccca accacttagt ttgaggcctg aagcctgtag gccagcagct	900
ggtggtgcag tgcacacgag ggggctggac ttgcctgtg atatctacat ctgggcgccc	960
ttggccggga cttgtgggt ctttctcctg tcaactgtta tcaccctta ctgcaaacgg	1020
ggcaggaaga agctgctcta catctttaag cagcctttca tgcgccctgt gcagacgact	1080
caagaggaag atggctgtag ctgccgattt ccagaagaag aagaaggagg atgtgaactg	1140
agagtgaagt tcagcaggag cgcagacgcc ccgcgtacc agcagggcc gaaccagctc	1200
tataacgagc tcaatctagg acgaagagag gactacgatg ttttgacaa gagacgtggc	1260
cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat	1320
gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc	1380
cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc	1440
tacgacgccc ttcacatgca ggccctgccc cctcgctaa	1479

<210> 170

<211> 2250

<212> DNA

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 170

atgctcctgc tggtgacgtc ccttctcctg tgcgaactgc cacaccagc tttcctgctg	60
ataccccagg aacagctcga ggaatcaggt ggtggcctgg ttaaaccga aggcagcttg	120
actcttacct gactgctag tggtttctcc ttctccagct catactatat gtgttgggtt	180
cgtaagctc caggcagggg cctcgagtgg atagcctgta tctacacttc atcaggtagc	240
gcatactacg ctaactgggc taagggccgc ttactatct ctcgaacaag tagcacaact	300
gtcacgttgc agatgacacg gcttaccgcg gcagatacgg caacctactt ttgcgtccgg	360
aacgcggtgg gctccagcta ctacctttac ctgtggggac caggcacgct ggttactgta	420
tcttctggca gtactagtgg tagtggaag cccggaagcg gggaaggctc caccaaggga	480
caggtcctga cccagacacc ttccccagtc tcagccgccg tgggcggaac tgtgacgata	540
agttgtcaag catctcagag cgtagcaggt aataactatc tgtcctggta tcagcaaaag	600
ccagggcagc cgcccaatct gcttatctat tcagtctcta cccttgccag cggcgtgcct	660
tcccggttta agggatcagg atcaggcact cagttcacac tgactatata cgatctcgaa	720
tgtgacgacg ccgcaacata ctactgtcag ggatactata atgatgggat ttgggccttc	780
ggggggggaa ccgaggtcgt ggttaaaacc accactccgg ctccccgacc acctactcct	840
gcccctacaa tcgctagcca gcctttgagt cttaggcctg aagctttagt gcctgccgca	900
ggcggggcag tgcacacaag gggccttgac ttgcctgtg atatctacat atgggcaccc	960
ctggctggaa cctgcggagt gtccttttg agtctctgta ttactctgta ctgcaagcgg	1020
ggaagaaaga agctgttgta cattttcaag cagccattca tgcgacccgt ccagaccaca	1080
caagaggaag acggctgtag ttgcagggtt cctgaagagg aagagggcgg atgcgagctc	1140
cgcgtgaaat tcagtagatc cgcagatgcc cctgcttacc agcaggggca aaaccagctg	1200
tataacgaat tgaatctggg acgccgagag gaatacgacg tgctcgacaa gagacgtggg	1260
cgtgatccag agatgggtgg caaaccgccg cgtaagaacc ctcaagaggg gctgtacaat	1320
gaactccaaa aggataagat ggccgaagct tattccgaaa ttggcatgaa aggggaacgc	1380
cggcgcgga aaggccacga cggactttac cagggtctta gcaccgcgac aaaggacacc	1440
tacgacgcat tgcataatgca ggcaactccca cccaggggca gcggtgaggg ccgcgggagt	1500
ttgctcacct gcggagacgt ggaagaaaac ccagggtccga tggtagagaa ggggtgaagag	1560
gataatatgg ccattatcaa agagttcatg cgctttaagg ttcatatgga aggctccgtg	1620
aacggtcacg agtttgagat cgagggagag ggtgaaggca ggccttacga aggaacccaa	1680
acagcaaagc tgaaagtaac caaaggcggc ccattgccct tcgcatggga catcctgagt	1740
ccccagttta tgtacggcag taaggcctat gtaaagcacc ccgcggacat ccctgattat	1800
ttgaaattgt cattcccaga gggcttcaaa tgggaaagag ttatgaactt tgaagacggc	1860
ggcgtcgtta ccgtgactca ggacagttct ctccaagatg gggaatttat ttacaaagtt	1920
aaattgcgag gcacaaactt ccctagcgac ggcccagtaa tgcagaagaa aaccatgggt	1980

tggaagcct ctagcgaacg gatgtacccg gaagacggag cactgaaggg cgagatcaag	2040
caacggctca agttgaagga cggcggccat tatgatgcag aggtgaaaac cacatacaag	2100
gcaaagaagc cgggtccagct tcccggcgct tacaacgtga atattaagct ggatataact	2160
tcccataatg aagactacac tatcgttagg cagtatgaaa gggcagaggg tcgccattcc	2220
actggtggga tggatgaatt gtacaagtag	2250

<210> 171
 <211> 2301
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 171	
atgctccttc tggtgacgag cctcttgctc tgcgaattgc ctcatcccgc attcctgctc	60
ataccccagg agcaattgga agaatcaggt ggtggacttg taaagcctga gggttcactc	120
acccttacgt gcaccgccag cggatttagt tttagctctt cctattatat gtgttgggta	180
agacaagccc ctggtagggg tttggaatgg atagcctgca tatatacgag ctcaggaagt	240
gcttattatg ctaactgggc aaagggcagg tttacaatct ctggaaccag ctccaccacc	300
gtcacccttc agatgactcg cctcactgcg gcagacacag caacgtatct ctgtgtgcgg	360
aacgcagtag gatctagcta ttatttgtac ctttggggcc cgggaacgct cgttactgtt	420
tcttctggaa gcaccagcgg atcagggaaa cccggtagcg gcgaaggtag tacgaagggt	480
caagtctga cccaaacccc ctctcccgtg tccgcagcag taggcggaac tgttactatt	540
tcttgccagg cctctcaaag cgctgctggt aacaactatc tcagctggta tcagcaaaag	600
cctggtcagc caccaaactt cttgatttac tccgtttcca cgcttgcttc tggagtcccc	660
tcacgattta aagggtctgg aagtgggact cagtttacct tgaccattag cgatcttgaa	720
tgtgacgacg cggcaacata ttattgccag gggactata atgacggtat ctgggcattc	780
ggcggcggca ctgaggttgt ggtgaaaggc ggtggcggaa gtggcggagg aggctcaggt	840
ggcggcgggt ctggtggaac aaccactcct gcccctcggc cccaacacc cgcacctacc	900
atagccagtc aacctttgtc tctgcgtccc gaggttgta gaccgctgc tgggtggggct	960
gtccatacaa ggggtttgga ctttgctgc gacatatata tttgggcgcc cttggctggt	1020
acttgaggag tcctgctgct ctctctcgtt ataactgt actgcaaaag aggtcggaag	1080
aagcttcttt atatcttcaa gcaaccattc atgcgcccgg ttcaaaccac ccaagaggaa	1140
gacggctgct cctgccggtt tccagaggaa gaagaggcg ggtgtgaatt gaggtcaaaa	1200
tttagtcgga gtgccgacgc gcccgcttat caacaagggc aaaaccagct gtacaatgag	1260
ttgaatctgg gcagacgtga ggagtatgac gttcttgaca agcgtagagg tagggatcct	1320
gaaatgggtg gcaaaccacc gcgtaagaat ccacaggaag ggctctataa cgaactgcag	1380
aaggataaaa tggcagaagc ttactccgag atcggtatga aagggaacg acgtcagagg	1440
aaaggccatg acgggctcta tcaaggcctg agtacggcta caaaggacac ctacgatgcc	1500

cttcatatgc aggctctgcc acctcgaggg tcaggtgaag gcaggggttc tctcttgact	1560
tgcggtgatg tagaagaaaa tcctgggccca atggtgagca aaggggaaga ggacaatatg	1620
gctatcatca aagagttcat gcgattcaag gtacatatgg aaggaagtgt caatggccat	1680
gaatttgaga tcgaaggcga aggtgagggga cgaccttatg aggggtactca aactgcaaag	1740
ttgaaagtga ccaaagggtg tcccctgccc ttgctgtggg atatcctcag cccacaattt	1800
atgtatgggt ctaaggcata cgtaagcat cccgccgata tccctgatta tctgaaactc	1860
agctttcccg agggcttcaa atgggagcgt gtgatgaatt ttgaggatgg cggcgttgtg	1920
actgtgaccc aggatagctc actccaagac ggcgaattca ttacaaaagt gaagctgcgg	1980
ggaacaaatt ttccctcaga tggccagtg atgcaaaaga agacaatggg ctgggaagct	2040
agttcagaac gcatgtatcc tgaggatggt gccctgaagg gagaaataaa acaaagattg	2100
aaattgaaag atggcgggtca ctatgacgct gaagtaaaga caacttataa agccaagaag	2160
cccgtagaac tgccaggcgc ctataatgta aatattaagt tggacatcac ctacacaac	2220
gaagattata ccatcgctga gcagtacgaa agagcagagg gccgtcatag tacaggcggg	2280
atggatgaat tgtacaaata g	2301

<210> 172
 <211> 2250
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 172	
atgctgctct tggttaaccag cctgctcctg tgcgagcttc ctcatccggc ctttctgttg	60
atcccgaag ttctcaccca gacaccttcc cccgtttctg ccgctgtcgg cggtagggtc	120
accatctctt gtcaagcaag tcaaagtgtc gcgggaaata attatctgag ctggtatcaa	180
cagaaacccg gtcaaccccc aaaccttctg atctactccg tgtctaccct cgcttctggc	240
gtcccatcaa ggtttaaagg ctctggctctt gggacccaat tcacacttac aatctctgat	300
ctggagtgtg atgacgctgc tacctactac tgtcaaggat actacaatga tggaatctgg	360
gcatttggtg gtgggaccga agttgtagtt aagggatcaa caagtgggag tggtaagcca	420
ggcagcgggg aagggtccac caaaggga gaacaattgg aagagagcgg aggaggcctg	480
gttaaaccag agggctccct cactctgacc tgtacagcct caggatttag cttttcttca	540
tcttattata tgtgttgggt gaggcaagct ccgggccgtg gtctcgagt gattgcctgt	600
atatacacca gtcgggatc cgcctattac gcgaactggg ccaaaggaag gtttacaatc	660
tctaggacgt cctcaactac tgtgacactt caaatgacac gacttacagc ggcggacact	720
gcgacatatt tctgtgtgcg gaatgcggta ggttcatctt actatttgta tctttgggga	780
cctggtacac tcgtcactgt ctctctact accactcctg ctccaaggcc cccaaccca	840
gccctacta tagcttccca accactgtca ctcaggccag aagcatgtag gcctgcagcg	900

ggtggtgctg ttcatacgcg tgggctggat ttcgcctgtg acatttacat atgggctccg	960
ctggcgggca catgtggtgt gctgctgctg tccctggtca tcaccctcta ctgtaagagg	1020
ggacgaaaga agcttcttta catcttcaaa caacccttta tgcgtccggt ccaaacaacc	1080
caggaagaag atggatgctc ctgtcgatct cccgaagaag aagaaggcgg ttgtgaactg	1140
agagttaagt tctctcgctc agccgacgct ccggcatatc aacaaggcga aaatcagctc	1200
tacaatgaat tgaatctcgg gagacgagag gaatatgacg tgttggacaa aaggcgcggt	1260
cgtgaccag agatgggtgg caaaccacgg cgcaagaacc ctcaggaagg actttacaac	1320
gagctccaaa aggacaaaat ggctgaagca tattccgaga taggcatgaa gggtgaaagg	1380
cgtaggggca aagggcacga cggcctttat cagggcctct ctacggccac gaaggatacg	1440
tatgacgcgt tgcacatgca agccttgccg ccaaggggta gcggagaagg aagagggtct	1500
ttgctgactt gtggcgacgt cgaagaaaac cctggaccaa tggtaagcaa aggtgaggaa	1560
gataatatgg ccatcatcaa agaatttatg agattcaaag tgcacatgga aggcagcgtg	1620
aatggccatg aatttgaaat tgagggcgag ggagaaggcc gcccctacga aggaacccaa	1680
actgccaac tcaaagtgc taaaggcggg ccgctgcctt ttgcttgga tattctctcc	1740
ccacaattca tgtatggatc caaggcttat gttaaaccatc ccgcagatat tcccgattac	1800
ctgaaattgt catttccga gggattcaag tgggagaggg ttatgaattt tgaggacggt	1860
gggtagtta cagttactca ggactcttct cttcaagatg gggaatttat ctacaaggtc	1920
aaattgcggg gcacaaattt tccctctgat ggaccctga tgcaaaagaa gacaatggga	1980
tgggaagcaa gttctgaacg tatgtatcca gaagatgggg ctttgaaagg cgagataaaa	2040
caaaggctga agctcaaaga tgggtggacac tacgatgcag aggtcaagac aacatataag	2100
gctaagaaac ctgttcagct ccctggggct tacaacgtta atattaaact ggacattact	2160
tctcacaatg aggattacac gatagtggaa cagtacgaaa gagctgaggg acggcatagt	2220
acaggcggca tggacgaact gtataaatga	2250

<210> 173
 <211> 2301
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 173	
atgctgcttc tggtaacctc actgctcctg tgtgaactgc ctatcctgc attcctgctt	60
ataccccaag tcctcacgca aacaccaagt ccagtaagcg cagccgtcgg tgggactgtt	120
accattagtt gtcaggctag tcaatcagtc gctggaaaca attatctctc atggtatcaa	180
caaaagccag gccaaaccacc aaatctgctc atttactctg tctccacact ggcatccggc	240
gtcccagatc ggtttaagggt tagtgggtct ggaactcaat ttaccctgac aatctcagat	300
ctcgagtgcg acgatgctgc cacatattat tgtcaaggat attataacga tgggatctgg	360
gctttcggcg gtgggaccga agtcgtcgtg aaagggtcca ctagtggttc tggtaagccc	420

ggttcagggg aaggtagtagt aaaagggcaa gagcaacttg aagaatccgg tggcgggctt	480
gttaaacctg aaggtagcct caccttgacc tgcaccgccca gtggcttctc atttagtagt	540
tcatactata tgtgctgggt tcgccaagcc cccgggcgcg gactggagtg gatcgcttgc	600
atatacactt ctagtggaag cgcctactat gccaaactggg ccaaaggctg gtttactatc	660
tcaagaacca gctccactac tgtgaccctt caaatgacct ggctgacagc cgccgatact	720
gccacatact tttgtgtccg caatgcggtc ggacagtagct actatctgta cctctgggga	780
ccagggaacct tggtcacagt gtcattctggc gggggggggtt ccgggtggggg gggatctggc	840
ggcggcggat ctgggtggaac cacgacccca gcacccagac cacctactcc ggctccaacc	900
attgcttcac aaccattgtc actcaggccc gaggcctgcc ggccagccgc aggcggcgct	960
gtgcatactc ggggactgga cttcgcatgt gacatttata tttgggcacc gctcgccgga	1020
acatgcgggg tttctgttgc gtccttgggt ataaccttgt actgtaaaag aggtcgcaag	1080
aagctccttt atattattcaa acaaccattc atgcggcccc tccaaacaac ccaggaagag	1140
gatgggtgca gttgtcgctt tccagaagaa gaggaagggt gctgcgaatt gagagtaaaa	1200
ttctctcgca gcgcagatgc acccgcttac cagcaaggac aaaaccaact ttataacgaa	1260
cttaacctgg ggcgccggga agagtacgat gttcttgaca agcggagagg tcgcgacca	1320
gaaatgggcg gtaagccgcg acggaagaat cccaagaag gtctttataa tgagctcaa	1380
aaggacaaga tggctgaggc atactcagag atagggatga aaggcgagcg gagacggggc	1440
aaggggcatg atggcctcta ccaaggattg tccacagcaa ctaaggatac ttacgatgct	1500
ctgcacatgc aagcccttc cccgcgtggc tccggcgagg gtagagggtc tctcctgact	1560
tgcggagacg tggagaagaaa cccgggacct atggtctcta aaggcgaaga ggataacatg	1620
gccataatca aggagtttat gcggttcaag gtacatatgg aaggtagcgt taatgggcat	1680
gaattcgaaa tagagggaga aggcgaagg agaccttatg aaggacaca aacagctaaa	1740
ctgaaagtaa ccaagggcgg acctcttcct ttcgcttggg atatccttag ccctcaattt	1800
atgtatgggt ccaaggcgta cgtaagcat cccgctgata ttcccgacta cctcaaactt	1860
tcattttcag agggctttta atgggaacgc gttatgaatt ttgaggacgg cggggttgtc	1920
actgtgacct aggattcttc cctgcaagat ggcaattta tctataaagt caaactgaga	1980
ggtacaaact ttccttcga cggacctgtg atgcaaaaaga aaacgatggg ctgggaagct	2040
tcttccgagc ggatgtatcc agaggacgga gccctgaagg gcgaaataaa acaacgcctc	2100
aaactgaagg acggcggccca ttacgatgca gaggttaaga cgacttataa agcaaagaaa	2160
cctgtccaac tgcctggtgc atataacgtc aacataaaac tggacatcac atcccataat	2220
gaggactata ccattgttga acaatacgaa cgggctgaag gcaggcattc aaccggtggc	2280
atggatgaac ttacaagtg a	2301

<210> 174
 <211> 2259
 <212> DNA

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 174

atgctgctcc tggtcacttc actcctcttg tgtgaacttc cccacccggc atttctcctg	60
atcccacaag agcaactgga agaatccggg ggggggctcg tcaagcccga aggtagcctc	120
actttgactt gtaccgcctc aggctttagt ttctcttcca gttattatat gtgttgggtc	180
cggcaggctc ctggaagagg gctcgaatgg atcgctgtga tctataccag ctcaggagc	240
gcctattatg ccaactgggc aaaaggccgt ttcactatct ctaggacttc atcaactact	300
gtgactcttc aaatgacccg gctgacagca gctgacactg caacctactt ttgcgtccgg	360
aatgcagtth gctcctcata ctacctctat ttgtggggac ccggcactct ggtaacagtc	420
tcaagcggga gcacttccgg ctcagggaaa cctggatccg gggaaggaa cactaagggt	480
caagtgttta cccaaacacc gtctcccgtg tcagcggctg tgggcggcac tgtgactata	540
agttgtcagg catcccaatc agtggctgga aacaactatt tgagctggta tcaacaaaag	600
cccggtcaac cccctaattc cctgatttat tcagtgtcca ctctcgcttc tggcgtgcct	660
agcaggttta aaggttccgg gtcagggtaca cagtttacc tgacgatatc cgacctgaa	720
tgcgatgacg ctgccaccta ctactgccag ggctactata atgacggaat ttgggcattt	780
ggtggtggca ccgaagtcgt agtcaaaaca accacgccc cccaaggcc gccgaccca	840
gccccgacta tagccagtca accactctca ttgagaccg aagcatgtcg tcccgtgctg	900
ggtggagccg tccacactcg tggccttgac ttgcctgtg atattttatat ctgggctcca	960
ctcgcaggca cctgcggtgt gctgctcctg agtctctgca ttacccttta ttgcaagcgg	1020
ggccggaaga agctcttgta tatatttaag caacctttta tgagaccgt gcaaaccacc	1080
caagaggaag acgggtgtag ttgccgtttt cctgaagagg aagaaggcgg atgcgaattg	1140
cgagtcaaat tttcccggtc tgcggatgcc cccgcgtatc aacaaggcca aaatcagctg	1200
tacaatgaat tgaatctggg acggagagag gaatatgatg tacttgacaa gcgacgcggc	1260
cgagatcctg aaatgggcgg aaagcctcgc cgcaagaacc cccaggaagg actctacaat	1320
gagctgcaga aggataaaat ggcagaagct tatagcgaaa ttggaatgaa aggcgaaagg	1380
cggcgtggta agggatcatga tggcctttat cagggactta gcaccgctac taaagacacg	1440
tatgatgctt tgcacatgca agcacttcca cccgcggct caggcgaggg acggggtagc	1500
ctgttgacgt gtggcgacgt ggaagagaat ccagggccaa tggatatctaa gggagaggaa	1560
ctctttacgg gtgtcgtccc tatactgggtg gaactcgatg gtgatgttaa tggccataag	1620
ttttctgtgt ctggggaagg cgaaggcgac gctacttatg gcaaactcac cttgaaattt	1680
atttgacta ctgggaagtt gcccgctcca tggccaacct tcgttaccac attgacgtat	1740
ggcgtgcaat gtttctccag ataccctgac cacatgaagc aacacgactt cttcaagtcc	1800
gcgatgcccg aaggatacgt acaagaacgg acgatcttct ttaaagacga tggcaattac	1860
aaaacaagag cggaagtga gtttgaagg gatacgtctg tgaaccgtat tgaactgaaa	1920

ggaatcgact ttaaggaaga cggtaatatt cttggtcata agcttgagta caactataac	1980
agccacaatg tatatatcat ggccgataag cagaagaatg gcatcaaagt aaattttaaa	2040
ataaggcata acatagagga cgggagtgtg caacttgcag atcactatca gcagaataca	2100
ccaattgggg acgggccagt gctgttgccct gataatcatt atctgagcac ccaaagcgcc	2160
ctctccaaag accccaacga aaagcgcgat cacatgggcc tgctggaatt tgtcacggct	2220
gcaggtatca cactcgggat ggacgagttg tataagtga	2259

<210> 175
 <211> 2241
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 175	
atgttgctct tggtgaccag tcttcttttg tgtgagctgc cgcattccgc atttctgttg	60
atccctcaag agcagctgga agaatcaggc ggtggactgg ttaaaccga agggctccctt	120
acgcttacat gtactgcatc cgggttcagt ttctcatcat catactacat gtgctgggtg	180
agacaagctc caggagagg tctggaatgg atcgctgta tctatacatc ctctggaagc	240
gcgtactatg ccaattgggc taaaggctcg ttcactatct cccgaacatc ttctactact	300
gttacgcttc aaatgactag attgacagcg gccgacacag caacctactt ttgtgttcgt	360
aacgccgtcg gatcaagcta ctatctgtat ttgtggggtc ccggcaccct ggttactgtc	420
agcagcggga gtacctcagg ttcaggaaaa ccggcgagcg gcgagggcag cactaaaggg	480
caggctctga ctcaaagcc ctctcctgtc tcagcggctg ttggtggcac cgtcacaatt	540
tcttgccaag caagtcaaag tgttgcggtt aataattatt tgagctggta tcaacaaaag	600
cctggacagc cgcctaacct gtcattttac tctgtatcta cattggcttc tggagtgtcc	660
agcagattta aaggaagtgg gagggtgaact cagtttacgt tgacaattag tgatcttgag	720
tgtgatgacg ctgcaacctt ctactgcaa ggttattaca atgacggaat ttgggctttt	780
ggcggcgagg cagaagtcgt tgtcaaaatt gaggttatgt acccaccacc ctatctggat	840
aatgagaaaa gcaatggtac tattatccat gtaaaggga agcatctctg tcctagccct	900
ctctttccag ggcccagtaa accatttttg gttctcgtcg ttgtgggcgg cgtgctcgcc	960
tggtattcat tgctcgtaac agttgccttt attattttct gggtaagcg cggccggaag	1020
aagttgctgt acattttcaa acaaccattt atgcgcccag ttcaaactac ccaagaagag	1080
gatgggtgct catgtaggtt ccctgaagaa gaagaaggcg gatgagagct cagagtgaaa	1140
ttctcccgtc ctgcagatgc tccggcttat cagcaagggc aaaatcagct gtacaacgag	1200
cttaaccttg gtaggcgaga agaatatgac gttctggata aaagacgcgg cagagacca	1260
gagatgggcg ggaaccaag gcgcaagaat cccaagagg gtttgataa tgagctgcaa	1320
aaggacaaaa tggctgaagc ttattccgag attggtatga aaggagaaag acgaagagg	1380

aagggccatg atggtttgta ccaaggtttg tcaacagcta ctaaagacac ttacgatgcg	1440
cttcatatgc aagcactccc gcctaggggc tccggggaag gaagggaag tctcctcacg	1500
tgtggagacg tcgaggagaa tccagggccg atggtttcaa aggggtgaaga ggataacatg	1560
gctattataa aagagttcat gagatttaaa gtgcatatgg aaggcagcgt caacggccat	1620
gaattcgaaa ttgagggtga ggggtgaaggt cgtccgtatg aagggactca aacggcgaaa	1680
ttgaaagtta ctaaaggcgg gccgctccct tttgcgtggg acatattgag cccccagttt	1740
atgtatgggt ctaaagctta tgtgaaacac ccagctgaca taccagacta tcttaaattg	1800
tcctttcctg aaggattcaa atgggaacgc gtcatgaatt ttgaggatgg cggggttgtg	1860
acagtgactc aagattcaag tcttcaggat ggggaattta tatacaaagt caagcttcgc	1920
ggtacaaatt ttccgtcaga tggccccgtc atgcaaaaga agacaatggg atgggaagcg	1980
tcaagcgaac gcatgtaccc tgaggacggg gcattgaaag gcgaaatcaa acaaaggctt	2040
aagctcaagg atggcgggtca ttatgatgcg gaagtcaaga ctacatataa ggccaagaag	2100
cccgtacagc ttcttggcgc ttataatgtg aatattaaac ttgatatcac cagccacaac	2160
gaagattata ctatcgtaga acagtatgag agagccgaag ggcggcattc aacaggtggt	2220
atggacgaat tgtacaagtg a	2241

<210> 176
 <211> 2052
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 176	
atggcatctc cgctgacgag atttctatcc cttaatttgt tgctgctagg cgagtcaata	60
attctcgggt caggcgaagc tcaagaacag ctggaagaat caggcggcgg gctggttaag	120
ccagagggtt ctctgaccct cacgtgcacc gcctctggat ttagcttctc cagctcctat	180
tatatgtgct gggtcggca agccccctggc cgcggcctag agtggatcgc ttgtatctat	240
acgagctctg ggtcagctta ttatgcgaat tgggcaaaag gtcgctttac aatttctaga	300
acttcaagca cactgtgtac tcttcaaatt acacgcctaa ccgcggccga tacagcaacc	360
tatttctgtg tgaggaatgc cgtcggttca tcctattacc tgtacctgtg gggacccggg	420
accctcgtga ctgtcagttc tggttctaca tccggaagcg ggaagcctgg gtcaggcgag	480
ggaagtacta aaggtcaagt gctgacgcaa acaccgagtc ccgtttctgc tgccgtaggc	540
ggtacagtga ccatctcttg ccaggccagt caatcagtgg ctgggaacaa ctacctgtcc	600
tggtagcaaac aaaagcccgg tcaaccgccc aatctttctca tctactccgt gtccacactc	660
gccagcgggg tccccagccg cttcaagggg agcgggaagcg gcacacaatt tacgctgaca	720
attagcgact tggaatgcga cgatgcagcg acctattact gtcaaggcta ttataatgat	780
ggtatatggg cttttggtgg tggcactgaa gtcgtagtca aaactaccaa accagtgtctg	840
cgcacgccat cccccgtgca ccctactggc acttctcagc cccagagacc tgaagactgt	900

cgccccaggg gcagcgttaa gggcactgga ttggacttcg catgtgatat ttacatctgg	960
gcgccactgg cgggaatctg tgtagctctc ctgctaagcc ttattattac tcttatttgt	1020
taccacaagt ggatcaggaa gaaatttccc catatcttta agcaaccatt taagaaaact	1080
acaggagcgg cgcaggaaga ggatgcctgc agttgtcggg gcccccaaga ggaagagggc	1140
ggcggcggcg gatatgaatt gagagcaaaa ttttccaggt cagctgaaac ggccgcaa	1200
ctacaagatc ccaatcaact ctataatgag cttaatctag gacgtcgcg	1260
gtccttgaga agaagcgtgc cagagacccc gaaatggg	1320
aaccctcaag agggagtcta taacgccctg cagaaagaca aaatggccga agcgtattcc	1380
gaaatcggga ctaagggaga aaggcgcagg ggtaaaggcc atgacggtct atatcaaggc	1440
ttgagtacgg caacgaaaga cacgtatgac gccctgcata tgcagacact tgcaccaga	1500
gggtctgggtg aagggcgcgg cagccttctg acctgcggag atgtggaaga aaatcctgg	1560
cctatgaatc ctgcaatttc cgtcgctttg ctgttgagcg tacttcaagt gtctcgggga	1620
caaaaggcca cgtctctcac cgctgccta gtcaatcaga atttgcggct cgattgtaga	1680
cacgaaaata acacgaagga taactccatc caacatgaat tttcactcac ccgcgaaaag	1740
aggaaacatg tattgagcgg cactttgggc atcccagaac atacctatcg atctcgtgta	1800
accctgagta atcaacccta tatcaagggt ctgactctgg ccaactttac taccaaggac	1860
gaaggagatt atttctgtga gtcagggtc tcaggagcca acccgatgtc cagcaacaag	1920
tctatctctg tgtatagaga caagctggta aaatgtggcg ggatctcact gcttgttcaa	1980
aacacctcat ggatgctact actgctcctg tcactgtctc tgctgcaagc cctggatttc	2040
atctcactct aa	2052

<210> 177
 <211> 2052
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 177	
atggcttctc cactgacaag atttctcagc ctcaacttgc tcctactcgg tgagagtatt	60
atcctgggaa gcggagaggc gcaagtactt acgcagacac cgtcaccgt gtctgcagcc	120
gtgggcggca ctgtaaccat tagttgccaa gcttcccaga gtgttgagg taataactac	180
ctttcttgggt accagcaaaa gcctggacaa ccgcctaatt tactcatcta cagcgtttct	240
accctcgcca gtggagtacc cagccgtttc aaaggaagcg gcagcgggac ccaatttact	300
cttactatta gtgatctgga atgcgacgat gcggctacct actattgcca aggatattat	360
aatgacggaa tatgggcgtt tggcggcggg acagaggctg tagtgaaagg atcaacatct	420
ggatctggta agcctggttc aggggaaggc tctactaagg gacaagagca actggaagaa	480
agcggcggcg gactgggttaa acccgaagga agtctaacgc tcacttgac agctagtggg	540

ttctccttct caagctcata ctacatgtgt tgggttaggc aagctcctgg aaggggactg	600
gaatggatcg cctgcatata tacatcttcc ggatctgctt attacgctaa ttgggctaaa	660
ggacgattta ctatcagccg aacctcatct accacagtga cattgcaa at gacgcgtttg	720
accgccgctg ataccgccac ctacttttgt gtccggaatg ccgtcggtag ttcttattac	780
ctttatctct ggggacccgg caccctcgtc accgtcagta gtactacgaa acccgtcttg	840
agaacccta gtccagtga cccacgggc acctctcaac cccaacgccc cgaagattgt	900
cgccaagag gctctgtaaa gggcaccggc cttgacttcg catgtgatat ctatatttgg	960
gccccactag ccgggatctg tgttgctctt ctcttttcac tcattatcac cttgatttgt	1020
taccacaagt ggataagaaa gaaatttcca catatcttta aacagccatt caagaagacc	1080
accggcgccg ctcaagaaga agatgcatgt tcctgtcgtt gtccacaaga ggaagaaggg	1140
gggggtggtg gatatgagtt gcgagctaaa ttagtcgct ctgcagaaac tgcggcaaat	1200
cttcaagatc caaatcaact ttataatgaa cttaatctcg gccgccgca ggagtatgat	1260
gtgcttgaaa agaaacgcgc tcgcgatccc gagatgggcg gaaaacaaca acggcggcgg	1320
aatccccaag aggggtgtcta taacgccctt caaaaggaca agatggccga ggcatactct	1380
gaaataggga cgaaaggga gaggcgcaga ggaaaaggac atgacggctt gtaccaagga	1440
ctgagcaccg caactaaaga tacttatgat gctctacaca tgcaaact cgccccacgc	1500
ggaagcgggtg agggaagagg tagcctactg acttggtggag acgtggaaga aaacccggt	1560
cctatgaatc cagcgattag tgtggcactc ctgttgctcg tcttgcaagt aagccggggc	1620
cagaaagtaa ctagcctaac ggcgtgcctg gtgaaccaga acctgaggct cgactgcaga	1680
catgaaaata atacaaaaga taactccata caacatgagt tctctctcac ccgcgagaag	1740
agaaaacatg tcctttctgg aactcttggg attccagagc acacctatag aagcagagtc	1800
acattgagta accaaccata cattaaagt ctgacacttg ctaatttcac caaaaagat	1860
gagggcgact atttctgtga acttagggta agtggagcta atcccatgag tagcaataaa	1920
tcaattagcg tgtatcgca taagctagtc aaatgtggcg gtatttcct tcttgttcaa	1980
aatacttcat ggatgctact cctgctcctc tcattgagct tgctgcaagc actcgatttc	2040
atcagtttgt ag	2052

<210> 178
 <211> 2064
 <212> DNA
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<400> 178	
atggcatccc ctctcacgag attcctcagc ctcaatctgt tgttgctcgg agaaagcatt	60
attttgggga gtggtgaggc gcaatccctc gaggaatccg gtggtgacct agtaaagcca	120
ggagctagcc tcaccctgac gtgcactgca tccggaatag atttcagcga tatatattac	180
atatcctggg tccgccaagc acctggtaaa ggactcgaat ggattgcttg tacgtatgca	240

ggtagctccg gcagcactta ctacgccacc tgggcaaagg gccgatttac tattagcaaa	300
gccagcagca ccacagttac acttcaaagt acatcactga ccgcagctga caccgcaacc	360
tacttctgcg cacgcgatcg atatccagga acatcaggac ggggtgtatgg tatggacctc	420
tgggggtccgg gaaccttggt cacggtatca tcaggctcaa ccagcggctc cggtaaacc	480
gggtctggtg agggaagcac taaaggagtt gtcattgacc aaactccatc cagcgtctca	540
gagcctgtgg gcgggactgt gactatcaaa tgtcaagctt cccaaagtat ttctgatctc	600
ctttcatggt atcagcaaaa gccgggacaa ccccaaaac ttctgatcta tagcgctct	660
actctggcca gcggagttag ttccagatgt aagggaagcg gatcaggtag agagtttacg	720
ctaactatct ctgaccttga atgtgctgat gcggctacat attattgtca atgtaactat	780
tacagtccaa cctacgggaa cgggtttggc ggcggcacag aagttgtcgt caaaactaca	840
aagcctgtgc tgagaacacc ttacactgtg caccgacgg gaacttcca gccacagagg	900
cccgaagatt gccgccctcg gggaagcgta aaagggacgg gcctcgattt tgcattgat	960
atatatatgtt gggctcctct ggacggcatt tgtgttgac tccttctcag cttattatc	1020
acgcttattt gctaccataa atggatagc aagaagttt cacacatct taagcaacca	1080
ttcaagaaga ctacaggcgc tgcccaagaa gaggatgctt gcagctgtag atgtcctcaa	1140
gaggaagagg gtggtggtgg cggatatgaa ctgagggcta aattcagccg atccgccgag	1200
acagccgcca atttgcaaga tcccaatcaa ctatataacg aactaaatct gggaagacgg	1260
gaagagtatg acgtcctcga aaagaaacgc gcacgagacc ccgaaatggg cgggaagcag	1320
caacggcggc gcaatcccca agaagggtt tataatgcac tccaaaagga taaaatggct	1380
gaggcctaca gcgagatagg gactaaagga gaacgacgac gcggcaaagg ccatgacgga	1440
ctttaccaag ggctttccac agcaacaaaa gacacttatg atgccctgca tatgcagaca	1500
ttggctccca gaggaagtgg agaggggcgc ggaagtctt ttacttgtgg cgacgtagaa	1560
gaaaatccag gccgatgaa tccagccata agcgtggcgt tgctgctctc tgtgctgcaa	1620
gtgagccgag gtcaaaaggt aacctcattg accgcgtgcc tcgtgaatca aaatctgcgc	1680
cttgactgcc gccatgaaaa caataccaaa gacaattcca tacagcacga attttcattg	1740
acccgcgaaa agcggaaaca cgttttgagc ggaaccctcg gaatacctga gcatacttat	1800
cgctcacgcg tcaccctaag caaccagcca tatatcaagg tcttgacttt ggccaatttc	1860
acaacaaaag atgaaggcga ttacttttgt gaactccggg tatctggtgc taatcctatg	1920
tccagtaata agtccatttc cgtgtatcgc gacaaattgg tcaaatgtgg tggaatctca	1980
ttgctagtgc aaaacacctc ttggatgttg ttgcttctc tgagtttgc actgcttcaa	2040
gctctggact tcatatctct ttag	2064

<210> 179

<211> 2064

<212> DNA

<213> Artificial sequence

<220>

<223> synthetic sequence

<400> 179

atggccagcc cgctaaccgc attcctgtca ctaaattctgc ttctgctcgg ggaatcaata	60
atcctaggct caggcgaagc ggtagtcatt acccaaactc catcttctgt gtcagaacca	120
gtcgggtggga cggttaccat aaagtgccag gccagccaaa gcatatcaga tctcctttca	180
tggtatcaac agaaaccagg gcaaccccca aagctcctga tatatagtgc ttccaccctg	240
gcctcaggag tatcctctag gtttaaaggt agtggaaagt gtacggaatt cacgctcacc	300
attagtgatc tagaatgcgc cgacgcagca acatactact gtcaatgtaa ctattactca	360
ccaacgtacg ggaatggatt tgggtggtggc accgaagtgg ttgtaaaggg cagcacttct	420
gggagcggga aaccaggaag tggagaagga agcacaaaag gccagtcact ggaagaaagt	480
ggcggggatc tcgtgaagcc tggcgctca ctaactctca cttgcaccgc gtcaggcatc	540
gatttttagtg atatatata tattagctgg gtgcgacaag caccaggaaa aggtctggaa	600
tggattgcct gcacatatgc agggctcttca ggctccacct actacgccac atgggcaaaa	660
ggcagattta ccatatcaaa agctagctcc acaacagtca ctctacaaat gacaagcctc	720
accgcagctg aactgccac ttacttctgc gctcgcgatc gttatcctgg tacatccgga	780
cgggtctatg gtatggatct ctggggaccc ggcaactctt ttacagttag ctccactaca	840
aaaccgtac ttcggacacc aagtccggtc catcctactg gtacatctca accccagagg	900
cccgaagatt gcaggccgcg gggttctgtg aaaggtaccg ggcttgattt tgcgtgcgac	960
atctacattt gggcacctct ggcaggaatt tgcgtgcac ttttgctctc cttataatc	1020
actctgatat gttatcacia atggattcgg aagaagtcc cgcacatctt taaacaacct	1080
ttcaagaaga caacaggggc ggcccaagaa gaggacgctt gctcatgcag atgcccgcag	1140
gaagaagagg gtggtggcgg tggatatgag ctacgcgcca aattttcaag aagtgcggaa	1200
acagctgcca atttgagga cccaaaccaa ctgtataacg aactgaattt gggtcgaagg	1260
gaagaatatg atgtacttga aaagaaaagg gccagagatc ccgaaatggg cggaagcag	1320
caacgccgca gaaaccaca agaaggcgtg tacaatgctc ttcagaaaga caaatggcc	1380
gaagcttatt ccgaaatcgg cactaaggga gagagaagac gcggaaggg gcacgatggc	1440
ctgtatcaag gtttgtctac ggcaacaaaa gatacttatg acgcactcca tatgcaaaca	1500
cttgcccaa ggggatctgg tgaaggctgt ggctccctgc ttacctgcgg agatgtggaa	1560
gaaaatccag gccctatgaa ccctgcgatt tctgtggcac ttctactgtc cgtcctgcag	1620
gtgtctagag gacaaaaggt tacttctcta acggcttgtc tcgtgaacca aaacctagg	1680
ctcgactgcc gacacgaaaa taatactaag gataattcca ttcaacatga attttctctt	1740
accagggaga aacggaagca tgtgctcagc ggcacgctag gaattccga gcacacatat	1800
cgatccaggg tgacactctc aaatcaaccc tacatcaaag tcctcaccct agcaaaactc	1860
acaactaagg acgagggcga ctacttttgt gagttgcgag taagtggggc aaaccaatg	1920
tcttccaaca agagcattag tgtataccgc gacaaactcg taaaatgtgg tggaatcagc	1980

cttttggtgc aaaataccag ctggatgctt ttgctcttgc tttccctgtc actactgcaa 2040

gccctcgact ttatcagtct ttaa 2064

<210> 180

<211> 309

<212> PRT

<213> Vaccinia virus

<400> 180

Met Thr Arg Leu Pro Ile Leu Leu Leu Ile Ser Leu Val Tyr Ala
1 5 10 15

Thr Pro Phe Pro Gln Thr Ser Lys Lys Ile Gly Asp Asp Ala Thr Leu
20 25 30

Ser Cys Asn Arg Asn Asn Thr Asn Asp Tyr Val Val Met Ser Ala Trp
35 40 45

Tyr Lys Glu Pro Asn Ser Ile Ile Leu Leu Ala Ala Lys Ser Asp Val
50 55 60

Leu Tyr Phe Asp Asn Tyr Thr Lys Asp Lys Ile Ser Tyr Asp Ser Pro
65 70 75 80

Tyr Asp Asp Leu Val Thr Thr Ile Thr Ile Lys Ser Leu Thr Ala Arg
85 90 95

Asp Ala Gly Thr Tyr Val Cys Ala Phe Phe Met Thr Ser Pro Thr Asn
100 105 110

Asp Thr Asp Lys Val Asp Tyr Glu Glu Tyr Ser Thr Glu Leu Ile Val
115 120 125

Asn Thr Asp Ser Glu Ser Thr Ile Asp Ile Ile Leu Ser Gly Ser Thr
130 135 140

His Ser Pro Glu Thr Ser Ser Glu Lys Pro Asp Tyr Ile Asp Asn Ser
145 150 155 160

Asn Cys Ser Ser Val Phe Glu Ile Ala Thr Pro Glu Pro Ile Thr Asp
165 170 175

Asn Val Glu Asp His Thr Asp Thr Val Thr Tyr Thr Ser Asp Ser Ile
180 185 190

Asn Thr Val Ser Ala Thr Ser Gly Glu Ser Thr Thr Asp Glu Thr Pro
195 200 205

Glu Pro Ile Thr Asp Lys Glu Asp His Thr Val Thr Asp Thr Val Ser
210 215 220

Tyr Thr Thr Val Ser Thr Ser Ser Gly Ile Val Thr Thr Lys Ser Thr
225 230 235 240

Thr Asp Asp Thr Tyr Asn Asp Asn Asp Thr Val Pro Pro Thr Thr Val
245 250 255

Gly Gly Ser Thr Thr Ser Ile Ser Asn Tyr Lys Thr Lys Asp Phe Val
260 265 270

Glu Ile Phe Gly Ile Thr Ala Leu Ile Ile Leu Ser Ala Val Ala Ile
275 280 285

Phe Cys Ile Thr Tyr Tyr Ile Cys Asn Lys Arg Ser Arg Lys Tyr Lys
290 295 300

Thr Glu Asn Lys Val
305

<210> 181
<211> 317
<212> PRT
<213> Vaccinia virus

<400> 181

Met Lys Thr Ile Ser Val Val Thr Leu Leu Cys Val Leu Pro Ala Val
1 5 10 15

Val Tyr Ser Thr Cys Thr Val Pro Thr Met Asn Asn Ala Lys Leu Thr
20 25 30

Ser Thr Glu Thr Ser Phe Asn Asn Asn Gln Lys Val Thr Phe Thr Cys
35 40 45

Asp Gln Gly Tyr His Ser Ser Asp Pro Asn Ala Val Cys Glu Thr Asp
50 55 60

Lys Trp Lys Tyr Glu Asn Pro Cys Lys Lys Met Cys Thr Val Ser Asp
65 70 75 80

Tyr Val Ser Glu Leu Tyr Asp Lys Pro Leu Tyr Glu Val Asn Ser Thr
85 90 95

Met Thr Leu Ser Cys Asn Gly Glu Thr Lys Tyr Phe Arg Cys Glu Glu
100 105 110

Lys Asn Gly Asn Thr Ser Trp Asn Asp Thr Val Thr Cys Pro Asn Ala
115 120 125

Glu Cys Gln Pro Leu Gln Leu Glu His Gly Ser Cys Gln Pro Val Lys
130 135 140

Glu Lys Tyr Ser Phe Gly Glu Tyr Ile Thr Ile Asn Cys Asp Val Gly
145 150 155 160

Tyr Glu Val Ile Gly Ala Ser Tyr Ile Ser Cys Thr Ala Asn Ser Trp
165 170 175

Asn Val Ile Pro Ser Cys Gln Gln Lys Cys Asp Ile Pro Ser Leu Ser
180 185 190

Asn Gly Leu Ile Ser Gly Ser Thr Phe Ser Ile Gly Gly Val Ile His
195 200 205

Leu Ser Cys Lys Ser Gly Phe Ile Leu Thr Gly Ser Pro Ser Ser Thr
210 215 220

Cys Ile Asp Gly Lys Trp Asn Pro Ile Leu Pro Thr Cys Val Arg Ser
225 230 235 240

Asn Glu Lys Phe Asp Pro Val Asp Asp Gly Pro Asp Asp Glu Thr Asp
245 250 255

Leu Ser Lys Leu Ser Lys Asp Val Val Gln Tyr Glu Gln Glu Ile Glu
260 265 270

Ser Leu Glu Ala Thr Tyr His Ile Ile Ile Val Ala Leu Thr Ile Met
275 280 285

Gly Val Ile Phe Leu Ile Ser Val Ile Val Leu Val Cys Ser Cys Asp
290 295 300

Lys Asn Asn Asp Gln Tyr Lys Phe His Lys Leu Leu Pro
305 310 315

<210> 182
<211> 314
<212> PRT
<213> Vaccinia virus

<400> 182

Met Thr Arg Leu Pro Ile Leu Leu Leu Ile Ser Leu Val Tyr Ala
1 5 10 15

Thr Pro Phe Pro Gln Thr Ser Lys Lys Ile Gly Asp Asp Ala Thr Leu
20 25 30

Ser Cys Asn Arg Asn Asn Thr Asn Asp Tyr Val Val Met Ser Ala Trp
35 40 45

Tyr Lys Glu Pro Asn Ser Ile Ile Leu Leu Ala Ala Lys Ser Asp Val
50 55 60

Leu Tyr Phe Asp Asn Tyr Thr Lys Asp Lys Ile Ser Tyr Asp Ser Pro
65 70 75 80

Tyr Asp Asp Leu Val Thr Thr Ile Thr Ile Lys Ser Leu Thr Ala Arg
85 90 95

Asp Ala Gly Thr Tyr Val Cys Ala Phe Phe Met Thr Ser Thr Thr Asn
100 105 110

Asp Thr Asp Lys Val Asp Tyr Glu Glu Tyr Ser Thr Glu Leu Ile Val
115 120 125

Asn Thr Asp Ser Glu Ser Thr Ile Asp Ile Ile Leu Ser Gly Ser Thr
130 135 140

His Ser Pro Glu Thr Ser Ser Lys Lys Pro Asp Tyr Ile Asp Asn Ser
145 150 155 160

Asn Cys Ser Ser Val Phe Glu Ile Ala Thr Pro Glu Pro Ile Thr Asp
165 170 175

Asn Val Glu Asp His Thr Asp Thr Val Thr Tyr Thr Ser Asp Ser Ile
180 185 190

Asn Thr Val Ser Ala Ser Ser Gly Glu Ser Thr Thr Asp Glu Thr Pro
195 200 205

Glu Pro Ile Thr Asp Lys Glu Asp His Thr Val Thr Asp Thr Val Ser
210 215 220

Tyr Thr Thr Val Ser Thr Ser Ser Gly Ile Val Thr Thr Lys Ser Thr
225 230 235 240

Thr Asp Asp Ala Asp Leu Tyr Asp Thr Tyr Asn Asp Asn Asp Thr Val
245 250 255

Pro Pro Thr Thr Val Gly Gly Ser Thr Thr Ser Ile Ser Asn Tyr Lys
260 265 270

Thr Lys Asp Phe Val Glu Ile Phe Gly Ile Thr Ala Leu Ile Ile Leu
275 280 285

Ser Ala Val Ala Ile Phe Cys Ile Thr Tyr Tyr Ile Tyr Asn Lys Arg
290 295 300

Ser Arg Lys Tyr Lys Thr Glu Asn Lys Val
305 310

<210> 183
<211> 317
<212> PRT
<213> Vaccinia virus

<400> 183

Met Lys Thr Ile Ser Val Val Thr Leu Leu Cys Val Leu Pro Ala Val
1 5 10 15

Val Tyr Ser Thr Cys Thr Val Pro Thr Met Asn Asn Ala Lys Leu Thr
20 25 30

Ser Thr Glu Thr Ser Phe Asn Asp Lys Gln Lys Val Thr Phe Thr Cys
35 40 45

Asp Gln Gly Tyr His Ser Ser Asp Pro Asn Ala Val Cys Glu Thr Asp
50 55 60

Lys Trp Lys Tyr Glu Asn Pro Cys Lys Lys Met Cys Thr Val Ser Asp
65 70 75 80

Tyr Ile Ser Glu Leu Tyr Asn Lys Pro Leu Tyr Glu Val Asn Ser Thr
85 90 95

Met Thr Leu Ser Cys Asn Gly Glu Thr Lys Tyr Phe Arg Cys Glu Glu
100 105 110

Lys Asn Gly Asn Thr Ser Trp Asn Asp Thr Val Thr Cys Pro Asn Ala
115 120 125

Glu Cys Gln Pro Leu Gln Leu Glu His Gly Ser Cys Gln Pro Val Lys
130 135 140

Glu Lys Tyr Ser Phe Gly Glu Tyr Met Thr Ile Asn Cys Asp Val Gly
145 150 155 160

Tyr Glu Val Ile Gly Ala Ser Tyr Ile Ser Cys Thr Ala Asn Ser Trp
165 170 175

Asn Val Ile Pro Ser Cys Gln Gln Lys Cys Asp Met Pro Ser Leu Ser
180 185 190

Asn Gly Leu Ile Ser Gly Ser Thr Phe Ser Ile Gly Gly Val Ile His
195 200 205

Leu Ser Cys Lys Ser Gly Phe Thr Leu Thr Gly Ser Pro Ser Ser Thr
210 215 220

Cys Ile Asp Gly Lys Trp Asn Pro Val Leu Pro Ile Cys Val Arg Thr
225 230 235 240

Asn Glu Glu Phe Asp Pro Val Asp Asp Gly Pro Asp Asp Glu Thr Asp
245 250 255

Leu Ser Lys Leu Ser Lys Asp Val Val Gln Tyr Glu Gln Glu Ile Glu
260 265 270

Ser Leu Glu Ala Thr Tyr His Ile Ile Ile Val Ala Leu Thr Ile Met
275 280 285

Gly Val Ile Phe Leu Ile Ser Val Ile Val Leu Val Cys Ser Cys Asp
290 295 300

Lys Asn Asn Asp Gln Tyr Lys Phe His Lys Leu Leu Pro
305 310 315

<210> 184
<211> 315
<212> PRT
<213> Vaccinia virus

<400> 184

Met Thr Arg Leu Pro Ile Leu Leu Leu Ile Ser Leu Val Tyr Ala
1 5 10 15

Thr Pro Phe Pro Gln Thr Ser Lys Lys Ile Gly Asp Asp Ala Thr Leu
20 25 30

Ser Cys Asn Arg Asn Asn Thr Asn Asp Tyr Val Val Met Ser Ala Trp
35 40 45

Tyr Lys Glu Pro Asn Ser Ile Ile Leu Leu Ala Ala Lys Ser Asp Val
50 55 60

Leu Tyr Phe Asp Asn Tyr Thr Lys Asp Lys Ile Ser Tyr Asp Ser Pro
65 70 75 80

Tyr Asp Asp Leu Val Thr Thr Ile Thr Ile Lys Ser Leu Thr Ala Arg
85 90 95

Asp Ala Gly Thr Tyr Val Cys Ala Phe Phe Met Thr Ser Pro Thr Asn
100 105 110

Asp Thr Asp Lys Val Asp Tyr Glu Glu Tyr Ser Thr Glu Leu Ile Val
115 120 125

Asn Thr Asp Ser Glu Ser Thr Ile Asp Ile Ile Leu Ser Gly Ser Thr
130 135 140

His Ser Pro Glu Thr Ser Ser Glu Lys Pro Asp Tyr Ile Asp Asn Ser
145 150 155 160

Asn Cys Ser Ser Val Phe Glu Ile Ala Thr Pro Glu Pro Ile Thr Asp
165 170 175

Asn Val Glu Asp His Thr Asp Thr Val Thr Tyr Thr Ser Asp Ser Ile
180 185 190

Asn Thr Val Ser Ala Thr Ser Gly Glu Ser Thr Thr Asp Glu Thr Pro
195 200 205

Glu Pro Ile Thr Asp Lys Glu Glu Asp His Thr Val Thr Asp Thr Val

210					215					220					
Ser 225	Tyr	Thr	Thr	Val	Ser 230	Thr	Ser	Ser	Gly	Ile 235	Val	Thr	Thr	Lys	Ser 240
Thr	Thr	Asp	Asp	Ala 245	Asp	Leu	Tyr	Asp	Thr 250	Tyr	Asn	Asp	Asn	Asp	Thr
Val	Pro	Ser	Thr 260	Thr	Val	Gly	Ser	Ser 265	Thr	Thr	Ser	Ile	Ser 270	Asn	Tyr
Lys	Thr 275	Lys	Asp	Phe	Val	Glu	Ile 280	Phe	Gly	Ile	Thr	Ala 285	Leu	Ile	Ile
Leu 290	Ser	Ala	Val	Ala	Ile	Phe 295	Cys	Ile	Thr	Tyr	Tyr 300	Ile	Cys	Asn	Lys
Arg 305	Ser	Arg	Lys	Tyr	Lys 310	Thr	Glu	Asn	Lys	Val 315					
<210>		185													
<211>		317													
<212>		PRT													
<213>		Vaccinia virus													
<400>		185													
Met 1	Lys	Thr	Ile	Ser 5	Val	Val	Thr	Leu	Leu 10	Cys	Val	Leu	Pro	Ala 15	Val
Val	Tyr	Ser	Thr 20	Cys	Thr	Val	Pro	Thr 25	Met	Asn	Asn	Ala	Lys 30	Leu	Thr
Ser	Thr	Glu 35	Thr	Ser	Phe	Asn	Asn 40	Asn	Gln	Lys	Val	Thr 45	Phe	Thr	Cys
Asp	Gln 50	Gly	Tyr	His	Ser	Ser 55	Asp	Pro	Asn	Ala	Val 60	Cys	Glu	Thr	Asp
Lys 65	Trp	Lys	Tyr	Glu	Asn 70	Pro	Cys	Lys	Lys	Met 75	Cys	Thr	Val	Ser	Asp 80
Tyr	Ile	Ser	Glu 85	Leu	Tyr	Asn	Lys	Pro	Leu 90	Tyr	Glu	Val	Asn 95	Ser	Thr
Met	Thr	Leu	Ser 100	Cys	Asn	Gly	Glu	Thr 105	Lys	Tyr	Phe	Arg	Cys 110	Glu	Glu
Lys	Asn	Gly 115	Asn	Thr	Ser	Trp	Asn	Asp 120	Thr	Val	Thr	Cys 125	Pro	Asn	Ala
Glu	Cys 130	Gln	Pro	Leu	Gln	Leu 135	Glu	His	Gly	Ser	Cys 140	Gln	Pro	Val	Lys

Glu Lys Tyr Ser Phe Gly Glu Tyr Met Thr Ile Asn Cys Asp Val Gly
145 150 155 160

Tyr Glu Val Ile Gly Ala Ser Tyr Ile Ser Cys Thr Ala Asn Ser Trp
165 170 175

Asn Val Ile Pro Ser Cys Gln Gln Lys Cys Asp Ile Pro Ser Leu Ser
180 185 190

Asn Gly Leu Ile Ser Gly Ser Thr Phe Ser Ile Gly Gly Val Ile His
195 200 205

Leu Ser Cys Lys Ser Gly Phe Ile Leu Thr Gly Ser Pro Ser Ser Thr
210 215 220

Cys Ile Asp Gly Lys Trp Asn Pro Val Leu Pro Ile Cys Val Arg Thr
225 230 235 240

Asn Glu Glu Phe Asp Pro Val Asp Asp Gly Pro Asp Asp Glu Thr Asp
245 250 255

Leu Ser Lys Leu Ser Lys Asp Val Val Gln Tyr Glu Gln Glu Ile Glu
260 265 270

Ser Leu Glu Ala Thr Tyr His Ile Ile Ile Val Ala Leu Thr Ile Met
275 280 285

Gly Val Ile Phe Leu Ile Ser Val Ile Val Leu Val Cys Ser Cys Asp
290 295 300

Lys Asn Asn Asp Gln Tyr Lys Phe His Lys Leu Leu Pro
305 310 315

<210> 186
<211> 333
<212> DNA
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 186
gacgttgtaa tgactcagac gccatcctcc gttagcgaac cagtcggagg tacagtgacc 60
ataaagtgcc aagcctctca gtctatatct gacctgttga gttggtatca acagaaaccg 120
ggacaacccc caaagttgct catctactct gcgtcaacac tcgcatcagg cgtctcaagc 180
agattcaaag ggagtgggtc cggtagcgaa tttactctta ccataagtga ccttgagtgc 240
gctgacgctg ctacttatta ttgccagtgt aactactatt ctccgaccta cggaatggg 300
ttcggaggcg gaactgaggt agtggttaaa aag 333

<210> 187
<211> 330

<212> DNA
<213> Artificial sequence

<220>
<223> synthetic sequence

<400> 187
gacgttgtaa tgactcagac gccatcctcc gttagcgaac cagtcggagg tacagtgacc 60
ataaagtgcc aagcctctca gtctatatct gacctgttga gttggtatca acagaaaccg 120
ggacaacccc caaagttgct catctactct gcgtcaacac tcgcatcagg cgtctcaagc 180
agattcaaag ggagtgggtc cggtagcgaa ttactctta ccataagtga ctttgagtgc 240
gctgacgctg ctacttatta ttgccagtgt aactactatt ctccgaccta cggaaatggg 300
ttcggaggcg gaactgaggt agtggttaaa 330